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Parkinson’s disease (PD) is one of the most common age-related movement disorders. 
The main pathological symptoms include a degeneration of dopaminergic neurons in 
the substantia nigra pars compacta (SNC) and the occurrence of Lewy bodies. As a 
result, PD patients typically exhibit severe motor symptoms like bradykinesia, tremor 
and strong gait impairments. Subtle gait impairments are attributed to the “non-motor” 
symptoms in the pre-motor phase of PD. In addition, PD patients can develop other 
non-motor symptoms like cognitive and olfactory impairments much earlier than the 
actual appearance of motor symptoms. Two main forms of PD are described: the 
familial form, caused by inherited mutations, and the sporadic form, mainly caused by 
environmental factors and risk genes. Mutations in the human gene Phosphatase and 
tensin homolog-induced kinase 1 (Pink1) are believed to lead to a loss of function of its 
kinase domain and is recessively inherited. In order to analyse possible PD related 
effects of Pink1 deficiency, the murine gene Pink1 was knocked out (KO) by deleting 
exon 2 & 3 (Pink1_del2/3). The phenotypes of this mouse line exhibiting complete loss 
of Pink1 function was described in a previous study.  
These mice exhibited olfactory impairments and decreased serotonergic innervation of 
the olfactory bulb (OB). Likewise, Pink1_del2/3 mice showed gait impairments, 
although no neuronal degeneration in SNC was observed in aged mice. In order to 
understand the underlying mechanism of the Pink1 deficiency-related phenotypes and 
to uncover possible compensatory mechanisms, transgenic mice with a specific KO of 
Pink1 in serotonergic or dopaminergic neurons were analysed at young and middle 
age (mid-aged). Mice underwent a behavioural screening of open field testing (OF) 
followed by acoustic startle reflex analysis/prepulse inhibition (ASR/PPI), CatWalk 
testing and olfactory analysis. In addition, dopaminergic neurons were quantified in the 
SNC and the content of dopamine and serotonin was also measured. Furthermore, the 
respective metabolites were analysed in different brain regions. Finally, serotonergic 
innervation in the OB was examined. Overall, young and mid-aged mutant mice of both 
mouse lines did not display highly significant impairments in the OF, ASR/PPI and 
olfactory testing. The CatWalk analysis revealed some PD-related parameters affected 
in mutant mice. The neurotransmitter content did not differ in the different brain regions 
nor did the number of dopaminergic neurons in the SNC or the serotonergic innervation 
 vi 
 
of the OB. In summary, a murine Pink1 deficiency in serotonergic or dopaminergic 
neurons did not lead to neuronal degeneration or biochemical changes. In addition, 
strong PD-related behavioural phenotypes were not observed. Nonetheless, both 
mouse lines exhibited subtle PD-related gait phenotypes. In conclusion, the 
serotonergic and dopaminergic system potentially plays a role in the development of 
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1.1 Parkinson’s disease 
Parkinson´s disease (PD) is one of the most common neurodegenerative disorders, 
first described in ancient times (Manyam, 1990, Jankovic, 2008). In 1690 the 
Hungarian physician Ferenc Pápai Páriz reported the occurrence of the cardinal PD 
motor symptoms: bradykinesia/akinesia, tremor, rigidity, and postural instability. A 
detailed description of the same symptoms by the British physician James Parkinson 
followed over 120 years later (Bereczki, 2010, Parkinson, 2002). Originally, James 
Parkinson named the disease “paralysis agitants” in his published “An essay on the 
shaking palsy” (Parkinson, 2002). Later in 1888, the “paralysis agitans” was named 
“maladie de Parkinson” or “Parkinson´s disease” by the physician Jean-Martin Charcot 
(Charcot et al., 1888). It became apparent that during the course of PD the pigmented 
cells in the substantia nigra pars compacta (SNC) – nowadays known as dopaminergic 
neurons – specifically succumb to cell death. Thus, the loss of dopaminergic neurons 
in the substantia nigra, together with the PD-specific occurrence of cellular inclusion 
bodies – the Lewy bodies (LB) – are regarded as being the pathological hallmarks of 
PD (Fahn, 2017, Goetz, 2011).  
The estimated worldwide incidence of PD ranges between 5 to > 35 new cases per 
100.000 individuals per year. The discrepancies are due to differences in the 
demographics of population-based studies and study methods. The incidence of PD is 
rare before the age of 50 years and increases up to 5 to 10-fold at an age of 60 to 90 
years (Poewe et al., 2017). The worldwide prevalence of PD is about 0.3% but 
increasing steadily with age up to > 3% in people at an age over 80 years, indicating 
that age is the greatest risk factor for developing PD (Poewe et al., 2017). In addition, 
apart from age, the incidence and prevalence of PD depends on, amongst other 
factors, ethnicity, geographic location, sex and genetics (Pringsheim et al., 2014, Picillo 
et al., 2017). In the future, the number of patients suffering from PD will increase as 




in Western Europe´s 5 most populous nations and the world´s 10 most populous 
nations, the number of PD patients over an age of 50 years will have more than 
doubled, that is from 2005 to 2030 from around 4 million to 9 million affected 
individuals. Although several surgical and pharmacological treatment options are 
available, a cure for PD is not yet available. This results in a heavy burden on patients, 
caregivers, families, health and social support system (Rodriguez-Blazquez et al., 
2015).  
Current treatment of PD patients relies mostly on the use of pharmacologic agents, like 
L-3,4-dihydroxyphenylalanine (L-DOPA), in order to improve motor symptoms  and 
quality of life (Pires et al., 2015). Unfortunately, chronic treatment with L-DOPA can 
lead to involuntary movements called dyskinesia, and patients develop tolerance to the 
treatment (Lloyd et al., 1975, Pires et al., 2015). Hence, apart from pharmacotherapy, 
functional neurosurgery, gene therapy and cell-based therapies are the PD therapeutic 
approaches that are currently used in clinics, in clinical trials or still tested in preclinical 
research (Pires et al., 2015). Still, all these therapeutic approaches aim at relieving the 
symptoms of PD and thus to rectify the loss of dopaminergic neurons in the SNC, which 
is part of the basal ganglia (Rice et al., 2011). Importantly, these therapeutic options 
are not preventive, nor disease modifying nor do they take into account the 
multisystemic nature of the disease (see below). Thus in order to develop these 
preventive and disease modifying therapies, it is of highest importance to understand 
the aetiology of the disease in order to develop and discover new therapeutic avenues 
to slow down, halt or even prevent the development of the disease. 
 
1.2 Symptoms and pathology of PD 
Apart from the loss of dopaminergic neurons in SNC, another dominant pathological 
characteristic in PD is the occurrence of cytoplasmic inclusion bodies – LB (Spillantini 
et al., 1997, Holdorff, 2006). Braak used the progressive occurrence of LB to define 
different stages of disease progression. He described how the disease progresses 
most likely in an upward direction starting from the dorsal motor nucleus of the nervus 
vagus in the brainstem and the olfactory bulb (stage I). Hence, PD pathology 
progresses over the pons (stage II) to the midbrain (stage III) and the basal 
prosencephalon and mesocortex (stage IV) and finally to the cortex and neocortex 





1.2.1 Motor symptoms of PD  
Due to the loss of dopaminergic neurons, typical motor symptoms of PD occur. These 
are bradykinesia and akinesia that is slower movements or speed and decreased 
spontaneous movements respectively. A rhythmic involuntary movement of body parts, 
known as tremor, is also observed in PD patients. In addition, PD patients suffer from 
muscle rigidity, which results in an increased resistance to passive movements. All the 
aforementioned motor symptoms of PD are rather an early feature of clinically 
diagnosed PD, whereas postural instability with a flexed posture are dominant in late 
PD stages (Smith et al., 2012).  
Loss of dopaminergic neurons in the SNC results in dysfunctional basal ganglia 
circuitry – the underlying basis of the observed motor symptoms. The basal ganglia 
refers to a group of subcortical nuclei, which are engaged primarily in motor control 
among other functions like motor learning, behaviour and emotion (Lanciego et al., 
2012). In detail, the basal ganglia comprise – among others – the striatum to which the 
caudate nucleus (CN), putamen (Put) and the nucleus accumbens (Acb) refer 
(Lanciego et al., 2012). All these three nuclei are considered as (1) input nuclei, which 
receive information mainly from the cortex, thalamus and substantia nigra. The basal 
ganglia (2) output nuclei consist of the internal segment of the globus pallidus (GPi) 
and the substantia nigra pars reticulate (SNR), which send basal ganglia information 
to the thalamus and mesencephalic motor regions, like the pedunculopontine nucleus 
(PPN). Neurons, located between the input and output neurons of the basal ganglia 
are defined as (3) intrinsic nuclei and comprise the external segment of the globus 
pallidus (GPe), the subthalamic nucleus (STN) and the previously mentioned SNC 
(Lanciego et al., 2012, Poewe et al., 2017). Dopaminergic neurons of the SNC 
innervate striatal neurons, which are subdivided into projection neurons (90%) and 
interneurons (10%). Projection neurons are also named medium-sized spiny neurons 
and express the dopamine receptor subtype 1 (D1R) and subtype 2 (D2R). Under 
healthy conditions, dopaminergic neurons of the SNC and cortical neurons activate 
striatal D1R expressing neurons of the direct pathway. Subsequently, these neurons 
lead to an inhibition of the GPi and SNR, which inhibit the thalamus. Since the inhibition 
of the thalamus is inhibited, thalamic neurons lead to a cortical excitation (Figure 1.1). 
In turn, dopaminergic neurons of the SNC inhibit striatal D2R expressing neurons of 
the indirect pathway, whereas cortical neurons activate striatal D2R expressing 




GPe, which inhibits the activation of GPi and SNR by STN neurons. Hence, thalamic 
input to the cortex is inhibited (Figure 1.1). In summary, the direct pathway leads to an 
enhancement of motor activity whereas the indirect pathway results in an inhibition of 
motor activity. Apart from the mentioned network within the basal ganglia, the basal 
ganglia receive additional inputs by interacting with the (sub)cortical projections in 
order to select and inhibit simultaneously occurring signals (Vogt Weisenhorn et al., 
2016, Lanciego et al., 2012, Poewe et al., 2017).  
This simplified model of the basal ganglia circuitry is part of the explanation for the 
motor deficits described in PD patients. Since dopaminergic neurons in the SNC die, 
there is a reduction of dopaminergic nerve terminals in the striatum, which leads altered 
information processing within the direct and indirect pathway of the basal ganglia. As 
a result, the  γ-Aminobutyric acid(GABA)ergic signalling of the output neurons is 





Figure 1.1: Simplified overview of basal ganglia motor circuit under healthy and PD conditions.  
Under healthy condition for the direct pathway, dopaminergic neurons of the SNC activate striatal D1R 
expressing neurons, which results in an inhibited inhibition of the thalamus and a resulting excitation of 
cortical neurons and an enhancement of motor activities. For the indirect pathway, dopaminergic 
neurons of the SNC inhibit D2R expressing neurons, which results in an inhibited inhibition of the STN 
and an excitation of inhibiting neurons in GPi and SNR. Under PD condition, direct and indirect pathways 






1.2.2 Non-motor symptoms of PD  
Previous studies showed that several non-motor symptoms likely precede the onset of 
motor impairments and characterize the prodromal phase of the disease, which can 
take up to 20 years. As non-motor symptoms are considered slight gait alterations, 
sleep problems, dysfunction in the autonomic system (constipation), sensory 
dysfunction, like olfactory problems, or dysfunction in the mood system, like anxiety 
and depression (Poewe et al., 2017, Chaudhuri and Schapira, 2009, Wolters et al., 
2000, Dijkstra et al., 2014). These “unspecific” non-motor symptoms might be due to 
an ongoing degeneration of the dopaminergic system, that can be, however, 
compensated for largely. Indeed, during the prodromal phase, motor symptoms 
become apparent when more than 50% of the dopaminergic neurons in the SNC are 
lost (Schapira et al., 2017, Schwarz et al., 2000). In addition, the multisystemic nature 
of the non-motor symptoms suggests the involvement of neuronal systems beyond the 
dopaminergic system. For example depression is observed in 35 - 40% of PD patients 
and causes a severe loss of the quality of life (Cummings, 1992). However, one of the 
highest risk factors for depression is a decreased neurotransmission of the 
neurotransmitter serotonin (5-HT) (Tan et al., 2011). Alterations of 5-HT levels were 
also observed in PD patients including a loss of serotonergic neurons in the raphe 
nuclei of post mortem PD patient’s brain (Kish et al., 2008, Paulus and Jellinger, 1991). 
In sum, even though the neurodegeneration of dopaminergic neurons dominates PD 
pathology, the degenerative process affects far more than the dopaminergic system. 
Hence, in further PD research it is important to consider other neurotransmitter 
systems beyond the dopaminergic system. Moreover, there is an urgent need for 
research into the prodromal phase in order to develop disease halting or modifying 
therapies, if not prevention, before the SNC is damaged beyond a point of no return.  
  
 
1.3 Forms of PD 
Research over the last decades revealed that to date PD could be classified into two 
main groups defined by their aetiology. On the one hand, there is the sporadic form of 
PD – mainly occurring in the aged population – on the other hand, PD occurs as a 





1.3.1 Sporadic (idiopathic) PD  
The fact that PD is highly associated with age already points towards the multifactorial 
nature of disease aetiology. Indeed, age is the most important risk factor for developing 
PD (Bennett  et al., 1996). Nevertheless, further environmental factors contribute to 
the aetiology of the disease. For instance, a review about pesticides summarized and 
concluded that any pesticide causes a more than 50% increased chance of developing 
PD (Gunnarsson and Bodin, 2017). Stress as a risk factor for developing PD was 
discussed, since stress can lead to dysregulated levels of dopamine, which in turn may 
be neurotoxic (Hemmerle et al., 2012, Metz, 2007, Smith et al., 2002). In addition, 
stress accelerates PD motor symptoms, which was shown in PD rat models injected 
with 6-hydroxydopamine (6-OHDA) (Smith et al., 2008). In a population-based study, 
an increased risk of PD was associated with diabetes mellitus (Yang et al., 2017). Also 
the use of certain drugs like statins was associated with a higher risk of developing PD 
in a retrospective case-control study (Liu et al., 2017). Furthermore, the composition 
of the gut flora represents a PD risk factor. The microbiome connects to the nervous 
system via the vagus nerve and forming the microbiota-brain axis. Supporting this 
hypothesis, α-synuclein overexpressing mice born in a germ-free environment, 
developed mild PD pathophysiology – a phenotype that was aggravated by providing 
oral bacterial metabolites to the mice (Tremlett et al., 2017, Sampson et al., 2016). In 
addition, vitamin D deficiency was associated with PD by analysing vitamin D levels in 
PD patients (Wang et al., 2015). Conversely, certain factors decrease the risk of PD. 
As an example, in a Danish cohort study, a full truncal vagotomy was associated with 
a decreased risk of PD compared to control subjects followed up over more than 20 
years (Svensson et al., 2015). Analysis of several case-control and cohort studies of 
the consumption of tobacco were analysed with the upshot that an inverse association 
between cigarette smoking or also coffee drinking and the risk of PD was established 
(Li et al., 2015, Hernan et al., 2002).  
 
1.3.2 Familial PD 
Over the last 20 years, it also became evident that mutations in specific genes elicit 
certain forms of PD. About 5 to 10% of all PD patients suffer from a monogenetic form 
of PD, identified by linkage analysis (Klein and Westenberger, 2012). In these 
monogenetic forms of PD, highly penetrant rare mutations cause the disease in 




The mutation in the gene SNCA (PARK1/4; encoding α-synuclein), causing early-onset 
autosomal-dominant PD, was discovered almost 20 years ago by Polymeropoulos and 
colleagues (Polymeropoulos et al., 1996, Polymeropoulos et al., 1997) and thus 
represents the first case of genetic PD. Over the last years, several pathogenic 
sequence variations were identified in SNCA (Polymeropoulos et al., 1997, Kruger et 
al., 1998, Zarranz et al., 2004, Lesage et al., 2013, Kiely et al., 2013, Proukakis et al., 
2013). Mutations in LRRK2 (PARK8; encoding leucine-rich repeat kinase 2, also 
known as dardarin) are the most frequent known cause of late-onset autosomal-
dominant PD. A minimum of six highly penetrant pathogenic mutations in LRRK2 have 
been described so far (Lill, 2016, Healy et al., 2008, Aasly et al., 2010, Nuytemans et 
al., 2008, Mata et al., 2005, Khan et al., 2005, Kachergus et al., 2005, Lu et al., 2005). 
An additional late-onset autosomal-dominant PD-causing mutation was described in 
the gene VPS35 (encoding vacuolar protein sorting 35) (Zimprich et al., 2011, Vilarino-
Guell et al., 2011).  
Mutations in the gene PARK2 (encoding Parkin) were firstly described as causing an 
early-onset autosomal-recessive PD (Kitada et al., 1998). Over 100 mutations were 
identified spanning all exons of PARK2. Mutations in PARK2 are the primary reason 
for autosomal-recessive PD (Abbas et al., 1999, Hedrich et al., 2004). Mutations in DJ-
1 (PARK7), causing an early-onset autosomal-recessive PD, are extremely rare 
(Hernandez et al., 2016) but include about ten different reported mutations (Klein and 
Westenberger, 2012, Bonifati et al., 2003). Another gene causing an early-onset 
autosomal-recessive form of PD is Pink1 (PARK6, encoding phosphatase and tensin 
homolog (PTEN)-induced kinase 1) with a disease outbreak in the fourth decade of life 
exhibiting a slow disease progression (Al-Rumayyan et al., 2017). More than 60 




Pink1 is ubiquitously expressed throughout the human and rodent brain and peripheral 
tissue mostly in skeletal muscle, heart and testis (Taymans et al., 2006, d'Amora et al., 
2011, Gandhi et al., 2006, Oliveras-Salva et al., 2011, Unoki and Nakamura, 2001, 
Blackinton et al., 2007). Pink1 is highly expressed in brain regions containing 
serotonergic and dopaminergic neurons (Taymans et al., 2006). There are two PINK1 




molecular weight of 63 kDa and (2) the cleaved PINK1 with a molecular weight of 52 
kDa (Beilina et al., 2005, Yamano and Youle, 2013). The human gene Pink1 spans 
eight exons. Structurally Pink1 is composed of an N-terminal mitochondrial targeting 
sequence (MTS), followed by a transmembrane domain (TMD) and highly conserved 
serine-threonine kinase domain (Silvestri et al., 2005, Zhou et al., 2008). Indeed, two 
thirds of Pink1 mutations cause a loss-of-function affecting the kinase domain (Valente 
et al., 2004b, Valente et al., 2004a, Klein and Westenberger, 2012). Pink1 exerts 
several cellular functions; the most important is involved in the control of mitochondrial 
biology.  
In short, in healthy mitochondria, fl_Pink1 undergoes a continuous turnover at very low 
levels in cells with physiological polarized mitochondria. For this purpose, the cytosolic 
fl_Pink1 is transported into the mitochondria via the TOM complex (on the outer 
mitochondrial membrane, OMM) and TIM complex (on the inner mitochondrial 
membrane, IMM) (Jin et al., 2010). Here, a mitochondrial processing peptidase (MPP), 
located in the matrix, cleaves off the MTS of the fl_Pink1. Afterwards the TMD is 
cleaved within the hydrophobic site by the inner mitochondrial membrane protease 
presenilin-associated rhomboid like protease (PARL) between the amino acids Ala103 
and Phe104 (Greene et al., 2012, Meissner et al., 2011). The resulting 52 kDa Pink1 
is released into the cytosol and degraded by the proteasome via the N-end-rule 
pathway (Yamano and Youle, 2013). In case of disrupted mitochondrial membrane 
potential, the cytosolic fl_Pink1 is directed to the OMM, where it undergoes 
dimerization and autophosphorylation in order to recruit Parkin to the OMM and to 
regulate mitophagy by interaction with each other (Okatsu et al., 2012, Okatsu et al., 
2015, Yang et al., 2006). Further main functions of Pink1 signalling include regulation 
of complex I activity, phosphorylation of proteins in the apoptotic pathway, regulation 
of mitochondrial trafficking or implication in inflammatory responses (Arena and 
Valente, 2017).  
In sum, the molecular functions of Pink1 are manifold and thus mutations in this gene 
are likely to result in dysfunction of many systems. Indeed PINK1 function has already 
been implicated in liver function, tumorigenesis and diabetes (Arena and Valente, 
2017). The discovery of the PD associated genes and their functional analysis in model 
systems revealed that – amongst others – impaired central cellular processes, such as 
mitochondrial function, autophagy and cytoskeletal integrity are at the centre stage of 




functions in different neuronal populations, leading to distinct phenotypes, a notion that 
can only be addressed by conditional mutagenesis.  
 
1.5 Mouse models of Pink1 
Since loss-of-function mutations in Pink1 genes lead to hereditary autosomal recessive 
PD, studies on Pink1 deficient animal models became of interest (Klein and 
Westenberger, 2012). Several Pink1 loss-of-function mouse models were developed 
in the past in order to recapitulate the pathological features presented in human 
patients and to contribute to the understanding of human PD (Oliveras-Salva et al., 
2011).  
One of the first Pink1 mouse models was described in 2007 by Zhou and colleagues 
(Zhou et al., 2007b). By using RNA interference (RNAi), they silenced Pink1 gene 
expression in more than 95% in mouse brain. They could not observe any 
degeneration of dopaminergic neurons in the SNC nor a decrease of DA, or its 
metabolites 3.4 dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in 
the striatum at an age of 6 months. In addition, Pink1 RNAi mice did not exhibit 
differences in time spent on a rotating rod, a test for motor function, specifically for 
balance. This indicates that Pink1 knockout (KO) in mice does not result in 
neurodegeneration or motor impairments (Zhou et al., 2007a).  
Also in 2007, a Pink1 KO mouse model was analysed by Kitada and colleagues 
exhibiting a deletion within the gene spanning exons 4 - 7 (Kitada et al., 2007). 
Likewise, Kitada and colleagues could not discover an altered number of dopaminergic 
neurons in the Pink1 KO mice at the age of 2 - 3 months and 8 - 9 months. The tissue 
content of  DA was unchanged in the striatum in these  Pink1 KO mice, which correlates 
with the unchanged mRNA and protein levels as well as with the activity of the enzyme 
tyrosine hydroxylase (TH), the rate-limiting enzyme of catecholamine biosynthesis 
(Daubner et al., 2011). However, Pink1 KO revealed a decrease in evoked DA release 
in striatal slices at an age of 2 - 3 months. This indicates an altered dopamine release 
in Pink1 KO mice (Kitada et al., 2007).  
 
In another study, these mice of Kitada and colleagues (Kitada et al., 2007) were further 
analysed with respect to mitochondrial function (Gautier et al., 2008). The aconitase 
activity in striatum decreased in mutant mice. There was no alteration in the 




months old Pink1 KO mice; however, there was a slight increase in the number of large 
mitochondria at both ages. Respiration was impaired in mitochondria isolated from the 
striatum but not from the cerebral cortex of 3 - 4 months old mutant mice. Interestingly, 
there were mitochondrial defects upon exposure to oxidative stress as well as in 
mitochondria isolated from the cerebral cortex of old mutant mice. This indicates that 
aging and cellular stress exacerbates mitochondrial dysfunction in Pink1 KO mice. 
(Gautier et al., 2008). 
In another study these mice were exposed to the neurotoxin 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP). Pink1-deficient mice exhibited a significantly higher 
degeneration of dopaminergic neurons in the SNC and reduction of dopamine 
transporter (DAT) positive fibres in the striatum in comparison to wild type mice. The 
same effect was seen in mice with a shRNA-mediated knockdown (KD) of Pink1, which 
were also challenged with MPTP. Again, the Pink1 KO and the shRNA-mediated KD 
itself did not cause neurodegeneration. Interestingly, viral-mediated expression of DJ-
1 and Parkin in the Pink1 KO mice protected them from the loss of dopaminergic 
neurons in the SNC upon MPTP treatment. This indicates an induction of a possible 
compensatory mechanism upon murine Pink1 deficiency elicited by Parkin and DJ1 
and/or that Pink1 acts upstream of Parkin and DJ-1 function (Haque et al., 2012).  
Similar results were obtained in another Pink1 KO mouse line with a deletion of exons 
2 - 5 (Wood-Kaczmar et al., 2008). In this line mitochondrial stress was induced in 
dopaminergic neurons via overexpressing unfolded mitochondrial ornithine 
transcarbamylase under the TH promotor. This mitochondrial stress caused in wild 
types a significant reduction of dopaminergic neurons and of DA content in SNC. This 
pathology was accompanied by a significant reduction of rearing frequency. 
Interestingly, Pink1 KO mice under mitochondrial stress exhibited a significantly higher 
neurodegeneration and reduced rearing frequency compared to single mitochondrial 
stressed transgenic mice. Thus, loss of Pink1 intensifies the mitochondrial and 
behavioural phenotype (Moisoi et al., 2014).  
 
In contrast to the effects of MPTP and mitochondrial stress, chronic exposure to low 
dose rotenone in Pink1 KO mice from Kitada and colleagues (Kitada et al., 2007) did 
not lead to a degeneration in SNC. Furthermore, mitochondrial integrity and ATP 
production were unaltered (Martella et al., 2016). This indicates that low dose rotenone 




strong challenges are needed to reveal a synergistic effect between environmental and 
genetic PD-causing factors.  
Another study showed a higher loss of dopaminergic neurons in SNC upon α-synuclein 
overexpression in Pink1 KO mice (deletion of exon 1) compared to Pink1 KD mice 
overexpressing α-synuclein (Oliveras-Salva et al., 2014). This indicates that a Pink1 
KD is less vulnerable than a Pink1 KO in mice.   
In another Pink1 mouse line the pathogenic G309D mutation, identified in human 
linkage studies, was inserted into the mouse gene resulting in loss of Pink1 protein 
(Gispert et al., 2009). Thus, this mutation induced a loss-of-function, resulting in a 
Pink1 KO. Mutant mice showed a significant reduction of body weight at an age of 12 
and 16 months but not at an age of 4 months. Furthermore, mutant mice at 16 months 
showed significantly decreased locomotor activity in open field but no impairments in 
acoustic startle reflex. Even though dopaminergic neurons in SNC and nerve fibres in 
striatum were not degenerated in 18-month-old mutant mice, there was a significant 
reduction of striatal DA content at an age of 9 and 22 - 24 months. In addition, no LB 
in brainstem and SNC could be detected in aged mutant Pink1 KO mice. With respect 
to mitochondrial function, mutant Pink1 KO mice exhibited a significant progressive 
deficit of mitochondrial pre-protein import with age (3, 8 - 9 and 18 months) that 
correlated with deficits in mitochondrial respiration and thus ATP production. An 
increased mitochondrial fission and increased aggregation could, however, again only 
be observed under challenging conditions. (Gispert et al., 2009).  In sum, Gispert and 
collegues could uncover PD-related phenotypes due to a murine Pink1 deficiency.  
In a study of Akundi and colleagues, they targeted exons 4 - 5 in order to generate a 
Pink1 KO mouse line (Akundi et al., 2011). As in the study of Gispert et al., mutant 
mice of this mouse line also displayed a significant reduction of DA content in striatum 
at an age of 6, 8.5 and 12 months. There was also increased turnover 
(DOPAC+HVA/DA) of striatal DA while the number of dopaminergic neurons did not 
differ in 12-month-old mice. In addition, Pink1 deficiency caused an aberrant 
expression of genes that regulate the innate immune response. Likewise, mitochondria 
from 2-month-old mutant mice showed a decreased calcium loading capacity.  
Glasl et al. analysed Pink1 KO mice (Pink1_del2/3) generated from a conditional 
mouse line in which exons 2 - 3 were floxed. In order to obtain a ubiquitous KO of Pink1 
these conditional mice were bred with the ROSA26 Cre deleter line (Glasl et al., 2012). 




did not exhibit differences in open field and rotarod testing compared to wild type mice. 
However, for the first time a more sophisticated gait analysis was performed. Using the 
CatWalk system this analysis revealed gait parameters of the hind paws in 24 - 27 
months old male Pink1_del2/3 mice. Specifically, the base of support, print length and 
phase dispersion were altered, which is indicative of PD-related gait impairments. In 
addition, for the first time mutant male mice were also examined for a further non-motor 
symptom of PD: olfactory impairment. This analysis revealed an impairment in 
discrimination of binary mixtures and olfactory sensitivity. Concerning cognitive ability, 
as revealed by the object recognition test, Pink1-deficient animals did not exhibit 
impairments. Again – like in the other models – there was no dopaminergic 
neurodegeneration even at old ages, supported by the fact that striatal DA tissue 
content was not altered in 6-month-old mutant mice, like the number of neurons in the 
SNC and locus coeruleus in 6 and 19 months old mice. However, these mice showed 
a specific decreased innervation of serotonergic neurons in the glomerular layer of the 
olfactory bulb (OB). Interestingly, the number of serotonergic neurons in the raphe 
nuclei were not altered. Concerning mitochondrial parameters, the mitochondria of 
these mice did not exhibit morphological changes. Nevertheless, and most 
interestingly, after an acute viral Pink1 KD in primary cortical neurons of C57BL/6 wild 
type mice, a mitochondrial fragmentation was present three days after transduction. 
Interestingly, this effect was not observed five days after transduction. This specific 
experiment strongly hints towards compensatory mechanisms activated upon Pink1 
deficiency, thus counteracting detrimental effects elicited by the loss of Pink1 function. 
In sum, the analysis of these mice revealed that Pink1 deficiency leads to non-motor 
and slight motor symptoms of PD, indicative of the pre-symptomatic (prodromal) phase 
of the disease. There is also evidence of compensatory mechanisms at play. 
 
In summary, there are several different Pink1 KD/KO mouse models. Yet, in the 
unchallenged state, no line exhibits degeneration of dopaminergic neurons in the SNC. 
Determination of striatal DA tissue content resulted in conflicting data. The observed 
changes were small so that the detection of these small changes depends on sample 
size, model used and possibly also on different genetic backgrounds. Furthermore, 
these slight changes indicate that even though these models do not show the 
pathological hallmark(s) of late PD they might increase sensitivity to additional 




mitochondrial stress or toxins, neuronal degeneration in SNC, including less striatal 
fibres, could be observed. Thus, these models support the multiple hit theory of the 
aetiology of PD (Sulzer, 2007). It indicates that PD is indeed a multifactorial disease 
not elicited by one single factor, such as a dysfunction of a PD associated gene. This 
single dysfunction in the animal model may lead to features akin to the prodromal 
phase of PD. This is supported by the observation that at least in one model it was 
shown that Pink1 deficiency induces behaviour resembling non-motor symptoms of the 
disease (Glasl et al., 2012). Therefore, these animals are ideally suited to study this 
therapeutically important prodromal phase of the disease. They will be instrumental in 
identifying the neuronal systems implicated in disease aetiology, since, during the 
prodromal phase, the dysfunction of the dopaminergic system might not yet override 






Figure 1.2: Summary of published mouse lines implying a Pink1 deficiency. → not changed, ↑ up, ↓ down, TH = tyrosine hydroxylase, DA = dopamine, 









no of TH innervation of striatum HPLC** nr. of neurons innervation
Zhou et al., 2007 RNAi FVB 6 monhts → →   DA, DOPAC, HVA → rotating rod
2 -3 months → ↓ ↓ DA
8 - 9 months → ↓ DA
→ nr & ultrasturcture → cortex
↑  larger mito ↓ striatum
3 -4 months H2O2/heat shock ↓ cortex
→ nr & ultrasturcture ↓ cortex
↑  larger mito
→ → 
MPTP ↓ ↓
MPTP + ↑Parkin → 
MPTP + ↑DJ1 → 
MPTP ↓ ↓
→ → 
del exon 2 - 5 4,6,8,12 months ↑dOTC ↓ ↓ rearing
wildtype 4,6,8,12 months ↑dOTC ↓ ↓ DA ↓ rearing
Martella et al., 2016 del exon 4 -7 n.a. n.a. low dose rotenone → → → ePhys SNC and striatum
shRNA kd → → 
shRNA kd ↑ α-synuclein → 
del exon 1 ↑ α-synuclein ↓  ↑α-synuclein phospho.
4 months ↓ → body weight
9-10 months ↓ DA ↓ ↓ body weight
16 months ↓ spontan. Behaviour ↓ body weight, 
18 months → ↓
22 months ↓ DA
2 months ↓
6 months ↓ DA
8.5 months ↓ DA
12 months → ↓ DA
n.a. LPS ↑ cytokines, ↑ expression immuno
n.a. → → 
3-6 months → → DA →  5-HT ↓ 5-HT in OB →  open field, rotarod
↓ olfaction
↓ gait
n.a. acute Pink1 kd ↓ (compensated)
Others
→  open field, rotarod19-26 months → 
129/SvEvG309DGispert et al., 2009
Akundi et al., 2011 del exon 4-5 129/Sv;C57BL/6
C57BL/6del exon 2-3Glasl et al., 2012
C57BL/6 n.a.
Moisoi et al., 2014 n.a.
Oliveras-Salva et al., 2014 C57BL/6 n.a.
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Since PD is acknowledged as a multi-systemic disease, neurotransmitter systems 
beyond the dopaminergic system, such as the serotonergic or noradrenergic system 
are affected (Ohno et al., 2015, Thobois et al., 2017, Farrand et al., 2017, Gong et al., 
2017). Indeed, serotonergic neurons of the raphe nuclei innervate the basal ganglia 
with the densest innervation in the substantia nigra (Parent et al., 2011). Hence, a 
dysfunctional serotonergic system might play a role in the modulation of the 
dopaminergic output. However, the precise contribution of the serotonergic system to 
the development of PD-related symptoms is not known yet. To dissect and understand 
the role of different neuronal systems in PD symptoms, new approaches are needed. 
In the end, this would be useful knowledge in order to develop new therapies for PD. 
One such approach is the use of conditional mutagenesis in animal models of PD, 
which are concomitant to the full KO of the respective PD-related gene. Therefore, the 
focus of this project lies on the systemic analysis of conditional Pink1 KO, either in the 
dopaminergic or in the serotonergic system.  
In addition, PD is characterised by a disease outbreak at relatively late onset although 
PD-related genes are known to be expressed also during development (d'Amora et al., 
2011, Zechel et al., 2010, Kuhn et al., 2004). Thus, during development and in early 
adulthood compensatory mechanisms might be in place in order to deal with the effects 
of altered gene function. These still unidentified compensatory mechanisms might also 
be the underlying reason why most genetic mouse models do not exhibit overt PD 
pathology and PD symptoms (Antony et al., 2011). However, additional stressors like 
MPTP, Manganese or 6-OHDA induce PD pathology and PD symptoms in PD animal 
models (Haque et al., 2012, Langley et al., 2017, Rial et al., 2014). Indeed also 
challenged Pink1 KO mouse models exhibited PD symptoms (Haque et al., 2012, 
Moisoi et al., 2014, Oliveras-Salva et al., 2014). In addition, mitochondrial 
fragmentation – a PD-related phenotype – was shown with in vitro acute knockdown 
of Pink1. Interestingly, this phenotype was no longer present after several days, 
although the Pink 1 deficiency persisted (Glasl et al., 2012). In sum, there are hints for 
compensatory mechanisms that counteract the gene deficiency possibly already 
during development and/or young adulthood. However, these mechanisms might 
decline with increasing age – possibly due to the decrease in adult neurogenesis, the 
decline of Wnt-signalling and neurotrophic signalling – whereat PD-related phenotypes 




as stated above, the disease outbreak of PD only occurs when already more than 50% 
of dopaminergic neurons are gone, proceeded by the neuronal degeneration in other 
brain regions (Schapira et al., 2017, Chan-Palay, 1991, Schwarz et al., 2000). Thus, 
there might not only be compensatory mechanisms at the molecular level as described 
above but it is highly likely that compensatory mechanisms also at the neuronal circuit 







Aim of the study 
 
 
In the last few years, several studies of Pink1-deficient mice have shown that Pink1 
deficiency does not induce the full-blown neurodegenerative phenotype observed in 
Parkinson (PD) patients. However, slight alterations in the dopaminergic system have 
been associated with non-motor symptoms. Thus, these animals are veritable models 
of the prodromal phase of the disease and ideally suited to study this therapeutically 
important phase. In addition, the now available conditional mutagenesis has the 
potential to address two pressing questions in PD research:  
1. What is the contribution of further neuronal systems to the observed PD-related 
phenotypes in the full knockout (KO) mice?  
2. Are there compensatory mechanisms in place, hindering the outbreak of the 
disease until more than 50% of the dopaminergic neurons are lost? 
 
The first question can be addressed by specifically inducing Pink1 deficiency in other 
neuronal systems. The second question can be addressed by inducing a Pink1 
deficiency during adulthood so that compensatory mechanisms, possibly established 
during development, cannot prevent the occurrence of PD-related symptoms.  
 
Thus, the aims of this thesis were the:  
1. Analysis of mouse mutants in which Pink1 deficiency was specifically induced 
in the serotonergic system. This system was chosen because the KO of Pink1 
had an impact on the serotonergic innervation of the olfactory bulb and it is 
known that PD patients also exhibit a loss of serotonergic neurons.  
2. Analysis of inducible mouse mutants in which Pink1 deficiency was elicited in 
the dopaminergic system. By using this model, it will be possible to determine 
(i) whether compensatory mechanisms impede the occurrence of strong PD-
related phenotypes and (ii) to determine to which PD-related phenotypes the 




important, since some of the PD symptoms are refractory to dopamine 
replacement therapy. 
3. Performance of a longitudinal analysis of these mouse models in order to 
assess the impact of age on the phenotypes, since age represents the most 
important risk factor in the aetiology of PD.  
 
The analyses were performed in a comprehensive manner, that is, at two time points 
after a standardized battery of behavioural tests proven to detect PD-related 
phenotypes. Mice were sacrificed and analysed for neurotransmitter content in the 
striatum, ventral midbrain and olfactory bulb. Additionally, morphological analyses 
were performed on the number of dopaminergic neurons in the substantia nigra pars 
























3.1 Chemicals and working reagents 
Table 3.1: Overview of the used chemicals and working reagents 
Chemical Company Article 
3.4 Dihydroxyphenylacetic 
acid (DOPAC) 




Sigma Aldrich 1477-68-5 
5-Hydroxyindole-3-acetic 
acid (5-HIAA) 
Sigma Aldrich 54-16-0 
Acetonitrile Sigma Aldrich 57-05-8 
Agarose Biozym 870055 
Aqua-Poly/Mount Polysciences, Inc. 18606-20 














Thermo Scientific 45-0206 
Ethanol Sigma 1.00014.2500 






Sigma Aldrich E5134-1kg 
 
Fetal calf serum (FCS) Thermo Scientific 26140079  
GeneRulerTM 1 kb DNA 
Ladder + 6 x loading dye 
Thermo Fisher SM1333 
GeneRulerTM 100 bp DNA 
Ladder + 6 x loading dye 
Thermo Fisher SM0323 
 
Homovanillic acid (HVA) Sigma Aldrich 306-08-1 
Hydrogen chloride (HCl) 
32%  
Merck KGaA Z0317213408 
Hydrogen peroxide (H2O2) 
30% 
Sigma H1009-100mL 
Immersöl 518 F Zeiss 444960 
Internal standard (IS), 3.4-
Dihydroxybenzylamine 
(DHBA) 
Thermo Fisher 59-92-7 
Isopropanol Merck 113350 
Miglyol Caelo 3274 
Mobile phase Recipe 1210 
Neg-50 frozen section 
medium, 
colorless 
Thermo Scientific 6502 
odorant [S-], 
Methyl trans-cinnamate 
Sigma Aldrich 173282 
odorant [S+], 
2-Phenethyl acetate 
Sigma Aldrich 290580 




Perchloric acid solution  
(70%) 
Sigma Aldrich 7601-90-3 
Pertex Medite GmbH 41-4012-00 






AppliChem GmbH A1043,1000 
Proteinase K AppliChem, A3830,0500 





Sigma Aldrich 153-98-0 
 
sodium acetat trihydrate Sigma Aldrich 71188-5kg 
Sodium azide (NaN3) Sigma S2002 
Sodium chloride (NaCl) Merck Millipore 106404 
Sodium hydroxide (NaOH)  VWR  PROLABO 31624.290 
Sodium hydroxide (NaOH) 
– pellets used for pH 
titration of PFA solution 
Roth 9356.1 
solvent, Diethylphthalat Sigma Aldrich W512206 
Sterile Water Biorad 1632091EDU 
Sucrose Sigma S0389-5KG 
Tamoxifen Sigma Aldrich T5648 
Triton X-100 Bio-Rad, Cat.  161-0407 
Trizma® base Sigma T1503-5KG,  
Trizma® base Sigma Aldrich T1503-5kg 
Xylol Roth® 9713.3 
 
3.2 Complete packages (“Kits”) 
Table 3.2: Overview of the used complete packages (“Kits”) 
Complete package Company Article 
ABC Kit VECTASTAIN® 
Elite ABC KIT 
Biozol PK-6100 











Table 3.3: Overview of the used primary antibodies 
Antibody Company Article 
rabbit-anti-5-HT Immunostar 20080 
rabbit-anti-TH Pel Freez® P40101-0 
 
Table 3.4: Overview of the used secondary antibodies 
Antibody Company Article 
Alexa Fluor® 594 donkey 
anti-rabbit  
Mo Bi Tec A21207 
biotin-SP-conjugated 




Table 3.5: Overview of the used primer 
primer binding 
site 
sequence (5´-3´) Tm [°C] 
neocass_for_AH intron 1 GACAGTACTTGCCTAGCGTAG 61 
ex2_rev_AH Exon 2 CAGACACGCGCTTGGTTTTC 60 
ko_rev_AH intron 3 GAGCAATGCAGAAAGTCAGAGC 62 
 
neocass_for intron 1 GACAGTACTTGCCTAGCGTAGGTAG 67 
neocass_rev neo TTGCTCAGCGGTGCTGTCCATCT 66 
 
CRE-F unknown GATCGCTGCCAGGATATACG 60 
CRE-R unknown AATCGCCATCTTCCAGCAG 57 
 
Cre1_iDatcre unknown CTGCCAGGGACATGGCCAGG 67 
Cre2_iDatcre unknown GGTCAAATCCACAAAGCCTGGCA 65 
 









Table 3.6 Overview of the prepared solutions 
0.1 % PBS - T 0.1% Triton X-100 (v/v)  
add PBS  
0.2 % PBS - T 0.2% Triton X-100 (v/v)  
add PBS  
ABC solution 0.003% Avidin (v/v) 
0.003% biotinylated peroxidase (v/v) 
add 0.1% PBS-T 
DAB solution 1% DAB (w/v) 
add dest. H2O 
DAB working solution 5% DAB solution (v/v) 
0.075 % H2O2 (v/v) 
add Tris-HCL  
PBS  0.8% NaCl (w/v) 
0.02% KCl (w/v) 
0.18% Na2PO4.2H2O (w/v) 
0.03% KH2PO4 (w/v) 
add dest. H2O 
PFA (4%), pH 7.4  4% PFA (w/v) 
add pre-warmed PBS 
pH adjusted with NaOH pellets & HCl 
TAE buffer, pH 7.5 4.844% Trizma® base (w/v) 
2.722% Na-acetat Trihydrat (w/v) 
0.373% EDTA (w/v) 
add dest. H2O 
Tris-HCl, pH 7.5 12.11% Trizma® base (w/v) 
add dest. H2O 










Table 3.7 Overview of the used consumables 
Consumables Company Article 
96 well PCR plates Kisker G060/H/1E/OA-SS 
Cannula Sterican 20 G, 0.9 x 40 mm 
caps of 50 ml falcon tube   
Ø = 3 cm, h = 1 cm 
Falcon® 734-0453 
Cell strainer, 100 µm Falcon® 352360 
Clear snap cap Supelco 50970 
Coverslip Roth® H878 
Cryotubes, 2ml Greiner bio-one 122263 
Falcons tubes, 50 ml Sarstedt 62.547.254 
Microscope slides Thermo Fisher Scientific J1800AMNZ 
Nunclon ∆ Surface (24-
well) 
Thermo Fisher Scientific 142475 
Nunclon ∆ Surface (6-well) Thermo Fisher Scientific 140685 
Pasteur pipette, PE-LD, 
3.0 ml 
Brand 747750 
Pipette tips, TipOne®, 
10/20 µl 
Starlab S1120-3810 
Pipette tips, TipOne®, 
1000 µl 
Starlab S1126-7810 
Pipette tips, TipOne®, 20 
µl 
Starlab S1120-1810 
Pipette tips, TipOne®, 200 
µl 
Starlab S1120-8810 
safe-lock tubes 1.5 ml Eppendorf 0030120086 
safe-lock tubes 2.0 ml Eppendorf 0030120094 
shavings, Lignocel® J. Rettenmaier & Söhne S8-15 
Snap ring vial Supelco 29409-U 







Table 3.8 Overview of the used instruments 
Instruments Company Article 
10x Plan-Neofluar, NA 
0.30 
Zeiss 440331 
20x Plan-Neofluar, NA 
0.50 
Zeiss 1004 - 989 
40x EC Plan-Neofluar, NA 
0.75 
Zeiss 440350 
5x Plan-Neofluar, NA 0.15 Zeiss 440320 
Acoustic Startle Reflex 
Starter Package for Rat or 
Mouse 
Medium grid rod animal 
holder  
Sound attenuating cubicle 
Startle platform with load 
cell 
Startle platform attenuator 









ActiMot System TSE  
Ag/AgCl reference elec-
trode 
Thermo Fisher 044198 
 
Axio Cam MRc Zeiss 48-0026 
Axioplan 2 imaging Zeiss 201-0866 





20 - 200 µl, 12 channel 
Labnet international LN P4812-300 
cage barrier own construction 19 cm x 15 cm 15.5 cm  
(l x w x l) 




252 mm x 167 mm x 140 
mm  (l x w x h) poly-
carbonate, transparent 
CatWalk XT Noldus ZCWP-8001 
Centrifuge Thermo Fisher Heraeus Multifuge 3SR+ 
centrifuge 5425 Eppendorf 5424000410 
Comb for Gelsystem, 1.5 
mm 
 






50 inversions, 16 µl, 
Peqlab, 700-0528 
 
25 inversions, 40 µl, 
Peqlab, 700-0530 
 
20 inversions, 20 µl, 
Peqlab, 700-0512 
 
10 inversions, 46 µl, 
Peqlab, 700-0510 
Cryostat Thermo Fisher Scientific HM560 





Herolab E.A:S:Y Doc plus 440K 
Glassy Carbon Electrode Dionex 044113 
Heating plate IKA® Werke RCT basic 
Homogenizer Bandelin Electronics UW70, ultrasonic homo-
genizer 
ice machine Scotman AF 30 
incubator innova 4230 New Brunswick Scientific 8261-30-1008 
Laborwaage 2 kg / 0.1 g KERN 440-47N 
Liquid nitrogen Messer Cryosystems Chromas 600KU 
luxmeter, Mavolux Gossen 5032C BASE 




New: Column (C18, 
particle size: 4 µm, length: 
150 mm, diameter: 4.6 
mm) 
Thermo Fisher Accucore XL, 74104-
253030 
New: HPLC system 




Old: Column (C18, particle 
size: 3 µm, length: 150 
mm, diameter: 4.6 mm) 
Atlantis Columns Atlantis T3, 0127321741 
Old: HPLC system 




Orbital shaker Star Lab SC3D001201 







pH Level 1 inoLab 03280015 
Pipetboy Easypet  Eppendorf 4430000018   
Pipetman, 1 - 10 µl Gilson P10 
Pipetman, 2 - 20 µl Gilson P20 
Pipetman, 20 - 100 µl Gilson P100 
Pipetman, 50 - 200 µl Gilson P200 
Polymax 1040 Heidolph 543-42205-00-3  
power supplies for 
electrophoresis 
Pharmacia Biotech EPS 200 
precision scale Sartorius MC1 Laboratory LC 220 S 
Security Guard Cartridges Phenomenex LB71270310 




(l x w x h)   
thermomixer comfort Eppendorf 5355 000.011 
Ultrasonic bath Bandelin Sonorex RK 510S 
vortex-genie 2 Scientific Industries SI-0236 
water conditioning system Millipore Milli-Q biocel 
 
3.8 Software 
Table 3.9 Overview of the used software 
Software Company Article 
Stereo Investigator 11 mbf Bioscience  
Neurolucida mbf Bioscience  
(old) HPLC, PeakNet 5.2 Thermo Fisher  
(new) HPLC, Chromeleon 
6.5 
Thermo Fisher  
ActiMot Software TSE  
Advanced startle, SOF-
828 
Med associates  
CatWalk XT,10.5 Noldus  
EasyWin32 Herolab  
SPSS Statistics  IBM  
Graph Pad Prism Graphpad Software, Inc  
Microsoft Excel Microsoft Coorperation  
Microsoft Word Microsoft Coorperation  
Adobe Illustrator Adobe Systems  
 
3.9 Mouse lines 
3.9.1 Ethic statement 
All animals were handled and housed according to the approved federal guidelines for 
the use and care of laboratory animals (AZ 55.2-1-54-2532-144-10). 
 
3.9.2 Pink1_CKO  
The previous published paper (Glasl et al., 2012) explains the generation of the 




flanked by two loxP sites (floxed). In addition, a neomycin cassette was set upstream 
of the exon 2 and flanked by two FRT sites. The genotype of mice with a floxed exon 
2 and exon 3 of the Pink1 gene were defined as: Pink1:flox/flox when homozygous and 
Pink1:wt/flox when heterozygous. Mice obtaining the genotype Pink1:wt/wt did not 
exhibit any changes in the Pink1 gene (Figure 3.1). Mice were bred with the wild type 




Figure 3.1: Schematic overview of Pink1 in wild type, floxed and exon 2/3 deletion condition. 
Pink1: wt, wild type Pink1 is composed of 8 exons (purple). Pink1: flox, conditional knockout (CKO) of 
Pink1 with flanked exons 2 and 3 by loxP sited. A neomycin cassette (neo, grey) is positioned upstream 
of the exon 2, flanked by FRT (blue) sites. Pink1: del2/3, after cutting of the active Cre recombinase on 
the loxP sites, the exons 2 and 3 and neomycin cassette are cut out, resulting in a Pink1 knockout (KO). 
Primers used for genotyping were labelled (table 3.5 and table 4.1). 
 
3.9.3 Pet1_Cre_TG  
The previous published paper (Scott et al., 2005) describes the generation of the 
mouse line Pet1_Cre_TG. In summary, the Cre recombinase was set under the control 
of the Pet1 promotor in order to be expressed in serotonergic neurons in the brain 
(Hendricks et al., 2003). The genotype of mice expressing the Cre recombinase was 
defined as Cre:Cre+ in return the genotype of mice not expressing the Cre 
recombinase was defined as Cre:Cre-. Mice were obtained from Dr. Jan Deussing, 




mice from Prof.  Evan Deneris, Cave Western Reserve University, Cleveland, USA. 
The imported Pet1_Cre_TG mice were previously bred with inbred mice C57BL/6N of 
the MPI. Pet1_Cre_TG mice were transferred via in vitro fertilization (IVF) into the 
mouse facilities of the HMGU and bred with the wild type inbred mice C57BL/6J of the 
HMGU.  
 
3.9.4 Slc6a3_CreERT2_TG  
The previous published paper (Rieker et al., 2011) describes the generation of the 
mouse line Slc6a3_CreERT2_TG (DATCreERT2). In summary, a cassette encoding 
for a tamoxifen induced form of the Cre recombinase (CreERT2, (Feil et al., 2009)) 
was cloned in the ATG site of the murine Slc6a3 gene, encoding for the dopamine 
transporter (DAT), which is expressed in dopaminergic neurons of the central and 
peripheral nervous system (Cerruti et al., 1993, Ciliax et al., 1999, Miller et al., 1997). 
The genotype of mice expressing the Cre recombinase was defined as Cre:Cre+ in 
return the genotype of mice not expressing the Cre recombinase was defined as 
Cre:Cre-.  Mice were obtained from Dr. Jan Deussing, MPI, who in turn received the 
mice from Prof. Günther Schütz, University of Heidelberg, Heidelberg, Germany. The 
imported Slc6a3_CreERT2_TG mice were previously bred with inbred mice C57BL/6N 
of the MPI. Slc6a3_CreERT2_TG mice were transferred via IVF into the mouse 
facilities of the HMGU and bred with the wild type inbred mice C57BL/6J of the HMGU. 
 
3.9.5 Pink1_CKO x Pet1_Cre_TG (Pink1 x Pet) 
The Pink1_CKO mice were bred with Pet1_Cre_TG mice (Figure 3.2). The 
recombinase-mediated recombination removed the exons 2 and 3 with the neo 
cassette, resulting in a knockout (KO) of Pink1 in serotonergic neurons in the central 
nervous system, defined as mutant mice. The genotype of the mutant mice was defined 
as Cre:Cre+; Pink1:flox/flox. In comparison, mice expressing the Cre recombinase but 
possessing a wild type Pink1 gene, were specified as control group 1 with the genotype 
Cre:Cre+; Pink1:wt/wt. Mice, expressing no Cre recombinase but owning the floxed 
exons 2 and 3 were called control group 2 with the genotype Cre:Cre-; Pink1:flox/flox. 
Both control groups were littermates of the mutant mice. Only mice with homozygous 
floxed or wild type Pink1 gene were considered for the analysis. In contrast, Cre 
expressing mice (mutant and control 1) were always heterozygous for the Cre 




crossing with the Pink1_CKO mice (Figure 3.2). Since both mouse lines were bred on 
the different strains C57BL/6N (Pet1_Cre_TG) and C57BL/6J (Pink1_CKO), the 
resulting pups of the mouse line Pink1_CKO x Pet1_Cre_TG obtained a mixed genetic 
background of C57BL/6JN. 
 
3.9.6 Pink1_CKO x Slc6a3_CreERT2_TG (Pink1 x DAT) 
The Pink1_CKO mice were bred with Slc6a3_CreERT2_TG mice (Figure 3.2). The Cre 
recombinase CreERT2 was activated by injection of tamoxifen with an age of 10 weeks 
(Feil et al., 2009). At five consecutive days, a daily volume of 100 µl of sterile filtered 
tamoxifen solution in miglyol with a concentration of 20 mg/ml were injected 
intraperitoneal into the mice with a 20 G cannula. All tested mice were injected with 
tamoxifen independent of the genotype.  
 
After tamoxifen injection, the recombinase-mediated recombination removed the 
exons 2 and 3 with the neo cassette, resulting in a KO of Pink1 in dopaminergic 
neurons in the central and peripheral nervous system, defined as mutant mice. The 
genotype of the mutant mice was defined as Cre:Cre+; Pink1:flox/flox. In comparison, 
mice expressing the Cre recombinase but possessing a wild type Pink1 gene, were 
specified as control group 1 with the genotype Cre:Cre+; Pink1:wt/wt. Mice, expressing 
no Cre recombinase but owning floxed exons 2 and 3 were defined as control group 2 
with the genotype Cre:Cre-; Pink1:flox/flox. Both control groups were littermates of the 
mutant mice. Only mice with homozygous floxed or wild type Pink1 gene were 
considered for analysis. In contrast, Cre expressing mice (mutant and control 1) were 
always heterozygous for the Cre recombinase.  After the IVF of the 
Slc6a3_CreERT2_TG mice, pups were bred on several generation with the wild type 
inbred mice of the mouse strain C57BL/6J of the HMGU, which led to a mixed genetic 
background C57NL/6JN. Since the Pink1_CKO mice obtained the genetic background 
of C57BL/6J, the following pups of the crossing Pink1_CKO x Slc6a3_CreERT2 










Figure 3.2: Breeding scheme of Pink1 x Pet and Pink1 x DAT mice. The homozygous floxed 
Pink1_CKO mice were bred with the heterozygous Cre positive Pet1_Cre_TG, respectively 
Slc6a3_CreERT2_TG mice. The pups, heterozygous for Pink1: wt/flox and for Cre: Cre+ respectively 






















4.1 Mouse housing 
All mice were born and housed in the mouse facility C-Streifen. For behavioural 
analysis, mice at an age of about 3.5 months were exported into the German Mouse 
Clinic (GMC) where all behavioural testing took place. Afterwards mice were housed 
for about 8 months until they were re-tested in the GMC. The hygiene status of the C-
Streifen and GMC were kept constant via a specific pathogen free (SPF) barrier. The 
health monitoring was performed by following the Federation for Laboratory Animal 
Science Associations (FELASA) recommendations for the health monitoring of rodent 
and rabbit colonies in breeding and experimental units (Nicklas et al., 2002).  
 
Males and females were housed separately. In order to avoid social stress, the 
arrangement of animals in cages did not change over the time. In the mouse facilities 
C-Streifen and GMC, animals were group housed with a maximum of five animals in 
type II long (Tecniplast Greenline, Sealsafe plus TM GM500) cages in individually 
ventilated caging (IVC) systems. The IVC cages operated at positive pressure where 
exhausts were removed via the connected ventilation system. The cages were 
changed by the animal caretakers on a weekly or fortnightly basis to fresh new IVC 
cages, depending on the amount of animals per cage and breeding. Hereby mice were 
transferred using forceps in a Class II AllerGard changing station (nuaire, NU-617-
500E). All mice were served with fresh filtered water weekly. The temperature was kept 
between at 20 °C to 24 °C including a controlled humidity of 45 % to 65%. Mice were 
housed on a fixed 12 h light/dark cycle. Water (0.2 µm filtered) and food pellets 
(Altromin, 1314) were given ad libitum apart from the period of olfaction testing where 
a selected number of male mice were food restricted. The IVC cages were equipped 







4.2.1 DNA purification 
In order to purify the genomic DNA from the tail clips, the Wizard® Genomic DNA 
Purification Kit was used. Per tail clip, a mixture of 120 µl EDTA solutions and 500 µl 
Nuclei Lysis solution was prepared and samples were chilled on ice.  Tail clips with an 
optimal minimum length of 0.1 cm and 17.5 µl of Protinase K (20 mg/ml) were added 
to the EDTA/Nuclei Lysis solution and incubated over night at 55 °C. Afterwards, each 
sample was incubated for about 30 min at 37 °C with RNase solution and cooled down 
at room temperature for 5 min. Subsequent, 200 µl of protein precipitation solution 
were added followed by vortexing at high speed for 20 s and chilling on ice for 5 min. 
Thereafter, samples were centrifuged at 15000 x g at 4 °C and the supernatant was 
transferred into 600 µl isopropanol, gently mixed and centrifuged at 15000 x g. The 
supernatant was decanted and the DNA pellet was washed for two times with 70 % 
ethanol for 1 min at 15000 x g. The DNA pellet was air-dried, dissolved with 50 µl of 
H2O and stored at 4 °C.  
 
4.2.2 Polymerase chain reaction  
In order to identify the genotypes of the mice regarding the Pink1 gene and the 
presence of a construct expressing Cre recombinase, a combination of different 
primers (Table 3.4) were used for the polymerase chain reaction (PCR) (Figure 3.1).  
To detect the wild type Pink1 gene (Pink1 wt PCR), the primer neocass_for_AH, 
binding in the intron 1 and ex2_rev_AH, binding in the exon 2, were used, resulting in 
an amplified fragment of 781 bp. To detect the knockout of the exon 2 and exon 3 in 
the Pink1 gene (Pink1 del2/3 PCR), the primer neocass_for_AH and ko_rev_AH, 
binding in the intron 3, were used, resulting in an amplified fragment of 583 bp. To 
detect the conditional status of the Pink1 gene (Pink1 flox PCR) with loxP sites flanked 
exon 2 and exon 3 (floxed) and an upstream neo cassette, the primer neocass_for and 
neocass_rev, binding in the neo cassette, were used, resulting in an amplified fragment 
of 688 bp. To detect the construct, expressing for the Pet1_Cre recombinase, the 
primer CRE-F and CRE-R were used, resulting in an estimated amplified fragment of 
600 bp since the binding side of the primer is unknown. To detect the construct, which 
encodes the Dat_Cre recombinase, the primer Cre1_iDatcre and Cre2_iDatcre were 
used, resulting in an estimated amplified fragment of 500 bp since the binding side of 




The PCR mix (1x) was composed of 1.25 µl of the for_primer, 1.25 µl of the rev_primer, 
10 µl of the master mix, 11.5 µl of H2O with 1 µl DNA. The PCR programme is shown 
in table 4.1. The PCR reactions were pipetted in separate approaches. All PCR were 
performed for a minimum of two times per tail clip in order to avoid wrong interpretation 
of genotypes. In case of discrepancy of the genotypes, mice were re-genotyped or not 
considered for analysis.  
 
Table 4.1: PCR programme 
PCR Temperature 
[ °C] 








781 bp 94 35 s 
58.5 30 s 
72 50 s 









583 bp 94 35 s 
58.5 30 s 
72 50 s 










94 35 s 
63 30 s 
72 50 s 
72 5 min 
 
Pet1 Cre 




ca. 600 bp 95 30 s 
63 1 min 
72 1 min 
72 7 min 
 
Dat Cre 




ca. 500 bp 95 30 s 
60 30 s 
72 40 s 
72 5 min 
 
4.2.3 Visualization of PCR fragments 
For the detection of the amplified PCR products, a 2% agarose gel, containing ethidium 
bromide, was loaded with the PCR products and the DNA ladder. Before that, all PCR 
products were mixed with loading dye. If samples were filled on a big gel 
(PerfectBlue™ Gelsystem Maxi L), the gel was run for approximately 45 min at  
150 mA. If samples were filled on a smaller gel (PerfectBlue™ Gelsystem Maxi S), the 









tetraaceticacid (TAE) buffer was used as running buffer. Hence, for visualization of the 
PCR fragments, the agarose gel was put on a UV lightening plate and pictures were 
taken for documentation.  
 
4.3 Preparation of mouse brains 
In order to analyse the brain tissue, animals were sacrificed by cervical fractures, 
brains were removed and cut into two halves. Animals could not be perfused 
intracardially via pumping PBS and 4% paraformaldehyde (PFA) (w/v in PBS) into the 
blood system since one-half of the brain needed to be untreated to be used for 
neurotransmitter analysis. For this purpose, the brain regions olfactory bulb (OB), 
ventral midbrain (VM) and striatum (STR) were prepped, weighed and separately put 
into a cryotube and immediately shock frozen in liquid nitrogen and stored at -80 °C. 
In order to identify the exact weight of each prepped brain region, empty cryotubes 
were weighed before. The other halves of the brain were used for 
immunohistochemical analysis. The halves of the brain were separately transferred 
into falcon tubes filled with 50 ml of 4% PFA solution (w/v in PBS) and post-fixed for 
48 hrs. Afterwards the brain halves were transferred into 20% sucrose solution (w/v in 
PBS) in which 0.001% of NaN3 (v/v in sucrose solution) was diluted to protect tissue 
from contamination. Since mouse brains were not intracardially perfused, the half 
brains were more sensitive to cutting. Therefore, brains were not frozen and instead 
were stored at 4 °C.  
 
4.4 Mouse line characterisation 
In order to proof the selective KO of Pink1 in the serotonergic and dopaminergic mice, 
different brain regions containing serotonergic and dopaminergic neurons, including 
control regions, were genotyped with respect to the gene Pink1. 
  
4.4.1 Proof of selective Pink1 knockout in serotonergic neurons 
Mice from the mouse line Pink1 x Pet were killed by cervical fracture, brains were taken 
out and immediately shock frozen on dry ice. Afterwards brains were cut into 200 µm 
thick layers with the cryostat and transferred on to microscope slides. With the help of 
a needle, the raphe nuclei were scratched out and transferred into the Nuclei Lysis 
solution with EDTA in order to purify the DNA (see 4.2.1). The transcription factor Pet1 




cerebellum (CB) or cortex (cort.) (Hendricks et al., 2003). In addition, Pink1 is 
synthesised in the RN, CB and cort. (Taymans et al., 2006, d'Amora et al., 2011). 
Therefore, the tissue RN, CB and cort. were genotyped to show the presence of the 
floxed Pink1 and partially knocked out Pink1. For this purpose, the two PCR 
approaches were performed: Pink1 del2/3 PCR and Pink1 flox PCR as described in 
4.2.2.  
 
4.4.2 Proof of selective Pink1 knockout in dopaminergic neurons 
Mice from the mouse line Pink1 x DAT were sacrificed and mouse tissue was prepped 
as described in 4.3. The dopamine transporter (DAT) is produced amongst others in 
the OB, SNC and VTA (Cerruti et al., 1993, Ciliax et al., 1999, Miller et al., 1997) and 
less expected in the hippocampus (HC) and cortex (cort.). Peripherally, DAT was found 
among others in the kidney (kidn.). In addition, Pink1 is synthesised in the OB, HC, 
cort., MB and kidn. (Taymans et al., 2006, d'Amora et al., 2011). Therefore, the tissues 
OB, HC, cort., MB and kidn. were genotyped to show the presence of floxed Pink1 and 
partially a knockout of Pink1. For this purpose, the two PCR approaches were 
performed: Pink1 del2/3 PCR and Pink1 flox PCR as described in 4.2.2. In addition, 
the mouse line Pink1 x DAT was tested for potential leakiness of the CreERT2 
recombinase. Leakiness of CreERT2 is defined as a translocation of CreERT2 into the 
nucleus and recombination of the floxed DNA without previous injection of tamoxifen. 
Therefore, non-induced mice were also genotyped. Mutant mice and control group 2 
mice were considered for the analysis.  
 
4.5 Immunohistochemistry 
In order to research the neuroanatomy of dopaminergic neurons in the SNC and 
serotonergic innervation into the OB, the prepped murine brains were cut, stained and 
analysed stereologically.  
 
4.5.1 Cutting of mouse brains 
Brains were washed in PBS solution to remove the 20% sucrose (w/v in PBS) solution 
with 0.001% of NaN3 (v/v in sucrose solution). Hence, brains were put in an embedding 
mold, embedded with section medium, and quick-frozen on dry ice. The brain halves 
were cut sagittal, respectively horizontal, into 40 µm thick serial sections of six using 




20 °C including a blade temperature of 1 °C below the object temperature. Brain 
sections were stored in 6-well plates filled with PBS solution with 0.001% of NaN3 (w/v 
in PBS) solution at 4 °C. 
 
4.5.2 Staining of serotonergic innervation 
Horizontal sections of the Pink1 x Pet mice and sagittal sections of the Pink1 x DAT 
mice were used for the staining of serotonergic innervation. In order to simplify the 
handling of brain slices, apart from the staining steps in antibody solutions, brain slices 
were transferred into cell strainers that fit in 6-well plates.  Slices were washed two 
times with PBS for 5 min followed by two times with 0.2% PBS-T for 10 min. Hence, 
the slices were incubated in a 5% fetal calf serum (FCS) solution (v/v in 0.2 % PBS-T) 
for 2 h to block unspecific antigens. In order to detect serotonergic innervation, the 
neurotransmitter 5-HT (serotonin) was stained by incubating the slices in a 0.002 % 
primary antibody rabbit-anti-5-HT (Immunostar) solution (v/v in 0.2% PBS-T) over night 
at 4 °C. Staining steps were performed in 24-well plates with a lower volume of the 
used antibody solution and without using cell strainers. Afterwards, the unbound 
antibodies were removed by washing the slices three times for 5 min with 0.2% PBS-
T. Then, slices were incubated for 45 min at room temperature in a 0.002% secondary 
antibody dilution (v/v in 0.2% PBS-T) with the dye Alexa594 labelled donkey anti-rabbit 
antibody (Mi Bo Tec). Subsequently, slices were washed three times with 0.2% PBS-
T for 15 min, transferred on to microscope slides and mounted with Aqua Poly/Mount 
and cover slips.  
 
4.5.3 Staining of dopaminergic neurons 
Sagittal brain sections were used for staining dopaminergic cells. In order to simplify 
the handling of brain sections, apart from the staining steps with the antibodies, brain 
sections were transferred into cell strainers that fit in 6-well plates. Slices were washed 
three times with PBS for 10 min in order to remove the sucrose solution from the NaN3. 
Afterwards slices were transferred in 0.3% H2O2 solution (v/v in PBS) for 10 min in 
order to destroy the endogenous peroxidases. After washing with 0.1% PBS-T twice 
for 10 min, the slices were incubated in a 2% FCS solution (v/v in 0.1% PBS-T) for 2 h 
to block unspecific antigens. In order to detect dopaminergic neurons, the enzyme 
tyrosine hydroxylase (TH) was stained by incubating the slices in a 0.0001% primary 




Staining steps were performed in 24-well plates with a lower volume of the appropriate 
antibody solution and without using cell strainers. Afterwards the unbound antibodies 
were removed by washing the slices three times for10 min with 0.1% PBS-T. Then, 
slices were incubated for 45 min at room temperature in a 0.003% secondary antibody 
dilution (v/v in 0.1% PBS-T) with the biotin-SP-conjugated goat-anti-rabbit antibody 
(Jackson ImmunoResearch). Subsequently, slices were washed three times with 0.1% 
PBS-T for 15 min and incubated with the avidin biotin complex (ABC) solution for 45 
min, which was prepared 30 min prior to use. Slices were washed with PBS two times 
for 15 min followed by another washing step with Tris-HCL for 15 min. Finally, slices 
were incubated with the diaminobenzidine (DAB) working solution in the darkness 
since DAB is light sensitive. The incubation time was about 15 min; however, it 
depended on the reaction of the peroxidase with the H2O2. The resulting oxidation of 
the DAB caused a brown product. The reaction was stopped by washing the slices 
three times with PBS for 10 min. Thereafter, sections were transferred to microscope 
slides and dehydrated by incubation two times for 5 min in 70% Ethanol (v/v in dest. 
H2O), followed by incubation two times for 5 min in 96% Ethanol (v/v in dest. H2O). At 
the end, slices were incubated two times for 5 min in 100% Ethanol (v/v in dest. H2O) 
and two times for 5 min in Xylol. After dehydration processes, brain slices were 
coverslipped with pertex.  
 
4.6 Stereology 
In order to analyse the stained murine slices, a stereological quantification was 
performed.  
 
4.6.1 Quantification of dopaminergic neurons in substantia nigra pars compacta 
(SNC) 
For the quantification of dopaminergic cells, the microscope Axioplan 2 imaging with 
the camera Axio Cam MRc was used. Brain slices were sorted in a serial manner and 
seven slices including the substantia nigra pars compacta (SNC) (Figure 4.1 A -G) 
were used. Since brain slices were cut in a series of six with a thickness of 40 µm, a 
layer of approximately 1.4 mm was considered for quantification with stereotaxic 
coordinates of approximately lateral 2.0 mm to 0.6 mm.  For stereotactic quantification, 
the optical fractionator workflow of the software Stereo Investigator 11 (mfb 




in a random manner and to estimate a total number of cells in the marked region.  
Because of the dehydration process, slice thickness shrunk to a mounted thickness of 
30 µm. The size of the counting frame was 100 µm x 100 µm and the sampling grid 
size was 200 µm x 200 µm. The top guard zone was selected at 3 µm and the dissector 
height at 20 µm. The region of interest, the SNC was surrounded with a 5x 
magnification lens and cells were counted at a 20x magnification lens. In case of a 
missing section, the Stereo Investigator software was able to calculate an estimated 
number. All counting was done in an unbiased manner without knowing the sex and 
genotype of the researched mice during counting process. 
 
 
Figure 4.1: Serial overview of sagittal sections including substantia nigra pars compacta.  (A - 
G) Selected slices used for quantification of TH+ cells in a serial manner of six. The dashed lines depict 
the bordering around the substantia nigra pars compacta (SNC) containing positive labelled cells for TH 
indicating the dopaminergic neurons. The neighbouring region, substantia reticularis (SR) exhibit very 
sparely dopaminergic neurons. Sections are shown from lateral stereotaxic coordinates of 





4.6.2 Quantification of serotonergic fibres into the olfactory bulb (OB) 
For quantification of the serotonergic fibre density in the glomerular layer of the 
olfactory bulb, the microscope Axioplan 2 imaging with the camera Axio Cam MRc was 
used. The sections were chosen with stereotaxic coordinates of approximately Bregma 
- 4.28 mm. With the help of the Stereo Investigator 11 (mfb Bioscience), one slice per 
mouse was analysed by putting a regular grid with a grid size of 60 µm x 60 µm over 
the glomerular layer of the olfactory bulb and all fibres crossing the grid were counted 
by a magnification of 40x. A random area in the glomerular layer of the OB with a size 
of 0.12 - 0.18 mm2 in the Pink1 x Pet mice and 0.06 - 0.13 mm2 of the Pink1 x DAT 
mice was chosen. For quantification of the fibre numbers, the software Neurolucida 
(mfb Bioscience) was used. All counting was done in an unbiased manner without 
knowing the sex and genotype of the researched mice during the counting process. 
 
4.7 Analysis of neurotransmitter content 
In order to analyse the concentration of the neurotransmitter content in the brain 
regions: OB, VM and STR, samples were analysed with high performance liquid 
chromatography (HPLC) system coupled with the electrochemical detection (ECD). 
The catechol structures of the analytics were oxidised to quinone, which produced a 
current. The measured current was directly proportional to the concentration of the 
analysed analytics.  
 
4.7.1 Brain sample purification 
Brain regions of the 4 month old animals were firstly purified, starting with the Pink1 x 
Pet mice followed by the Pink1 x DAT mice. In addition, samples of the same brain 
region were purified on a same time point having always a random mixture of groups. 
Thereby the effect of degradation of neurotransmitters while stored at -80 °C was 
minimised within brain samples, mouse lines and age groups. For the sample 
preparation, 200 µl of cold perchloric acid solution were added to the frozen brain 
samples in order to keep the analytics stable and precipitated proteins. In addition,  
4 µl of cold 3.4-dihydroxybenzylamine (DHBA) was added as internal quantification 
standard (IS). The brain samples in mixture were thawed on ice. Afterwards, samples 
were lysed by 30 seconds of ultrasonication on ice with a UW70 ultrasonic 
homogeniser for 30 s. The homogenates were centrifuged at 7879 x g for 10 min at  




sample vials and closed with clear snap cap, which were suitable for injection into the 
HPLC system. The rest of the supernatant was stored at -80 °C.  
 
4.7.2 HPLC measurements 
Preparation of brain samples led to a loss of analytes. Knowing the IS and the analytes 
have the same properties, it was assumed that the loss of analytes and IS was equal 
during sample preparation process, defined as recovery [%]. Deductive, the 
component in the IS and in the analytes in the brain tissue exhibited the same recovery 
[%]. Thereby it was possible to calculate the original amount of analytics in the brain 
tissue before sample preparation since the concentration of the IS was known. The 
HPLC system was calibrated daily before the measurement of the neurotransmitter 
content took place by using a one-point calibration with a linearity of the calibration 
curve of R2 > 0.99. The calibration solution contained the components dopamine (DA), 
3.4-Dihydroxyphenylacetic acid (DOPAC), epinephrine (E), homovanillic acid (HVA), 
norepinephrine (NE), 3-Methoxytyramine hydrochloride (3-MT*HCl), 5-Hydroxyindole-
3-acetic acid (5-HIAA), serotonin hydrochloride (5-HT*HCl), and 3.4-
Dihydroxybenzylamine (DHBA) serving as the IS. All components were mixed to a final 
concentration of 1 ng/µl for each component (w/v, respectively v/v in Perchloric acid 
solution). Since the concentrations of the individual compounds in the calibration 
solution were known, the concentration of the corresponding analytics in the brain 
tissue were set into ratio and calculated. 
The brain tissues of the 4 months old Pink1 x Pet and Pink1 x DAT mice were analysed 
with the HPLC system that consisted of the gradient pump GP40, the autosampler 
AS40, and the electro-chemical detector ED40. The injection volume of each sample 
into the HPLC system (old) was 40 µl. The isocratic mobile phase was diluted with  
6% acetronitrile (v/v) and exhibited a flow rate of 0.5 ml/min through the Atlantis T3 
column. The compartments of the column and the detector were heated to 30 °C. The 
software PeakNet 5.2 was used to control the system and to process the 
chromatograms. 
The brain tissues of the 12 months old Pink1 x Pet and Pink1 x DAT mice were 
analysed with the HPLC system that consisted of the gradient pump GP50, the 
autosampler AS50, and the electro-chemical detector ED50A in which a volume of 
each sample of 20 µl was injected. The isocratic mobile phase was diluted with 0.25% 




The column oven was set to 40 °C. The software Chromeleon 6.5 was used to control 
the system and to process the chromatograms. 
Prior to usage, the mobile phase was degassed in an ultrasonic bath. In the old and 
new HPLC system, a security guard cartridge in the same material according to the 
column was preceded to the column in order to prevent blocking and contamination of 
the column. All samples were injected once. The potential of the detector was set to 
0.7 V against an Ag/AgCl reference electrode.  
 
4.8 Behaviour analysis 
In order to analyse possible non-motor and motor phenotypes, mice went through a 
standardised behavioural testing battery in the GMC. 
Independent of the behavioural test, mice were tested in a blind random manner, apart 
from the knowledge of the sex. Males were always tested before females. About 30 
minutes before behavioural testing, animals were transported from the housing room 
into the testing room to habituate.  Animals were always tested separately and the 
body weight was recorded after testing. After finishing the testing of each mouse, the 
behavioural setup was cleaned with the disinfectant Pursept-A Xpress (Schülke). The 
behavioural testing started the earliest at 7 am and finished the latest at 5 pm, from 
Monday to Friday. The testing of CatWalk and olfaction were interrupted during the 
weekend.   
 
4.8.1 Open field testing (OF) 
In order to analyse the anxiety, locomotion and exploration, mice were tested in the 
open field. For this purpose, mice were placed in an open field area to record the 
movement of the mice by infrared sensors (Walsh and Cummins, 1976, Glasl et al., 
2012, Gates et al., 2011). Hereby the ActiMot System was used.  
The natural tendency to mice is to explore a novel environment. However, mice avoid 
open, unknown and potentially dangerous areas, which is represented by the centre of 
the open field (Choleris et al., 2001). Thereby, the open field test is used to test the 
anxiety-related behaviour by alterations in exploration. However, with increasing time 
and exploration, animals are more familiar with the environment and the centre 
becomes less stressful (Holter et al., 2015). Motor and/or balance problems can be 




speed movements can be also an indicator of motor problems but it could also reflect 
other changes in motivation or sensory modalities (Hölter and Glasl, 2012). 
Up to five parallel open field tests were performed since there were five ActiMot 
Systems available in the GMC. Each ActiMot System was individually enclosed in a 
small, sound-attenuated room with an area of one square meter and white walls. The 
light of each room was set to 200 Lux in the centre of the open field area as varying 
light intensities influence the activity of the mice (Trullas and Skolnick, 1993). Since 
open field testing results changes over the timing of the day, all animals were tested 
before noon when the light cycle started (Hollaway, 2007). 
The mice were placed into the open field periphery by putting the face of the mice 
towards the wall of the open field area. During the 20 min testing time, the spontaneous 
behaviour of the mice was recorded by the infrared sensors. The horizontal and vertical 
locomotor activity of the mice were monitored to give information about rearing 
frequency, distance travelled, location and the time course. 
The ActiMot System consisted of a square-shaped frame with a lateral length of  
48 cm (Figure 4.2). The frame was composed of two pairs of light-beam strips with 
each pair consisting of one transmitter strip and once receiver strip. Each strip was 
composed of 16 infrared light beam breaks with a distance of 28 mm. These basic light 
barrier strips were arranged at right angles to each other to determine the X and Y 
coordinates of the animals and following their location. The testing area consisted a 45 
cm square with a coloured light grey smooth floor. The periphery zone was defined by 
an eight cm thick border. Hence, the centre of the testing area possessed 41.5% of the 
total surface. The testing area was surrounded by a transparent acrylic 39.5 cm high 
wall. Thereby, two additional further pairs of light-beam strips were set in front of each 
other and above the light-beam strips of the XY axis to measure the Z coordinates. 
Thus, rearing behaviour could be also measured. The centre of gravity of the mouse 
was calculated by the numbers of interrupted light beams on an XY axis. The activity 
settings were set up to record movement at a speed of > 0 cm/s. The rearing frequency 






























Figure 4.2: Experimental setup of the open field testing. (A) Schematic drawing of the open field testing area. The length of the squared open field testing is 45 
cm with an 8 cm thick border, indicating the periphery. The inner centre was defined by a square with the length of 29 cm, resulting in 41.5% of the total testing 
area. To measure the movement of the mouse on the XY- axis, two pairs of infrared light beam sensors are installed in a rectangular angle. Each sensor pair is 
consisted of a transmitter (orange beam) and a receiver (blue beam). The height of the testing box conducts 39.5 cm. An additional pair of infrared light beam is 
installed on the wall at the height of 6.8 cm of the testing box to measure the movement of the mice on the Z-axis, interpreted as rearing. Each sensor consists 16 
infrared light beams with a distance of 28 mm to each other. Whenever an even number of infrared light beams (red dashed lines) is interrupted, the centre of 
gravity is calculated to lie between the adjacent sensors. (B) Birds eye view of the open field testing box with a rearing black mouse. The picture was taken by the 




4.8.2 Acoustic startle reflex / prepulse inhibition testing (ASR/PPI) 
In order to test the sensorimotor and hearing function, mice underwent an acoustic 
startle reflex (ASR) and prepulse inhibition (PPI) testing. The ASR measures the acute 
skeletal contraction due to an abrupt intensive acoustic stimulus. The most common 
form of modified ASR is the prepulse inhibition (PPI) testing. A short and less intensive 
sound is presented prior the ASR causing stimulus. As a result the ASR is reduced 
due to the prepulse (Lauer et al., 2017). PPI is related to neurological disorders like 
schizophrenia, obsessive compulsive disorder or Tourette syndrome, being 
characterised by a loss of gating in motor, cognitive and sensory manner (Braff et al., 
2001). For the testing of the ASR and the PPI, the Acoustic Startle Reflex Starter 
Package for Rat or Mouse and corresponding materials of Med associates were used. 
About 10 minutes before testing, mice were put into an animal holder (figure 4.3 A), 
which enclosed the animal. In order to avoid that animals will escape from animal 
holders, tape was used to fix the doors properly. For testing, mice were placed 
separately into the sound attenuating cubicle (figure 4.3 B). The cubicle was equipped 
with Styrofoam to diminish noise and consisted of a startle platform with a load cell on 
top. The animal holder with the locked mouse was fixated on that load cell. The load 
cell transduced the measured force and created an electrical signal in a direct 
proportional manner. From this, it followed that during the testing time, all movements 
of the mice were recorded. The platform with load cell was connected to the startle 
platform attenuator, which included a loud speaker to produce the background noise 
of 65 dB and a loud speaker for the different acoustic stimuli. Each animal was tested 
for about 1 hour and 16 minutes, whereat up to eight animals were tested 







Figure 4.3: Experimental setup for acoustic startle reflex and prepulse inhibition testing. (A) 
Overview of eight animals sitting in an animal holder, which is closed on both sides by doors. The doors 
are fixated with tape. (B) Overview of the sound attenuating cubicle without a testing mouse. Inside of 
the cubicle, the animal holders are fixated on the load cell, which is fixated with the startle platform. 
Movements of the mice are transmitted as an electrical signal to the startle platform attenuator. The 
startle platform attenuator includes loud speakers for the background noise and the particular stimuli. 
Picture (B) was taken by the technician Jan Einicke from Institute of Developmental Genetics at the 
Helmholtz Zentrum München. 
 
Two different approaches were tested: the ASR and the PPI. For the ASR testing, 
animals were exposed to stimuli with different sound pressure levels: null stimulus 
(NS), 70 dB, 80 dB, 85 dB, 90 dB, 100 dB, 110 dB and 120 dB. Henceforth these stimuli 
are called single stimulus (SS, figure 4.4). Testing the NS was necessary to consider 
the normal body movement of the mice while being exposed to a background white 
noise of 65 dB. Each SS was composed of white noise with a duration of 40 ms. In 
order to analyse the PPI, animals were exposed to a 110 dB white noise stimulus (SP, 
figure 4.4), which was proceeded by a prepulse tone with a frequency of 12 khz (PP, 
figure 4.4). The sound pressure of the PP differed and included the following values: 
67 dB, 69 dB, 73 dB and 81 dB with a duration of 10 ms respectively. The interval 
between the PP and SP was 50 ms. Testing session started with a 5 min long 
acclimation period. Followed by five consecutive SS with 110 dB, which were not taken 
into account for analysis. Afterwards, SS and SP stimuli with different sound pressure 
level alternated in a random manner whereat each trial was exposed for ten times, 
organised in ten blocks with each trial type occurring once per block. The inter-trial 
interval varied between 20 s to 30 s. 
In order to analyse the data, the maximal peak-to-peak amplitudes were taken to define 
the reflex. The corresponding software of the used hardware analysed automatically 
the maximum peak values and expressed it in arbitrary units. The PPI was calculated 
by taking the difference of the maximum peak values caused by the SS with 110 dB 
and SP (110 dB) with different prepulse sound pressures, set in relation to the 






Figure 4.4: Schematic flowchart of acoustic startle reflex and prepulse inhibition. To test the ASR, 
animals are exposed to single stimuli (SS) with different sound pressure levels: 70 dB, 80 dB, 85 dB, 90 
dB, 100 dB, 110 dB, 120 dB with a stimulus duration of 40 ms. Each acoustic stimulus causes a certain 
reaction of the animals, schematically represented in the curve. To test the PPI, animals are exposed 
to a 40 ms lasting stimulus with a sound pressure of 110 dB (SP) including a proceeded prepulse (PP). 
The prepulse differs in sound pressure: 67 dB, 69 dB, 73 dB and 81 dB and lasts 10 ms. The time 
interval between the PP and SP takes 50 ms. The PPI is calculated by subtracting the maximum peak 
value of the curve caused by the SS with 110 dB (a) with the maximum peak value of the curve caused 
by the SP (b), putting it into the ratio to the maximum peak value of SS and expressing it in percentages.  
 
 
4.8.3 CatWalk testing (CW) 
Since Parkinson’s disease (PD) is typical a movement disorder, animals gait and 
movement were tested. Hereby, the automatic gait analysis system Catalk XT Noldus 
was used because it enables animals to walk freely without forcing animals to move, 
which resembles more the natural movement. The CatWalk system is of advantage 
since animals are able to walk at the speed that their gait (ab)normalities or endurance 
will allow (Batka et al., 2014).  In order to analyse the gait or movement, mice went 
through a testing with the CatWalk XT Noldus system. Animals were able to run at their 
own intrinsic speed in an unforced manner through a guided corridor whereat the 
contact areas and the body contour of the animals was videotaped by giving 
information about the gait of the animals (Hölter and Glasl, 2012). 
The CatWalk XT system is composed of a glass plate, which was surrounded by black 
plastic walls to form a corridor with the dimensions of 130 x 68 x 152 cm (L x W x H). 
The endings of the corridor were open to enter and exit the walkway (figure 4.5). The 
walkway formed the part of the corridor, which was videotaped, with the dimensions of 




cycles per run. The ceiling of the walkway was illuminated by red light (625 nm red 
LED) with a voltage of about 18 V. Red light was used to avoid distracting mice by 
bright light since mice have a dichromatic colour vision and are not able to detect the 
red colour (Jacobs et al., 2007). However, the red lights enabled the experimenter to 
see the body contour of the mouse, which was necessary to detect the correct 
classification of the paws. Underneath the glass plate, a high-speed video camera (100 
fps) was positioned to videotape and to detect the contact areas of the glass plate. 
This was possible by green light (535 nm green LED) which illuminated the glass plate 
with a voltage of 15 to 16 V. After contacting the glass plate, the green light was 
scattered and videotaped. The horizontal and vertical size of a single pixel was about 
0.78 mm. The camera was connected to the computer. Each recorded pixel gave 
information about brightness, which allowed the experimenter to get information about 
intensity of the different paws. In addition, the CatWalk XT system software was also 
able to interpret other parameters related to the paws and the spatial and temporal 
relationship between the paws.  
Each day before testing, light in the testing room was set to 80 Lux. To motivate 
animals to run over the walkway, the home cage was set at the end of the corridor 
since mice smelled their home and the cage members. The home cage was covered 
by a black goal box to keep mice away from light. In addition, to avoid other mice 
entering the corridor by climbing out of the home cage, the cage itself was covered by 
a stainless steel lid of the cage type II PC (figure 4.5). Each run started with the 
placement of one front paw on the walkway and finished with leaving the walkway with 
one of the hind paw. Animals were not trained before testing, however, the first runs 
were not considered in the data analysis since mice´ gait was different for the first trials. 
After passing the walkway, mice were taken out of the goal box and re-placed at the 
starting of the corridor. In the best case, mice exhibited a minimum of five “good runs” 
characterized by a consistent movement without interruptions or hitches. In case, one 
mouse needed more than circa 45 min to achieve the five “good runs”, the testing of 
that mouse was finished and re-done at another time point to avoid that the mouse felt 





















Figure 4.5: Experimental setup of CatWalk XT. Mice are put on the entry of the corridor to run over 
the glass plate, which is illuminated by green LED light to enable the camera (indicated by the arrow) to 
record the paw of the mice. The exit of the corridor ends in the goal box, which covers the home cage, 
to motivate the mice to run over the walkway. The corridor is illuminated by red LED light to visualise 
the recorded movie and to detect front prints.  
 
A few days before the CatWalk testing procedure all mice were weighed to get 
information about the average span of weights between the different groups and sex. 
The average weight was used to set up the green light intensity in the programme 
CatWalk XT. This was done by putting an animal with an average weight on the glass 
plate followed by adjusting the camera gain and green intensity threshold. The younger 
animals were recorded with a camera gain of around 13 dB, compared to the older 
animals, which were videotaped with a camera gain of 8 to 9 dB. The green intensity 
threshold ranged between 0.05 and 1.4.  
Afterwards, run criteria were set to define a run as compliant or not compliant. The 
minimum run duration was set to 0.5 seconds followed by the maximum run duration 
of 10 seconds. In addition, the maximum variation of speed was set to 40% including 
an average speed between 30 cm/s and 90 cm/s because intensive speed variation 
could cause problems in standardisation (Batka et al., 2014). The minimum numbers 
of consecutive steps were set to a number of 10. The green and red light were set to 
automatic detection and were almost identical during the testing of different mouse 
cohorts (see above). Since mice contaminated the glass plate by excrement and urine, 
the plate needed to be cleaned several times between CatWalk testing. To avoid some 
background being measured as a paw, the background was snapped several times 
especially after cleaning. For the analysis, four out of the five compliant runs were 








analysed in order to avoid high variation within one mouse. In some few cases, mice 
did not perform well on running over the walkway and a total number of five or four 
“good” runs could not be videotaped. In that case, a minimum of three runs were 
considered for analysis per mouse. Next to the run criteria, each movie was double 
checked for the quality of the paw prints. Since the camera frequency rate was 100 
frames per second and animals needed about 2 s to pass the walkway, a movie was 
composed of around 200 pictures. The position of the paw prints could be detected 
and labelled automatically via the use of the automatic footprint classification (AFC). 
However, often some paws needed to be re-labelled manually due to some 
mismatches of two paws. In case the background disturbed the AFC, the green 
intensity threshold was increased manually for each run 
 
4.8.4 Olfactory testing (Olfac.) 
In order to test the olfactory ability, mice went through a testing of discrimination of 
binary mixtures and sensitivity testing of a diluted odorant (Glasl et al., 2012, Schellinck 
et al., 2001). Female mice were not tested because previous published literature did 
not show indications of an impairment in olfaction of female Pink1 KO mice (Glasl et 
al., 2012). This suggests that female mice lacking Pink1 in serotonergic or 
dopaminergic neurons might not exhibit olfactory impairments. 
During the training, conditioning and olfactory testing, mice were kept singly in a type 
IIL mouse cages filled with some shavings material.  A stainless steel lid and a soft lid 
covered the cages. Before the testing, animals were habituated for 15 min in the testing 
cage. The mice were placed on a restricted feeding regime to maintain their body 
weight at around 90% body weight of their free-feeding level. The body weight 
restriction started three days before the training and kept on going for the whole of the 
training and conditioning procedure including all olfactory testing.  
During the experiment, one or two dishes were horizontally placed on a T-carrier, which 
were separated by a vertical barrier (Figure 4.6 A). For each trial, dishes were filled 
with fresh scented shavings. When two dishes were used, both were presented 
randomly to avoid a side effect. For each trial, the T-carrier was put to the front part of 
the testing cage. The mice were separated from the T-carrier by a cage barrier inside 
the testing cage (figure 4.6 B). Afterwards, the cage barrier was taken out of the cage 
(figure 4.6 C). The behaviour of the mouse was observed followed by a decision by the 




chocolate piece (figure 4.6 D & E). Then, the T-carrier was pulled out of the cage (figure 
4.6 F) and the cage barrier was put back into the testing cage ensuring that the mouse 
is in the back part of the cage. 
Before the olfactory testing, mice needed to go through a three to four day long 1) 
training phase to get used of the taste of chocolate and to dig in a dish filled with 
shavings of chocolate (figure 4.7 (1)). To enable this, three chocolate pieces were put 
on top of the shavings in one dish. After the mice ate the chocolate, new chocolate 
pieces were presented. The chocolate pieces were presented for five times. On the 
next day, three chocolate pieces were placed on top, in the middle and at the bottom 
of the dish filled with bedding. The mice needed to bury to reach the hidden chocolate 
pieces.  After three times of digging for the chocolate, only two chocolate pieces were 
hidden in the shavings. The mice could not see the chocolate piece anymore. However, 
the mice needed to dig for an additional six times. On the next day, only one piece of 
chocolate was buried in the shaving and the mice needed to grub for six times. If the 
mice did not dig well enough, an extra training day was added. 
Subsequently, the 2) conditioning phase followed, where mice learned to connect 
the food reward with the odorant [S+] (figure 4.7 (2)). For the first two days, mice 
needed to differentiate between the odorant 2-Phenethyl acetate, defined as [S+] and 
the solvent Diethylphthalat. The odorant [S+] was diluted with the solvent to a 10% 
(v/v) working concentration. Two dishes were presented, one dish filled with scented 
shavings of [S+] and the other dish filled with solvent soaked shavings. Both dishes 
were immersed in a ratio of 1 ml of odorant or solvent per 3 g shavings. This ratio was 
consistent for the following testing. For the first three trials, a chocolate piece was 
placed on top of the dish with the [S+] odorant whereas the dish with solvent was not 
covered by a chocolate piece. The mice needed to eat the chocolate and connect the 
chocolate with the odorant [S+]. For the next six trials, a chocolate piece was hidden 
in the dish with the odorant [S+] and in the dish with the solvent. On the next day, the 
last six trials were repeated. For the completely conditioning phase, mice were only 
allowed to dig in the dish with the [S+] odorant and to eat the chocolate. In case the 
mice dug in the dish with the solvent, the trial was stopped. In addition, it was prohibited 






















Figure 4.6: Sequence of the binary mixture testing. (A) Two dishes are horizontally placed on a T-carrier. (B) The T-carrier is put in the front part of the testing 
cage. The mice are separated from the T-carrier by a cage barrier inside the testing cage. (C) Afterwards, the cage barrier is taken out of the cage. (D) The mouse 




Next, the mice needed to discriminate between a dish scented with the odorant [S+] 
and a dish scented with the odorant [S-], Methyl trans-cinnamate (figure 4.7 (2)). Both 
odorants were diluted in a 10% (v/v) working concentration. The mice were previously 
trained to dig in a dish with the odorant [S+]. Firstly, a piece of chocolate was buried 
on top of the dish with [S+] where the mice needed to dig for the chocolate for six trials. 
Afterwards, the chocolate was placed on both dishes with the odorants [S+] and [S-]. 
Digging in the dish with the odorant [S+] was considered as the correct choice. Digging 
in the dish with the odorant [S-] was contemplated as the wrong choice, the trial was 
stopped, and the mice were prohibited to eat the chocolate piece. 
The actual testing started with the 3) binary mixture discrimination test where mice 
needed to differentiate between a mixture of the odorants [S+] and [S-] (figure 4.7 (3)). 
Both odorants were diluted to a working concentration of 10% (v/v). This working 
concentration was defined as 100% of the particular odorant. The dish containing the 
odorant [S+] is called “dish I”. The dish containing the odorant [S-] is defined as “dish 
II”. The odorants [S+] and [S-] were mixed in consistent steps to make the odorants 
increasingly similar (table 4.2).  
 
Table 4.2: Mixture of odorants in binary discrimination test.  
dish I dish II 
% [S+] : % [S-] % [S-] : % [S+] 
100 : 0 0 : 100 
70 : 30 70 : 30 
55 : 45 55 : 45 
53 : 47 53 : 47 
51 : 49 51 : 49 
 
The correct choice of the mouse was defined by its first indication to dig in the dish I 
with a higher concentration of [S+] and rewarded by a given piece of chocolate. In case 
the mouse failed in the discrimination of [S+], both dishes were immediately removed, 








Subsequently to the binary mixtures discrimination test, the 4) sensitivity test was 
performed (figure 4.7 (4)). Here, mice needed to choose between a “dish III” and “dish 
IV”. The “dish III” was scented with the stepwise diluted odorant [S+] compared to “dish 
IV” scented with solvent. The 10% (v/v) working concentration of [S+] was stepwise 
binary diluted with the solvent thus a 5% (v/v) concentration of [S+] is the first dilution 
step followed by the second dilution step of 2.5% (v/v) concentrated [S+] and further 
on (table 4.3). The correct choice of the mouse was defined by its first indication to dig 
in the “dish III” scented with the odorant [S+] and rewarded with a given piece of 
chocolate. In cases where the mouse failed to detect the diluted odorant [S+], both 
dishes were removed immediately. The trial was finished and evaluated as incorrect 
choice. After three correct responses in a row, the mouse reached a higher dilution 
step followed by a lower concentration of [S+]. If a mouse dug twice in a row in the 
wrong “dish IV”, the mouse was re-tested with the one step higher concentrated dilution 
step until the mouse reached the three correct choices again.  The highest dilution step 
with three successful in correct choices of “dish III” was defined as the sensitivity 
threshold.  
 










dilution steps % [S+] (v/v) concentration [S+] (v/v) 
stock  100.00 100 
working concentration 10.00 1.0E+01 
1 5.00 5.0E+00 
2 2.50 2.5E+00 
3 1.25 1.3E+00 
4 0.63 6.3E-01 
5 0.31 3.1E-01 





Figure 4.7: Process of the training, conditioning, discrimination test of binary mixtures and sensitivity test. The tested mice need to run through a training 
and conditioning before the actual olfactory testing are performed. At the first training days, the mice need to get used to the taste of chocolate and to learn to dig 
for the chocolate. Afterwards, the mice are conditioned to connect the chocolate with the odorant [S+] and to discriminate between the odorants [S+] and the 
odorant [S-]. Thereupon in the discrimination test of binary mixtures, mice need to differentiate two stepwise-diluted mixtures of the two odorants [S+] and [S-]. At 






For all statistical testing, the programs SPSS and GraphPad Prism were used. The 
independent variables were defined by sex and genotype. All statistical tests were 
performed in a two-tailed manner. A statistical significance was defined when p < 0.05 
=*; p < 0.01 = ** and p < 0.001 = ***. The aim was to determine possible genotype 
effects with significant differences between the mutant mice compared to both tested 
controls. Only in case the values of the dependent variables of both controls differed 
significantly from those of the mutant mice, these variables were interpreted as a 
genotype effect caused by the KO of Pink1 in the serotonergic or dopaminergic 
neurons. However, it was important to consider that the two independent variables 
could possibly interact. Therefore, in addition, the sex was always analysed separately. 
The multiple comparisons of different genotype groups were done by the post hoc 
Bonferroni test.   
For the quantification of dopaminergic neurons and the selected neurotransmitter, 
three groups of genotypes per sex were analysed (control 1: Cre:Cre+; Pink1:wt/wt; 
mutant: Cre:Cre+; Pink1:flox/flox and  control 2: Cre:Cre-; Pink1:flox/flox). In sum, the 
six groups were analysed via the 2-way analysis of variances (ANOVA) test, where the 
number of dopaminergic neurons and selective neurotransmitter formed the single 
dependent variable.  
For the quantification of serotonergic fibers, two groups of genotypes per sex were 
tested (mutant: Cre:Cre+; Pink1:flox/flox and control 2: Cre:Cre-; Pink1:flox/flox). In 
sum, the two groups were analysed via the 2-way ANOVA, where the density of 
serotonergic fibers formed the dependent variable.  
In the OF, ASR/PPI and CatWalk testing, the three genotype groups per sex were 
analysed (control 1: Cre:Cre+; Pink1:wt/wt; mutant: Cre:Cre+; Pink1:flox/flox and  
control 2: Cre:Cre-; Pink1:flox/flox). In sum, the three groups were analysed via the 2-
way ANOVA test, where one of the several parameters of each test formed the single 
dependent variable.  
In the olfaction testing, the three genotype groups of male mice were analysed (control 
1: Cre:Cre+; Pink1:wt/wt; mutant: Cre:Cre+; Pink1:flox/flox and control 2: Cre:Cre-; 
Pink1:flox/flox). In sum, the three groups were analysed via the 1-way ANOVA test, 
where the dependent variable formed on the one hand the percentage of correct 













Since Pink1 full knockout (KO) (Pink1_del2/3) mice showed evidence of slight motor 
and definitive non-motor symptoms of Parkinson’s disease (PD) (Glasl et al., 2012), 
the major aim was to dissect the influences of distinct neurotransmitter systems on 
these PD-related phenotypes. For this purpose, transgenic mice with a specific 
knockout of Pink1 in serotonergic or in dopaminergic neurons were generated: 
Pink1_CKO x Pet1_Cre_TG (Pink1 x Pet) and Pink1_CKO x Slc6a3_CreERT2_TG 
(Pink1 x DAT) (material 3.9). Using this approach, also possible systemic 
compensatory mechanisms at play in the Pink1_del2/3 mice (Glasl et al., 2012) might 
be overcome. After validation of the specific KO of Pink1 in serotonergic or 
dopaminergic neurons, these mouse lines underwent a set of behavioural testing: open 
field (OF), acoustic startle reflex (ASR) and prepulse inhibition (PPI), CatWalk (CW) 
and olfaction test (Olfac.) (figure 5.1, blue squares). A dominant pathological hallmark 
of PD is the degeneration of dopaminergic neurons in the substantia nigra pars 
compacta (SNC) (Fearnley and Lees, 1991), which was not detectable in the 
Pink1_del2/3 mice (Glasl et al., 2012). To determine whether the specific KO of Pink1 
in the particular neurotransmitter system thus leads to this parkinsonian phenotype, 
immunohistochemical staining for tyrosine hydroxylase (TH) was performed and 
dopaminergic neurons in the SNC were quantified stereologically. In addition, the 
neurotransmitter content of certain brain regions was analysed via high performance 
liquid chromatography (HPLC) measurements. As Pink1_del2/3 mice exhibited an 
impaired serotonergic innervation into the olfactory bulb (OB) (Glasl et al., 2012), the 
OB of the Pink1 x Pet and Pink1 x DAT mice were stained immunohistochemically for 
serotonin (5-HT) and serotonergic fibres were quantified stereologically (figure 5.1, 
green squares). In addition, because PD is an age-related disease (Poewe et al., 
2017), mice were analysed behaviourally at an age of 4 - 7 months and re-tested at an 
age of 14 - 18 months, henceforth defined as young and mid-aged animals (cohort 1). 




animals, a separate cohort was analysed, which did not undergo behavioural testing 
(cohort 2) (figure 5.1).  
 
 
Figure 5.1: Schedule of analysis of the Pink1 x Pet and Pink1 x DAT mice based on behavioural, 
neuroanatomical screening. Pink1 x Pet and Pink x DAT mice of the cohort 1 were born in 
summer/autumn 2014 and behaviourally tested with a young age of 4 - 7 months (blue squares). 
Afterwards mice were re-tested with mid-age of 14 - 18 months (blue squares), followed by 
immunohistochemical staining of TH+ and 5-HT+ cells and neurotransmitter quantification via HPLC 
measurements (green squares). In order to obtain neuroanatomical data from young mice, additional 
cohorts were used, labelled as cohort 2. These mice were born in autumn 2014 and summer 2015 and 
analysed with an age of 4 months. OF = open field, ASR = acoustic startle reflex, PPI = prepulse 
inhibition, CW = CatWalk, Olfac. = olfaction test, prep = preparation of mouse organs, TH = staining of 
tyrosine hydroxylase positive cells, HPLC = identification of the neurotransmitter content via high 
performance liquid chromatography, 5-HT = staining of serotonin positive cells, count = quantification of 
immuno positive cells, black arrows indicate the scheduling.  
 
In total, 73 mice of the mouse line Pink1 x Pet and 69 mice of the mouse line Pink x 
DAT were initially tested for behavioural changes at young ages. Over time, the 
number of mice was reduced due to genotype-independent illness or age-related 
dying. Thus, 67 mid-aged mice of the mouse line Pink1 x Pet and 64 mid-aged mice 
of the mouse line Pink1 x DAT underwent the behavioural testing. A total number of 
41 - 46 mice were considered for the analysis of TH+ cells in the SNC in young and 
mid-aged mice of both mouse lines. 48 animals were analysed in order to detect the 
neurotransmitter content of young and mid-aged Pink1 x Pet and Pink1 x DAT mice. 
The serotonergic innervation into the OB was only researched in mid-aged mutant (mt) 
and control 2 (ctrl.2) mice, with 8 - 12 mice per mouse line (figure 5.2). A detailed 






Figure 5.2: Total number of analysed animals. Pink1 x Pet and Pink1 x DAT mice were analysed with 
young and mid-age in behaviour, neuroanatomy and neurotransmitter content. Two cohorts per mouse 
line were used (cohort 1: white background, cohort 2: grey background). OF = open field ASR = acoustic 
starle reflex, PPI = prepulse inhibition, CW = CatWalk, Olfac. = olfaction, TH = quantification of TH+ cells, 
HPLC = quantification of neurotransmitter content via HPLC, 5-HT quantification of 5-HT+ cells. 
 
The interest was to figure out possible genotype effects with Pink1 deficiency in 
serotonergic and dopaminergic neurons. The Pink1 x Pet mouse line was generated 
by crossing a Cre recombinase expressing mouse line (under a Pet1 promotor) with 
conditional Pink1 mice (Scott et al., 2005, Glasl et al., 2012) (materials 3.9.3). In 
addition, the Pink1 x DAT mouse line originated by crossing a mouse line expressing 
a tamoxifen-induced form of Cre recombinase (which was cloned in the Slc6a3 gene) 
with the conditional Pink1 KO line (Rieker et al., 2011, Feil et al., 2009, Glasl et al., 
2012) (materials 3.9.4). The resulting Cre recombinase expressing mice, which were 
homozygous for the floxed Pink1 were defined as mutant mice (mt), labelled as 
Cre:Cre+; Pink1:flox/flox. In order to control for a potential Cre recombinase effect and 






- control 1 (ctrl.1): Cre:Cre+; Pink1:wt/wt  
 (expression of Cre recombinase and wild type Pink1)  
 
- control 2 (ctrl.2): Cre:Cre-; Pink1:flox/flox  
(absence of Cre recombinase and presence of floxed exon 2 and 3).  
 
Parameters in the mutant mice were only considered statistically significant when they 
differed significantly compared to both control groups. It is important to note that 
significant differences in parameters between the two control groups or, more 
importantly, between only one control group and the mutant mice were regarded as 
being irrelevant for Pink1 function in the respective neurotransmitter system and were 
thus neglected. These differences might have occurred due to either a Cre-effect per 
se, or more likely the presence of the floxed allele. In order to figure out potential sex-
specific genotype effects, each group was tested separately for males and females. 
Data from the olfaction test were statistically analysed with a 1-way ANOVA, followed 
by Bonferroni post hoc test. All other analyses were analysed statistically using a 2-
way ANOVA test, followed by the Bonferroni post hoc test. When genotype effects 
were sex dependent, male and female data was shown separately. When there was 
no interaction between sex and genotype, data of males and females were pooled.  
 
5.1 Validation of neuronal population specific recombination of Pink1  
In order to prove the functionality of the conditional approach of the floxed Pink1 and 
the Cre recombinase mediated deletion of exon 2 and 3, a PCR based genotyping in 
different tissues and brain regions was performed. For this purpose, samples were 
considered that included and excluded the neuronal populations targeted by the Cre-
driven recombination, i.e. the serotonergic and the dopaminergic neurons. The PCR 
strategy was based on the detection of a 583 bp DNA fragment, by using the primer 
neocass_for_AH and ko_rev_AH  in order to prove the deletion of exon 2 and 3 in a 








Figure 5.3: Schematic overview of Pink1 in wild type, floxed and exon 2/3 deletion condition. 
Pink1: wt, wild type Pink1 is composed of 8 exons (purple). Pink1: flox, conditional knockout (CKO) of 
Pink1 with flanked exons 2 and 3 by loxP sited. A neomycin cassette (neo, grey) is positioned upstream 
of the exon 2, flanked by FRT (blue) sites. Pink1: del2/3, after cutting of the active Cre recombinase on 
the loxP sites, the exons 2 and 3 and neomycin cassette are cut out, resulting in a Pink1 knockout (KO). 
Primers are labelled, which were used for genotyping (table 3.5 and table 4.1). 
 
The PCR product indicative of the floxed Pink1 alleles (688bp) could be detected in all 
tissues of the Pink1 x Pet and Pink1 x DAT mice, irrespective of the presence and 
absence of the Cre recombinase (figure 5.4, Pink1 flox PCR).  
The anterior brainstem with the raphe nuclei is a region containing the most 
serotonergic neurons. Confirming the Cre-mediated recombination of Pink1 in Pink1 x 
Pet mice specifically in this region, the PCR product representing the Pink1 allele with 
a deletion in exon 2 and 3 (583 bp) could be detected only in this part of the brain. The 
selectivity of this recombination in serotonergic neurons was supported by the absence 
of the “deleted” allele in other brain regions, such as the cerebellum and cortex (cort.), 
where serotonergic neurons are sparse (figure 5.4, C). 
The OB, midbrain (MB) and kidney (kidn.) contain dopaminergic neurons. Confirming 
the tamoxifen-induced Cre-mediated recombination of Pink1 in these tissues in Pink1 
x DAT mice, the PCR product representing the Pink1 allele with a deletion in exon 2 
and 3 (583 bp) could be detected in the OB, MB and kidney. The selectivity of this 
recombination in dopaminergic neurons was supported by the absence of the detection 
of this “deleted” allele in other brain regions, such as the hippocampus (HC) and cortex, 
where dopaminergic neurons are sparse (figure 5.4, C). In cases where the mice were 
not injected with tamoxifen, a Cre-mediated recombination was not detectable, proving 
the absence of leaky Cre recombinase (figure 5.4, K). In general, tamoxifen was 






Figure 5.4: Proof of Pink1 deficiency in serotonergic and dopaminergic neurons in Pink1 x Pet 
and Pink1 x DAT mice. Pink1 flox PCR) The PCR product of the floxed Pink1 allele could be proved in 
Pink1 x Pet and Pink1 x DAT mice.  Pink1 del2/3 PCR) The PCR product for the Pink1 allele obtaining 
deleted exons 2/3 could be proved in the raphe nuclei (RN), the region with the most serotonergic 
neurons, of the Pink1 x Pet mice. The PCR product for the Pink1 allele obtaining deleted exons 2 and 3 
could be proved in the olfactory bulb (OB, midbrain (MB) and kidney (kidn.), regions with dopaminergic 
neurons, of the Pink1 x DAT mice, however only in case of tamoxifen injection. In the absence of 
tamoxifen, the exons 2 and 3 were not deleted since the Cre recombinase did not show leakiness.   
 
To summarize the PCR based characterization: The Pink1 x Pet and Pink1 x DAT 
mouse line exhibited a selective Cre recombinase driven recombination of the exons 
2 and 3 in the Pink1 allele in serotonergic and dopaminergic brain regions, respectively, 
thus highly likely in the respective neuronal populations. In addition, no recombination 
in the Pink1 x DAT mice was detectable if mice were not induced with tamoxifien. Thus, 
the inducible Cre-recombinase does not reveal gross ectopic activity in non-treated 
animals.  
 
5.2 Neuroanatomical analysis 
Since PD symptoms are still mainly regarded as being induced by a dysfunctional 
dopaminergic system, both mouse lines were analysed regarding the morphological 
integrity of this system. Furthermore, since in the Pink1_del2/3 mice a specific 
morphological impairment of the serotonergic neurons (i.e. the serotonergic 
innervation of the olfactory bulb was detected (Glasl et al., 2012)) the integrity of this 
system was analysed as well. The following analysis was performed:  
1. Quantification of the numbers of dopaminergic neurons in the SNC of the ventral 




2. Determination of the tissue content of the both neurotransmitters and distinct 
metabolites in the target regions of these neurons, to evaluate possible dysfunction in 
dopamine (DA) and serotonin (5-HT) metabolism and release, 
3. As well as the serotonergic innervation of the olfactory bulb, to evaluate 
dysfunctional serotonergic input into the OB. 
 
5.2.1 Morphological integrity of the dopaminergic system 
In order to analyse the number of dopaminergic neurons in the SNC, cryosections of 
both mouse lines were stained immunohistochemically using an anti-TH antibody as 
marker for this neuronal population. The number of positive neurons was determined 
by stereological means, at young and middle ages (methods 4.5 and 4.6).  
No significant differences in the number of TH+ cells in the SNC of the young and mid-
aged mutant Pink1 x Pet and Pink1 x DAT mice were detected compared to the control 
groups. The statistics of the number of TH+ cells is summarized in the ANOVA table 
A11 and shown in the appendix. A summary of the descriptive statistics is listed in table 
A12 in the appendix. 
 
Figure 5.5: Number of dopaminergic neurons in substantia nigra pars compacta of Pink1 x Pet 
and Pink1 x DAT mice at young and mid-age. Three different genotype groups were tested indicated 
with different colours. All groups were tested in males and females and shown in a grouped manner. 




Cre:Cre-; Pink1:flox/flox.  (A & B) Pink1 x Pet mice. (C & D) Pink1 x DAT mice. Both mouse lines with a 
young age (A & C) and mid-age (B & D), did not exhibit significant differences in the number of TH+ cells 
in the mutant mice compared to control mice. The data are shown as whisker plots with the median as 
the horizontal line in a box, which demonstrates 50% of the data surrounded by whiskers containing the 
central 95% of the data. 
 
5.2.2 Tissue content of dopamine and serotonin in the target regions of the 
neurons 
In order to analyse the content of DA, 5-HT and its metabolites in the OB, striatum 
(STR) and VM, brain tissue was purified and analysed via HPLC. The different 
substances: DA, 3.4-Dihydroxyphenylacetic acid (DOPAC), epinephrine (E), 
homovanillic acid (HVA), norepinephrine (NE), 3-Methoxytyramine (3-MT), 5-
Hydroxyindole-3-acetic acid (5-HIAA) and 5-HT were considered for the analysis 
(methods 4.7). Epinephrine was not detectable in several mice, hence excluded from 
the analysis.  
The analysis revealed no significant differences in the content of dopamine, serotonin 
and their metabolites in the three brain regions OB, STR and VM neither in young or 
mid-aged mutant Pink1 x Pet and Pink1 x DAT mice compared to the control groups 
(Figure 5.6 & 5.7). The statistical comparison for each substance is summarized in the 
ANOVA tables A13 – A16 and shown in the appendix. A summary of the descriptive 







Figure 5.6: Dopamine content in olfactory bulb, striatum and ventral midbrain of Pink1 x Pet and 
Pink1 x DAT mice at young and mid-age. Three different genotype groups were tested indicated with 
different colours. All groups were tested in males and females and shown in a grouped manner. Blue = 
control 1: Cre:Cre+; Pink1:wt/wt. Red = mutant: Cre:Cre+; Pink1:flox/flox. Green = control 2: Cre:Cre-; 
Pink1:flox/flox.  A - F) Pink1 x Pet mice. G - L) Pink1 x DAT mice. Both mouse lines with a young age 
(A - C, G - I) and mid-age (D - F, J - L) did not exhibit significant differences in the dopamine content in 
the olfactory bulb (OB), striatum (STR) and ventral midbrain (VM) in the mutant mice compared to control 
mice. The data are shown as whisker plots with the median as the horizontal line in a box, which 








Figure 5.7: Serotonin content in olfactory bulb, striatum and ventral midbrain of Pink1 x Pet and 
Pink1 x DAT mice at young and mid- age. Three different genotype groups were tested indicated with 
different colours. All groups were tested in males and females and shown in a grouped manner. Blue = 
control 1: Cre:Cre+; Pink1:wt/wt. Red = mutant: Cre:Cre+; Pink1:flox/flox. Green = control 2: Cre:Cre-; 
Pink1:flox/flox.  A - F) Pink1 x Pet mice. G - L) Pink1 x DAT mice. Both mouse lines with a young age 
(A - C, G - I) and mid-age (D - F, J - L) did not exhibit significant differences in the serotonin content in 
the olfactory bulb (OB), striatum (STR) and ventral midbrain (VM) in the mutant mice compared to control 
mice. The data are shown as whisker plots with the median as the horizontal line in a box, which 
demonstrates 50% of the data surrounded by whiskers containing the central 95% of the data. 
 
5.2.3 Morphological integrity of the serotonergic innervation of the olfactory bulb 
In the Pink1_del2/3 mice, a selective reduction of serotonergic innervation of the 
glomerular layer of the olfactory bulb has been observed (Glasl et al., 2012). Thus, in 
both mouse lines this innervation was analysed by staining immunohistochemically 
using an anti-5-HT antibody as marker for this neuronal population. The density of 
positive neuronal fibers was determined by stereological means at young and middle 
ages in order to detect whether a) Pink1 acts cell autonomously in the serotonergic 
neurons with respect to this phenotype and b) Pink1 deficiency in dopaminergic 




No significant differences of the serotonergic innervation of the glomerular layer of the 
OB in young and mid-aged mutant Pink1 x Pet and Pink1 x DAT mice were detected 
compared to the control groups (Figure 5.8). The statistics of the 5-HT+ innervation is 
summarized in the ANOVA table A11 and shown in the appendix. A summary of the 
descriptive analysis of 5-HT+ innervation is listed in the table A12 in the appendix. 
 
 
Figure 5.8: Density of serotonergic fibres into the olfactory bulb in Pink1 x Pet and Pink1 x DAT 
mice at mid-age. Two different genotype groups were tested indicated with different colours. Red = 
mutant: Cre:Cre+; Pink1:flox/flox. Green = control 2: Cre:Cre-; Pink1:flox/flox.  (A) Pink1 x Pet mice. (B) 
Pink1 x DAT mice. Both mouse lines did not exhibit significant differences in the serotonergic innervation 
of the glomerular layer of the olfactory bulb. The data are shown as whisker plots with the median as 
the horizontal line in a box, which demonstrates 50% of the data surrounded by whiskers containing the 
central 95% of the data.  
 
To summarize the neuroanatomical and biochemical analysis: Both conditional mouse 
lines revealed no alterations in either the dopaminergic or the serotonergic system 
concerning their morphological and/or biochemical integrity. Thus, (i) conditional 
inducible Pink1 deficiency in the dopaminergic system is not sufficient to induce 
dopaminergic neurodegeneration, thus cannot overcome any – if present – 
compensatory mechanisms in place in mice until the age of 14 - 17 months. In addition, 
(ii) the reduced innervation of the olfactory bulb by serotonergic fibers in the full KO is 
not based on cell autonomous mechanisms of serotonergic neurons and is not 





5.3 Analysis of activity and anxiety-related behaviour 
PD patients suffer from motoric impairments, such as a decreased locomotor activity. 
In addition, neuropsychiatric disturbances like anxiety abnormalities are reported in PD 
cases (Jankovic, 2008). In order to analyse the influence of a Pink1 deficiency in 
serotonergic and dopaminergic neurons on locomotion, exploration and anxiety-
related behaviour, mice were tested in the OF  (Tatem et al., 2014, Gould et al., 2009).  
For this purpose, mice were placed in an open field arena to record the movement of 
the mice by infrared sensors (Walsh and Cummins, 1976, Gates et al., 2011). Hereby 
the ActiMot System was used. The horizontal and vertical locomotor activity of the mice 
were monitored to gather information concerning rearing frequency, distance travelled, 
location (methods, figure 4.2).  
The OF parameters Distance travelled [cm], Resting time [sec], Permanence time [sec] 
and Average speed [cm/sec] were examined separately in the centre, periphery and in 
the whole arena, respectively, over the 20 min time (Permanence time [sec] of whole 
area equals the 20 min testing time and was equal for all mice). In addition to that, the 
% Time spent in the centre [%], the % Distance travelled in the centre [%] and the 
Number of rearing [#] were examined within 5 min intervals and in total, in order to 
study the behavioural progress over time. Likewise, the Latency to enter in the centre 
[sec] and the Number of entries in the centre [#] were analysed. In total 32 different OF 
parameters were investigated.  
The statistics of the OF results are summarized in the ANOVA tables A19 – A22 and 
shown in the appendix. A summary of the descriptive analysis of the parameter: Total 
distance travelled [cm], Total number of rearing [#], % Time spent in centre [%] and 
Centre resting time [sec] is listed in the table A23 in the appendix. 
 
5.3.1 Total distance travelled [cm] 
In order to analyse locomotion, the parameter Total distance travelled [cm] was 
analysed. There were no significant differences detectable in the Total distance 
travelled [cm] between the mutant mice and the control groups in both mouse lines at 






Figure 5.9: Total distance travelled [cm] of Pink1 x Pet and Pink1 x DAT mice at young and mid- 
age. Three different genotype groups were tested indicated with different colours. All groups were tested 
in males and females and shown in a grouped manner. Blue = ctrl.1: Cre:Cre+; Pink1:wt/wt. Red = mt: 
Cre:Cre+; Pink1:flox/flox. Green = ctrl.2: Cre:Cre-; Pink1:flox/flox.  (A & B) Pink1 x Pet mice. (C & D) 
Pink1 x DAT mice. Both mouse lines with a young age (A & C) and mid-age (B & D) did not exhibit 
significant differences in the Total distance travelled [cm] between the mutant and control mice. The 
data are shown as whisker plots with the median as the horizontal line in a box, which demonstrates 
50% of the data surrounded by whiskers containing the central 95% of the data.  
 
5.3.2 Total number of rearing [#] 
In order to analyse the explorative behaviour, the parameter total rearing [#] was 
measured in the open field. The young and mid-aged mutant mice of both mouse lines 
did not show significant differences in the Total number of rearing [#] compared to the 






Figure 5.10: Total number of rearing [#] of Pink1 x Pet and Pink1 x DAT mice at young and mid- 
age. Three different genotype groups were tested indicated with different colours. All groups were tested 
in males and females and shown in a grouped manner. Blue = ctrl.1: Cre:Cre+; Pink1:wt/wt. Red = mt: 
Cre:Cre+; Pink1:flox/flox. Green = ctrl.2: Cre:Cre-; Pink1:flox/flox. (A & B) Pink1 x Pet mice. (C & D) 
Pink1 x DAT mice. Both mouse lines with a young age (A & C) and mid-age (B & D) did not exhibit 
significant differences in the Total number of rearing [#] between the mutant and control mice. The data 
are shown as whisker plots with the median as the horizontal line in a box, which demonstrates 50% of 
the data surrounded by whiskers containing the central 95% of the data.  
 
5.3.3 % Time spent in centre [%] 
In order to get information about the anxiety-related behaviour the % Time spent in 
centre [%] was analysed. The young and mid-aged mutant mice of both mouse lines 
did not exhibit a significant difference in the % Time spent in the centre [%] compared 







Figure 5.11: % Time spent in centre [%] of Pink1 x Pet and Pink1 x DAT mice at young and mid-
age. Three different genotype groups were tested indicated with different colours. All groups were tested 
in males and females and shown in a grouped manner. Blue = ctrl.1: Cre:Cre+; Pink1:wt/wt. Red = mt: 
Cre:Cre+; Pink1:flox/flox. Green = ctrl.2: Cre:Cre-; Pink1:flox/flox.  (A & B) Pink1 x Pet mice. (C & D) 
Pink1 x DAT mice. Both mouse lines with a young age (A & C) and mid-age (B & D), did not exhibit 
significant differences in the Time spent in centre [sec] between the mutant and control mice. The data 
are shown as whisker plots with the median as the horizontal line in a box, which demonstrates 50% of 
the data surrounded by whiskers containing the central 95% of the data.  
 
 
5.3.4 Centre resting time [sec] 
In order to get additional information about the anxiety-related behaviour, the Centre 
resting time [sec] was analysed. The young Pink1 x Pet mutant mice rested on average 
46.07 sec (SD = 22.87) in the centre where the mice of the ctrl.1 rested 32.76 sec (SD= 
16.02) and the ctrl.2 rested 23.26 sec (SD = 14.49). The mutant Pink1 x Pet mice 
rested significantly more time in the centre compared to both control groups (F (2,70) = 






Figure 5.12: Centre resting time [sec] in Pink1 x Pet mice at young age. Three different groups 
were tested indicated with different colours. Blue = ctrl.1: Cre:Cre+; Pink1:wt/wt. Red = mt: Cre:Cre+; 
Pink1:flox/flox. Green = ctrl.2: Cre:Cre-; Pink1:flox/flox.  All groups were tested in males and females 
and shown in a grouped manner. The young mutant mice rested significantly more time in the centre 
compared to both controls groups (F (2,70) = 8.863, mt vs ctrl.1, p = 0.031; mt vs ctrl.2, p = 0.0001). 
The data are shown as whisker plots with the median as the horizontal line in a box, which demonstrates 
50% of the data surrounded by whiskers containing the central 95% of the data. For statistical analysis 
the multivariant 2-way ANOVA was used followed by the multiple comparison with the post hoc test 
Bonferroni. p-value ≤ 0.05 = *, p-value ≤ 0.001 = ***. 
 
To summarize the OF testing: The young Pink1 x Pet mutant mice (Cre:Cre+; 
Pink1:flox/flox) rested significantly more time in the centre [sec] compared to the 
control groups (Cre:Cre+, Pink1:wt/wt and Cre:Cre-; Pink1:flox/flox). Apart from that, 
no other parameter, analysed in the open field, was significantly affected in the mutant 
mice compared to the control groups in the young and mid-aged Pink x Pet and Pink 
x DAT mice.  
 
5.4 Analysis of basic reflex pathway and sensorimotor gating 
The ASR is a stereotyped motor response to an abrupt and intense acoustic stimulus, 
which is expressed by a contraction of the major muscles (Zhang et al., 2008). When 
a less intense acoustic stimulus is presented immediately before the acoustic stimulus, 
the reflex is attenuated. This phenomenon is called PPI of the ASR. PPI is a measure 
for sensorimotor gating, which reflects the filtering function of irrelevant information 
(Zoetmulder et al., 2014). ASR and PPI are defined as a biomarker for healthy brain 




with PPI deficits. Likewise, animals with striatal lesions exhibited PPI deficits 
(Vuillermot et al., 2011). Since PD is characterized by a loss of striatal dopaminergic 
neurons, the interest was to study the ASR and PPI in the present mouse models of 
PD (Fearnley and Lees, 1991). 
In order to examine the ASR and PPI, animals were placed in a sound attenuated box 
in which the animals were exposed to random stimuli at different sound levels. The 
resulting muscular reflex reaction was measured using a startle platform (methods 
figure 4.3). In order to examine the ASR, stimuli with a sound pressure of 70 dB, 80 
dB, 85 dB, 90 dB, 100 dB, 110 dB and 120 dB were used. In order to avoid body weight 
effects, all data from ASR were corrected for body weight. The background movement 
of the mice was detected by the null stimulus (NS). The PPI was studied by a stimulus 
with 110 dB preceded by different prepulses with the sound pressure levels of 67 dB, 
69 dB, 73 dB and 81 dB.  
The statistics of the ASR and PPI results are summarized in the ANOVA tables A24 & 
A25 and shown in the appendix. Summaries of the descriptive analysis of the ASR and 
PPI are listed in the tables A26 - A29 in the appendix.  
 
5.4.1 Acoustic startle reflex (ASR) 
In order to analyse the integrity of the brain circuitry of the reflex pathway from auditory 
nerve to the reticulospinal tract the ASR was analysed (Zhang et al., 2008). Mid-aged 
male mutant Pink1 x Pet mice startled on average 13.856 [arbitrary units (a.u.)] (SD = 
4.725) whereas the mice of the ctrl.1 startled 7.432 a.u. (SD = 2.646) and the ctrl.2 
startled 8.835 a.u. (SD = 2.279). The male mutant Pink1 x Pet mice startled 
significantly more at a sound pressure level of 120 dB compared to both male control 





Figure 5.13: Acoustic startle reflex Pink1 x Pet and Pink1 x DAT mice at young and mid-age. 
Three different groups were tested indicated with different colours. Blue = ctrl.1: Cre:Cre+; Pink1:wt/wt. 
Red = mt: Cre:Cre+; Pink1:flox/flox. Green = ctrl.2: Cre:Cre-; Pink1:flox/flox.  All groups were tested in 
males and females, indicated by the letters “m” and “f”.The ordinates represent the ASR, which is the 
amount of movement (reflex) due to an acoustic stimulus, expressed in arbitrary units. The abscissa 
represent the stimuli steps with increasing sound pressure level starting from 70 dB up to 120 dB. The 
null stimulus was measured to identify the background movement without a stimulus. (A & B) Pink1 x 
Pet mice. (C & D) Pink1 x DAT mice. The young (A & C) mutant mice did not show significant differences 
in acoustic startle reflex compared to the control groups. (B) The mid-aged male mutant mice startled 
significantly more compared to both control groups at the stimulus of 120 dB (F (2,29) = mt vs ctrl1: p = 
0.001; mt vs ctrl.2, p = 0.013). (D) The mid-aged mutant mice did not show significant differences in 
acoustic startle reflex compared to the control groups. For statistical analysis, data were analysed with 
multivariant 2-way ANOVA testing followed by the post hoc test with Bonferroni, p ≤ 0.05 = *. The data 










5.4.2 Prepulse inhibition (PPI) 
In order to analyse the filtering mechanism of the brain, the PPI was analysed. The 
mutant mice of the tested mouse lines did not exhibit significant differences in PPI 
compared to both control groups (figure 5.14).  
 
Figure 5.14: Prepulse inhibition of Pink1 x Pet and Pink1 x DAT mice at young and mid-age. Three 
different groups were tested indicated with different colours. Blue = ctrl.1: Cre:Cre+; Pink1:wt/wt. Red = 
mt: Cre:Cre+; Pink1:flox/flox. Green = ctrl.2: Cre:Cre-; Pink1:flox/flox.  All groups were tested in males 
and females, indicated by the letters “m” and “f”. The ordinates represent the PPI, which is the 
percentage reduction of the startle reflex due to pre-stimuli before the actual stimulus with a sound 
pressure of 110 dB. The abscissa represents the different pre-stimuli from 67 dB up to 81 dB. The global 
analysis shows the mean of the PPI over the different pre stimuli. (A & B) Pink1 x Pet (C & D) Pink1 x 
DAT mice. The young (A & C) and mid-aged (B & D) mutant mice did not show significant differences 
in prepulse inhibition compared to the control groups. The data of different mice per group are 
summarized and presented with +/- S.E.M. 
 
To summarize the ASR and PPI testing: The male mutant mid-aged Pink1 x Pet mice 
startle significantly more at a sound pressure level of 120 dB compared to both male 
control groups. Apart from that, mutant mice did not show significant differences 




5.5 Analysis of the gait 
Apart from the typical motor symptoms like bradykinesia, rest tremor or muscle rigidity 
PD patients exhibit gait disturbances. Gait impairments develop already in the very 
early stages of the disease, which usually becomes more severe at later stages (Erro 
and Stamelou, 2017). In order to research the influence of Pink1 deficiency on 
serotonergic and dopaminergic neurons on gait at different ages, mice were analysed 
with the CatWalk XT system. Animals were placed on a glass plate where free walking 
of the mice was enabled. A camera underneath the glass plate recorded the walk 
(Holter et al., 2015)  (methods, figure 5.4).   
An array of different parameters were analysed including the temporal sequence 
during walking, the comparison of paw placements, the interlimb coordination and the 
individual paw. In total 35 different parameters were considered for the analysis of the 
single and grouped paws. A description of the CW parameters is listed in table A30 in 
the appendix. Whereas the main findings of this analysis are depicted below, 
supplementary information is given in the appendix: the statistics of the CW results are 
summarized in the ANOVA tables A31 - 46 and shown in the appendix. A summary of 
the descriptive analysis of Pink1 x Pet mice of the selected CW parameter: Minimum 
intensity [pixel] of LF paws, % Max contact at [%] of left front (LF) paws and front paws 
(FP), and phase dispersion of LF-RF (left front - right front) paws is listed in the table 
A47 in the appendix. A summary of the descriptive analysis of Pink1 x DAT mice of the 
selected CW parameter: Stance duration [sec] of right hind (RH) paws and hind paws 
(HP), Body speed [cm/sec] of left hind (LH) paws and HP, Swing speed [cm/sec] of LH 
paws and HP and Base of support of HP is listed in the tables A48 - A49 in the 
appendix.  
 
5.5.1 Gait in Pink1 x Pet mice 
Minimum intensity [pixel], LF paws: The LF paws of the young male Pink1 x Pet mutant 
mice were placed on the glass plate with a minimum intensity of 28.74 pixel (SD = 
0.38). The pixel was recorded in a range from 0 to a maximum of 255 pixel. Hence, 
lower numbers refer to a lower intensity of placed paws on the glass plate. The young 
male ctrl.1 mice placed the LF paw with a minimum intensity of 29.19 pixel (SD = 0.47) 
on the glass plate and the young male ctrl.2 mice reached a minimum intensity of the 
LF paws of 29.28 [pixel] (SD = 0.39). The young male Pink1 x Pet mutant mice showed 




and exhibited significantly lower minimum intensities of the LF paws in comparison to 
the ctrl.2 (F (2,27) = 4.455, p = 0.062) (Figure 5.15, A).  
 
% Maximum contact at [%], LF paws: In addition, young female Pink1 x Pet mutant 
mice established a maximum contact of the LF paws with the glass plate after 40.02 
% (SD = 4.93) of the total glass contact time. The LF paws of the young female ctrl.1 
mice reached the glass contact after 32.81% (SD = 7.08) and ctrl.2 mice after 33.24% 
(SD = 5.92) of the total glass contact time. The young female Pink1 x Pet mutant mice 
required significantly more percentage time in order to reach the maximum contact of 
the LF paws with the glass plate in comparison to the both control groups (F (2,35) = 
4.774, mt vs ctrl1: p = 0.023; mt vs ctrl.2, p = 0.035) (Figure 5.15, B). 
The same effect was observed in the mid-aged female Pink1 x Pet mice, where the LF 
paws of the mutant mice took significantly more percentage time in order to reach the 
maximum contact of the glass plate compared to both control groups (F (2,32) = 5.151, 
mt vs ctrl1: p = 0.015; mt vs ctrl.2, p = 0.043). Here, the LF paws of the young female 
Pink1 x Pet mutant mice established a maximum contact with the glass plate after 
42.37% (SD = 3.81) of the total glass contact time. The LF paws of the young female 
ctrl.1 mice reached the glass contact after 34.85% (SD = 7.39) and ctrl.2 mice after 
36.02% (SD = 5.44) of the total glass contact time (Figure 5.15, C). 
 
% Maximum contact at [%], FP paws: Next to the LF paws, a similar effect occurred in 
the FP of the mid-aged female Pink1 x Pet mice, where the mutant mice placed the FP 
after 45.66% (SD = 4.02) of the total contact time with the glass plate at a maximum 
contact. The FP of the mid-aged female ctrl.1 mice reached the maximum contact after 
40.69% (SD = 5.00) and ctrl.2 mice after 38.57% (SD = 4.85) of the total glass contact 
time. The mid-aged female Pink1 x Pet mutant showed a tendency to higher 
percentage time in comparison to the ctrl.2 mice and needed significantly more 
percentage time to place the FP at maximum contact in comparison to the ctrl.1 mice 
(F (2.32) = 6.639, mt vs ctrl1: p = 0.056; mt vs ctrl.2, p = 0.003) (Figure 5.15, D). 
 
Phase dispersion [%], LF-RF: Mid-aged female Pink1 x Pet mutant mice exhibited an 
impairment in the temporal relationship between the placement of the LF and RF paws 
(Phase dispersion %) compared to both control groups (F (2.32) = 8.358, mt vs ctrl1: p 
= 0.002; mt vs ctrl.2, p = 0.005). A phase dispersion of 50.00% describes an optimal 




aged female Pink1 x Pet mice reached a near optimum phase dispersion (ctrl.1: 
49.28% (SD = 2.26) and ctrl.2: 49.67% (SD = 2.26)) in contrast to the mutant mice 
(52.77%, SD = 2.57). The mid-aged female mutant Pink1 x Pet mice exhibited 
significantly higher percentages in phase dispersion of LF-RF paws (F (2,32) = 8.358, mt 
vs ctrl.1: p = 0.002; mt vs ctrl.2, p = 0.005) (Figure 5.15, E). 
 
 
Figure 5.15: Affected gait parameters Pink1 x Pet mice at young and mid-age. Three different 
groups were tested indicated with different colours. Blue = ctrl.1: Cre:Cre+; Pink1:wt/wt. Red = mt: 
Cre:Cre+; Pink1:flox/flox. Green = ctrl.2: Cre:Cre-; Pink1:flox/flox.  Males and females were tested 




tendency to place the LF paws with a lower minimum intensity as compared to the ctrl.1 (F (2,27) = 
4.455, p = 0.032) and exhibited significant lower minimum intensities of the LF paws in comparison to 
the ctrl.2 (F (2,27) = 4.455, p = 0.062). B) Young and C) mid-aged female mutant mice required 
significantly more percentage time in order to establish a maximum contact with the LF paws on the 
glass plate compared to both control groups (young: (F (2,35) = 4.774, mt vs ctrl1: p = 0.023; mt vs 
ctrl.2, p = 0.035; mid-aged: (F (2,32) = 5.151, mt vs ctrl1: p = 0.015; mt vs ctrl.2, p = 0.043)). D) Mid-
aged female mutant mice showed a tendency to a higher percentage time of establishing the maximum 
contact of the FP with the glass plate compared to the ctrl.1 (F (2.32) = 6.639, p = 0.056). However, 
mid-aged female mutant mice established a significant higher percentage maximum contact time 
compared to the ctrl.2 (F (2.32) = 6.639, p = 0.003). E) Mid-aged female mutant mice established 
significantly higher percentages of phase dispersion compared to both control groups (F (2.32) = 8.358, 
mt vs ctrl1: p = 0.002; mt vs ctrl.2, p = 0.005). For statistical analysis, data were analysed with 
multivariant 2-way ANOVA testing followed by the post hoc test with Bonferroni, p ≤ 0.05 = *. The data 
are shown as whisker plots with the median as the horizontal line in a box, which demonstrates 50% of 
the data surrounded by whiskers containing the central 95% of the data. 
 
 
5.5.2 Gait in Pink1 x DAT mice 
Stance duration [sec], RH paws: Stance duration is the duration of paw contact with 
the glass plate during one paw placement. The RH paws of the young Pink1 x DAT 
mutant mice exhibited a stance duration of 0.11 sec (SD = 0.01), whereas the ctrl.1 
mice required 0.10 sec (SD = 0.02) and the ctrl.2 mice required 0.10 sec (SD = 0.02). 
The RH paws of the young Pink1 x DAT mutant mice exhibited a significantly higher 
stance duration as compared to both control groups (F (2,66) = 4.282, mt vs ctrl1:  
p = 0.028; mt vs ctrl.2: p = 0.038) (Figure 5.16, A).  
 
Stance duration [sec], HP: A similar effect was observed in the stance duration of the 
HP of the young Pink1 x DAT mutant mice. Here, the mutant mice exhibited a stance 
duration of 0.11 sec (SD = 0.01), the ctrl.1 mice of 0.10 sec (SD = 0.02) and the ctrl.2 
mice of 0.11 sec (SD = 0.02). The young mutant mice exhibited a significantly higher 
stance duration of the HP compared to the ctrl.1 mice (F (2,66) = 3.711, p = 0.033) and 
showed a tendency to higher stance duration of the HP to the ctrl.2 mice (F (2,66) = 
3.711, p = 0.090) (Figure 5.16, B).  
 
Body speed [cm/sec], LH paws: The speed of the body from one initial contact of the 
LH paw to the next initial contact of the young Pink1 x DAT mutant mice was  
24.23 cm/sec (SD = 4.57). The young ctrl.1 mice showed a body speed of the LH paw 
of 27.55 cm/sec (SD = 4.63) and the ctrl.2 mice of 27.52 cm/sec (SD = 5.29). The 
young mutant Pink1 x DAT mice showed a tendency to a slower body speed of the LH 
paw as compared to both control groups (F (2.66) = 3.515, mt vs ctrl1: p = 0.068; mt vs 





Body speed [cm/sec], HP: The same effect was observed in the body speed of the HP, 
where young Pink1 x DAT mutant mice showed a tendency to a slower body speed 
compared to both control groups (F (2.66) = 3.288, mt vs ctrl1: p = 0.092; mt vs ctrl.2,  
p = 0.070). The young mutant mice exhibited a body speed of HP of 24.27 cm/sec  
(SD =4.56), the ctrl.1 mice of 27.42 cm/sec (SD = 4.55) and the ctrl.2 mice of  
27.51 cm/sec (SD = 5.37) (Figure 5.16, D).  
 
Swing speed [cm/sec], LH paws: The young Pink1 x DAT mutant mice swung the LH 
paws during the time without with the glass plate (swing phase) with a speed of 55.91 
cm/sec (SD = 10.39) where the LH paws of the ctrl.1 mice swung with a speed of 64.19 
cm/sec (SD = 10.41) and of ctrl.2 mice with a speed of 64.24 cm/sec (SD = 11.61). 
The young Pink1 x DAT mutant mice swung the LH paws with a significantly slower 
speed compared to both control groups (F (2.66) = 6.095, mt vs ctrl.1: p = 0.007; mt vs 
ctrl.2: p = 0.006) (Figure 5.16, E). 
 
Swing speed [cm/sec], HP: The same effect was observed in the swing speed of the 
HP of the young Pink1 x DAT mice. The young Pink1 x DAT mutant mice swung the 
HP with a speed of 55.60 cm/sec (SD = 10.37), the ctrl.1 mice with a speed of 62.71 
cm/sec (SD = 8.62) and the ctrl.2 mice with a speed of 62.25 cm/sec (SD = 11.15). 
The young Pink x DAT mutant mice swung the HP during the swing phase significantly 
slower compared to both control groups (F (2.66) = 4.541, mt vs ctrl.1: p = 0.017; mt vs 
ctrl.2, p = 0.024) (Figure 5.16, F). 
 
Base of support [cm], HP: The mid-aged male Pink1 x DAT mutant mice displayed a 
distance between the HP of 2.81 cm (SD = 0.21). In comparison the ctrl.1 mice showed 
HP distances of 3.19 cm (SD = 0.22) and ctrl.2 mice of 3.07 cm (SD = 0.20). The mid-
aged male mutant mice put the HP significantly closer together compared to both 
control groups (F (2, 28) = 8.405, mt vs ctrl.1: p = 0.001; mt vs ctrl.2, p = 0.035) (Figure 







Figure 5.16: Affected gait parameters in Pink1 x Pet mice at young and mid-age. Three different 
groups were tested indicated with different colours. Blue = ctrl.1: Cre:Cre+; Pink1:wt/wt. Red = mt: 
Cre:Cre+; Pink1:flox/flox. Green = ctrl.2: Cre:Cre-; Pink1:flox/flox.  Males and females were tested 




hind paws.  A) Young mutant mice exhibited a significantly higher stance duration of the RH paws 
compared to both control groups (F (2,66) = 4.282, mt vs ctrl1: p = 0.028; mt vs ctrl.2: p = 0.038). B) 
The young mutant mice showed a significantly higher stance duration of the HP compared to the ctrl.1 
and a tendency to higher stance duration compared to the ctrl.2 (F (2,66) = 3.711; mt vs ctrl.1: p = 0.033; 
mt vs ctrl.2: p = 0.090). E & F) The young mutant mice swung the LH and HP significantly slower 
compared to both control groups (LH: F (2,66) = 6.095, mt vs ctrl.1: p = 0.007; mt vs ctrl.2: p = 0.006; 
HP: F (2,66) = 4.541, mt vs ctrl.1: p = 0.017; mt vs ctrl.2: p = 0.024). G & H) The young mutant mice 
showed a tendency to a slower body speed with the LH paws and HP compared to both control groups 
(LH: F (2,66) = 3.515, mt vs ctrl.1: p = 0.068; mt vs ctrl.2: p = 0.064; HP: F (2,66) = 3.288, mt vs ctrl.1: 
p = 0.092; mt vs ctrl.2: p = 0.070). The mid-aged male mutant mice put the HP significantly closer 
together compared to control groups (F (2, 28) = 8.405, mt vs ctrl.1: p = 0.001; mt vs ctrl.2, p = 0.035). 
For statistical analysis, data were analysed with the 2-way ANOVA testing followed by the post hoc test 
with Bonferroni, p ≤ 0.05 = *. The data are shown as whisker plots with the median as the horizontal line 





Figure 5.17: Exemplified print view of Pink1 x DAT mice at mid-age. ctrl.1: Cre:Cre+; Pink1:wt/wt. 
mt: Cre:Cre+; Pink1:flox/flox. ctrl.2: Cre:Cre-; Pink1:flox/flox.  The running direction goes from the right 
side to the left side, indicated by the white arrow. Each example shows two step cycles of the left hind 
and right hind paw. The dotted lines indicate the base of support, which is the distance [cm] of the both 
hind paws. The vertical dotted line of the mutant mice Cre:Cre+, Pink1:flox/flox is shorter compared to 
that one of the both control groups. 
 
To summarize the CW testing: Both tested mouse lines Pink1 x Pet and Pink1 x DAT 
displayed selective affected parameters due to the Pink1 deficiency in serotonergic 
and dopaminergic neurons.  
The young male Pink1 x Pet mutant mice established partially a lower minimum 
intensity of the LF paw compared to the control groups. In addition, young female  
Pink1 x Pet mutant mice displayed higher percentage time until the LF paws reached 
the maximum contact compared to the control groups. This phenotype was also 
present in the mid-aged female Pink1 x Pet mutant mice. In addition, the FP paws of 
the mid-aged female Pink1 x Pet mutant mice needed more percentage time compared 
to the control groups in order to reach the maximum contact with the glass plate.  Apart 
from the individual paw-related parameters, mid-aged female Pink x Pet mutant mice 
showed higher percentages in phase dispersion of the LF-RF paws, which represents 
the interlimb coordination.  
The young Pink1 x DAT mutant mice took more time in the stance duration of the RH 
paws and HP, exhibited a slower swing speed of the LH paws and HP and showed a 
decreased body speed of the LH paws and HP in comparison to both control groups.  




decreased base of support in comparison to both control groups, which represents the 
comparative paws.  
 
5.6 Analysis of the olfactory function 
Olfactory impairments are dominant in more than 90% of PD patients (Schapira et al., 
2017). Male Pink1_del2/3 mice developed olfactory dysfunction due to the Pinkl1 
deficiency (Glasl et al., 2012). In order to dissect the influence of the distinct 
neurotransmitter systems on the olfactory dysfunction with Pink1 deficiency, Pink1 x 
Pet and Pink1 x DAT mice were tested for olfactory function. Therefore, mice were 
tested using two different approaches: testing of olfactory discrimination of binary 
mixtures and testing of olfactory sensitivity threshold. Before that, mice were trained to 
the odorant [S+] by rewarding them with chocolate pellets. During the testing of binary 
mixture discrimination, mice needed to choose the odorant [S+], which was diluted with 
the odorant [S-] at different concentration levels of 100%, 70%, 55%, 53% and 51%, 
for example a mixture of 51% includes 51% of the odorant [S+] and 49% of the odorant 
[S-]. The percentage of correct choices was recorded. Afterwards, mice were exposed 
to the odorant, which was diluted in a stepwise manner and recorded until mice were 
able to detect the diluted odorant [S+] (methods figure 4.7). Since only male 
Pink1_del2/3 mice were previously tested on olfactory performance, only male Pink1 
x Pet and Pink1 x DAT mice were considered for olfactory testing. The statistics of the 
olfactory testing results are summarized in the ANOVA table A50 and shown in the 
appendix. A summary of the descriptive analysis of the olfaction tests are listed in the 
table A51 in the appendix.  
 
5.6.1 Analysis of binary mixture discrimination 
In order to analyse the olfactory fine discrimination, mice were tested on a binary 
discrimination task. The mutant mice of the tested mouse lines did not exhibit 
significant differences in the percentage of correct choices of the odorant [S+]  





Figure 5.18: Binary mixtures testing of Pink1 x Pet and Pink1 x DAT mice at young and mid-age. 
Three different groups were tested indicated with different colours. Blue = ctrl.1: Cre:Cre+; Pink1:wt/wt. 
Red = mt: Cre:Cre+; Pink1:flox/flox. Green = ctrl.2: Cre:Cre-; Pink1:flox/flox. Only male mice were 
tested, indicated by the letter “m” in the legend. The original 10% concentrated odorant [S+] and [S-] 
were labelled as 100% concentrated. All odorants percentages stand for volume percent (v/v).  The 
ordinates represent the percentage of successful discrimination of the odorant [S+] that was in mixture 
with the odorant [S-]. The abscissa represents the different concentrations 100%, 70%, 55%, 53% and 
51% (v/v) of the odorant [S+] in mixture with the odorant [S-]. (A & B) Pink1 x Pet mice. (C & D) Pink1 x 
DAT mice. Both mouse lines with a young age (A & C) and mid-age (B & D), did not exhibit significant 
differences in discrimination of the odorant [S+] in a mixture with the odorant [S-].The data of different 














5.6.2 Analysis of olfactory sensitivity 
In order to analyse the olfactory sensitivity, the threshold of diluted odorant [S+] of the 
mice was detected. The mutant mice of the tested mouse lines did not exhibit 
significant differences in the sensitivity threshold of the odorant [S+] compared to both 
control groups (figure 5.19).  
 
Figure 5.19: Testing of olfactory sensitivity threshold of Pink1 x Pet and Pink1 x DAT mice at 
young and mid-age. Three different groups were tested indicated with different colours. Blue = ctrl.1: 
Cre:Cre+; Pink1:wt/wt. Red = mt: Cre:Cre+; Pink1:flox/flox. Green = ctrl.2: Cre:Cre-; Pink1:flox/flox. Only 
male mice were tested, indicated by the letter “m” in the legend. The ordinates represent the threshold 
of dilution steps of the odorant [S+] until which mice were able to detect the diluted odorant [S+]. (A & 
B) Pink1 x Pet mice. (C & D) Pink1 x DAT mice. Both mouse lines with a young age (A & C) and mid-
age (B & D), did not exhibit significant differences in threshold of dilution steps of the odorant [S+]. The 
data are shown as whisker plots with the median as the horizontal line in a box, which demonstrates 
50% of the data surrounded by whiskers containing the central 95% of the data. 
 
To summarize the olfactory testing: The young and mid-aged Pink1 x Pet and Pink1 x 
DAT mutant mice did not exhibit significant differences in the olfactory binary 
discrimination and sensitivity threshold of the odorant [S+] compared to both control 





The Pink1 x Pet and Pink1 x DAT mouse lines did not show PD-related 
neuropathological alteration due to the deficiency of Pink1 in serotonergic and 
dopaminergic neurons. Neither a neurodegeneration of dopaminergic neurons in the 
SNC or an impaired serotonergic innervation into the olfactory bulb was observed in 
the mutant mice. Furthermore, no changes were observed in the content of dopamine 
and serotonin and its metabolites in different brain tissues. Equally, the analysed mice 
did not reveal olfactory impairments. Young and mid-aged (male) mutant Pink1 x Pet 
mice exhibited small genotype effects in the OF testing and in the ASR. In addition, 
Pink1 x Pet mutant mice showed PD-related gait phenotypes, mainly the left front paw 
was affected. Also, young and old Pink1 x DAT mice displayed PD-related gait 
impairments due to affected hind paws. Taken together, Pink1 x Pet and Pink1 x DAT 
mice exhibited slight PD-related non-motor symptoms, which were partially sex related 
(summarized in figure 5.20).  
 
 
Figure 5.20 Summary of Pink1 x Pet and Pink1 x DAT phenotypes. Pink1 x Pet and Pink1 x DAT 
mice were analysed with a young and mid-aged age in PD-related neuropathology, motor and non-
motor symptoms. Both mouse lines showed slight non-motor symptoms related phenotypes in young 
and mid-aged age. n.a = not applicable, sex = only significant in one sex, → not changed, ↑ up, ↓ down, 
DA = dopamine, SNC = substantia nigra pars compacta, OB = olfactory bulb, STR = striatum, VM = 












age [months] age [months] age [months] age [months]
→ → → →
→ → → →
→ n.a. → → n.a. →
Motor symptomes → 3.8 → 14.4 → 4.3 → 15.3
Anxiety Open filed test ↓ 3.8 → 14.4 → 4.3 → 15.3
ASR → ↑sex → →
PPI → → → →
front paws ↓sex ↓sex → →
hind paws → → ↓ ↓sex
discrimination → → → →





















Pink x Pet, young Pink1 x Pet, mid-aged  Pink1 x DAT, young Pink1 x DAT, mid-agedSpecification
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Discussion & Outlook 
 
 
Based on a previous study of Glasl and colleagues, a murine Pink1 deficiency did not 
lead to neuronal degeneration in the substantia nigra pars compacta (SNC) or overt 
motor-phenotypes. Nevertheless, selected age-dependent non-motor phenotypes in 
olfaction and gait, including alterations in the serotonergic system, were observed 
(Glasl et al., 2012). This raises the question concerning the integrity of different 
neurotransmitter systems in Parkinson’s disease (PD)-related phenotypes in young 
and aged animals. In addition, an in vitro acute knockdown (KD) of Pink1 caused a 
mitochondrial phenotype, which was compensated over time. Therefore, another 
question focussed on the potential compensatory mechanism consequent to Pink1 
deficiency (Glasl et al., 2012).  
 
In order to study:  
(1) The precise contribution of the dopaminergic or serotonergic neurotransmitter 
systems in respect to the PD-related symptoms,  
(2) The potential compensatory mechanism consequent to Pink1 deficiency, hindering 
the outbreak of PD and  
(3) The impact of age on the outbreak of PD-related symptoms,  
Two conditional Pink1 knockout (KO) mouse lines were generated: the first is a mouse 
line with a Pink1 deficiency in dopaminergic neurons induced during early adulthood 
and the second line where Pink1 was constitutively eliminated in the serotonergic 
neurons. Both mouse lines were systemically analysed at both young adult and middle 
age. Animals underwent a thorough behavioural analysis with respect to PD-related 
motor and non-motor symptoms, as well as a neuroanatomical and biochemical 
analysis of the brain. In summary, neither of the mouse lines revealed PD-related 
neurodegeneration and neurotransmitter anomalies. However, there were some PD-
related gait phenotypes. Furthermore, other behavioural testing did not show 





6.1 Serotonergic and dopaminergic system 
The selective KO of Pink1, neither in the constitutive serotonergic KO nor in the 
inducible dopaminergic KO, led to a degeneration of dopaminergic neurons in the SNC, 
independent of young or middle age.  
These results suggest that Pink1 deficiency in the serotonergic system does not 
influence dopaminergic neurons in the substantia nigra with respect to survival. This 
notion was conceivable taking into account that serotonergic neurons innervate the 
dopaminergic neurons of the substantia nigra and that serotonin might act as a 
neuroprotective agent (Chilmonczyk et al., 2017).  In addition, the number of 
serotonergic neurons in the raphe nuclei themselves did not succumb to cell death in 
the analysed mouse models (data not shown, personal communication). Furthermore, 
the content of dopamine and its metabolites in the analysed brain regions: olfactory 
bulb (OB), ventral midbrain (VM) and striatum (STR), exhibited no alterations in either 
of the analysed mouse lines, irrespective of age. This supports the neuropathological 
finding of no gross alterations in both systems in both mouse lines. However, we 
cannot exclude that a Pink1 deficiency has an impact on neurotransmitter release as 
it has been reported by several laboratories (Kitada et al., 2007, Moisoi et al., 2014, 
Gispert et al., 2009, Akundi et al., 2011). In order to determine such a release problem, 
a micro dialysis experiment would be of interest.  
Considering mouse models with a constitutive KO of Parkin, Pink1, DJ-1 and even a 
triple KO of these three genes, none of them established degeneration of dopaminergic 
neurons. Hence analysis of  conditional acute KO mouse models of PD are necessary 
in order to target the single pathways and to circumvent potential compensatory 
mechanisms (Kitada et al., 2009, Glasl et al., 2012, Perez and Palmiter, 2005, 
Goldberg et al., 2005). Nevertheless, neither the full constitutive KO of Pink1, nor the 
inducible KO of Pink1 in dopaminergic neurons, nor the KO of Pink1 in serotonergic 
neurons induces overt neurodegeneration of dopaminergic or serotonergic neurons. 
Thus, at least for Pink1 deficiency there are no compensatory mechanisms established 
during development, which might have been overcome by the inducible KO, in contrast 
to the conditional Parkin KO. This is of specific interest since Pink1 deficiency was 
induced in young adulthood in the dopaminergic neurons, similar to the acute deletion 
of Parkin via lentiviral injection in mice (Shin et al., 2011, Yang et al., 2006). However, 
the absence of neuronal degeneration in the conditional Pink1 x DAT mouse line is in 




KO of Parkin indeed leads to dopaminergic neurodegeneration (Shin et al., 2011). 
These results are surprising because Pink1 and Parkin display in vitro interaction, 
suggesting that Pink1 acts upstream of Parkin (Kondapalli et al., 2012, Okatsu et al., 
2012, Kane et al., 2014). Likewise, studies on acute Pink1 KD flies demonstrated 
mitochondrial alteration and neuronal degeneration, which was suppressed by Parkin 
overexpression (Clark et al., 2006, Yang et al., 2006). This would entail the interacting 
Pink1 and Parkin in vivo playing a role in the development of PD-related phenotypes 
and pathology. However, since an acute KD of murine Pink1 in dopaminergic neurons 
did not lead to neuronal degeneration, Pink1 and Parkin interaction in dopaminergic 
neurons might not have an impact on the development of PD-related symptoms. It is 
also possible that Pink1 in vivo in dopaminergic neurons of mice acts independently of 
Parkin, potentially through an additional pathway.  
The absence of neurodegeneration in all these models, specifically in the Pink1 full 
KO, is in sharp contrast to the human situation. Human PD patients suffering from 
inherited Pink1 mutation are prone a cell loss in SNC (Puschmann, 2013). A possible 
explanation for the absence of neurodegeneration in Pink1-deficient mice compared to 
humans is the amount of neuromelanin (NM) in the SNC. NM is distributed in 
dopaminergic neurons and NM containing neurons of the SNC are highly vulnerable 
to degeneration in PD (Depboylu et al., 2007). In human brains, NM is detectable 
whereas the presence of NM in rodent brain is under debate, which in turn indicates a 
higher amount of NM in the human brain (Fedorow et al., 2005). Nonetheless, since 
dopaminergic neurons also die in rats and flies with Pink1 deficiency, there might be 
further factors and pathways eliciting species-specific dopaminergic 
neurodegeneration (Park et al., 2006, Yang et al., 2006, Dave et al., 2014, Villeneuve 
et al., 2016).  
Aging per se is the greatest risk factor for the development of PD, since the prevalence 
of developing PD increases more than 400 times from 50  to 80 years of age  (Collier 
et al., 2011, Rodriguez et al., 2015). Therefore, the aim was to understand the influence 
of age as a covariate consequent to Pink1 deficiency in selected neurotransmitter 
systems, since PD-related phenotypes of Pink1 deficient mice were observed in aged 
animals (Glasl et al., 2012). Considering the number of dopaminergic neurons, a Pink1 
deficiency in the serotonergic or dopaminergic system did not alter compared to the 
control mice. However, dopaminergic neurons do also die with increasing age in 
healthy persons, it is possible that the quantity of cell loss is the main difference 




constitutive KO of Pink1, no aging effect was observed in the longitudinal study. Since 
the analysed mid-aged mice did not reach the age-related maximum peak of their 
lifetime, potential cell loss differences might have occurred at a later time point, much 
later than the normal life span of the mice. On the other hand, PD patients carrying a 
Pink1 mutation develop an early-onset PD at an estimated age of younger than 40 
years. This is much earlier than the mean age of onset of PD with about 60 years (Lees 
et al., 2009). However, it is under debate whether potential compensatory mechanisms 
protect the constitutive dopaminergic neurons that die with increasing age. Overall, 
aging plays an important role in PD and clarifying the biological basis of aging might 
contribute to understanding the underlying mechanism of PD (Rodriguez et al., 2015). 
It will be important to determine if, at a molecular level, ageing in mice can be compared 
to ageing in humans. This is necessary to draw definitive conclusions concerning the 
underlying molecular mechanisms that account for the absence of neurodegeneration 
in mice. If it reflects a true species-specific effect, studying mice would become even 
more important to be able to learn about potential compensatory mechanisms and 
even about neuroprotective strategies.  
In summary, a KO of Pink1 in dopaminergic and serotonergic neurons does not trigger 
dopaminergic neuronal degeneration nor influences the content of dopamine, 
serotonin and its metabolites.  Since the KO of Pink1 in dopaminergic neurons in this 
study was done in an acute manner at an age of 10 weeks, potential compensatory 
mechanisms during development could have been overcome. Thus, Pink1 in 
dopaminergic neurons is not involved in compensation of neuronal degeneration. In 
addition, Pink1 was constitutively eliminated in serotonergic neurons. The published 
phenotype of altered serotonergic innervation of the OB in Pink1_del2/3 mice was not 
replicated by the constitutive Pink1 KO in serotonergic neurons. Hence, the 
serotonergic system – with Pink1 deficiency – did not contribute to the changes in 
serotonergic innervation in the OB. It can thus be concluded that, Pink1 is not acting 
in a cell autonomous manner. 
 
6.2 Locomotor and explorative function  
Gispert and colleagues described locomotor impairments in the open field (OF) testing 
by a reduction of distance travelled, rearing frequency and movement time in aged 
Pink1 KO mice (Gispert et al., 2009). Even though these mice did not display neuronal 
degeneration, the striatal dopamine level was altered. Pink1 deficiencies in 




absence of a locomotor phenotype was likely since there was no alteration in striatal 
dopamine level nor were dopaminergic neurons degenerated. Indeed, first motor 
symptoms in PD patients were described after more than 50% of dopaminergic 
neurons in the SNC were lost, therefore the absence of a locomotor phenotype with 
Pink1 deficiency in serotonergic or dopaminergic neurons are in accordance with the 
neuroanatomical and biochemical results (Schapira et al., 2017, Grosch et al., 2016).  
  
Interestingly, young mutant Pink1 x Pet mice rested significantly longer in the centre 
compared to both control groups. This is a first indication of an anxiety-related 
phenotype. Nevertheless, it needs to be considered that a clear anxiolytic phenotype 
of longer resting time in the centre might also correlate with other parameters like a 
longer overall resting time [s] and total distance travelled in the centre [cm] or centre 
average speed [cm/s]. Since these parameters were not affected in the young Pink1 x 
Pet mice, a clear anxiety-related behaviour is still under debate and would need to be 
researched with additional behavioural tests, like forced swim test or light dark box 
test. Still, it is known that anxiety-related behaviour is influenced by the serotonergic 
system (Baldwin and Rudge, 1995). Hence, Pink1 in serotonergic neurons might play 
a specific role in controlling anxiety-related behaviour. However, it has to be mentioned 
that PD patients suffer from an increased anxiety, which is in contrast to the observed 
anxiolytic behaviour in these mice, since anxious mice are more likely to avoid open 
unknown places (Jankovic, 2008, Seibenhener and Wooten, 2015). The content of 
serotonin did not fluctuate in the analysed brain regions: OB, VM and STR. 
Nevertheless, the amygdala is a key player in the development of anxiety and is 
prominently modulated by serotonin (Bocchio et al., 2016). Therefore, further analysis 
on the serotonin content in the amygdala would be of interest in the sense that a 
specific serotonergic deficit in these brain regions might have been induced by the 
Pink1 deficiency.  
In summary, a Pink1 deficiency in selected neurotransmitter systems did not lead to 
overt locomotor and explorative impairments possibly due to an insufficient induction 
of neuronal cell death in both neurotransmitter systems, hence no compensatory 
mechanism could be detected.  
 
6.3 Acoustic startle reflex and prepulse inhibition in PD 
The mid-aged male mutant Pink1 x Pet mice startled significantly more compared to 




the relevance of this finding has to be ascertained. These results are in agreement with 
studies on a PD patient with a Pink1 mutation, who exhibited hyperreflexia symptoms 
(Zhang et al., 2005). It is known that serotonin is involved in reflex modulation (Schmidt 
and Jordan, 2000). However, further studies would be necessary, in order to 
understand the serotonergic influence in Pink1 deficient mice on possible reflex-related 
parameters, such as nerve conductance velocity testing or electrophysiological 
analysis to study the function of reflex arcs.  
On the other hand, this phenotype could also be due to mutant mice exhibiting less 
hearing loss compared to both control groups upon ageing. Indeed, serotonin plays an 
important role in the neuronal circuit in hearing processing. Human studies have shown 
that citalopram, a serotonin reuptake inhibitor, has a positive impact on the acoustic 
processing in older people (Cruz et al., 2004). In addition, it is known that a decreased 
serotonergic receptor expression correlates with the age-dependent hearing loss 
(Tadros et al., 2007). Hence, a Pink1 deficiency possibly influences the gene 
expression of these serotonergic receptors and may explain why mutant mice undergo 
less hearing loss. However, post mortem studies on PD patients revealed an increased 
number of serotonergic receptors (Ballanger et al., 2010), which is contradictory to the 
hypothesis above. Thus, further analysis of serotonergic receptors in Pink1 x Pet mice 
would be of interest, in order to discern a potential correlation of serotonergic receptors 
to hearing loss. Nevertheless, improved hearing capability consequent to a Pink1 
deficiency is contradictory to studies on PD patients, who develop age-dependent 
peripheral hearing impairments (Vitale et al., 2012).  
 
6.4 Gait in PD 
As a rough overview, Pink1 x Pet (female) mutant mice exhibited significant differences 
compared to the control groups in the parameter Max contact at [%] of the (left) front 
paws and temporal relation of the front paws, described by Phase dispersion [%]. The 
mutant Pink1 x DAT mice showed significant differences in parameters concerned with 
speed and the position of the footprint i.e. the base of support.  
Gait alterations were already described in PD patients with Pink1 mutations (Siuda et 
al., 2014). Interestingly, the Pink1_del2/3 mice, which were tested in the study of Glasl 
and colleagues, exhibited similar phenotypes (Glasl et al., 2012). Male Pink1 deficient 
mice tended to exhibit a higher Max Contact [%] compared to the control mice. 
Referring to the present study, female mutant Pink1 x Pet mice showed a significant 




hind paws of male Pink1 deficient mice were affected in contrast to the affected female 
(left) front paws of mutant Pink1 x Pet mice. In addition, male Pink1 deficient mice 
showed impairments in phase dispersion of diagonal paws. The parameter phase 
dispersion was also affected in the female mutant Pink1 x Pet mice. However, female 
front paws were affected.   
Pink1 x DAT male mutant mice showed a tendency and significant difference 
compared to both control groups in a lower base of support. This parameter was also 
significantly reduced in the male Pink1_del2/3 mice published by Glasl and colleagues, 
showing a dopamine dependent gait phenotype (Glasl et al., 2012). In support of that, 
treatment of PD patients with L-3.4-Dihydroxyphenylalanine (L-DOPA) improved the 
kinematic parameter swing velocity, which was significantly reduced in mutant Pink1 x 
DAT mice (Blin et al., 1991). In another study of PD patients, dopamine depletion was 
shown to impair gait automaticity, showing a gait dependency on dopamine (Gilat et 
al., 2017).  
Considering the procedure of CatWalk testing, mice receive no prior training, which 
might result in higher variations within the different runs and a lowered power of 
significance. Since several parameters were analysed in the CatWalk testing, the 
possibility of false positive results can increase. Therefore, in order to interpret data 
from CatWalk analysis in a robust manner, new untested cohorts exhibiting a Pink1 
deficiency in the selected neurotransmitter systems would need to be tested on a 
CatWalk system to confirm the observed PD-related gait phenotypes. It needs to be 
considered that Pink1_del2/3 mice were tested on another CatWalk system compared 
to mice in the present study. This could influence the comparison of the different mouse 
lines because results of both CatWalk versions differ (Zimprich et al., 2017). In order 
to understand the present gait phenotype in Pink1 deficient mice, further morphological 
and functional studies on the neuronal network with respect to gait would be of interest.  
In sum, a Pink1 deficiency in serotonergic and dopaminergic systems plays a role in 
gait, which was already described in the Pink1 KO mice in the study of Glasl and 
colleagues (Glasl et al., 2012). Interestingly, parameters that were affected in the 
Pink1_del2/3 mice were described in both analysed mouse lines, indicating that the 
serotonergic and dopaminergic system are involved in PD-related gait impairments 
consequent to Pink1 deficiency.  
It is important to note that in contrast to the altered gait parameters in the two lines 
studied in this thesis, the full KO of Pink1 exhibited a more robust pattern of gait 




system also other systems are involved. In this respect it has to be mentioned that 
Pink1 is most strongly expressed in muscles (mammalian walking recruits up to 80 
individual muscles, which generates a high complexity of unique burst pattern) 
(Sharples et al., 2014) as well as in interneurons and motoneurons in the spinal cord 
(d'Amora et al., 2011, Morimoto et al., 2010). Hence, a Pink1 deficiency might play an 
important role in gait performance, since muscles per se could be impaired. 
 
Dopamine and serotonin play an important role in the neuronal modulation of the spinal 
cord in order to produce locomotor patterns, which are essential for responding to 
environmental conditions (Sharples et al., 2014, Harris-Warrick and Cohen, 1985). 
Dopaminergic and serotonergic neurons were found in the spinal cord, in addition 
various serotonergic populations of the brainstem innervate the spinal cord (Hou et al., 
2016, Ghosh and Pearse, 2014). Dopamine influences the central pattern generator 
(CPG) in a dose-dependent opposing manner. On the one hand, high doses of 
dopamine recruits the D1 receptors and mediates an excitatory action, whereas low 
doses of dopamine recruits D2 receptors and mediates an inhibitory action (Clemens 
et al., 2012). In addition, dopamine modulates the locomotor rhythm by influencing 
multiple molecular targets in motor neurons and interneurons (Sharples, 2017). 
Serotonin acts on the motor neurons and interneurons by binding to different types of 
serotonergic receptors in the spinal cord in order to control the CPG activation, motor 
neuron output (via 5-HT2 receptors) and locomotion of the CPG (via 5-HT7 receptors) 
(Slawinska et al., 2014). Likewise, serotonin acts in an excitatory and inhibitory action 
on the motor neurons (Wang and Dun, 1990). Impairments of the serotonergic system 
during the perinatal period causes alterations in locomotion and motor neuron 
innervation (Pearlstein et al., 2011). Since the Pink1 deficiency in serotonergic neurons 
was constitutive, a potential alteration in serotonin release could be a reason for the 
observed gait alteration. Even though serotonin and dopamine levels in the brain were 
not altered in the OB, VM and STR, the peripheral neurotransmitter content and 
release were not quantified. It is possible that minor neurotransmitter changes might  
impose gross locomotor alterations, since for example dopamine acts in a dose 
dependent opposing manner on the CPG (Clemens et al., 2012). Thus, further analysis 
of the neurotransmitter content in the spinal cord would be of interest. Interestingly, 
non-motor gait alterations were observed in young and mid-aged mice upon a Pink1 




6.5 Olfaction in Parkinson’s disease  
As described in the analysis of Pink1_del2/3 mice in the study of Glasl and colleagues, 
it was shown that a murine Pink1 deficiency caused impairments in discrimination of 
binary mixtures and olfactory sensitivity (Glasl et al., 2012). Nevertheless, a selective 
KO of Pink1 in dopaminergic nor serotonergic neurons did not replicate the previously 
published data. This meant that there was no significant influence on the olfactory 
capability with Pink1 deficiency in the specific neurotransmitter systems. Furthermore, 
the innervation of the olfactory bulb by serotonergic nerve fibres was not changed. The 
latter is in contrast to the Pink1_del2/3 mice, which indicates that the decreased 
serotonergic innervation is not due to a deficiency of Pink1 in the serotonergic neurons 
(Glasl et al., 2012). It might however be influenced by an altered environment in the 
OB due to Pink1 deficiency, since Pink1 is highly expressed in the OB (Taymans et al., 
2006). In any case, this point would need further investigation.  
It would be conceivable that the described olfactory impairments in Pink1_del2/3 mice 
are caused possibly by the impaired serotonergic innervation in the OB. This is in 
agreement with previous analysis of serotonergic fibres, which influence for example 
the dopaminergic and γ-Aminobutyric acid (GABA)ergic periglomerular interneurons in 
the OB. They in turn regulate the olfactory sensory neurons and the subsequent 
olfactory processing (Dugue and Mainen, 2009). On the other hand, dopamine might 
not play a key role in the establishment of olfactory problems and hyposmia in PD 
patients. This is because the degree of hyposmia is independent of the stage of 
dopaminergic degeneration and the amount of L-DOPA treatment (Doty, 2012).  
Since no strong olfactory phenotype was observed in the mice of the present study, 
the underlying mechanism of the previously described phenotype in Pink1_del2/3 mice 
is still under debate. The Pink1_del2/3 mice were tested at an older age (27 months) 
compared to the mice of the present study. Olfactory dysfunction increases with age, 
with the result that a possible effect in the tested mice of the present study was missed  
due to the younger age (Doty and Kamath, 2014). Zhou and colleagues figured out 
that PD patients with an older age of onset were characterized by more olfactory 
symptoms compared to early-onset PD patients (Zhou et al., 2013). Possibly mutant 
Pink1 x Pet and Pink1 x DAT mice would also exhibit (if at all) only minor olfactory 
impairments if tested at an age older than 20 months, supported by the mild olfactory 
impairments in Pink1 PD patients and Pink1_del2/3 mice (Zhou et al., 2013, Doty, 
2012, Glasl et al., 2012). In order to figure out possible mild olfactory impairments in 




be of benefit. Olfactory impairments were already described in other PD mouse 
models, like ATP13a2 KO mouse model by another olfactory test, the “Burried Pellet 
Test”, which gives information about the overall olfactory ability but not about fine 
discrimination and olfactory sensitivity (Lehmkuhl et al., 2014). In sum, olfactory testing 
of PD mouse models is valuable to yield more information about potential non-motor 
symptoms. Nonetheless, it needs to be considered that it is challenging to discover 
mild olfactory impairments. Apart from the possible structural and functional 
impairment of the OB, Pink1 deficient mice could also exhibit impairments in higher 
brain regions for olfactory processing like, for example, the anterior olfactory nucleus 
and piriform and periamygdaloid cortex (Doty, 2012) for which Pink1 deficiency in 
dopaminergic and serotonergic neurons is – based on our results –  not decisive.  
 
6.7 Concluding remarks 
The questions of the study were to discern the potential contribution of the serotonergic 
and dopaminergic system to the PD-related phenotypes consequent to Pink1 
deficiency and to reveal potential compensatory mechanisms, including the impact of 
age. For this purpose, two conditional mouse lines were analysed, exhibiting a 
selective KO of Pink1 in serotonergic or dopaminergic neurons. Neither of the mouse 
lines exhibited clear PD-related pathologies nor motor phenotypes. However, some 
slight alterations in the non-motor phenotype “gait” were observed in both mouse lines, 
independent of age. Overall the serotonergic and dopaminergic system are involved in 
the PD-related gait phenotypes with Pink1 deficiency. However, no gross 
compensatory mechanism could be uncovered including the absence of a PD-related 
phenotype, which occurred in an age-dependent manner. Nevertheless, Pink1 x Pet 
and Pink1 x DAT mouse lines are useful mouse models of the prodromal phase of PD 
in order to study non-motor symptoms concerning gait. Since PD is a multifactorial 
disease, potential PD-related phenotypes in the Pink1 x Pet and Pink1 x DAT mice 
were hidden due to the lack of a stressor (Sulzer, 2007). In order to mimic the 
multifactorial nature of the disease, analysis of these mice under stressful conditions 
would be of interest. Since non-motor symptoms in PD patients are likely to occur much 
earlier than the motor symptoms, further studies in the mouse models exhibiting 
prodromal symptoms of PD might be instrumental for developing new preventive 







Table A1: Overview of analysed young male Pink1 x Pet mice of the cohort 1 
 
Mice were born in the mouse facility “C-Streifen” and were tested in the mouse facility “GMC”. Some movies of CatWalk testing (red colour) could not be analysed 
and were not considered for the analysis. Some animals, tested in olfaction testing, could not be considered for the analysis (red colour). OF = open field, ASR = 
acoustic startle reflex, PPI = prepulse inhibition. The age is expressed in months.  
 
ID C-Streifen ear nr.  ID GMC sex genotype born date age date age date age begin date age end date age
30132737 160 30319982 m Cre:Cre+; Pink1:wt/wt 27.07.2014 24.11.2014 4.0 01.12.2014 4.2 16.12.2014 4.7
30132739 162 30319983 m Cre:Cre+; Pink1:wt/wt 27.07.2014 24.11.2014 4.0 01.12.2014 4.2 16.12.2014 4.7
30132758 177 30319984 m Cre:Cre+; Pink1:wt/wt 27.07.2014 20.11.2014 3.9 01.12.2014 4.2 12.12.2014 4.6 28.01.2015 6.2 25.02.2015 7.1
30132976 194 30319985 m Cre:Cre+; Pink1:wt/wt 27.07.2014 20.11.2014 3.9 01.12.2014 4.2 12.12.2014 4.6 28.01.2015 6.2 25.02.2015 7.1
30133497 218 30319986 m Cre:Cre+; Pink1:wt/wt 31.07.2014 20.11.2014 3.7 01.12.2014 4.1 15.12.2014 4.6 28.01.2015 6.0 25.02.2015 7.0
30133511 232 30319987 m Cre:Cre+; Pink1:wt/wt 31.07.2014 24.11.2014 3.9 01.12.2014 4.1 12.12.2014 4.5 28.01.2015 6.0 25.02.2015 7.0
30133538 268 30319988 m Cre:Cre+; Pink1:wt/wt 30.07.2014 20.11.2014 3.8 01.12.2014 4.1 15.12.2014 4.6 28.01.2015 6.1 25.02.2015 7.0
30133543 273 30319989 m Cre:Cre+; Pink1:wt/wt 31.07.2014 24.11.2014 3.9 01.12.2014 4.1 16.12.2014 4.6
30133545 275 30319990 m Cre:Cre+; Pink1:wt/wt 31.07.2014 24.11.2014 3.9 01.12.2014 4.1 16.12.2014 4.6
30133553 281 30319991 m Cre:Cre+; Pink1:wt/wt 01.08.2014 20.11.2014 3.7 01.12.2014 4.1 12.12.2014 4.4 28.01.2015 6.0 25.02.2015 6.9
30133560 288 30319992 m Cre:Cre+; Pink1:wt/wt 01.08.2014 20.11.2014 3.7 01.12.2014 4.1 12.12.2014 4.4 28.01.2015 6.0 25.02.2015 6.9
30135140 396 30319994 m Cre:Cre+; Pink1:wt/wt 23.08.2014 20.11.2014 3.0 01.12.2014 3.3 16.12.2014 3.8
30133601 319 30319995 m Cre:Cre+; Pink1:wt/wt 02.08.2014 20.11.2014 3.7 01.12.2014 4.0 15.12.2014 4.5 28.01.2015 6.0 25.02.2015 6.9
30132719 152 30319966 m Cre:Cre+; Pink1:flox/flox 28.07.2014 20.11.2014 3.8 01.12.2014 4.2 12.12.2014 4.6 28.01.2015 6.1 25.02.2015 7.1
30132752 171 30319967 m Cre:Cre+; Pink1:flox/flox 28.07.2014 20.11.2014 3.8 01.12.2014 4.2 12.12.2014 4.6
30132756 175 30319968 m Cre:Cre+; Pink1:flox/flox 27.07.2014 20.11.2014 3.9 01.12.2014 4.2 12.12.2014 4.6 28.01.2015 6.2 25.02.2015 7.1
30132759 178 30319969 m Cre:Cre+; Pink1:flox/flox 27.07.2014 20.11.2014 3.9 01.12.2014 4.2 12.12.2014 4.6 28.01.2015 6.2 25.02.2015 7.1
30132975 193 30319970 m Cre:Cre+; Pink1:flox/flox 27.07.2014 20.11.2014 3.9 01.12.2014 4.2 12.12.2014 4.6 28.01.2015 6.2 25.02.2015 7.1
30132978 196 30319971 m Cre:Cre+; Pink1:flox/flox 27.07.2014 24.11.2014 4.0 01.12.2014 4.2 16.12.2014 4.7
30133014 211 30319972 m Cre:Cre+; Pink1:flox/flox 29.07.2014 20.11.2014 3.8 01.12.2014 4.2 12.12.2014 4.5
30133523 253 30319973 m Cre:Cre+; Pink1:flox/flox 31.07.2014 24.11.2014 3.9 01.12.2014 4.1 15.12.2014 4.6
30133533 263 30319974 m Cre:Cre+; Pink1:flox/flox 30.07.2014 24.11.2014 3.9 01.12.2014 4.1 15.12.2014 4.6 28.01.2015 6.1 25.02.2015 7.0
30133579 308 30319975 m Cre:Cre+; Pink1:flox/flox 01.08.2014 24.11.2014 3.8 01.12.2014 4.1 15.12.2014 4.5 28.01.2015 6.0 25.02.2015 6.9
30133761 349 30319976 m Cre:Cre+; Pink1:flox/flox 03.08.2014 24.11.2014 3.8 01.12.2014 4.0 16.12.2014 4.5 28.01.2015 5.9 25.02.2015 6.9
30133765 353 30319977 m Cre:Cre+; Pink1:flox/flox 03.08.2014 24.11.2014 3.8 01.12.2014 4.0 16.12.2014 4.5 28.01.2015 5.9 25.02.2015 6.9
439 30146250 m Cre:Cre+; Pink1:flox/flox 29.01.2015
589 30147537 m Cre:Cre+; Pink1:flox/flox 14.02.2015
30132721 154 30319956 m Cre:Cre-; Pink1:flox/flox 28.07.2014 20.11.2014 3.8 01.12.2014 4.2 12.12.2014 4.6 28.01.2015 6.1 25.02.2015 7.1
30132722 155 30319957 m Cre:Cre-; Pink1:flox/flox 28.07.2014 20.11.2014 3.8 01.12.2014 4.2 12.12.2014 4.6 28.01.2015 6.1 25.02.2015 7.1
30133505 226 30319958 m Cre:Cre-; Pink1:flox/flox 31.07.2014 24.11.2014 3.9 01.12.2014 4.1 12.12.2014 4.5 28.01.2015 6.0 25.02.2015 7.0
30133568 296 30319959 m Cre:Cre-; Pink1:flox/flox 01.08.2014 20.11.2014 3.7 01.12.2014 4.1 12.12.2014 4.4 28.01.2015 6.0 25.02.2015 6.9
30133584 313 30319960 m Cre:Cre-; Pink1:flox/flox 01.08.2014 24.11.2014 3.8 01.12.2014 4.1 15.12.2014 4.5 28.01.2015 6.0 25.02.2015 6.9
30133610 328 30319961 m Cre:Cre-; Pink1:flox/flox 02.08.2014 20.11.2014 3.7 01.12.2014 4.0 15.12.2014 4.5 28.01.2015 6.0 25.02.2015 6.9
30134063 368 30319962 m Cre:Cre-; Pink1:flox/flox 07.08.2014 24.11.2014 3.6 01.12.2014 3.9 16.12.2014 4.4
30135122 389 30319963 m Cre:Cre-; Pink1:flox/flox 24.08.2014 20.11.2014 2.9 01.12.2014 3.3 16.12.2014 3.8 28.01.2015 5.2 25.02.2015 6.2
30135123 390 30319964 m Cre:Cre-; Pink1:flox/flox 24.08.2014 20.11.2014 2.9 01.12.2014 3.3 16.12.2014 3.8 28.01.2015 5.2 25.02.2015 6.2
508 30146318 m Cre:Cre-; Pink1:flox/flox 31.01.2015
525 30146335 m Cre:Cre-; Pink1:flox/flox 01.02.2015
young
OF ASR/PPI Catwalk Olfaction






Table A2: Overview of analysed mid-aged male Pink1 x Pet mice of the cohort 1 
 
Mice were born in the mouse facility “C-Streifen” and were tested in the mouse facility “GMC”. Some movies of CatWalk testing (red colour) could not be analysed 
and were not considered for the analysis. Some animals, tested in olfaction testing, could not be considered for the analysis (red colour). OF = open field, ASR = 
acoustic startle reflex, PPI = prepulse inhibition, TH = immunohistochemical staining of TH+ cells, 5-HT = immunohistochemical staining of 5-HT+ cells, HPLC = 
quantification of neurotransmitter content via HPLC, OB = olfactory bulb, STR = striatum, VM = ventral midbrain, date est. = estimated date. The age is expressed 
in months.  
 
TH 5-HT
ID C-Streifen ear nr.  ID GMC sex genotype born date age date age date age begin date age end date age date age date est. date OB date STR date VM date
30132737 160 30319982 m Cre:Cre+; Pink1:wt/wt 27.07.2014 06.10.2015 14.5 13.10.2015 20.0 02.11.2015 15.4 17.03.2016 19.97 01.06.2016 16.06.2016 04.07.2016 30.06.2016
30132739 162 30319983 m Cre:Cre+; Pink1:wt/wt 27.07.2014 06.10.2015 14.5 13.10.2015 14.8 02.11.2015 15.4 17.03.2016 19.97 16.06.2016 05.07.2016 01.07.2016
30132758 177 30319984 m Cre:Cre+; Pink1:wt/wt 27.07.2014 06.10.2015 14.5 13.10.2015 14.8 02.11.2015 15.4 17.11.2015 15.9 07.12.2015 16.6 17.03.2016 19.97 01.06.2016 17.06.2016 05.07.2016 01.07.2016
30132976 194 30319985 m Cre:Cre+; Pink1:wt/wt 27.07.2014 06.10.2015 14.5 12.10.2015 14.7 03.11.2015 15.5 17.11.2015 15.9 07.12.2015 16.6 17.03.2016 19.97 20.06.2016 06.07.2016 30.06.2016
30133497 218 30319986 m Cre:Cre+; Pink1:wt/wt 31.07.2014 06.10.2015 14.4 13.10.2015 14.6 03.11.2015 15.3 17.11.2015 15.8 07.12.2015 16.5 17.03.2016 19.83 01.06.2016 20.06.2016 05.07.2016 04.07.2016
30133511 232 30319987 m Cre:Cre+; Pink1:wt/wt 31.07.2014 06.10.2015 14.4 12.10.2015 14.6 03.11.2015 15.3 17.11.2015 15.8 07.12.2015 16.5
30133538 268 30319988 m Cre:Cre+; Pink1:wt/wt 30.07.2014 06.10.2015 14.4 13.10.2015 14.7 03.11.2015 15.4 17.11.2015 15.8 07.12.2015 16.5
30133543 273 30319989 m Cre:Cre+; Pink1:wt/wt 31.07.2014 06.10.2015 14.4 13.10.2015 14.6 03.11.2015 15.3 17.03.2016 19.83 01.06.2016 20.06.2016 04.07.2016 04.07.2016
30133545 275 30319990 m Cre:Cre+; Pink1:wt/wt 31.07.2014 06.10.2015 14.4 13.10.2015 14.6 03.11.2015 15.3 17.03.2016 19.83 01.06.2016 27.06.2016 05.07.2017 01.07.2016
30133553 281 30319991 m Cre:Cre+; Pink1:wt/wt 01.08.2014 12.10.2015 14.6 03.11.2015 15.3 17.11.2015 15.8 07.12.2015 16.4 17.03.2016 19.80 01.06.2016
30133560 288 30319992 m Cre:Cre+; Pink1:wt/wt 01.08.2014 06.10.2015 14.4 12.10.2015 14.6 04.11.2015 15.3 17.11.2015 15.8 07.12.2015 16.4 17.03.2016 19.80 01.06.2016 27.06.2016 01.08.2016 30.06.2016
30135140 396 30319994 m Cre:Cre+; Pink1:wt/wt 23.08.2014
30133601 319 30319995 m Cre:Cre+; Pink1:wt/wt 02.08.2014 06.10.2015 14.3 12.10.2015 14.5 04.11.2015 15.3 17.11.2015 15.7 07.12.2015 16.4
30132719 152 30319966 m Cre:Cre+; Pink1:flox/flox 28.07.2014 06.10.2015 14.5 12.10.2015 14.7 02.11.2015 15.4 17.11.2015 15.9 07.12.2015 16.6 17.03.2016 19.93 01.06.2016
30132752 171 30319967 m Cre:Cre+; Pink1:flox/flox 28.07.2014
30132756 175 30319968 m Cre:Cre+; Pink1:flox/flox 27.07.2014 06.10.2015 14.5 13.10.2015 14.8 02.11.2015 15.4 17.11.2015 15.9 07.12.2015 16.6 17.03.2016 19.97 16.06.2016 05.07.2016 30.06.2016
30132759 178 30319969 m Cre:Cre+; Pink1:flox/flox 27.07.2014 06.10.2015 14.5 13.10.2015 14.8 02.11.2015 15.4 17.11.2015 15.9 07.12.2015 16.6 17.03.2016 19.97 01.06.2016 16.06.2016 06.08.2016 01.07.2016
30132975 193 30319970 m Cre:Cre+; Pink1:flox/flox 27.07.2014 06.10.2015 14.5 13.10.2015 14.8 02.11.2015 15.4 17.11.2015 15.9 07.12.2015 16.6 17.03.2016 19.97 01.06.2016 16.06.2016 05.07.2016 30.06.2016
30132978 196 30319971 m Cre:Cre+; Pink1:flox/flox 27.07.2014 06.10.2015 14.5 13.10.2015 14.8 03.11.2015 15.5 17.03.2016 19.97 01.06.2016 20.06.2016 06.07.2016 01.07.2016
30133014 211 30319972 m Cre:Cre+; Pink1:flox/flox 29.07.2014 06.10.2015 14.5 13.10.2015 14.7 03.11.2015 15.4 17.03.2016 19.90 20.06.2016 05.07.2016 04.07.2016
30133523 253 30319973 m Cre:Cre+; Pink1:flox/flox 31.07.2014 06.10.2015 14.4 13.10.2015 14.6 03.11.2015 15.3 17.03.2016 19.83 01.06.2016 20.06.2016 06.07.2016 01.07.2016
30133533 263 30319974 m Cre:Cre+; Pink1:flox/flox 30.07.2014 06.10.2015 14.4 13.10.2015 14.7 03.11.2015 15.4 17.11.2015 15.8 07.12.2015 16.5 17.03.2016 19.87 01.06.2016 27.06.2016 05.07.2016 01.07.2016
30133579 308 30319975 m Cre:Cre+; Pink1:flox/flox 01.08.2014 06.10.2015 14.4 12.10.2015 14.6 03.11.2015 15.3 17.11.2015 15.8 07.12.2015 16.4
30133761 349 30319976 m Cre:Cre+; Pink1:flox/flox 03.08.2014 06.10.2015 14.3 13.10.2015 14.5 03.11.2015 15.2 17.11.2015 15.7 07.12.2015 16.4 17.03.2016 19.73 01.06.2016 27.06.2016 05.07.2016 01.07.2016
30133765 353 30319977 m Cre:Cre+; Pink1:flox/flox 03.08.2014 06.10.2015 14.3 14.10.2015 14.6 04.11.2015 15.3 17.11.2015 15.7 07.12.2015 16.4
439 30146250 m Cre:Cre+; Pink1:flox/flox 29.01.2015 08.09.2016 19.60 06.10.2016
589 30147537 m Cre:Cre+; Pink1:flox/flox 14.02.2015 08.09.2016 19.07 06.10.2016
30132721 154 30319956 m Cre:Cre-; Pink1:flox/flox 28.07.2014 06.10.2015 14.5 12.10.2015 14.7 02.11.2015 15.4 17.11.2015 15.9 07.12.2015 16.6 17.03.2016 19.93 01.06.2016 17.06.2016 04.07.2016 04.07.2016
30132722 155 30319957 m Cre:Cre-; Pink1:flox/flox 28.07.2014 06.10.2015 14.5 12.10.2015 14.7 02.11.2015 15.4 17.11.2015 15.9 07.12.2015 16.6 17.03.2016 19.93 01.06.2016 17.06.2016 05.07.2016 30.06.2016
30133505 226 30319958 m Cre:Cre-; Pink1:flox/flox 31.07.2014 06.10.2015 14.4 12.10.2015 14.6 02.11.2015 15.3 17.11.2015 15.8 07.12.2015 16.5 17.03.2016 19.83 01.06.2016 16.06.2016 06.07.2016 01.07.2016
30133568 296 30319959 m Cre:Cre-; Pink1:flox/flox 01.08.2014 06.10.2015 14.4 12.10.2015 14.6 02.11.2015 15.3 17.11.2015 15.8 07.12.2015 16.4 17.03.2016 19.80 01.06.2016 20.06.2016 05.07.2016 30.06.2016
30133584 313 30319960 m Cre:Cre-; Pink1:flox/flox 01.08.2014 06.10.2015 14.4 12.10.2015 14.6 03.11.2015 15.3 17.11.2015 15.8 07.12.2015 16.4 17.03.2016 19.80 01.06.2016 22.06.2016 04.07.2016 01.07.2016
30133610 328 30319961 m Cre:Cre-; Pink1:flox/flox 02.08.2014 06.10.2015 14.3 12.10.2015 14.5 03.11.2015 15.3 17.11.2015 15.7 07.12.2015 16.4 17.03.2016 19.77 01.06.2016 20.06.2016 05.07.2016 04.07.2016
30134063 368 30319962 m Cre:Cre-; Pink1:flox/flox 07.08.2014 06.10.2015 14.2 12.10.2015 14.4 03.11.2015 15.1
30135122 389 30319963 m Cre:Cre-; Pink1:flox/flox 24.08.2014 06.10.2015 13.6 12.10.2015 13.8 03.11.2015 14.5 17.11.2015 15.0 07.12.2015 15.7 17.03.2016 19.03 01.06.2016 27.06.2016 05.07.2016 01.07.2016
30135123 390 30319964 m Cre:Cre-; Pink1:flox/flox 24.08.2014 06.10.2015 13.6 12.10.2015 13.8 03.11.2015 14.5 17.11.2015 15.0 07.12.2015 15.7 17.03.2016 19.03 01.06.2016 27.06.2016 05.07.2016 01.07.2016
508 30146318 m Cre:Cre-; Pink1:flox/flox 31.01.2015 08.09.2016 19.53 06.10.2016
525 30146335 m Cre:Cre-; Pink1:flox/flox 01.02.2015 08.09.2016 19.50 06.10.2016
prepASR/PPI Olfaction HPLCCatwalkOF





Table A3: Overview of analysed young female Pink1 x Pet mice of the cohort 1 
 
Mice were born in the mouse facility “C-Streifen” and were tested in the mouse facility “GMC”. Some movies of CatWalk testing (labelled in red colour) could not 
be analysed and were not considered for the analysis. OF = open field, ASR = acoustic startle reflex, PPI = prepulse inhibition. The age is expressed in months.  
 
 
ID C-Streifen ear nr.  ID GMC sex genotype born date age date age date age begin date age end date age
30132724 157 30320025 f Cre:Cre+; Pink1:wt/wt 28.07.2014 25.11.2014 4.0 02.12.2014 4.2 18.12.2014 4.8
30132745 168 30320026 f Cre:Cre+; Pink1:wt/wt 27.07.2014 24.11.2014 4.0 02.12.2014 4.3 17.12.2014 4.8
30132769 188 30320027 f Cre:Cre+; Pink1:wt/wt 27.07.2014 24.11.2014 4.0 01.12.2014 4.2 17.12.2014 4.8
30132772 191 30320028 f Cre:Cre+; Pink1:wt/wt 27.07.2014 24.11.2014 4.0 01.12.2014 4.2 16.12.2014 4.7
30133503 224 30320029 f Cre:Cre+; Pink1:wt/wt 31.07.2014 25.11.2014 3.9 02.12.2014 4.1 18.12.2014 4.7
30133556 284 30320030 f Cre:Cre+; Pink1:wt/wt 01.08.2014 25.11.2014 3.9 02.12.2014 4.1 17.12.2014 4.6
30133588 317 30320031 f Cre:Cre+; Pink1:wt/wt 01.08.2014 25.11.2014 3.9 02.12.2014 4.1 17.12.2014 4.6
30133589 318 30320032 f Cre:Cre+; Pink1:wt/wt 01.08.2014 25.11.2014 3.9 02.12.2014 4.1 18.12.2014 4.6
30133611 329 30320033 f Cre:Cre+; Pink1:wt/wt 02.08.2014 25.11.2014 3.8 02.12.2014 4.1 19.12.2014 4.6
30133612 330 30320034 f Cre:Cre+; Pink1:wt/wt 02.08.2014 25.11.2014 3.8 02.12.2014 4.1 19.12.2014 4.6
30133763 351 30320035 f Cre:Cre+; Pink1:wt/wt 03.08.2014 25.11.2014 3.8 02.12.2014 4.0 19.12.2014 4.6
30133764 352 30320036 f Cre:Cre+; Pink1:wt/wt 03.08.2014 25.11.2014 3.8 02.12.2014 4.0 19.12.2014 4.6
30135108 386 30320037 f Cre:Cre+; Pink1:wt/wt 24.08.2014 25.11.2014 3.1 02.12.2014 3.3 17.12.2014 3.8
30135128 395 30320038 f Cre:Cre+; Pink1:wt/wt 24.08.2014 24.11.2014 3.1 02.12.2014 3.3 18.12.2014 3.9
30132711 151 30320010 f Cre:Cre+; Pink1:flox/flox 27.07.2014 24.11.2014 4.0 01.12.2014 4.2 16.12.2014 4.7
30132743 166 30320011 f Cre:Cre+; Pink1:flox/flox 27.07.2014 24.11.2014 4.0 02.12.2014 4.3 17.12.2014 4.8
30132770 189 30320012 f Cre:Cre+; Pink1:flox/flox 27.07.2014 24.11.2014 4.0 01.12.2014 4.2 17.12.2014 4.8
30133018 215 30320013 f Cre:Cre+; Pink1:flox/flox 29.07.2014 25.11.2014 4.0 02.12.2014 4.2 17.12.2014 4.7
30133502 223 30320014 f Cre:Cre+; Pink1:flox/flox 31.07.2014 25.11.2014 3.9 02.12.2014 4.1 18.12.2014 4.7
30133517 238 30320015 f Cre:Cre+; Pink1:flox/flox 31.07.2014 25.11.2014 3.9 02.12.2014 4.1 18.12.2014 4.7
30133555 283 30320016 f Cre:Cre+; Pink1:flox/flox 01.08.2014 25.11.2014 3.9 02.12.2014 4.1 17.12.2014 4.6
30133769 357 30320017 f Cre:Cre+; Pink1:flox/flox 03.08.2014 24.11.2014 3.8 02.12.2014 4.0 19.12.2014 4.6
30134065 370 30320018 f Cre:Cre+; Pink1:flox/flox 07.08.2014 25.11.2014 3.7 02.12.2014 3.9 16.12.2014 4.4
30135109 387 30320019 f Cre:Cre+; Pink1:flox/flox 24.08.2014 25.11.2014 3.1 02.12.2014 3.3 17.12.2014 3.8
30135124 391 30320020 f Cre:Cre+; Pink1:flox/flox 24.08.2014 24.11.2014 3.1 02.12.2014 3.3 18.12.2014 3.9
577 30146744 f Cre:Cre+; Pink1:flox/flox 08.02.2015
655 30157188 f Cre:Cre+; Pink1:flox/flox 12.06.2015
30132708 148 30319996 f Cre:Cre-; Pink1:flox/flox 27.07.2014 24.11.2014 4.0 01.12.2014 4.2 16.12.2014 4.7
30132755 174 30319997 f Cre:Cre-; Pink1:flox/flox 28.07.2014 24.11.2014 4.0 01.12.2014 4.2 16.12.2014 4.7
30132768 187 30319998 f Cre:Cre-; Pink1:flox/flox 27.07.2014 24.11.2014 4.0 02.12.2014 4.3 17.12.2014 4.8
30132981 199 30319999 f Cre:Cre-; Pink1:flox/flox 27.07.2014 24.11.2014 4.0 02.12.2014 4.3 17.12.2014 4.8
30132996 203 30320000 f Cre:Cre-; Pink1:flox/flox 28.07.2014 25.11.2014 4.0 02.12.2014 4.2 17.12.2014 4.7
30132997 204 30320001 f Cre:Cre-; Pink1:flox/flox 28.07.2014 25.11.2014 4.0 02.12.2014 4.2 17.12.2014 4.7
30133016 213 30320002 f Cre:Cre-; Pink1:flox/flox 29.07.2014 25.11.2014 4.0 02.12.2014 4.2 17.12.2014 4.7
30133510 231 30320003 f Cre:Cre-; Pink1:flox/flox 31.07.2014 25.11.2014 3.9 02.12.2014 4.1 18.12.2014 4.7
30133527 257 30320004 f Cre:Cre-; Pink1:flox/flox 31.07.2014 25.11.2014 3.9 02.12.2014 4.1 19.12.2014 4.7
30133528 258 30320005 f Cre:Cre-; Pink1:flox/flox 31.07.2014 25.11.2014 3.9 02.12.2014 4.1 19.12.2014 4.7
30135126 393 30320006 f Cre:Cre-; Pink1:flox/flox 24.08.2014 24.11.2014 3.1 02.12.2014 3.3 18.12.2014 3.9
30135144 401 30320007 f Cre:Cre-; Pink1:flox/flox 23.08.2014 25.11.2014 3.1 02.12.2014 3.4 19.12.2014 3.9
30133000 207 30320008 f Cre:Cre-; Pink1:flox/flox 28.07.2014 25.11.2014 4.0 02.12.2014 4.2 18.12.2014 4.8
30133001 208 30320009 f Cre:Cre-; Pink1:flox/flox 28.07.2014 25.11.2014 4.0 02.12.2014 4.2 18.12.2014 4.8
492 30146303 f Cre:Cre-; Pink1:flox/flox 31.01.2015
576 30146743 f Cre:Cre-; Pink1:flox/flox 07.02.2015
female Pink1 x Pet, cohort 1





Table A4: Overview of analysed mid-aged female Pink1 x Pet mice of the cohort 1 
 
Mice were born in the mouse facility “C-Streifen” and were tested in the mouse facility “GMC”. OF = open field, ASR = acoustic startle reflex, PPI = prepulse 
inhibition, TH = immunohistochemical staining of TH+ cells, 5-HT = immunohistochemical staining of 5-HT+ cells, HPLC = quantification of neurotransmitter content 




ID C-Streifen ear nr.  ID GMC sex genotype born date age date age date age begin date age end date age date age date est. date OB date STR date VM date
30132724 157 30320025 f Cre:Cre+; Pink1:wt/wt 28.07.2014 07.10.2015 14.5
30132745 168 30320026 f Cre:Cre+; Pink1:wt/wt 27.07.2014 07.10.2015 14.6 14.10.2015 14.8 04.11.2015 15.5 18.03.2016 20.00 16.06.2016 04.07.2016 30.06.2016
30132769 188 30320027 f Cre:Cre+; Pink1:wt/wt 27.07.2014 07.10.2015 14.6 14.10.2015 14.8 04.11.2015 15.5 18.03.2016 20.00 01.06.2016 16.06.2016 05.07.2016 01.07.2016
30132772 191 30320028 f Cre:Cre+; Pink1:wt/wt 27.07.2014 07.10.2015 14.6 14.10.2015 14.8 04.11.2015 15.5 18.03.2016 20.00
30133503 224 30320029 f Cre:Cre+; Pink1:wt/wt 31.07.2014 07.10.2015 14.4 14.10.2015 14.7 04.11.2015 15.4
30133556 284 30320030 f Cre:Cre+; Pink1:wt/wt 01.08.2014 07.10.2015 14.4 14.10.2015 14.6 04.11.2015 15.3 18.03.2016 19.83 01.06.2016 16.06.2016 01.08.2016 01.07.2016
30133588 317 30320031 f Cre:Cre+; Pink1:wt/wt 01.08.2014 07.10.2015 14.4 14.10.2015 14.6 05.11.2015 15.4 18.03.2016 19.83 01.06.2016
30133589 318 30320032 f Cre:Cre+; Pink1:wt/wt 01.08.2014 07.10.2015 14.4 14.10.2015 14.6 05.11.2015 15.4
30133611 329 30320033 f Cre:Cre+; Pink1:wt/wt 02.08.2014 07.10.2015 14.4 14.10.2015 14.6 05.11.2015 15.3 18.03.2016 19.80 01.06.2016 20.06.2016 04.07.2016 04.07.2016
30133612 330 30320034 f Cre:Cre+; Pink1:wt/wt 02.08.2014
30133763 351 30320035 f Cre:Cre+; Pink1:wt/wt 03.08.2014 07.10.2015 14.3 14.10.2015 14.6 05.11.2015 15.3 18.03.2016 19.77 20.06.2016 05.07.2016 01.07.2016
30133764 352 30320036 f Cre:Cre+; Pink1:wt/wt 03.08.2014 07.10.2015 14.3 14.10.2015 14.6 05.11.2015 15.3 18.03.2016 19.77 01.06.2016 27.06.2016 05.07.2016 01.07.2016
30135108 386 30320037 f Cre:Cre+; Pink1:wt/wt 24.08.2014 07.10.2015 13.6 14.10.2015 13.9 05.11.2015 14.6 18.03.2016 19.07 01.06.2016 20.06.2016 05.07.2016 04.07.2016
30135128 395 30320038 f Cre:Cre+; Pink1:wt/wt 24.08.2014 07.10.2015 13.6 14.10.2015 13.9 06.11.2015 14.6 18.03.2016 19.07 01.06.2016 27.06.2016 06.07.2016 30.06.2016
30132711 151 30320010 f Cre:Cre+; Pink1:flox/flox 27.07.2014 07.10.2015 14.6 14.10.2015 14.8 04.11.2015 15.5 18.03.2016 20.00
30132743 166 30320011 f Cre:Cre+; Pink1:flox/flox 27.07.2014 07.10.2015 14.6 14.10.2015 14.8 04.11.2015 15.5 18.03.2016 20.00 01.06.2016 17.06.2016 06.07.2016 30.06.2016
30132770 189 30320012 f Cre:Cre+; Pink1:flox/flox 27.07.2014 07.10.2015 14.6 14.10.2015 14.8 04.11.2015 15.5 18.03.2016 20.00 01.06.2016 17.06.2016 05.07.2016 30.06.2016
30133018 215 30320013 f Cre:Cre+; Pink1:flox/flox 29.07.2014 07.10.2015 14.5 14.10.2015 14.7 04.11.2015 15.4 18.03.2016 19.93 20.06.2016 06.07.2016 30.06.2016
30133502 223 30320014 f Cre:Cre+; Pink1:flox/flox 31.07.2014 07.10.2015 14.4 14.10.2015 14.7 04.11.2015 15.4 18.03.2016 19.87 01.06.2016 20.06.2016 05.07.2016 04.07.2016
30133517 238 30320015 f Cre:Cre+; Pink1:flox/flox 31.07.2014 07.10.2015 14.4 14.10.2015 14.7 05.11.2015 15.4 18.03.2016 19.87 01.06.2016 20.06.2016 05.07.2016 30.06.2016
30133555 283 30320016 f Cre:Cre+; Pink1:flox/flox 01.08.2014 07.10.2015 14.4 14.10.2015 14.6 05.11.2015 15.4 18.03.2016 19.83 01.06.2016 27.06.2016 04.07.2016 01.07.2016
30133769 357 30320017 f Cre:Cre+; Pink1:flox/flox 03.08.2014 07.10.2015 14.3 14.10.2015 14.6 05.11.2015 15.3 18.03.2016 19.77 01.06.2016 27.06.2016 04.07.2016 01.07.2016
30134065 370 30320018 f Cre:Cre+; Pink1:flox/flox 07.08.2014
30135109 387 30320019 f Cre:Cre+; Pink1:flox/flox 24.08.2014 07.10.2015 13.6 14.10.2015 13.9 05.11.2015 14.6 18.03.2016 19.07 01.06.2016 16.06.2016 06.07.2016 01.07.2016
30135124 391 30320020 f Cre:Cre+; Pink1:flox/flox 24.08.2014 07.10.2015 13.6 14.10.2015 13.9 05.11.2015 14.6
577 30146744 f Cre:Cre+; Pink1:flox/flox 08.02.2015 08.09.2016 19.27 06.10.2016
655 30157188 f Cre:Cre+; Pink1:flox/flox 12.06.2015 08.09.2016 15.13 06.10.2016
30132708 148 30319996 f Cre:Cre-; Pink1:flox/flox 27.07.2014 07.10.2015 14.6 14.10.2015 14.8 04.11.2015 15.5 18.03.2016 20.00 01.06.2016 17.06.2016 06.07.2016 01.07.2016
30132755 174 30319997 f Cre:Cre-; Pink1:flox/flox 28.07.2014 07.10.2015 14.5 14.10.2015 14.8 04.11.2015 15.5
30132768 187 30319998 f Cre:Cre-; Pink1:flox/flox 27.07.2014 07.10.2015 14.6 14.10.2015 14.8 04.11.2015 15.5 18.03.2016 20.00 01.06.2016 20.06.2016 05.07.2016 01.07.2016
30132981 199 30319999 f Cre:Cre-; Pink1:flox/flox 27.07.2014 07.10.2015 14.6 14.10.2015 14.8 04.11.2015 15.5
30132996 203 30320000 f Cre:Cre-; Pink1:flox/flox 28.07.2014 07.10.2015 14.5 14.10.2015 14.8 04.11.2015 15.5 18.03.2016 19.97 16.06.2016 05.07.2016 01.07.2016
30132997 204 30320001 f Cre:Cre-; Pink1:flox/flox 28.07.2014 07.10.2015 14.5 14.10.2015 14.8 05.11.2015 15.5 18.03.2016 19.97 01.06.2016 17.06.2016 05.07.2016 05.08.2016
30133016 213 30320002 f Cre:Cre-; Pink1:flox/flox 29.07.2014 07.10.2015 14.5 14.10.2015 14.7 05.11.2015 15.5 18.03.2016 19.93 01.06.2016 20.06.2016 05.07.2016 30.06.2016
30133510 231 30320003 f Cre:Cre-; Pink1:flox/flox 31.07.2014 07.10.2015 14.4 14.10.2015 14.7 05.11.2015 15.4
30133527 257 30320004 f Cre:Cre-; Pink1:flox/flox 31.07.2014 07.10.2015 14.4 14.10.2015 14.7 05.11.2015 15.4 18.03.2016 19.87 01.06.2016 20.06.2016 06.07.2016 04.07.2016
30133528 258 30320005 f Cre:Cre-; Pink1:flox/flox 31.07.2014 07.10.2015 14.4 14.10.2015 14.7 05.11.2015 15.4 18.03.2016 19.87 01.06.2016 04.07.2016 06.07.2016 30.06.2016
30135126 393 30320006 f Cre:Cre-; Pink1:flox/flox 24.08.2014 07.10.2015 13.6 14.10.2015 13.9 05.11.2015 14.6 18.03.2016 19.07 01.06.2016 20.06.2016 06.07.2016 01.07.2016
30135144 401 30320007 f Cre:Cre-; Pink1:flox/flox 23.08.2014
30133000 207 30320008 f Cre:Cre-; Pink1:flox/flox 28.07.2014 07.10.2015 14.5 14.10.2015 14.8 06.11.2015 15.5
30133001 208 30320009 f Cre:Cre-; Pink1:flox/flox 28.07.2014 07.10.2015 14.5 14.10.2015 14.8 06.11.2015 15.5 18.03.2016 19.97
492 30146303 f Cre:Cre-; Pink1:flox/flox 31.01.2015 08.09.2016 19.53 06.10.2016
576 30146743 f Cre:Cre-; Pink1:flox/flox 07.02.2015 08.09.2016 19.30 06.10.2016
ASR/PPI Catwalk prepOF







Table A5: Overview of analysed young male Pink1 x DAT mice of the cohort 1 
 
Mice were born in the mouse facility “C-Streifen” and were tested in the mouse facility “GMC”. Some animals, tested in olfaction testing, could not be considered 
for the analysis (red colour). OF = open field, ASR = acoustic startle reflex, PPI = prepulse inhibition. The age is expressed in months.  
 
ID C-Streifen ear nr. ID GMC sex genotype born date age date age date age begin date age end date age
30139019 119 30327195 m Cre:Cre+; Pink1:wt/wt 06.10.2014 16.02.2015 4.4 23.02.2015 4.7 31.03.2015 5.9 22.04.2015 6.6 20.05.2015 7.5
30139298 124 30327196 m Cre:Cre+; Pink1:wt/wt 06.10.2014 16.02.2015 4.4 23.02.2015 4.7 31.03.2015 5.9 22.04.2015 6.6 20.05.2015 7.5
30139375 146 30327199 m Cre:Cre+; Pink1:wt/wt 07.10.2014 16.02.2015 4.4 23.02.2015 4.6 31.03.2015 5.8 22.04.2015 6.6 20.05.2015 7.5
30139468 168 30327201 m Cre:Cre+; Pink1:wt/wt 09.10.2014 16.02.2015 4.3 23.02.2015 4.6 01.04.2015 5.8 22.04.2015 6.5 20.05.2015 7.4
30139385 150 30327204 m Cre:Cre+; Pink1:wt/wt 07.10.2014 16.02.2015 4.4 23.02.2015 4.6 01.04.2015 5.9
30139585 195 30327207 m Cre:Cre+; Pink1:wt/wt 09.10.2014 16.02.2015 4.3 23.02.2015 4.6 01.04.2015 5.8 22.04.2015 6.5 20.05.2015 7.4
30140012 303 30327209 m Cre:Cre+; Pink1:wt/wt 16.10.2014 16.02.2015 4.1 23.02.2015 4.3 01.04.2015 5.6 22.04.2015 6.3 20.05.2015 7.2
30140014 305 30327210 m Cre:Cre+; Pink1:wt/wt 16.10.2014 16.02.2015 4.1 23.02.2015 4.3 01.04.2015 5.6 22.04.2015 6.3 20.05.2015 7.2
30139617 208 30327211 m Cre:Cre+; Pink1:wt/wt 10.10.2014 16.02.2015 4.3 23.02.2015 4.5 02.04.2015 5.8 22.04.2015 6.5 20.05.2015 7.4
30139723 282 30327226 m Cre:Cre+; Pink1:wt/wt 13.10.2014 16.02.2015 4.2 23.02.2015 4.4 02.04.2015 5.7
30139728 287 30327228 m Cre:Cre+; Pink1:wt/wt 10.10.2014 16.02.2015 4.3 23.02.2015 4.5 02.04.2015 5.8
30140161 351 30327233 m Cre:Cre+; Pink1:wt/wt 15.10.2014 16.02.2015 4.1 23.02.2015 4.4 02.04.2015 5.6
30139633 216 30327192 m Cre:Cre+; Pink1:flox/flox 10.10.2014 16.02.2015 4.3 23.02.2015 4.5 31.03.2015 5.7 22.04.2015 6.5 20.05.2015 7.4
30140046 317 30327193 m Cre:Cre+; Pink1:flox/flox 17.10.2014 16.02.2015 4.1 23.02.2015 4.3 31.03.2015 5.5 22.04.2015 6.2 20.05.2015 7.2
30139423 162 30327200 m Cre:Cre+; Pink1:flox/flox 09.10.2014 16.02.2015 4.3 23.02.2015 4.6 31.03.2015 5.8 22.04.2015 6.5 20.05.2015 7.4
30139480 180 30327202 m Cre:Cre+; Pink1:flox/flox 09.10.2014 16.02.2015 4.3 23.02.2015 4.6 31.03.2015 5.8
30139606 201 30327208 m Cre:Cre+; Pink1:flox/flox 10.10.2014 16.02.2015 4.3 23.02.2015 4.5 01.04.2015 5.8 22.04.2015 6.5 20.05.2015 7.4
30140048 319 30327216 m Cre:Cre+; Pink1:flox/flox 17.10.2014 16.02.2015 4.1 23.02.2015 4.3 01.04.2015 5.5 22.04.2015 6.2 20.05.2015 7.2
30140053 324 30327217 m Cre:Cre+; Pink1:flox/flox 16.10.2014 16.02.2015 4.1 23.02.2015 4.3 02.04.2015 5.6 22.04.2015 6.3 20.05.2015 7.2
30140054 325 30327218 m Cre:Cre+; Pink1:flox/flox 16.10.2014 16.02.2015 4.1 23.02.2015 4.3 01.04.2015 5.6 22.04.2015 6.3 20.05.2015 7.2
30139717 278 30327225 m Cre:Cre+; Pink1:flox/flox 13.10.2014 16.02.2015 4.2 23.02.2015 4.4 02.04.2015 5.7
30139730 289 30327227 m Cre:Cre+; Pink1:flox/flox 10.10.2014 16.02.2015 4.3 23.02.2015 4.5 02.04.2015 5.8
30140162 352 30327234 m Cre:Cre+; Pink1:flox/flox 15.10.2014 16.02.2015 4.1 23.02.2015 4.4 02.04.2015 5.6 22.04.2015 6.3 20.05.2015 7.2
30139618 209 30327190 m Cre:Cre-; Pink1:flox/flox 10.10.2014 16.02.2015 4.3 23.02.2015 4.5 31.03.2015 5.7 22.04.2015 6.5 20.05.2015 7.4
30139631 214 30327191 m Cre:Cre-; Pink1:flox/flox 10.10.2014 16.02.2015 4.3 23.02.2015 4.5 31.03.2015 5.7 22.04.2015 6.5 20.05.2015 7.4
30139299 125 30327197 m Cre:Cre-; Pink1:flox/flox 06.10.2014 16.02.2015 4.4 23.02.2015 4.7 31.03.2015 5.9 22.04.2015 6.6 20.05.2015 7.5
30139533 185 30327203 m Cre:Cre-; Pink1:flox/flox 09.10.2014 16.02.2015 4.3 23.02.2015 4.6 31.03.2015 5.8
30139672 245 30327213 m Cre:Cre-; Pink1:flox/flox 13.10.2014 16.02.2015 4.2 23.02.2015 4.4 01.04.2015 5.7 22.04.2015 6.4 20.05.2015 7.3
30139674 247 30327214 m Cre:Cre-; Pink1:flox/flox 13.10.2014 16.02.2015 4.2 23.02.2015 4.4 02.04.2015 5.7
30139675 248 30327215 m Cre:Cre-; Pink1:flox/flox 13.10.2014 16.02.2015 4.2 23.02.2015 4.4 01.04.2015 5.7 22.04.2015 6.4 20.05.2015 7.3
30140055 326 30327219 m Cre:Cre-; Pink1:flox/flox 16.10.2014 16.02.2015 4.1 23.02.2015 4.3 01.04.2015 5.6 22.04.2015 6.3 20.05.2015 7.2
30139693 257 30327222 m Cre:Cre-; Pink1:flox/flox 12.10.2014 16.02.2015 4.2 23.02.2015 4.5 02.04.2015 5.7 22.04.2015 6.4 20.05.2015 7.3
30139716 277 30327224 m Cre:Cre-; Pink1:flox/flox 13.10.2014 16.02.2015 4.2 23.02.2015 4.4 02.04.2015 5.7
30140043 314 30327231 m Cre:Cre-; Pink1:flox/flox 16.10.2014 16.02.2015 4.1 23.02.2015 4.3 02.04.2015 5.6
30140160 350 30327232 m Cre:Cre-; Pink1:flox/flox 15.10.2014 16.02.2015 4.1 23.02.2015 4.4 02.04.2015 5.6 22.04.2015 6.3 20.05.2015 7.2
male Pink1 x DAT, cohort 1
young




Table A6: Overview of analysed mid-aged male Pink1 x DAT mice of the cohort 1 
 
Mice were born in the mouse facility “C-Streifen” and were tested in the mouse facility “GMC”. Some animals, tested in olfaction testing, could not be considered 
for the analysis (red colour). OF = open field, ASR = acoustic startle reflex, PPI = prepulse inhibition, TH = immunohistochemical staining of TH+ cells, 5-HT = 
immunohistochemical staining of 5-HT+ cells, HPLC = quantification of neurotransmitter content via HPLC, OB = olfactory bulb, STR = striatum, VM = ventral 






ID C-Streifen ear nr. ID GMC sex genotype born date age date age date age begin date age end date age date age date est. date OB date STR date VM date
30139019 119 30327195 m Cre:Cre+; Pink1:wt/wt 06.10.2014 12.01.2016 15.4 19.01.2016 15.7 01.02.2016 16.1 14.03.2016 17.5 08.04.2016 18.3 20.04.2016 18.73 15.06.2016 14.07.2016 28.07.2016 21.07.2016
30139298 124 30327196 m Cre:Cre+; Pink1:wt/wt 06.10.2014 12.01.2016 15.4 19.01.2016 15.7 01.02.2016 16.1 14.03.2016 17.5 08.04.2016 18.3 20.04.2016 18.73 15.06.2016 13.07.2016 29.07.2016 21.07.2016
30139375 146 30327199 m Cre:Cre+; Pink1:wt/wt 07.10.2014 12.01.2016 15.4 20.01.2016 15.7 02.02.2016 16.1 14.03.2016 17.5 08.04.2016 18.3 20.04.2016 18.70 15.06.2016 13.07.2016 27.07.2016 15.07.2016
30139468 168 30327201 m Cre:Cre+; Pink1:wt/wt 09.10.2014 12.01.2016 15.3 19.01.2016 15.6 01.02.2016 16.0 14.03.2016 17.4 08.04.2016 18.2 20.04.2016 18.63 15.06.2016 14.07.2016 28.07.2016 22.07.2016
30139385 150 30327204 m Cre:Cre+; Pink1:wt/wt 07.10.2014 12.01.2016 15.4 19.01.2016 15.6 01.02.2016 16.1 20.04.2016 18.70
30139585 195 30327207 m Cre:Cre+; Pink1:wt/wt 09.10.2014 12.01.2016 15.3 19.01.2016 15.6 01.02.2016 16.0 14.03.2016 17.4 08.04.2016 18.2 20.04.2016 18.63 15.06.2016 14.07.2016 28.07.2016 21.07.2016
30140012 303 30327209 m Cre:Cre+; Pink1:wt/wt 16.10.2014 12.01.2016 15.1 20.01.2016 15.4 01.02.2016 15.8 14.03.2016 17.2 08.04.2016 18.0 20.04.2016 18.40 15.06.2016 13.07.2016 29.07.2016 21.07.2016
30140014 305 30327210 m Cre:Cre+; Pink1:wt/wt 16.10.2014 12.01.2016 15.1 20.01.2016 15.4 02.02.2016 15.8 14.03.2016 17.2 08.04.2016 18.0 20.04.2016 18.40 15.06.2016
30139617 208 30327211 m Cre:Cre+; Pink1:wt/wt 10.10.2014 12.01.2016 15.3 20.01.2016 15.6 02.02.2016 16.0 14.03.2016 17.4 08.04.2016 18.2 20.04.2016 18.60
30139723 282 30327226 m Cre:Cre+; Pink1:wt/wt 13.10.2014 12.01.2016 15.2 20.01.2016 15.5 02.02.2016 15.9 22.03.2016 17.53 07.07.2016 28.07.2016 12.08.2016
30139728 287 30327228 m Cre:Cre+; Pink1:wt/wt 10.10.2014 12.01.2016 15.3 20.01.2016 15.6 02.02.2016 16.0 22.03.2016 17.63 15.06.2016 07.07.2016 27.07.2016 15.07.2016
30140161 351 30327233 m Cre:Cre+; Pink1:wt/wt 15.10.2014 01.12.2016
30139633 216 30327192 m Cre:Cre+; Pink1:flox/flox 10.10.2014 12.01.2016 15.3 19.01.2016 15.5 01.02.2016 16.0 14.03.2016 17.4 08.04.2016 18.2 20.04.2016 18.60 15.06.2016 14.07.2016 27.07,2016 22.07.2016 01.12.2016
30140046 317 30327193 m Cre:Cre+; Pink1:flox/flox 17.10.2014 12.01.2016 15.1 19.01.2016 15.3 01.02.2016 15.7 14.03.2016 17.1 08.04.2016 18.0 20.04.2016 18.37 15.06.2016 07.07.2016 28.07.2016 22.07.2016
30139423 162 30327200 m Cre:Cre+; Pink1:flox/flox 09.10.2014 12.01.2016 15.3 19.01.2016 15.6 01.02.2016 16.0 14.03.2016 17.4 08.04.2016 18.2 20.04.2016 18.63 15.06.2016 13.07.2016 29.07.2016 21.07.2016 01.12.2016
30139480 180 30327202 m Cre:Cre+; Pink1:flox/flox 09.10.2014 12.01.2016 15.3 19.01.2016 15.6 01.02.2016 16.0 22.03.2016 17.67 15.06.2016 07.07.2016 27.07.2016 21.07.2016
30139606 201 30327208 m Cre:Cre+; Pink1:flox/flox 10.10.2014 12.01.2016 15.3 20.01.2016 15.6 02.02.2016 16.0 14.03.2016 17.4 08.04.2016 18.2 20.04.2016 18.60 15.06.2016 13.07.2016 28.07.2016 15.07.2016
30140048 319 30327216 m Cre:Cre+; Pink1:flox/flox 17.10.2014 12.01.2016 15.1 20.01.2016 15.3 02.02.2016 15.8 14.03.2016 17.1 08.04.2016 18.0 20.04.2016 18.37
30140053 324 30327217 m Cre:Cre+; Pink1:flox/flox 16.10.2014 12.01.2016 15.1 20.01.2016 15.4 02.02.2016 15.8 14.03.2016 17.2 08.04.2016 18.0 20.04.2016 18.40 15.06.2016 14.07.2016 29.07.2016 22.07.2016
30140054 325 30327218 m Cre:Cre+; Pink1:flox/flox 16.10.2014
30139717 278 30327225 m Cre:Cre+; Pink1:flox/flox 13.10.2014 12.01.2016 15.2 19.01.2016 15.4 01.02.2016 15.9 22.03.2016 17.53 15.06.2016 13.07.2016 27.07.216 12.08.2016
30139730 289 30327227 m Cre:Cre+; Pink1:flox/flox 10.10.2014 12.01.2016 15.3 20.01.2016 15.6 01.02.2016 16.0 22.03.2016 17.63 15.06.2016 07.07.2016 29.07.2016 15.07.289
30140162 352 30327234 m Cre:Cre+; Pink1:flox/flox 15.10.2014 12.01.2016 15.1 20.01.2016 15.4 02.02.2016 15.8 14.03.2016 17.2 08.04.2016 18.0 20.04.2016 18.43
30139618 209 30327190 m Cre:Cre-; Pink1:flox/flox 10.10.2014 12.01.2016 15.3 19.01.2016 15.5 01.02.2016 16.0 14.03.2016 17.4 08.04.2016 18.2 20.04.2016 18.60 15.06.2016 14.07.2016 28.07.2016 15.07.2016 01.12.2016
30139631 214 30327191 m Cre:Cre-; Pink1:flox/flox 10.10.2014 12.01.2016 15.3 19.01.2016 15.5 01.02.2016 16.0 14.03.2016 17.4 08.04.2016 18.2 20.04.2016 18.60 15.06.2016 14.07.2016 28.07.2016 21.07.2016 01.12.2016
30139299 125 30327197 m Cre:Cre-; Pink1:flox/flox 06.10.2014 12.01.2016 15.4 19.01.2016 15.7 01.02.2016 16.1 14.03.2016 17.5 08.04.2016 18.3 20.04.2016 18.73 15.06.2016 13.07.2016 27.07.2016 21.07.2016
30139533 185 30327203 m Cre:Cre-; Pink1:flox/flox 09.10.2014 12.01.2016 15.3 19.01.2016 15.6 01.02.2016 16.0 22.03.2016 17.67 15.06.2016 07.07.2016 28.07.2016 12.08.2016
30139672 245 30327213 m Cre:Cre-; Pink1:flox/flox 13.10.2014 12.01.2016 15.2 20.01.2016 15.5 01.02.2016 15.9 14.03.2016 17.3 08.04.2016 18.1 20.04.2016 18.50 13.07.2016 29.07.2016 21.07.2016
30139674 247 30327214 m Cre:Cre-; Pink1:flox/flox 13.10.2014
30139675 248 30327215 m Cre:Cre-; Pink1:flox/flox 13.10.2014
30140055 326 30327219 m Cre:Cre-; Pink1:flox/flox 16.10.2014 12.01.2016 15.1 20.01.2016 15.4 02.02.2016 15.8 14.03.2016 17.2 08.04.2016 18.0 20.04.2016 18.40 15.06.2016
30139693 257 30327222 m Cre:Cre-; Pink1:flox/flox 12.10.2014 12.01.2016 15.2 20.01.2016 15.5 02.02.2016 15.9 14.03.2016 17.3 08.04.2016 18.1 20.04.2016 18.53 15.06.2016
30139716 277 30327224 m Cre:Cre-; Pink1:flox/flox 13.10.2014 12.01.2016 15.2 20.01.2016 15.5 02.02.2016 15.9 22.03.2016 17.53 07.07.2016 28.07.2016 15.07.2016
30140043 314 30327231 m Cre:Cre-; Pink1:flox/flox 16.10.2014 12.01.2016 15.1 20.01.2016 15.4 02.02.2016 15.8 22.03.2016 17.43 15.06.2016 13.07.2016 28.07.2016 15.07.2016 01.12.2016
30140160 350 30327232 m Cre:Cre-; Pink1:flox/flox 15.10.2014 12.01.2016 15.1 19.01.2016 15.4 01.02.2016 15.8 14.03.2016 17.2 08.04.2016 18.0 20.04.2016 18.43 15.06.2016 04.08.2016 27.07.2016 21.07.2016
OF ASR/PPI Catwalk prepOlfaction HPLC
mid aged




Table A7: Overview of analysed young female Pink1 x DAT mice of the cohort 1 
 
Mice were born in the mouse facility “C-Streifen” and were tested in the mouse facility “GMC”. Some movies of CatWalk testing (labelled in red colour) could not 




ID C-Streifen ear nr. ID GMC sex genotype born date age date age date age begin date age end date age
30139647 224 30327235 f Cre:Cre+; Pink1:wt/wt 11.10.2014 17.02.2015 4.3 24.02.2015 4.5 07.04.2015 5.9
30139649 226 30327236 f Cre:Cre+; Pink1:wt/wt 11.10.2014 17.02.2015 4.3 24.02.2015 4.5 07.04.2015 5.9
30140171 361 30327237 f Cre:Cre+; Pink1:wt/wt 23.10.2014 17.02.2015 3.9 24.02.2015 4.1 07.04.2015 5.5
30139017 117 30327241 f Cre:Cre+; Pink1:wt/wt 06.10.2014 17.02.2015 4.5 23.02.2015 4.7 02.04.2015 5.9
30139362 133 30327244 f Cre:Cre+; Pink1:wt/wt 07.10.2014 17.02.2015 4.4 24.02.2015 4.7 07.04.2015 6.1
30139479 179 30327252 f Cre:Cre+; Pink1:wt/wt 09.10.2014 17.02.2015 4.4 24.02.2015 4.6 08.04.2015 6.0
30140018 309 30327260 f Cre:Cre+; Pink1:wt/wt 16.10.2014 17.02.2015 4.1 24.02.2015 4.4 08.04.2015 5.8
30139652 229 30327264 f Cre:Cre+; Pink1:wt/wt 12.10.2014 17.02.2015 4.3 24.02.2015 4.5 08.04.2015 5.9
30139719 280 30327274 f Cre:Cre+; Pink1:wt/wt 13.10.2014 17.02.2015 4.2 24.02.2015 4.5 08.04.2015 5.9
30139734 293 30327277 f Cre:Cre+; Pink1:wt/wt 10.10.2014 17.02.2015 4.3 24.02.2015 4.6 08.04.2015 6.0
30139021 121 30327243 f Cre:Cre+; Pink1:flox/flox 06.10.2014 17.02.2015 4.5 23.02.2015 4.7 02.04.2015 5.9
30139371 142 30327246 f Cre:Cre+; Pink1:flox/flox 07.10.2014 17.02.2015 4.4 24.02.2015 4.7 07.04.2015 6.1
30139482 182 30327253 f Cre:Cre+; Pink1:flox/flox 09.10.2014 17.02.2015 4.4 24.02.2015 4.6 07.04.2015 6.0
30139484 184 30327254 f Cre:Cre+; Pink1:flox/flox 09.10.2014 17.02.2015 4.4 24.02.2015 4.6 07.04.2015 6.0
30139537 189 30327255 f Cre:Cre+; Pink1:flox/flox 09.10.2014 17.02.2015 4.4 24.02.2015 4.6 07.04.2015 6.0
30139424 163 30327256 f Cre:Cre+; Pink1:flox/flox 09.10.2014 17.02.2015 4.4 24.02.2015 4.6 07.04.2015 6.0
30139471 171 30327257 f Cre:Cre+; Pink1:flox/flox 09.10.2014 17.02.2015 4.4 24.02.2015 4.6 08.04.2015 6.0
30139610 205 30327259 f Cre:Cre+; Pink1:flox/flox 10.10.2014 17.02.2015 4.3 24.02.2015 4.6 08.04.2015 6.0
30139654 231 30327265 f Cre:Cre+; Pink1:flox/flox 12.10.2014 17.02.2015 4.3 24.02.2015 4.5 08.04.2015 5.9
30139655 232 30327266 f Cre:Cre+; Pink1:flox/flox 12.10.2014 17.02.2015 4.3 24.02.2015 4.5 08.04.2015 5.9
30139680 253 30327270 f Cre:Cre+; Pink1:flox/flox 13.10.2014 17.02.2015 4.2 24.02.2015 4.5 08.04.2015 5.9
30139733 292 30327276 f Cre:Cre+; Pink1:flox/flox 10.10.2014 17.02.2015 4.3 24.02.2015 4.6 08.04.2015 6.0
30139013 113 30327239 f Cre:Cre-; Pink1:flox/flox 06.10.2014 17.02.2015 4.5 23.02.2015 4.7 02.04.2015 5.9
30139016 116 30327240 f Cre:Cre-; Pink1:flox/flox 06.10.2014 17.02.2015 4.5 23.02.2015 4.7 07.04.2015 6.1
30139372 143 30327247 f Cre:Cre-; Pink1:flox/flox 07.10.2014 17.02.2015 4.4 24.02.2015 4.7 07.04.2015 6.1
30139373 144 30327248 f Cre:Cre-; Pink1:flox/flox 07.10.2014 17.02.2015 4.4 24.02.2015 4.7 07.04.2015 6.1
30139377 148 30327249 f Cre:Cre-; Pink1:flox/flox 07.10.2014 17.02.2015 4.4 24.02.2015 4.7 07.04.2015 6.1
30139476 176 30327251 f Cre:Cre-; Pink1:flox/flox 09.10.2014 17.02.2015 4.4 24.02.2015 4.6 07.04.2015 6.0
30139638 221 30327262 f Cre:Cre-; Pink1:flox/flox 10.10.2014 17.02.2015 4.3 24.02.2015 4.6 08.04.2015 6.0
30139665 242 30327267 f Cre:Cre-; Pink1:flox/flox 12.10.2014 17.02.2015 4.3 24.02.2015 4.5 08.04.2015 5.9
30139683 256 30327268 f Cre:Cre-; Pink1:flox/flox 13.10.2014 17.02.2015 4.2 24.02.2015 4.5 08.04.2015 5.9
30139678 251 30327269 f Cre:Cre-; Pink1:flox/flox 13.10.2014 17.02.2015 4.2 24.02.2015 4.5 08.04.2015 5.9
30139682 255 30327271 f Cre:Cre-; Pink1:flox/flox 13.10.2014 17.02.2015 4.2 24.02.2015 4.5 08.04.2015 5.9
30139699 263 30327272 f Cre:Cre-; Pink1:flox/flox 12.10.2014 17.02.2015 4.3 24.02.2015 4.5 08.04.2015 5.9
Olfaction
young




Table A8: Overview of analysed mid-aged female Pink1 x DAT mice of the cohort 1 
 
Mice were born in the mouse facility “C-Streifen” and were tested in the mouse facility “GMC”. OF = open field, ASR = acoustic startle reflex, PPI = prepulse 
inhibition, TH = immunohistochemical staining of TH+ cells, 5-HT = immunohistochemical staining of 5-HT+ cells, HPLC = quantification of neurotransmitter content 





ID C-Streifen ear nr. ID GMC sex genotype born date age date age date age begin date age end date age date age date est. date OB date STR date VM date
30139647 224 30327235 f Cre:Cre+; Pink1:wt/wt 11.10.2014 13.01.2016 15.3 19.01.2016 15.5 03.02.2016 16.0 21.03.2016 17.57 15.06.2016 14.07.2016 27.07.2016 15.07.2016
30139649 226 30327236 f Cre:Cre+; Pink1:wt/wt 11.10.2014 13.01.2016 15.3 19.01.2016 15.5 03.02.2016 16.0 21.03.2016 17.57 15.06.2016 15.07.2016 27.07.2016 15.07.2016
30140171 361 30327237 f Cre:Cre+; Pink1:wt/wt 23.10.2014 13.01.2016 14.9 19.01.2016 15.1 03.02.2016 15.6 21.03.2016 17.17 07.07.2016 27.07.2016 22.07.2016
30139017 117 30327241 f Cre:Cre+; Pink1:wt/wt 06.10.2014 13.01.2016 15.5 19.01.2016 15.7 03.02.2016 16.2 21.03.2016 17.73 15.06.2016 13.07.2016 28.07.2016 22.07.2016
30139362 133 30327244 f Cre:Cre+; Pink1:wt/wt 07.10.2014 13.01.2016 15.4 19.01.2016 15.6 03.02.2016 16.1 21.03.2016 17.70 15.06.2016 07.07.2016 29.07.2016 21.07.2016
30139479 179 30327252 f Cre:Cre+; Pink1:wt/wt 09.10.2014 13.01.2016 15.4 19.01.2016 15.6 03.02.2016 16.1 21.03.2016 17.63 15.06.2016 07.07.2016 29.07.2016 21.07.2016
30140018 309 30327260 f Cre:Cre+; Pink1:wt/wt 16.10.2014 13.01.2016 15.1 19.01.2016 15.3 04.02.2016 15.9 21.03.2016 17.40 15.06.2016 07.07.2016 27.07.2016 12.08.2016
30139652 229 30327264 f Cre:Cre+; Pink1:wt/wt 12.10.2014 13.01.2016 15.3 19.01.2016 15.5 04.02.2016 16.0 21.03.2016 17.53
30139719 280 30327274 f Cre:Cre+; Pink1:wt/wt 13.10.2014 13.01.2016 15.2 19.01.2016 15.4 04.02.2016 16.0 21.03.2016 17.50 15.06.2016 14.07.2016 28.08.2016 21.07.2016
30139734 293 30327277 f Cre:Cre+; Pink1:wt/wt 10.10.2014 13.01.2016 15.3 19.01.2016 15.5 04.02.2016 16.1 21.03.2016 17.60 15.06.2016 01.12.2016
30139021 121 30327243 f Cre:Cre+; Pink1:flox/flox 06.10.2014 13.01.2016 15.5 19.01.2016 15.7 03.02.2016 16.2 21.03.2016 17.73 07.07.2016 28.07.2016 22.07.2016 01.12.2016
30139371 142 30327246 f Cre:Cre+; Pink1:flox/flox 07.10.2014 13.01.2016 15.4 19.01.2016 15.6 03.02.2016 16.1 21.03.2016 17.70 15.06.2016 13.07.2016 28.07.2016 21.07.2016 01.12.2016
30139482 182 30327253 f Cre:Cre+; Pink1:flox/flox 09.10.2014 13.01.2016 15.4 19.01.2016 15.6 03.02.2016 16.1 21.03.2016 17.63 15.06.2016 13.07.2016 27.07.2016 21.07.2016
30139484 184 30327254 f Cre:Cre+; Pink1:flox/flox 09.10.2014 13.01.2016 15.4 19.01.2016 15.6 03.02.2016 16.1 21.03.2016 17.63 14.07.2016 27.07.2016 15.07.2016
30139537 189 30327255 f Cre:Cre+; Pink1:flox/flox 09.10.2014 13.01.2016 15.4 19.01.2016 15.6 03.02.2016 16.1 21.03.2016 17.63 15.06.2016 14.07.2016 28.07.2016 15.07.2016
30139424 163 30327256 f Cre:Cre+; Pink1:flox/flox 09.10.2014 13.01.2016 15.4 19.01.2016 15.6 03.02.2016 16.1 21.03.2016 17.63 15.06.2016 14.07.2016 28.07.2016 21.07.2016
30139471 171 30327257 f Cre:Cre+; Pink1:flox/flox 09.10.2014 13.01.2016 15.4 19.01.2016 15.6 04.02.2016 16.1 21.03.2016 17.63 15.06.2016 13.07.2016 27.07.2016 21.07.2016
30139610 205 30327259 f Cre:Cre+; Pink1:flox/flox 10.10.2014 13.01.2016 15.3 19.01.2016 15.5 04.02.2016 16.1 21.03.2016 17.60 15.06.2016 07.07.2016 28.07.2016 22.07.2016
30139654 231 30327265 f Cre:Cre+; Pink1:flox/flox 12.10.2014 13.01.2016 15.3 19.01.2016 15.5 04.02.2016 16.0 21.03.2016 17.53 15.06.2016
30139655 232 30327266 f Cre:Cre+; Pink1:flox/flox 12.10.2014 13.01.2016 15.3 19.01.2016 15.5 04.02.2016 16.0 22.03.2016 17.57
30139680 253 30327270 f Cre:Cre+; Pink1:flox/flox 13.10.2014
30139733 292 30327276 f Cre:Cre+; Pink1:flox/flox 10.10.2014 13.01.2016 15.3 19.01.2016 15.5 04.02.2016 16.1
30139013 113 30327239 f Cre:Cre-; Pink1:flox/flox 06.10.2014 13.01.2016 15.5 19.01.2016 15.7 03.02.2016 16.2 21.03.2016 17.73 13.07.2016 28.07.2016 22.07.2016 01.12.2016
30139016 116 30327240 f Cre:Cre-; Pink1:flox/flox 06.10.2014 13.01.2016 15.5 19.01.2016 15.7 03.02.2016 16.2 21.03.2016 17.73 15.06.2016 07.07.2016 27.07.2016 15.07.2016 01.12.2016
30139372 143 30327247 f Cre:Cre-; Pink1:flox/flox 07.10.2014 13.01.2016 15.4 19.01.2016 15.6 03.02.2016 16.1 21.03.2016 17.70 15.06.2016 14.07.2016 28.07.2016 21.07.2016 01.12.2016
30139373 144 30327248 f Cre:Cre-; Pink1:flox/flox 07.10.2014 13.01.2016 15.4 19.01.2016 15.6 03.02.2016 16.1 21.03.2016 17.70 15.06.2016 13.07.2016 27.07.2016 21.07.2016
30139377 148 30327249 f Cre:Cre-; Pink1:flox/flox 07.10.2014 13.01.2016 15.4 19.01.2016 15.6 03.02.2016 16.1 22.03.2016 17.73 14.07.2016 27.07.2016 15.07.2016
30139476 176 30327251 f Cre:Cre-; Pink1:flox/flox 09.10.2014 13.01.2016 15.4 19.01.2016 15.6 03.02.2016 16.1 21.03.2016 17.63 15.06.2016 11.07.2016 27.07.2016 21.07.2016
30139638 221 30327262 f Cre:Cre-; Pink1:flox/flox 10.10.2014 13.01.2016 15.3 19.01.2016 15.5 03.02.2016 16.0 21.03.2016 17.60 15.06.2016 04.08.2016 29.07.2016 21.07.2016
30139665 242 30327267 f Cre:Cre-; Pink1:flox/flox 12.10.2014 13.01.2016 15.3 19.01.2016 15.5 04.02.2016 16.0 21.03.2016 17.53 15.06.2016 04.08.2016 27.07.2016 12.08.2016
30139683 256 30327268 f Cre:Cre-; Pink1:flox/flox 13.10.2014 13.01.2016 15.2 19.01.2016 15.4 04.02.2016 16.0 21.03.2016 17.50 15.06.2016
30139678 251 30327269 f Cre:Cre-; Pink1:flox/flox 13.10.2014 13.01.2016 15.2 19.01.2016 15.4 04.02.2016 16.0 21.03.2016 17.50
30139682 255 30327271 f Cre:Cre-; Pink1:flox/flox 13.10.2014 13.01.2016 15.2 19.01.2016 15.4 04.02.2016 16.0
30139699 263 30327272 f Cre:Cre-; Pink1:flox/flox 12.10.2014 13.01.2016 15.3 19.01.2016 15.5 04.02.2016 16.0
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Table A9: Overview of analysed Pink1 x Pet mice of the cohort 2 
 
TH = immunohistochemical staining of TH+ cells, 5-HT = immunohistochemical staining of 5-HT+ cells, 
HPLC = quantification of neurotransmitter content via HPLC, OB = olfactory bulb, STR = striatum, VM = 






ear nr. ID C-Streifen sex genotype born prep age date est. date OB date STR date VM 
745 30157395 m Cre:Cre+; Pink1:wt/wt 14.06.2015 30.09.2015 3.60 02.11.2015 14.01.2016 20.01.2016 03.12.2015
746 30157396 m Cre:Cre+; Pink1:wt/wt 14.06.2015 30.09.2015 3.60 02.11.2015 15.01.2016 25.01.2016 14.12.2015
775 30157425 m Cre:Cre+; Pink1:wt/wt 15.06.2015 30.09.2015 3.57 02.11.2015 15.01.2016 20.01.2016 14.12.2015
937 30161163 m Cre:Cre+; Pink1:wt/wt 18.07.2015 19.11.2015 4.13 02.11.2015 18.01.2016 28.01.2016 16.12.2015
948 30161820 m Cre:Cre+; Pink1:wt/wt 18.07.2015 19.11.2015 4.13 02.11.2015 14.01.2016
953 30161825 m Cre:Cre+; Pink1:wt/wt 18.07.2015 19.11.2015 4.13 02.11.2015
988 30161942 m Cre:Cre+; Pink1:wt/wt 25.07.2015 19.11.2015 3.90 02.11.2015 18.01.2016 25.01.2016 15.12.2015
909 30159757 m Cre:Cre+; Pink1:wt/wt 08.07.2015 02.11.2015 3.90 29.01.2016 14.12.2015
917 30159920 m Cre:Cre+; Pink1:wt/wt 08.07.2015 02.11.2015 3.90 13.01.2016 20.01.2016 10.12.2015
980 30161927 m Cre:Cre+; Pink1:wt/wt 25.07.2015 19.11.2015 3.90 19.01.2016 27.01.2016 16.12.2015
671 30157204 m Cre:Cre+; Pink1:flox/flox 13.06.2015 30.09.2015 3.63 02.11.2015 14.01.2016 21.01.2016 03.12.2015
679 30157212 m Cre:Cre+; Pink1:flox/flox 13.06.2015 30.09.2015 3.63 02.11.2015 15.01.2016 14.12.2015
713 30157363 m Cre:Cre+; Pink1:flox/flox 13.06.2015 30.09.2015 3.63 28.01.2016 14.12.2015
739 30157389 m Cre:Cre+; Pink1:flox/flox 14.06.2015 30.09.2015 3.60 18.01.2016 27.01.2016 15.12.2015
752 30157402 m Cre:Cre+; Pink1:flox/flox 14.06.2015 30.09.2015 3.60 02.11.2015 13.01.2016 10.12.2015
753 30157403 m Cre:Cre+; Pink1:flox/flox 14.06.2015 30.09.2015 3.60 02.11.2015 14.01.2016 21.01.2016 10.12.2015
755 30157405 m Cre:Cre+; Pink1:flox/flox 14.06.2015 02.10.2015 3.67 15.01.2016 27.01.2016 16.12.2015
765 30157415 m Cre:Cre+; Pink1:flox/flox 15.06.2015 02.10.2015 3.63 02.11.2015 15.01.2016 25.01.2016 17.12.2016
789 30157439 m Cre:Cre+; Pink1:flox/flox 15.06.2015 02.10.2015 3.63 02.11.2015 29.01.2016
795 30157445 m Cre:Cre+; Pink1:flox/flox 15.06.2015 02.10.2015 3.63 02.11.2015 18.01.2016 21.01.2016
670 30157203 m Cre:Cre-; Pink1:flox/flox 13.06.2015 30.09.2015 3.63 02.11.2015 13.01.2016 03.12.2015
680 30157213 m Cre:Cre-; Pink1:flox/flox 13.06.2015 30.09.2015 3.63 02.11.2015 15.01.2016 20.01.2016 14.12.2015
710 30157360 m Cre:Cre-; Pink1:flox/flox 13.06.2015 30.09.2015 3.63 02.11.2015 15.01.2016 14.12.2015
719 30157369 m Cre:Cre-; Pink1:flox/flox 13.06.2015 30.09.2015 3.63 12.01.2016 20.01.2016 23.12.2016
790 30157440 m Cre:Cre-; Pink1:flox/flox 15.06.2015 30.09.2015 3.57 02.11.2015 13.01.2016 20.01.2016 10.12.2015
814 30158282 m Cre:Cre-; Pink1:flox/flox 19.06.2015 02.11.2015 4.53 19.01.2016 27.01.2016 15.12.2015
817 30158285 m Cre:Cre-; Pink1:flox/flox 19.06.2015 02.11.2015 4.53 18.01.2016 25.01.2016 15.12.2015
823 30158291 m Cre:Cre-; Pink1:flox/flox 19.06.2015 02.11.2015 4.53 02.11.2015 19.01.2016 27.01.2016 17.12.2015
903 30159751 m Cre:Cre-; Pink1:flox/flox 05.07.2015 02.11.2015 4.00 02.11.2015 28.01.2016
929 30160674 m Cre:Cre-; Pink1:flox/flox 10.07.2015 02.11.2015 3.83 02.11.2015 29.01.2016
653 30157186 f Cre:Cre+; Pink1:wt/wt 12.06.2015 30.09.2015 3.67 02.11.2015 13.01.2016 21.01.2016 09.12.2015
688 30157221 f Cre:Cre+; Pink1:wt/wt 13.06.2015 30.09.2015 3.63 02.11.2015
690 30157223 f Cre:Cre+; Pink1:wt/wt 13.06.2015 30.09.2015 3.63 02.11.2015
703 30157235 f Cre:Cre+; Pink1:wt/wt 13.06.2015 30.09.2015 3.63 02.11.2015 15.01.2016 14.12.2015
707 30157239 f Cre:Cre+; Pink1:wt/wt 14.06.2015 02.10.2015 3.67 19.01.2016 25.01.2016 15.12.2015
714 30157364 f Cre:Cre+; Pink1:wt/wt 13.06.2015 30.09.2015 3.63 02.11.2015 12.01.2016 20.01.2016 10.12.2015
728 30157378 f Cre:Cre+; Pink1:wt/wt 13.06.2015 02.10.2015 3.70 02.11.2015 13.01.2016 21.01.2016 09.12.2015
747 30157397 f Cre:Cre+; Pink1:wt/wt 14.06.2015 02.10.2015 3.67 02.11.2015 15.01.2016 27.01.2016 16.12.2015
763 30157413 f Cre:Cre+; Pink1:wt/wt 14.06.2015 02.10.2015 3.67 02.11.2015 18.01.2016 28.01.2016 15.12.2015
771 30157421 f Cre:Cre+; Pink1:wt/wt 15.06.2015 02.10.2015 3.63 19.01.2016 29.01.2016 15.12.2015
931 30160676 f Cre:Cre+; Pink1:wt/wt 10.07.2015 02.11.2015 3.83 28.01.2016
683 30157216 f Cre:Cre+; Pink1:flox/flox 13.06.2015 30.09.2015 3.63 02.11.2015 14.01.2016 21.01.2016
687 30157220 f Cre:Cre+; Pink1:flox/flox 13.06.2015 30.09.2015 3.63 02.11.2015
726 30157376 f Cre:Cre+; Pink1:flox/flox 13.06.2015 30.09.2015 3.63 14.01.2016 27.01.2016 14.12.2015
727 30157377 f Cre:Cre+; Pink1:flox/flox 13.06.2015 02.10.2015 3.70 02.11.2015 12.01.2016 20.01.2016 10.12.2015
734 30157384 f Cre:Cre+; Pink1:flox/flox 13.06.2015 02.10.2015 3.70 02.11.2015 13.01.2016 21.01.2016 09.12.2015
735 30157385 f Cre:Cre+; Pink1:flox/flox 13.06.2015 02.10.2015 3.70 02.11.2015 15.01.2016 27.01.2016 16.12.2015
756 30157406 f Cre:Cre+; Pink1:flox/flox 14.06.2015 02.10.2015 3.67 29.01.2016
773 30157423 f Cre:Cre+; Pink1:flox/flox 15.06.2015 02.10.2015 3.63 02.11.2015 19.01.2016 25.01.2016 16.12.2015
981 30161928 f Cre:Cre+; Pink1:flox/flox 25.07.2015 19.11.2015 3.90 18.01.2016 28.01.2016 15.12.2015
985 30161932 f Cre:Cre+; Pink1:flox/flox 25.07.2015 19.11.2015 3.90 19.01.2016 15.12.2015
993 30161950 f Cre:Cre+; Pink1:flox/flox 26.07.2015 19.11.2015 3.87 17.12.2015
656 30157189 f Cre:Cre-; Pink1:flox/flox 12.06.2015 30.09.2015 3.67 02.11.2015 13.01.2016 20.01.2016 03.12.2015
659 30157192 f Cre:Cre-; Pink1:flox/flox 12.06.2015 30.09.2015 3.67 18.01.2016 23.12.2015
664 30157197 f Cre:Cre-; Pink1:flox/flox 12.06.2015 30.09.2015 3.67 14.01.2016 25.01.2016 14.12.2015
672 30157205 f Cre:Cre-; Pink1:flox/flox 13.06.2015 30.09.2015 3.63 12.01.2016 21.01.2016 09.12.2015
675 30157208 f Cre:Cre-; Pink1:flox/flox 13.06.2015 30.09.2015 3.63 13.01.2016 21.01.2016
694 30157227 f Cre:Cre-; Pink1:flox/flox 13.06.2015 02.10.2015 3.70 02.11.2015
706 30157238 f Cre:Cre-; Pink1:flox/flox 14.06.2015 02.10.2015 3.67 02.11.2015 19.01.2016 25.01.2016 15.12.2015
772 30157422 f Cre:Cre-; Pink1:flox/flox 15.06.2015 02.10.2015 3.63 02.11.2015 15.01.2016 28.01.2016 16.12.2015
783 30157433 f Cre:Cre-; Pink1:flox/flox 15.06.2015 02.10.2015 3.63 02.11.2015 19.01.2016 28.01.2016 16.12.2015
799 30157449 f Cre:Cre-; Pink1:flox/flox 15.06.2015 02.10.2015 3.63 02.11.2015 29.01.2016 17.12.2015
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Table 10: Overview of analysed Pink1 x DAT mice of the cohort 2 
 
TH = immunohistochemical staining of TH+ cells, 5-HT = immunohistochemical staining of 5-HT+ cells, 
HPLC = quantification of neurotransmitter content via HPLC, OB = olfactory bulb, STR = striatum, VM = 





ear nr. ID C-Streifen sex genotype born prep age date est. date OB date STR date VM 
799 30159083 m Cre:Cre+; Pink1:wt/wt 29.06.2015 20.11.2015 4.80 19.02.2016 11.03.2016 10.02.2016
819 30159160 m Cre:Cre+; Pink1:wt/wt 29.06.2015 20.11.2015 4.80 11.04.2016 25.02.2016 11.03.2016 09.02.2016
835 30159176 m Cre:Cre+; Pink1:wt/wt 29.06.2015 20.11.2015 4.80 11.04.2016 24.02.2016 11.03.2016
860 30159217 m Cre:Cre+; Pink1:wt/wt 29.06.2015 02.11.2015 4.20 11.04.2016 12.02.2016 26.02.2016 03.02.2016
899 30159256 m Cre:Cre+; Pink1:wt/wt 30.06.2015 02.11.2015 4.17 11.04.2016 12.02.2016 26.02.2016 02.02.2016
909 30159598 m Cre:Cre+; Pink1:wt/wt 30.06.2015 02.11.2015 4.17 15.02.2016 02.03.2016 02.02.2016
916 30159622 m Cre:Cre+; Pink1:wt/wt 30.06.2015 03.11.2015 4.20 11.04.2016 19.02.2016 01.03.2016 25.02.2016
932 30159686 m Cre:Cre+; Pink1:wt/wt 30.06.2015 03.11.2015 4.20 11.04.2016 05.02.2016
954 30159713 m Cre:Cre+; Pink1:wt/wt 03.07.2015 03.11.2015 4.10 11.04.2016 18.02.2016 02.03.2016 05.02.2016
818 30159159 m Cre:Cre+; Pink1:flox/flox 29.06.2015 20.11.2015 4.80 24.02.2016 11.03.2016 09.02.2016
820 30159161 m Cre:Cre+; Pink1:flox/flox 29.06.2015 20.11.2015 4.80 09.02.2016
825 30159166 m Cre:Cre+; Pink1:flox/flox 29.06.2015 20.11.2015 4.80 11.04.2016 24.02.2016 11.03.2016
833 30159174 m Cre:Cre+; Pink1:flox/flox 29.06.2015 02.11.2015 4.20 15.02.2016 10.03.2016 03.02.2016
872 30159229 m Cre:Cre+; Pink1:flox/flox 29.06.2015 02.11.2015 4.20 11.04.2016 01.02.2016
874 30159231 m Cre:Cre+; Pink1:flox/flox 29.06.2015 02.11.2015 4.20 12.02.2016 26.02.2016 03.02.2016
892 30159249 m Cre:Cre+; Pink1:flox/flox 30.06.2015 03.11.2015 4.20 11.04.2016 12.02.2016 01.03.2016 05.02.2016
897 30159254 m Cre:Cre+; Pink1:flox/flox 30.06.2015 03.11.2015 4.20 11.04.2016 18.02.2016 01.03.2016 04.02.2016
938 30159692 m Cre:Cre+; Pink1:flox/flox 30.06.2015 03.11.2015 4.20 11.04.2016 19.02.2016 01.03.2016 25.02.2016
949 30159708 m Cre:Cre+; Pink1:flox/flox 03.07.2015 03.11.2015 4.10 11.04.2016 18.02.2016 09.03.2016
743 30159018 m Cre:Cre-; Pink1:flox/flox 27.06.2015 19.11.2015 4.83 11.04.2016 15.02.2016 01.03.2016 01.02.2016
780 30159055 m Cre:Cre-; Pink1:flox/flox 29.06.2015 19.11.2015 4.77 19.02.2016 10.03.2016 04.02.2016
786 30159070 m Cre:Cre-; Pink1:flox/flox 29.06.2015 19.11.2015 4.77 19.02.2016 26.02.2016 05.02.2016
842 30159183 m Cre:Cre-; Pink1:flox/flox 29.06.2015 19.11.2015 4.77 11.04.2016 19.02.2015 11.03.2016 10.02.2016
867 30159224 m Cre:Cre-; Pink1:flox/flox 30.06.2015 02.11.2015 4.17 11.04.2016 15.02.2015 25.02.2106 03.02.2016
876 30159233 m Cre:Cre-; Pink1:flox/flox 29.06.2015 02.11.2015 4.20 11.04.2016 02.03.2016
908 30159597 m Cre:Cre-; Pink1:flox/flox 30.06.2015 02.11.2015 4.17 11.04.2016 10.03.2016
951 30159710 m Cre:Cre-; Pink1:flox/flox 03.07.2015 02.11.2015 4.07 11.04.2016 12.02.2015 02.03.2016 03.02.2016
992 30161146 m Cre:Cre-; Pink1:flox/flox 20.07.2015 19.11.2015 4.07 11.04.2016 24.02.2015 10.02.2016
1027 30161729 m Cre:Cre-; Pink1:flox/flox 24.07.2015 19.11.2015 3.93 11.04.2016 25.02.2015 09.02.2016
744 30159019 f Cre:Cre+; Pink1:wt/wt 27.06.2015 19.11.2015 4.83 11.04.2016 09.02.2016
747 30159022 f Cre:Cre+; Pink1:wt/wt 27.06.2015 19.11.2015 4.83 11.04.2016 24.02.2016 09.03.2016 10.02.2016
816 30159157 f Cre:Cre+; Pink1:wt/wt 29.06.2015 19.11.2015 4.77 24.02.2016 11.03.2016
883 30159240 f Cre:Cre+; Pink1:wt/wt 30.06.2015 19.11.2015 4.73 11.04.2016
894 30159251 f Cre:Cre+; Pink1:wt/wt 30.06.2015 02.11.2015 4.17 11.04.2016 15.02.2016 26.02.2016 03.02.2016
895 30159252 f Cre:Cre+; Pink1:wt/wt 30.06.2015 02.11.2015 4.17 11.04.2016 12.02.2016 26.02.2016 01.02.2016
910 30159599 f Cre:Cre+; Pink1:wt/wt 30.06.2015 02.11.2015 4.17 11.04.2016 12.02.2016 01.03.2016 03.02.2016
931 30159650 f Cre:Cre+; Pink1:wt/wt 30.06.2015 02.11.2015 4.17 11.04.2016 18.02.2016 01.03.2016 05.02.2016
965 30159723 f Cre:Cre+; Pink1:wt/wt 05.07.2015 03.11.2015 4.03 11.04.2016 18.02.2016 02.03.2016 05.02.2016
973 30159731 f Cre:Cre+; Pink1:wt/wt 07.07.2015 03.11.2015 3.97 18.02.2016 09.03.2016 10.02.2016
736 30158914 f Cre:Cre+; Pink1:flox/flox 27.06.2015 19.11.2015 4.83 11.04.2016 18.02.2015 02.03.2016 04.02.2016
753 30159028 f Cre:Cre+; Pink1:flox/flox 28.06.2015 19.11.2015 4.80 11.04.2016 18.02.2015 02.03.2016 04.02.2016
777 30159052 f Cre:Cre+; Pink1:flox/flox 28.06.2015 19.11.2015 4.80 11.04.2016 25.02.2016
781 30159056 f Cre:Cre+; Pink1:flox/flox 29.06.2015 19.11.2015 4.77 11.04.2016 25.02.2015 10.03.2016
889 30159246 f Cre:Cre+; Pink1:flox/flox 30.06.2015 02.11.2015 4.17 12.02.2015 10.03.2016
913 30159602 f Cre:Cre+; Pink1:flox/flox 30.06.2015 02.11.2015 4.17 11.04.2016 12.02.2015 26.02.2016 02.02.2016
925 30159644 f Cre:Cre+; Pink1:flox/flox 30.06.2015 02.11.2015 4.17 01.02.2016
940 30159694 f Cre:Cre+; Pink1:flox/flox 30.06.2015 02.11.2015 4.17 11.04.2016 15.02.2015 25.02.2016 02.02.2016
947 30159706 f Cre:Cre+; Pink1:flox/flox 30.06.2015 02.11.2015 4.17 11.04.2016 19.02.2015 01.03.2016 01.02.2016
983 30161137 f Cre:Cre+; Pink1:flox/flox 20.07.2015 19.11.2015 4.07 24.02.2015 09.03.2016 10.02.2016
761 30159036 f Cre:Cre-; Pink1:flox/flox 28.06.2015 19.11.2015 4.80 11.04.2016
775 30159050 f Cre:Cre-; Pink1:flox/flox 28.06.2015 19.11.2015 4.80 11.04.2016
864 30159221 f Cre:Cre-; Pink1:flox/flox 29.06.2015 02.11.2015 4.20 15.02.2015 26.02.2016 02.02.2016
888 30159245 f Cre:Cre-; Pink1:flox/flox 30.06.2015 02.11.2015 4.17 15.02.2015 25.02.2016
896 30159253 f Cre:Cre-; Pink1:flox/flox 30.06.2015 02.11.2015 4.17 11.04.2016 15.02.2015 26.02.2016 01.02.2016
927 30159646 f Cre:Cre-; Pink1:flox/flox 30.06.2015 02.11.2015 4.17 11.04.2016 19.02.2015 02.03.2016 03.02.2016
930 30159649 f Cre:Cre-; Pink1:flox/flox 30.06.2015 03.11.2015 4.20 11.04.2016 18.02.2015 02.03.2016 02.02.2016
961 30159719 f Cre:Cre-; Pink1:flox/flox 04.07.2015 03.11.2015 4.07 11.04.2016 18.02.2015 02.03.2016 04.02.2016
962 30159720 f Cre:Cre-; Pink1:flox/flox 04.07.2015 03.11.2015 4.07 11.04.2016 24.02.2015 11.03.2016 04.02.2016








Table A11: ANOVA table of TH+ cells and 5-HT+ cells of young and mid-aged Pink1 x Pet and Pink1 x DAT mice 
 
 





age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 7 5897.86 459.08 ctrl. 1 8 5917.50 1910.70 ctrl. 1 7 7431.43 1584.49 ctrl. 1 7 7355.00 580.25
mt 7 5074.29 1328.32 mt 6 6042.50 1907.09 mt 7 8058.57 1812.43 mt 7 7200.00 1932.46
ctrl. 2 7 6585.00 1168.27 ctrl. 2 6 6342.50 1842.34 ctrl. 2 7 8593.57 920.17 ctrl. 2 7 8241.43 818.79
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 7 7688.57 1463.94 ctrl. 1 8 7173.75 1167.46 ctrl. 1 8 8898.75 1490.36 ctrl. 1 8 8301.25 984.08
mt 6 8300.00 1017.11 mt 7 7092.86 1648.90 mt 8 7680.00 1446.86 mt 7 8387.86 1219.64
ctrl. 2 8 7601.25 1077.97 ctrl. 2 8 8036.25 943.58 ctrl. 2 8 7901.25 1527.35 ctrl. 2 7 8509.29 1778.16
age groups n mean SD age groups n mean SD
mt 2 6327.16 429.04 mt 2 10290.11 858.58
ctrl.2 2 6024.26 989.18 ctrl.2 2 10071.52 1337.99
age groups n mean SD age groups n mean SD
mt 3 10468.32 2019.66 mt 3 9557.75 363.92








































Table A13: ANOVA table of HPLC measurements of young Pink1 x Pet mice 
 
DOPAC = 3,4-Dihydroxyphenylacetic acid, NE =  Norepinephrine, 5-HIAA = 5-Hydroxyindole-3-acetic acid, HVA = Homovanillic acid, DA = Dopamine, 3-MT = 3-











F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
DOPAC 0.491 0.615 1.245 0.271 0.187 0.830 1.000 1.000 1.000 0.041 0.960 1.000 1.000 1.000 1.088 0.355 1.000 0.585 0.724
NE 0.712 0.496 1.510 0.226 2.337 0.109 1.000 1.000 0.823 1.931 0.170 1.000 0.207 0.591 0.757 0.481 0.864 0.932 1.000
5-HIAA 1.871 0.167 2.600 0.114 2.802 0.072 1.000 0.640 0.193 2.879 0.079 1.000 0.128 0.180 1.066 0.362 0.508 0.997 1.000
HVA 0.577 0.566 0.296 0.589 0.687 0.509 0.882 1.000 1.000 0.533 0.595 1.000 1.000 0.945 0.776 0.473 1.000 0.775 1.000
DA 1.148 0.327 3.142 0.084 0.205 0.815 0.412 1.000 1.000 0.339 0.716 1.000 1.000 1.000 0.974 0.394 0.571 1.000 1.000
3-MT 1.662 0.202 0.038 0.846 1.257 0.295 0.275 1.000 0.533 2.220 0.133 0.170 1.000 0.419 0.026 0.974 1.000 1.000 1.000
5-HT 1.628 0.208 0.121 0.730 1.569 0.220 1.000 0.643 0.263 2.711 0.090 1.000 0.194 0.151 0.175 0.841 1.000 1.000 1.000
DOPAC 0.662 0.521 1.646 0.206 0.620 0.543 1.000 0.939 1.000 0.292 0.750 1.000 1.000 1.000 0.918 0.415 1.000 0.570 1.000
NE 0.748 0.480 0.503 0.482 3.971 0.026 1.000 1.000 0.750 3.517 0.048 0.046 0.867 0.408 1.260 0.304 0.611 0.503 1.000
5-HIAA 0.336 0.717 7.272 0.010 2.225 0.121 1.000 1.000 1.000 0.695 0.510 0.860 1.000 1.000 1.984 0.163 0.201 0.541 1.000
HVA 0.398 0.674 0.614 0.438 0.554 0.579 1.000 1.000 1.000 0.255 0.777 1.000 1.000 1.000 0.850 0.442 1.000 0.662 1.000
DA 0.175 0.840 0.735 0.396 0.539 0.587 1.000 1.000 1.000 0.291 0.750 1.000 1.000 1.000 0.429 0.657 1.000 1.000 1.000
3-MT 1.066 0.354 1.210 0.278 0.018 0.982 1.000 0.461 1.000 0.471 0.631 1.000 1.000 1.000 0.661 0.527 1.000 0.790 1.000
5-HT 0.409 0.667 0.264 0.610 1.631 0.208 1.000 1.000 1.000 2.656 0.094 0.110 0.367 1.000 0.190 0.828 1.000 1.000 1.000
DOPAC 0.051 0.951 0.379 0.542 0.456 0.637 1.000 1.000 1.000 0.169 0.846 1.000 1.000 1.000 0.292 0.750 1.000 1.000 1.000
NE 0.158 0.854 0.052 0.821 0.382 0.685 1.000 1.000 1.000 0.084 0.920 1.000 1.000 1.000 0.379 0.689 1.000 1.000 1.000
5-HIAA 1.551 0.224 8.955 0.005 0.475 0.625 1.000 0.666 0.288 2.007 0.159 1.000 0.398 0.228 0.183 0.834 1.000 1.000 1.000
HVA 1.215 0.307 0.536 0.468 0.317 0.730 0.475 1.000 0.662 0.843 0.445 1.000 1.000 0.633 0.742 0.488 0.715 1.000 1.000
DA 0.800 0.456 0.462 0.500 1.474 0.241 0.806 0.874 1.000 0.235 0.792 1.000 1.000 1.000 1.260 0.304 0.488 0.634 1.000
3-MT 1.121 0.336 0.496 0.485 0.236 0.791 1.000 .695 .601 0.655 0.530 1.000 .993 .977 0.592 0.562 1.000 1.000 .949
5-HT 1.327 0.276 0.256 0.615 0.906 0.412 1.000 1.000 0.333 1.957 0.166 1.000 0.299 0.310 0.636 0.539 0.846 1.000 1.000
Pink1 x Pet, young, HPLC











Table A14: ANOVA table of HPLC measurements of mid-aged Pink1 x Pet mice 
 
DOPAC = 3,4-Dihydroxyphenylacetic acid, NE =  Norepinephrine, 5-HIAA = 5-Hydroxyindole-3-acetic acid, HVA = Homovanillic acid, DA = Dopamine, 3-MT = 3-
Methoxytyramine, 5-HT = Serotonin, OB = olfactory bulb, STR = striatum, VM = ventral midbrain, black = data could not be measured, red: p-value ≤ 0.05, yellow = p-











F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
DOPAC 0.281 0.757 2.387 0.130 0.325 0.724 1.000 1.000 1.000 0.002 0.998 1.000 1.000 1.000 0.416 0.665 1.000 1.000 1.000
NE 0.316 0.731 1.166 0.286 0.575 0.567 1.000 1.000 1.000 0.048 0.953 1.000 1.000 1.000 0.543 0.589 1.000 1.000 1.000
5-HIAA 0.903 0.413 17.130 0.000 0.075 0.928 1.000 0.855 0.675 1.886 0.176 1.000 0.245 0.462 0.312 0.735 1.000 1.000 1.000
HVA 0.172 0.843 2.588 0.115 0.252 0.779 1.000 1.000 1.000 0.008 0.992 1.000 1.000 1.000 0.282 0.757 1.000 1.000 1.000
DA 0.039 0.961 1.018 0.319 0.199 0.820 1.000 1.000 1.000 0.070 0.932 1.000 1.000 1.000 0.137 0.873 1.000 1.000 1.000
3-MT
5-HT 0.479 0.623 3.142 0.084 0.038 0.962 1.000 1.000 1.000 0.293 0.749 1.000 1.000 1.000 0.245 0.785 1.000 1.000 1.000
DOPAC 5.007 0.011 0.496 0.485 0.681 0.512 1.000 0.049 0.016 3.240 0.059 1.000 0.224 0.073 1.874 0.178 1.000 0.305 0.348
NE 2.822 0.071 0.077 0.782 0.583 0.563 0.990 0.525 0.068 1.943 0.168 1.000 1.000 0.186 0.970 0.395 1.000 0.914 0.607
5-HIAA 4.429 0.018 4.851 0.033 0.272 0.763 1.000 0.132 0.018 2.371 0.118 1.000 0.276 0.180 2.314 0.124 0.926 0.841 0.130
HVA 5.120 0.010 0.480 0.492 0.227 0.798 0.966 0.117 0.009 2.411 0.114 1.000 0.560 0.124 3.528 0.048 1.000 0.200 0.057
DA 4.933 0.012 0.054 0.818 0.550 0.581 1.000 0.068 0.015 2.208 0.135 1.000 0.670 0.148 5.813 0.010 1.000 0.015 0.039
3-MT 5.578 0.007 0.105 0.748 0.902 0.414 1.000 0.043 0.009 3.343 0.055 1.000 0.332 0.056 2.915 0.076 1.000 0.105 0.224
5-HT 3.432 0.042 0.091 0.765 0.945 0.397 1.000 0.143 0.057 2.374 0.118 1.000 0.348 0.155 1.232 0.312 1.000 0.583 0.549
DOPAC 2.586 0.087 1.790 0.188 0.731 0.487 0.968 0.635 0.085 3.099 0.066 1.000 0.122 0.135 1.096 0.353 0.719 1.000 0.581
NE 0.434 0.651 1.868 0.179 0.392 0.678 1.000 1.000 1.000 0.711 0.503 1.000 0.810 1.000 0.227 0.799 1.000 1.000 1.000
5-HIAA 1.572 0.220 26.694 0.000 0.498 0.612 0.824 1.000 0.261 1.015 0.379 1.000 0.758 0.639 1.042 0.370 0.697 1.000 0.654
HVA 0.478 0.624 2.241 0.142 0.808 0.453 1.000 1.000 1.000 0.345 0.712 1.000 1.000 1.000 0.740 0.489 0.713 1.000 1.000
DA 0.163 0.850 0.306 0.583 0.982 0.383 1.000 1.000 1.000 0.380 0.688 1.000 1.000 1.000 0.701 0.507 1.000 0.750 1.000
3-MT 1.809 0.176 1.180 0.283 0.458 0.636 0.222 1.000 0.544 0.352 0.708 1.000 1.000 1.000 1.762 0.196 0.230 1.000 0.811
5-HT 0.092 0.912 1.108 0.298 0.135 0.874 1.000 1.000 1.000 0.345 0.712 1.000 1.000 1.000 0.003 0.997 1.000 1.000 1.000
Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-value
Pink1 x Pet, mid-aged, HPLC males females










Table A15: ANOVA table of HPLC measurements of young Pink1 x DAT mice  
 
DOPAC = 3,4-Dihydroxyphenylacetic acid, NE =  Norepinephrine, 5-HIAA = 5-Hydroxyindole-3-acetic acid, HVA = Homovanillic acid, DA = Dopamine, 3-MT = 3-












F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
DOPAC 2.477 0.096 2.930 0.094 0.719 0.493 0.524 1.000 0.100 3.219 0.060 0.367 1.000 0.062 0.243 0.786 1.000 1.000 1.000
NE 0.072 0.931 0.791 0.379 6.092 0.005 1.000 1.000 1.000 3.427 0.052 0.526 0.716 0.048 2.879 0.079 0.955 0.556 0.079
5-HIAA 0.349 0.707 5.838 0.020 1.193 0.313 1.000 1.000 1.000 1.124 0.344 0.653 0.599 1.000 0.220 0.805 1.000 1.000 1.000
HVA 5.212 0.010 0.166 0.686 1.607 0.213 0.166 0.676 0.008 5.370 0.013 0.171 0.694 0.012 0.624 0.545 1.000 1.000 0.838
DA 1.104 0.341 0.108 0.744 2.991 0.061 0.573 1.000 0.665 5.108 0.016 0.245 0.569 0.013 0.572 0.573 1.000 0.917 1.000
3-MT 0.704 0.501 0.375 0.543 1.133 0.332 1.000 1.000 0.810 2.692 0.091 0.102 1.000 0.403 0.240 0.789 1.000 1.000 1.000
5-HT 0.150 0.861 1.693 0.200 1.059 0.356 1.000 1.000 1.000 0.564 0.578 0.904 1.000 1.000 0.633 0.541 1.000 1.000 0.883
DOPAC 0.211 0.811 1.738 0.195 1.329 0.276 1.000 1.000 1.000 1.555 0.235 1.000 1.000 0.277 0.664 0.525 1.000 0.963 1.000
NE 0.101 0.904 1.176 0.284 0.853 0.433 1.000 1.000 1.000 0.412 0.668 1.000 1.000 1.000 1.368 0.276 0.599 0.430 1.000
5-HIAA 0.009 0.991 3.152 0.083 0.476 0.625 1.000 1.000 1.000 0.598 0.559 1.000 1.000 0.948 0.129 0.880 1.000 1.000 1.000
HVA 0.389 0.680 0.520 0.475 1.029 0.366 1.000 1.000 1.000 1.001 0.385 1.000 1.000 0.523 0.680 0.518 1.000 0.845 1.000
DA 0.947 0.396 2.442 0.126 0.724 0.491 0.820 0.645 1.000 2.836 0.081 0.093 1.000 0.340 0.629 0.543 1.000 0.838 1.000
3-MT 0.819 0.448 2.336 0.134 2.059 0.140 0.631 1.000 1.000 3.144 0.064 0.380 1.000 0.066 0.922 0.413 1.000 0.571 1.000
5-HT 0.948 0.396 2.665 0.110 0.471 0.628 0.684 0.760 1.000 1.386 0.272 0.368 1.000 0.756 0.586 0.565 1.000 0.883 1.000
DOPAC 0.453 0.639 3.526 0.068 0.580 0.564 1.000 1.000 1.000 0.167 0.847 1.000 1.000 1.000 0.949 0.404 0.595 1.000 1.000
NE 0.274 0.762 0.425 0.518 1.610 0.212 1.000 1.000 1.000 1.492 0.248 1.000 0.798 0.315 0.369 0.696 1.000 1.000 1.000
5-HIAA 1.047 0.360 6.257 0.016 2.089 0.137 0.886 1.000 0.525 1.604 0.225 1.000 0.405 0.410 1.639 0.219 0.308 0.581 1.000
HVA 0.959 0.392 1.081 0.304 0.712 0.497 1.000 0.506 1.000 0.227 0.799 1.000 1.000 1.000 1.654 0.216 0.447 0.360 1.000
DA 1.343 0.272 4.940 0.032 2.271 0.116 0.505 0.466 1.000 0.073 0.930 1.000 1.000 1.000 3.003 0.072 0.142 0.144 1.000
3-MT 0.077 0.926 0.048 0.827 0.413 0.664 1.000 1.000 1.000 0.280 0.758 1.000 1.000 1.000 0.190 0.828 1.000 1.000 1.000
5-HT 0.122 0.886 1.693 0.200 0.726 0.490 1.000 1.000 1.000 0.544 0.589 1.000 1.000 1.000 0.364 0.699 1.000 1.000 1.000
Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-value
Pink1 x Dat, young, HPLC males females










Table A16: ANOVA table of HPLC measurements of mid-aged Pink1 x DAT mice 
 
DOPAC = 3,4-Dihydroxyphenylacetic acid, NE =  Norepinephrine, 5-HIAA = 5-Hydroxyindole-3-acetic acid, HVA = Homovanillic acid, DA = Dopamine, 3-MT = 3-
Methoxytyramine, 5-HT = Serotonin, OB = olfactory bulb, STR = striatum, VM = ventral midbrain, black = data could not be measured, red: p-value ≤ 0.05, yellow = p-











F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
DOPAC 2.344 0.108 0.818 0.371 0.013 0.987 1.000 0.185 0.224 1.467 0.253 1.000 0.477 0.441 1.006 0.383 1.000 0.627 0.793
NE 1.856 0.169 0.231 0.634 1.076 0.350 1.000 0.833 0.185 0.384 0.686 1.000 1.000 1.000 3.207 0.061 0.269 1.000 0.069
5-HIAA 0.036 0.965 11.119 0.002 1.021 0.369 1.000 1.000 1.000 0.611 0.552 1.000 1.000 0.856 0.496 0.616 1.000 1.000 0.994
HVA 1.456 0.245 3.503 0.068 1.485 0.238 0.293 1.000 0.941 0.484 0.623 1.000 1.000 1.000 1.584 0.229 0.313 1.000 0.613
DA 0.929 0.403 0.154 0.697 1.589 0.216 1.000 0.610 0.937 1.221 0.315 0.432 0.875 1.000 1.280 0.299 1.000 1.000 0.374
3-MT 0.126 0.882 3.218 0.080 0.149 0.862 1.000 1.000 1.000 0.208 0.814 1.000 1.000 1.000 0.087 0.917 1.000 1.000 1.000
5-HT 0.014 0.986 6.142 0.017 2.037 0.143 1.000 1.000 1.000 1.306 0.292 0.472 0.602 1.000 0.849 0.442 0.669 1.000 1.000
DOPAC 1.428 0.251 9.231 0.004 0.292 0.748 1.000 0.650 0.346 2.243 0.131 1.000 0.161 0.443 0.669 0.523 1.000 1.000 0.781
NE 1.232 0.302 9.721 0.003 0.883 0.421 1.000 0.584 0.509 0.049 0.952 1.000 1.000 1.000 1.309 0.291 1.000 0.605 0.467
5-HIAA 0.104 0.901 18.120 0.000 0.078 0.925 1.000 1.000 1.000 0.326 0.725 1.000 1.000 1.000 0.001 0.999 1.000 1.000 1.000
HVA 4.155 0.023 7.468 0.009 2.098 0.135 1.000 0.024 0.142 0.753 0.483 1.000 0.820 1.000 4.009 0.034 1.000 0.053 0.093
DA 4.216 0.021 7.011 0.011 1.296 0.284 1.000 0.029 0.087 1.678 0.211 1.000 0.487 0.314 2.941 0.075 1.000 0.089 0.288
3-MT 1.874 0.166 7.186 0.010 0.831 0.443 0.958 0.179 1.000 1.528 0.240 0.331 0.636 1.000 1.302 0.293 1.000 0.441 0.669
5-HT 1.788 0.180 7.996 0.007 0.967 0.389 1.000 0.219 0.598 1.559 0.234 1.000 1.000 0.276 1.333 0.285 0.944 0.365 1.000
DOPAC 2.415 0.102 0.313 0.579 0.621 0.542 0.292 0.137 1.000 0.924 0.412 0.585 1.000 1.000 2.620 0.096 0.926 0.098 0.683
NE 3.347 0.045 0.099 0.755 0.118 0.889 0.142 0.063 1.000 1.800 0.190 0.442 0.282 1.000 1.603 0.225 0.525 0.332 1.000
5-HIAA 1.613 0.211 4.040 0.051 0.203 0.817 0.583 0.281 1.000 1.358 0.279 0.432 0.608 1.000 0.690 0.513 1.000 0.761 1.000
HVA 2.640 0.083 0.012 0.912 0.211 0.811 0.142 0.180 1.000 1.519 0.242 0.336 0.629 1.000 1.254 0.306 0.738 0.447 1.000
DA 3.160 0.053 0.245 0.623 1.447 0.247 0.969 0.050 0.425 1.307 0.292 1.000 0.903 0.382 2.711 0.090 0.427 0.098 1.000
3-MT 0.483 0.624 0.042 0.841 3.285 0.060 .861 1.000 1.000 1.805 0.214 .672 .299 1.000 2.533 0.134
5-HT 4.195 0.022 0.017 0.896 0.773 0.468 0.838 0.019 0.250 1.624 0.221 1.000 0.439 0.368 3.465 0.050 0.306 0.051 1.000
Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-value
Pink1 x Dat, mid-aged, HPLC males females










Table A17: Summary of results of DA [pg/ mg] content of young and mid-aged Pink1 x Pet and Pink1 x DAT mice 
 
DA = Dopamine, OB = olfactory bulb, STR = striatum, VM = ventral midbrain 
 
 
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 8 462.66 182.76 ctrl. 1 8 379.48 82.06 ctrl. 1 8 397.19 110.33 ctrl. 1 8 430.79 191.95
mt 8 515.97 107.30 mt 8 479.10 187.12 mt 8 397.66 121.14 mt 8 412.31 26.67
ctrl. 2 8 506.70 111.53 ctrl. 2 8 407.51 152.58 ctrl. 2 8 380.52 75.64 ctrl. 2 8 457.54 230.53
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 8 287.11 66.60 ctrl. 1 8 352.78 133.84 ctrl. 1 8 327.95 49.34 ctrl. 1 8 406.75 98.12
mt 8 361.91 67.22 mt 8 373.31 103.72 mt 8 388.01 72.99 mt 8 364.54 62.00
ctrl. 2 8 417.37 105.47 ctrl. 2 8 311.45 113.92 ctrl. 2 8 345.22 105.01 ctrl. 2 8 321.69 143.01
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 8 19,733.95 10,870.98 ctrl. 1 8 19,831.30 5,849.62 ctrl. 1 8 11,185.51 5,615.27 ctrl. 1 8 16,093.62 4,097.84
mt 8 16,283.67 8,299.20 mt 8 22,237.59 11,727.53 mt 8 16,575.42 5,999.70 mt 8 14,938.40 3,134.77
ctrl. 2 8 17,706.23 7,804.25 ctrl. 2 8 18,250.55 7,324.78 ctrl. 2 8 24,700.70 20,870.65 ctrl. 2 8 23,420.97 7,794.95
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 8 17,754.55 5,058.05 ctrl. 1 8 18,682.22 9,791.32 ctrl. 1 8 4,978.52 765.99 ctrl. 1 8 6,572.18 2,323.27
mt 8 13,372.47 2,584.19 mt 8 16,187.00 3,190.19 mt 8 5,133.20 1,291.07 mt 8 5,681.16 4,364.99
ctrl. 2 8 14,622.78 3,295.31 ctrl. 2 8 22,739.44 17,651.93 ctrl. 2 8 6,041.35 1,569.30 ctrl. 2 8 9,205.71 1,719.38
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 8 325.44 101.23 ctrl. 1 8 269.98 64.13 ctrl. 1 8 129.97 73.98 ctrl. 1 8 130.22 56.06
mt 8 286.29 113.09 mt 8 494.81 523.08 mt 8 105.06 44.73 mt 8 154.23 102.23
ctrl. 2 8 309.57 128.43 ctrl. 2 8 294.48 109.77 ctrl. 2 8 126.05 62.14 ctrl. 2 8 109.60 59.10
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 8 350.49 80.32 ctrl. 1 8 374.07 79.30 ctrl. 1 8 214.34 34.54 ctrl. 1 8 257.38 73.90
mt 8 334.90 116.78 mt 8 491.49 146.52 mt 8 229.70 54.59 mt 8 187.95 92.92
ctrl. 2 8 350.49 80.32 ctrl. 2 8 324.07 157.01 ctrl. 2 8 260.60 77.59 ctrl. 2 8 292.08 103.86
young mid-aged




males female males female
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DA in OB
young mid-aged








































Table A18: Summary of results of 5-HT content [pg/ mg] of young and mid-aged Pink1 x Pet and Pink1 x DAT mice 
 
 
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 8 535.74 199.62 ctrl. 1 8 565.97 148.03 ctrl. 1 8 800.21 275.07 ctrl. 1 8 983.65 270.19
mt 8 549.29 197.04 mt 8 621.08 169.28 mt 8 778.16 211.45 mt 8 903.05 253.65
ctrl. 2 8 755.02 234.47 ctrl. 2 8 592.95 232.08 ctrl. 2 8 863.88 204.26 ctrl. 2 8 1,032.29 528.49
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 8 352.58 98.75 ctrl. 1 8 445.95 164.41 ctrl. 1 8 593.78 101.32 ctrl. 1 8 810.07 164.28
mt 8 398.90 92.28 mt 8 402.83 63.16 mt 8 705.98 203.29 mt 8 689.22 142.56
ctrl. 2 8 378.27 68.33 ctrl. 2 8 389.66 43.06 ctrl. 2 8 604.91 136.50 ctrl. 2 8 778.49 252.58
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 8 673.73 272.30 ctrl. 1 8 583.42 199.13 ctrl. 1 8 613.43 227.26 ctrl. 1 8 878.59 228.63
mt 8 412.25 213.41 mt 8 662.33 463.16 mt 8 762.28 257.07 mt 8 884.23 131.62
ctrl. 2 8 600.68 211.69 ctrl. 2 8 567.82 264.54 ctrl. 2 8 1,337.13 1,165.66 ctrl. 2 8 1,091.53 466.22
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 8 527.41 158.97 ctrl. 1 8 593.72 314.30 ctrl. 1 8 821.38 133.02 ctrl. 1 8 1,096.99 256.65
mt 8 413.70 96.22 mt 8 486.80 118.06 mt 8 885.37 154.05 mt 8 945.40 333.44
ctrl. 2 8 444.12 159.58 ctrl. 2 8 665.21 466.22 ctrl. 2 8 949.79 148.51 ctrl. 2 8 1,182.69 287.85
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 8 941.81 192.50 ctrl. 1 8 951.72 236.01 ctrl. 1 8 613.43 227.26 ctrl. 1 8 878.59 228.63
mt 8 939.57 248.02 mt 8 1,121.65 409.87 mt 8 762.28 257.07 mt 8 884.23 131.62
ctrl. 2 8 1,139.96 252.49 ctrl. 2 8 1,067.59 246.22 ctrl. 2 8 1,337.13 1,165.66 ctrl. 2 8 1,091.53 466.22
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 8 854.03 259.72 ctrl. 1 8 1,008.67 340.92 ctrl. 1 8 821.38 133.02 ctrl. 1 8 1,096.99 256.65
mt 8 869.96 296.51 mt 8 1,100.90 287.49 mt 8 885.37 154.05 mt 8 945.40 333.44
ctrl. 2 8 972.71 166.80 ctrl. 2 8 823.37 541.14 ctrl. 2 8 949.79 148.51 ctrl. 2 8 1,182.69 287.85
young mid-aged
males female males females
5-HT in VM
young mid-aged
males female males female
young mid-aged
males female males females
5-HT in STR
young mid-aged
males female males female
young mid-aged
males female males females
5-HT in OB
young mid-aged








































Table A19: ANOVA table of OF testing of young Pink1 x Pet mice 
 






F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
Distance travelled, 5 min [cm] 1.958 0.149 0.241 0.625 0.190 0.828 0.249 1.000 0.272 0.820 0.450 0.649 1.000 1.000 1.422 0.254 0.718 1.000 0.348
Distance travelled, 10 min [cm] 0.598 0.553 0.125 0.724 1.367 0.262 0.956 1.000 1.000 1.493 0.240 1.000 0.288 0.770 0.623 0.542 1.000 1.000 0.858
Distance travelled, 15 min [cm] 1.823 0.170 0.271 0.605 0.512 0.601 0.421 0.243 1.000 2.543 0.095 0.711 0.095 0.748 0.465 0.632 1.000 1.000 1.000
Distance travelled, 20 min [cm] 2.895 0.062 0.133 0.716 0.125 0.883 0.111 0.116 1.000 1.619 0.214 0.499 0.329 1.000 1.476 0.242 0.351 0.506 1.000
Total distance travelled [cm] 1.561 0.217 0.083 0.774 0.465 0.630 0.257 0.714 1.000 1.420 0.257 0.640 0.376 1.000 0.800 0.457 0.705 1.000 1.000
Resting time [sec] 6.674 0.002 0.014 0.906 3.985 0.023 0.086 0.001 0.189 2.374 0.110 0.112 0.795 1.000 9.534 0.0005 0.854 0.001 0.008
Average speed [cm/sec] 0.793 0.457 0.139 0.711 0.894 0.414 0.591 1.000 1.000 0.963 0.393 1.000 0.546 1.000 0.852 0.435 1.000 1.000 0.671
Number of rearing, 5 min [#] 1.238 0.297 0.016 0.901 1.373 0.260 1.000 1.000 0.262 0.102 0.903 1.000 1.000 1.000 3.025 0.061 0.369 1.000 0.064
 Number of rearing, 10 min [#] 2.364 0.102 0.412 0.523 1.119 0.333 1.000 0.058 0.290 0.955 0.396 0.655 0.838 1.000 2.790 0.075 1.000 0.177 0.131
Number of rearing, 15 min [#] 1.527 0.225 1.809 0.183 2.113 0.129 1.000 0.284 0.150 0.405 0.671 1.000 1.000 1.000 3.842 0.031 0.655 0.560 0.026
Number of rearing, 20 min [#] 1.581 0.213 1.595 0.211 1.315 0.275 1.000 0.624 0.115 0.007 0.993 1.000 1.000 1.000 2.802 0.074 0.982 0.686 0.071
Total number of rearing [#] 2.114 0.129 0.800 0.374 2.102 0.130 1.000 0.194 0.076 0.337 0.716 1.000 1.000 1.000 4.409 0.019 0.736 0.358 0.016
Distance travelled [cm] 1.203 0.307 2.316 0.133 0.003 0.997 0.546 1.000 0.632 0.897 0.418 0.740 1.000 0.852 0.512 0.604 1.000 1.000 1.000
Resting time [sec] 8.863 0.0004 0.750 0.390 1.957 0.149 0.031 0.0001 0.193 2.997 0.065 0.095 0.194 1.000 8.054 0.001 0.305 0.001 0.060
Permanance time [sec] 3.487 0.036 1.451 0.233 0.151 0.860 1.000 0.172 0.063 3.068 0.061 1.000 0.114 0.098 1.154 0.327 1.000 0.966 0.445
Average speed [cm/sec] 1.826 0.169 0.375 0.542 0.420 0.659 1.000 0.188 0.968 1.934 0.162 1.000 0.181 0.561 0.347 0.709 1.000 1.000 1.000
% Distance travelled, 5 min [%] 0.442 0.645 0.958 0.331 0.185 0.832 1.000 1.000 1.000 0.428 0.656 1.000 1.000 1.000 0.187 0.830 1.000 1.000 1.000
% Distance travelled, 10 min  [%] 2.191 0.120 0.983 0.325 0.588 0.558 1.000 0.408 0.265 2.391 0.108 1.000 0.278 0.134 0.306 0.738 1.000 1.000 1.000
% Distance travelled, 15 min  [%] 1.237 0.297 3.488 0.066 0.348 0.708 1.000 0.820 0.712 1.267 0.296 1.000 0.400 0.697 0.295 0.746 1.000 1.000 1.000
% Distance travelled, 20 min  [%] 1.929 0.153 4.456 0.039 0.278 0.758 0.926 1.000 0.244 2.189 0.129 0.559 1.000 0.153 0.451 0.640 1.000 1.000 1.000
% Total distance travelled  [%] 2.020 0.141 3.776 0.056 0.389 0.679 1.000 0.851 0.265 2.562 0.093 1.000 0.300 0.105 0.314 0.733 1.000 1.000 1.000
% Time spent in centre, 5 min  [%] 1.978 0.146 0.972 0.328 0.319 0.728 1.000 0.904 0.166 0.690 0.509 1.000 0.944 0.886 1.699 0.197 0.754 1.000 0.237
% Time spent in centre, 10 min  [%] 2.516 0.088 0.096 0.758 0.741 0.480 1.000 0.312 0.147 2.729 0.081 1.000 0.215 0.100 0.298 0.744 1.000 1.000 1.000
% Time spent in centre, 15 min  [%] 1.069 0.349 1.245 0.268 0.442 0.645 1.000 0.632 1.000 1.642 0.210 1.000 0.242 1.000 0.218 0.805 1.000 1.000 1.000
% Time spent in centre, 20 min  [%] 3.152 0.049 3.250 0.076 0.134 0.875 1.000 0.208 0.075 2.079 0.142 1.000 0.543 0.155 1.670 0.203 1.000 0.390 0.367
% Total time spent in centre  [%] 3.484 0.036 1.441 0.234 0.148 0.863 1.000 0.173 0.063 3.058 0.061 1.000 0.115 0.099 1.157 0.326 1.000 0.963 0.443
Latency to enter in the centre [sec] 1.479 0.235 1.014 0.317 1.597 0.210 1.000 0.778 0.628 1.371 0.269 1.000 0.454 0.452 0.080 0.923 1.000 1.000 1.000
Number of entries in the centre [#] 2.022 0.140 2.709 0.104 0.197 0.821 0.377 1.000 0.238 0.855 0.435 1.000 1.000 0.616 1.313 0.282 0.577 1.000 0.473
Distance travelled [cm] 2.073 0.134 0.652 0.422 0.967 0.385 0.395 0.268 1.000 2.616 0.089 1.000 0.088 0.499 0.694 0.506 0.740 1.000 1.000
Resting time [sec] 2.869 0.064 0.155 0.695 3.687 0.030 0.473 0.023 0.472 1.693 0.201 0.247 1.000 0.769 5.491 0.008 1.000 0.018 0.028
Permanance time [sec] 3.488 0.036 1.451 0.233 0.151 0.860 1.000 0.172 0.063 3.070 0.061 1.000 0.114 0.098 1.154 0.327 1.000 0.966 0.445
Average speed [cm/sec] 0.911 0.407 0.059 0.809 1.071 0.348 0.601 1.000 0.688 0.493 0.615 1.000 1.000 1.000 1.409 0.257 0.865 1.000 0.328
Genotype Sex Interaction Post hoc Bonferroni, p-value Genotype
males femalesPink1 x Pet, young, OF

















Table A20: ANOVA table of OF testing of mid-aged Pink1 x Pet mice 
 







F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
Distance travelled, 5 min [cm] 0.788 0.459 0.343 0.560 1.760 0.181 1.000 1.000 0.540 0.998 0.382 0.513 1.000 1.000 1.720 0.195 1.000 0.254 0.611
Distance travelled, 10 min [cm] 0.921 0.404 0.065 0.799 1.025 0.365 1.000 0.408 1.000 0.042 0.959 1.000 1.000 1.000 1.867 0.170 1.000 0.202 0.678
Distance travelled, 15 min [cm] 0.278 0.758 0.070 0.793 1.197 0.309 1.000 1.000 1.000 1.007 0.378 0.504 1.000 1.000 0.537 0.589 1.000 0.924 1.000
Distance travelled, 20 min [cm] 0.132 0.876 0.226 0.636 1.193 0.310 1.000 1.000 1.000 0.338 0.716 1.000 1.000 1.000 0.922 0.408 1.000 0.565 1.000
Total distance travelled [cm] 0.377 0.688 0.012 0.915 1.405 0.253 1.000 1.000 1.000 0.424 0.659 1.000 1.000 1.000 1.400 0.261 1.000 0.317 1.000
Resting time [sec] 0.310 0.735 0.255 0.616 3.870 0.026 1.000 0.934 1.000 0.925 0.408 1.000 1.000 0.585 4.558 0.018 1.000 0.027 0.076
Average speed [cm/sec] 0.342 0.712 0.028 0.868 1.813 0.172 1.000 1.000 1.000 0.449 0.643 1.000 1.000 1.000 1.783 0.184 1.000 0.211 0.839
Number of rearing, 5 min [#] 0.964 0.387 0.022 0.883 1.574 0.215 1.000 1.000 0.336 0.395 0.678 1.000 1.000 1.000 2.407 0.106 1.000 0.451 0.123
 Number of rearing, 10 min [#] 2.399 0.099 1.945 0.168 1.061 0.352 1.000 0.107 0.094 0.473 0.628 1.000 1.000 1.000 2.987 0.064 1.000 0.302 0.075
Number of rearing, 15 min [#] 1.178 0.315 4.042 0.049 1.212 0.305 1.000 0.631 0.278 0.842 0.441 0.640 1.000 1.000 1.625 0.212 1.000 0.301 0.565
Number of rearing, 20 min [#] 1.756 0.181 2.606 0.112 0.482 0.620 1.000 0.186 0.262 0.399 0.675 1.000 1.000 1.000 1.767 0.187 1.000 0.255 0.538
Total number of rearing [#] 1.933 0.154 2.305 0.134 0.958 0.389 1.000 0.245 0.117 0.222 0.802 1.000 1.000 1.000 2.573 0.092 1.000 0.211 0.159
Distance travelled [cm] 0.737 0.483 2.650 0.109 2.407 0.099 1.000 1.000 0.697 1.818 0.181 0.201 1.000 1.000 1.149 0.329 1.000 0.418 1.000
Resting time [sec] 0.289 0.750 9.379 0.003 3.284 0.044 1.000 1.000 0.686 0.555 0.580 1.000 0.913 1.000 6.511 0.004 1.000 0.015 0.010
Permanance time [sec] 1.466 0.239 4.683 0.034 1.300 0.280 0.525 1.000 0.504 2.454 0.104 0.133 1.000 0.361 0.044 0.957 1.000 1.000 1.000
Average speed [cm/sec] 0.228 0.797 0.535 0.467 1.530 0.225 1.000 1.000 1.000 0.386 0.684 1.000 1.000 1.000 1.280 0.291 0.684 0.399 1.000
% Distance travelled, 5 min [%] 1.434 0.246 0.492 0.486 1.225 0.301 0.451 1.000 0.631 1.869 0.173 0.239 1.000 0.483 0.014 0.986 1.000 1.000 1.000
% Distance travelled, 10 min  [%] 1.553 0.220 0.879 0.352 1.193 0.310 0.696 1.000 0.363 1.810 0.182 0.354 1.000 0.328 0.104 0.901 1.000 1.000 1.000
% Distance travelled, 15 min  [%] 0.242 0.786 1.739 0.192 0.464 0.631 1.000 1.000 1.000 0.719 0.496 1.000 1.000 0.767 0.019 0.981 1.000 1.000 1.000
% Distance travelled, 20 min  [%] 0.921 0.404 7.473 0.008 1.378 0.260 0.778 1.000 1.000 2.127 0.138 0.178 0.447 1.000 0.025 0.975 1.000 1.000 1.000
% Total distance travelled  [%] 1.230 0.299 4.191 0.045 1.610 0.208 0.566 1.000 0.798 2.345 0.114 0.133 1.000 0.474 0.021 0.979 1.000 1.000 1.000
% Time spent in centre, 5 min  [%] 1.283 0.284 0.710 0.403 0.559 0.574 0.488 1.000 0.659 1.212 0.313 0.421 1.000 0.942 0.197 0.822 1.000 1.000 1.000
% Time spent in centre, 10 min  [%] 1.347 0.268 1.709 0.196 1.689 0.193 1.000 1.000 0.385 1.958 0.160 0.360 1.000 0.257 0.335 0.718 1.000 1.000 1.000
% Time spent in centre, 15 min  [%] 0.374 0.690 1.983 0.164 0.841 0.436 1.000 1.000 1.000 1.259 0.300 0.787 1.000 0.426 0.103 0.903 1.000 1.000 1.000
% Time spent in centre, 20 min  [%] 1.234 0.298 8.181 0.006 1.138 0.327 0.476 1.000 1.000 1.999 0.154 0.196 0.510 1.000 0.185 0.832 1.000 1.000 1.000
% Total time spent in centre  [%] 1.455 0.241 4.677 0.035 1.296 0.281 0.528 1.000 0.511 2.444 0.105 0.134 1.000 0.365 0.042 0.959 1.000 1.000 1.000
Latency to enter in the centre [sec] 1.213 0.304 0.351 0.556 1.272 0.288 0.682 1.000 0.677 1.654 0.209 1.000 0.659 0.253 0.747 0.482 0.756 1.000 1.000
Number of entries in the centre [#] 1.156 0.322 0.084 0.773 1.269 0.289 1.000 0.530 0.395 0.349 0.708 1.000 1.000 1.000 2.378 0.108 1.000 0.129 0.440
Distance travelled [cm] 0.410 0.665 0.516 0.475 0.821 0.445 1.000 1.000 1.000 0.048 0.953 1.000 1.000 1.000 1.125 0.337 1.000 0.445 1.000
Resting time [sec] 0.502 0.608 0.324 0.571 3.182 0.048 1.000 1.000 1.000 1.125 0.339 1.000 1.000 0.434 2.879 0.070 1.000 0.088 0.279
Permanance time [sec] 1.466 0.239 4.683 0.034 1.300 0.280 0.525 1.000 0.504 2.454 0.104 0.133 1.000 0.361 0.044 0.957 1.000 1.000 1.000
Average speed [cm/sec] 0.386 0.682 0.056 0.813 1.650 0.201 1.000 1.000 0.991 0.547 0.585 1.000 1.000 1.000 1.556 0.226 1.000 0.275 0.866
Genotype Post hoc Bonferroni, p-value
Pink1 x Pet, mid-aged, OF
Post hoc Bonferroni, p-value
males females

















Table A21: ANOVA table of OF testing of young Pink1 x DAT mice 
 






F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
Distance travelled, 5 min [cm] 1.160 0.320 19.398 0.00004 0.108 0.898 0.343 1.000 0.488 0.473 0.628 1.000 1.000 1.000 0.691 0.508 0.953 1.000 0.905
Distance travelled, 10 min [cm] 0.271 0.763 10.149 0.002 2.357 0.103 1.000 1.000 1.000 1.634 0.211 0.797 0.247 1.000 1.106 0.343 0.497 0.882 1.000
Distance travelled, 15 min [cm] 0.592 0.556 11.866 0.001 1.035 0.361 0.846 1.000 0.785 0.887 0.422 1.000 0.819 0.739 0.753 0.479 0.769 1.000 1.000
Distance travelled, 20 min [cm] 0.075 0.928 6.845 0.011 0.259 0.773 1.000 1.000 1.000 0.086 0.918 1.000 1.000 1.000 0.227 0.798 1.000 1.000 1.000
Total distance travelled [cm] 0.630 0.536 16.952 0.0001 0.665 0.518 0.797 1.000 0.753 0.470 0.629 1.000 1.000 1.000 0.725 0.492 0.714 1.000 1.000
Resting time [sec] 1.016 0.368 0.031 0.860 0.409 0.666 1.000 1.000 0.506 0.538 0.589 1.000 1.000 1.000 0.838 0.442 0.894 0.716 1.000
Average speed [cm/sec] 0.771 0.467 15.164 0.0002 0.678 0.511 0.756 1.000 0.611 0.553 0.580 1.000 1.000 1.000 0.783 0.466 0.673 1.000 0.563
Number of rearing, 5 min [#] 1.369 0.262 2.629 0.110 1.565 0.217 0.299 1.000 1.000 0.088 0.916 1.000 1.000 1.000 2.653 0.086 0.098 1.000 0.307
 Number of rearing, 10 min [#] 0.603 0.550 0.089 0.767 3.050 0.054 1.000 1.000 1.000 1.341 0.276 0.575 0.426 1.000 2.646 0.087 0.090 1.000 0.407
Number of rearing, 15 min [#] 0.510 0.603 0.002 0.968 1.294 0.281 1.000 1.000 0.998 1.169 0.324 1.000 0.430 0.985 0.599 0.556 0.869 1.000 1.000
Number of rearing, 20 min [#] 0.344 0.710 0.066 0.799 1.104 0.338 1.000 1.000 1.000 0.926 0.407 0.979 0.598 1.000 0.505 0.609 0.995 1.000 1.000
Total number of rearing [#] 0.655 0.523 0.185 0.669 1.978 0.147 1.000 1.000 0.852 0.734 0.488 1.000 0.735 1.000 2.022 0.150 0.166 1.000 0.592
Distance travelled [cm] 0.701 0.500 2.619 0.111 0.600 0.552 1.000 0.727 1.000 0.029 0.971 1.000 1.000 1.000 1.076 0.353 1.000 1.000 1.000
Resting time [sec] 1.098 0.340 0.159 0.691 0.359 0.700 0.675 1.000 0.615 0.525 0.597 0.940 1.000 1.000 0.876 0.427 1.000 0.588 0.435
Permanance time [sec] 0.031 0.969 0.107 0.745 2.203 0.119 1.000 1.000 1.000 0.934 0.403 0.904 0.615 1.000 1.273 0.294 0.714 1.000 1.000
Average speed [cm/sec] 0.091 0.914 9.094 0.004 1.833 0.168 1.000 1.000 1.000 1.662 0.206 0.492 0.289 1.000 0.485 0.620 1.000 1.000 1.000
% Distance travelled, 5 min [%] 0.496 0.612 0.299 0.586 1.838 0.168 1.000 0.943 1.000 0.280 0.758 1.000 1.000 1.000 2.178 0.130 0.296 0.212 1.000
% Distance travelled, 10 min  [%] 0.916 0.405 0.787 0.378 2.264 0.112 1.000 0.478 1.000 0.398 0.675 1.000 1.000 1.000 3.061 0.061 0.200 0.085 1.000
% Distance travelled, 15 min  [%] 0.680 0.510 0.169 0.683 0.197 0.822 1.000 0.726 1.000 0.072 0.930 1.000 1.000 1.000 0.841 0.441 1.000 0.616 1.000
% Distance travelled, 20 min  [%] 0.230 0.795 0.259 0.613 0.758 0.473 1.000 1.000 1.000 0.204 0.817 1.000 1.000 1.000 0.835 0.443 0.648 1.000 1.000
% Total distance travelled  [%] 0.891 0.415 0.453 0.504 1.654 0.199 1.000 0.645 0.645 0.066 0.937 1.000 1.000 1.000 2.449 0.103 0.214 0.187 1.000
% Time spent in centre, 5 min  [%] 0.105 0.901 0.418 0.520 2.236 0.115 1.000 1.000 1.000 0.947 0.398 1.000 0.535 1.000 1.391 0.264 0.614 0.400 1.000
% Time spent in centre, 10 min  [%] 0.412 0.664 0.218 0.642 2.925 0.061 1.000 1.000 1.000 0.997 0.380 0.612 0.772 1.000 2.336 0.113 0.870 0.116 0.998
% Time spent in centre, 15 min  [%] 0.106 0.899 0.495 0.485 0.882 0.419 1.000 1.000 1.000 0.241 0.787 1.000 1.000 1.000 0.768 0.473 1.000 0.674 1.000
% Time spent in centre, 20 min  [%] 0.418 0.660 0.142 0.708 0.483 0.619 1.000 1.000 1.000 0.232 0.794 1.000 1.000 1.000 0.604 0.553 1.000 1.000 0.938
% Total time spent in centre  [%] 0.031 0.970 0.106 0.746 2.213 0.118 1.000 1.000 1.000 0.937 0.402 0.900 0.613 1.000 1.280 0.292 0.715 0.430 1.000
Latency to enter in the centre [sec] 3.835 0.027 0.034 0.854 0.497 0.611 0.144 1.000 0.035 1.635 0.211 0.809 1.000 0.251 2.245 0.123 0.295 0.168 0.561
Number of entries in the centre [#] 0.531 0.590 6.501 0.013 0.746 0.478 1.000 1.000 1.000 0.013 0.987 1.000 1.000 1.000 1.006 0.377 1.000 0.935 0.000
Distance travelled [cm] 1.160 0.320 19.592 0.00004 2.016 0.142 0.269 1.000 0.727 0.717 0.496 1.000 0.815 1.000 1.995 0.153 0.185 1.000 1.000
Resting time [sec] 0.917 0.405 0.149 0.701 0.849 0.432 1.000 1.000 0.644 1.012 0.375 1.000 0.499 1.000 0.681 0.514 0.911 0.970 0.435
Permanance time [sec] 0.031 0.969 0.107 0.745 2.203 0.119 1.000 1.000 1.000 0.934 0.404 0.904 0.615 1.000 1.273 0.294 0.714 1.000 1.000
Average speed [cm/sec] 1.000 0.374 16.776 0.0001 0.387 0.680 0.400 1.000 0.636 0.285 0.754 1.000 1.000 1.000 0.900 0.417 0.576 1.000 0.479
Genotype Post hoc Bonferroni, p-value
Pink1 x DAT, young, OF
Post hoc Bonferroni, p-value
males females

















Table A22: ANOVA table of OF testing of mid-aged Pink1 x DAT mice 
 






F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
Distance travelled, 5 min [cm] 3.175 0.049 5.737 0.020 0.034 0.967 1.000 0.313 0.035 3.272 0.053 1.000 0.288 0.055 0.971 0.390 1.000 1.000 0.538
Distance travelled, 10 min [cm] 4.206 0.020 0.136 0.714 0.880 0.420 0.188 1.000 0.016 2.930 0.070 0.098 1.000 0.221 2.501 0.099 1.000 0.516 0.108
Distance travelled, 15 min [cm] 3.000 0.058 0.097 0.757 0.367 0.694 0.665 0.655 0.046 0.766 0.474 1.000 1.000 0.683 2.393 0.109 0.898 0.797 0.111
Distance travelled, 20 min [cm] 2.905 0.063 0.149 0.701 1.573 0.216 0.589 0.818 0.055 0.529 0.595 1.000 1.000 1.000 3.166 0.057 0.247 1.000 0.061
Total distance travelled [cm] 3.878 0.026 0.618 0.435 0.290 0.749 0.445 0.527 0.018 1.634 0.213 1.000 1.000 0.246 2.366 0.111 0.832 0.876 0.113
Resting time [sec] 4.458 0.016 4.625 0.036 0.218 0.805 1.000 0.138 0.025 2.969 0.068 1.000 0.245 0.082 1.535 0.232 1.000 0.782 0.295
Average speed [cm/sec] 4.203 0.020 0.442 0.509 0.279 0.758 0.464 0.415 0.013 1.870 0.173 1.000 1.000 0.190 2.490 0.100 0.853 0.784 0.101
Number of rearing, 5 min [#] 1.301 0.280 0.001 0.976 1.081 0.346 1.000 1.000 0.382 2.082 0.144 1.000 0.242 0.282 0.565 0.574 0.902 1.000 1.000
 Number of rearing, 10 min [#] 4.192 0.020 5.829 0.019 0.455 0.637 1.000 0.195 0.023 1.105 0.345 1.000 1.000 0.449 3.708 0.036 1.000 0.157 0.047
Number of rearing, 15 min [#] 2.313 0.108 2.732 0.104 0.595 0.555 1.000 0.476 0.140 0.280 0.758 1.000 1.000 1.000 3.167 0.057 0.899 0.468 0.055
Number of rearing, 20 min [#] 2.756 0.072 5.295 0.025 0.974 0.384 0.984 0.724 0.100 1.195 0.318 1.000 0.490 0.682 2.414 0.107 0.290 1.000 0.139
Total number of rearing [#] 3.587 0.034 3.738 0.058 0.419 0.660 1.000 0.378 0.042 1.234 0.306 1.000 0.617 0.495 2.806 0.076 0.499 1.000 0.075
Distance travelled [cm] 3.280 0.045 0.469 0.496 0.981 0.381 0.644 0.592 0.038 0.714 0.499 1.000 1.000 0.817 2.842 0.074 0.979 0.534 0.074
Resting time [sec] 4.766 0.012 2.089 0.154 0.357 0.701 1.000 0.089 0.014 1.701 0.201 1.000 1.000 0.227 3.484 0.044 1.000 0.118 0.076
Permanance time [sec] 2.884 0.064 4.597 0.036 0.851 0.432 0.227 1.000 0.114 0.377 0.689 1.000 1.000 1.000 3.393 0.047 0.202 1.000 0.052
Average speed [cm/sec] 0.891 0.416 2.089 0.154 0.164 0.850 1.000 0.503 1.000 0.205 0.816 1.000 1.000 1.000 0.751 0.481 1.000 0.692 1.000
% Distance travelled, 5 min [%] 1.456 0.241 2.624 0.111 1.700 0.192 1.000 0.321 0.871 1.046 0.365 0.565 0.794 1.000 2.527 0.097 0.942 0.691 0.098
% Distance travelled, 10 min  [%] 0.829 0.441 4.637 0.035 0.439 0.647 1.000 1.000 0.709 0.128 0.881 1.000 1.000 1.000 0.987 0.384 1.000 1.000 0.525
% Distance travelled, 15 min  [%] 2.991 0.058 3.021 0.088 0.432 0.651 0.133 1.000 0.137 1.425 0.257 0.316 1.000 0.985 1.978 0.156 0.532 1.000 0.182
% Distance travelled, 20 min  [%] 1.504 0.231 5.666 0.021 2.287 0.111 0.387 1.000 0.785 0.316 0.731 1.000 1.000 1.000 4.415 0.021 0.066 1.000 0.030
% Total distance travelled  [%] 1.794 0.175 8.037 0.006 1.503 0.231 0.643 1.000 0.292 0.064 0.938 1.000 1.000 1.000 3.123 0.059 0.347 1.000 0.058
% Time spent in centre, 5 min  [%] 1.404 0.254 0.579 0.450 1.024 0.365 1.000 0.419 0.662 0.969 0.392 1.000 0.564 1.000 1.621 0.215 0.853 1.000 0.249
% Time spent in centre, 10 min  [%] 1.220 0.303 1.449 0.234 0.090 0.914 0.466 1.000 0.837 0.410 0.667 1.000 1.000 1.000 0.823 0.449 0.679 1.000 1.000
% Time spent in centre, 15 min  [%] 2.902 0.063 4.125 0.047 1.281 0.286 0.191 1.000 0.112 1.921 0.165 0.180 1.000 1.000 2.350 0.113 1.000 0.596 0.122
% Time spent in centre, 20 min  [%] 2.922 0.062 5.040 0.029 2.139 0.127 0.109 1.000 0.243 0.414 0.665 1.000 1.000 1.000 5.194  0.043 1.000 0.016
% Total time spent in centre  [%] 2.892 0.063 4.587 0.036 0.846 0.434 0.223 1.000 0.114 0.382 0.686 1.000 1.000 1.000 3.389 0.047 0.201 1.000 0.052
Latency to enter in the centre [sec] 0.864 0.427 1.176 0.283 0.297 0.744 1.000 1.000 0.552 0.503 0.610 1.000 1.000 1.000 0.765 0.474 0.793 1.000 0.948
Number of entries in the centre [#] 3.744 0.030 0.435 0.512 0.441 0.645 0.808 0.363 0.027 1.530 0.234 1.000 0.681 0.303 2.389 0.109 0.831 0.863 0.111
Distance travelled [cm] 3.247 0.046 3.073 0.085 0.057 0.944 0.493 0.679 0.031 1.806 0.183 1.000 0.919 0.204 1.578 0.223 0.893 1.000 0.260
Resting time [sec] 2.470 0.093 3.845 0.055 0.686 0.508 1.000 0.445 0.157 2.316 0.117 1.000 0.281 0.172 0.474 0.627 1.000 1.000 1.000
Permanance time [sec] 2.885 0.064 4.598 0.036 0.851 0.432 0.227 1.000 0.114 0.377 0.689 1.000 1.000 1.000 3.393 0.047 0.202 1.000 0.052
Average speed [cm/sec] 4.519 0.015 0.701 0.406 0.249 0.781 0.324 0.486 0.010 2.089 0.143 0.952 0.975 0.152 2.588 0.092 0.642 0.971 0.091
Genotype Post hoc Bonferroni, p-value
Pink1 x DAT, mid-aged, OF
Post hoc Bonferroni, p-value
males females

















Table A23: Summary of results of selected OF parameters of young and mid-aged Pink1 x Pet and Pink1 x DAT mice 
 
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 13 23340.81 4817.77 ctrl. 1 14 24820.91 4660.15 ctrl. 1 11 21219.28 4886.66 ctrl. 1 13 20314.08 4604.99
mt 12 21127.23 3500.45 mt 11 22002.96 5253.34 mt 11 19215.33 3778.88 mt 10 22247.24 5293.75
ctrl. 2 9 24151.16 4662.74 ctrl. 2 14 22855.26 7061.18 ctrl. 2 9 20758.98 7158.17 ctrl. 2 13 18189.26 7087.52
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 12 17948.42 4029.60 ctrl. 1 10 21533.21 5292.74 ctrl. 1 11 14490.86 4892.82 ctrl. 1 10 14307.15 4992.46
mt 11 17761.28 4561.77 mt 12 24246.79 5577.95 mt 10 16249.95 3205.91 mt 11 17276.85 5321.80
ctrl. 2 12 19239.37 3459.63 ctrl. 2 12 23115.30 4918.31 ctrl. 2 10 17753.65 4060.27 ctrl. 2 12 20027.43 7538.04
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 13 147.77 29.99 ctrl. 1 14 162.07 34.83 ctrl. 1 11 132.82 31.45 ctrl. 1 13 124.23 44.00
mt 12 157.58 22.28 mt 11 145.91 33.83 mt 11 125.82 24.53 mt 10 124.20 33.51
ctrl. 2 9 148.00 46.73 ctrl. 2 14 124.07 33.17 ctrl. 2 9 123.67 41.78 ctrl. 2 13 91.54 44.29
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 12 115.42 37.09 ctrl. 1 10 100.60 33.01 ctrl. 1 11 72.36 37.46 ctrl. 1 10 48.80 19.71
mt 11 101.64 42.16 mt 12 129.42 41.18 mt 10 73.70 17.67 mt 11 66.91 33.01
ctrl. 2 12 121.17 39.34 ctrl. 2 12 119.67 25.10 ctrl. 2 10 91.50 32.60 ctrl. 2 12 78.33 31.90
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 13 29.40 5.65 ctrl. 1 14 31.96 8.93 ctrl. 1 11 31.06 10.72 ctrl. 1 13 21.60 5.14
mt 12 29.29 8.90 mt 11 30.39 10.67 mt 11 22.82 4.48 mt 10 21.70 7.76
ctrl. 2 9 22.24 7.40 ctrl. 2 14 26.26 10.94 ctrl. 2 9 24.47 11.28 ctrl. 2 13 20.77 11.69
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 12 18.58 8.57 ctrl. 1 10 20.17 13.14 ctrl. 1 11 18.13 8.76 ctrl. 1 10 9.83 6.89
mt 11 22.38 11.42 mt 12 15.25 6.77 mt 10 21.28 9.30 mt 11 17.01 7.55
ctrl. 2 12 17.71 5.01 ctrl. 2 12 21.11 8.38 ctrl. 2 10 20.57 8.05 ctrl. 2 12 19.16 10.64
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 13 27.43 9.73 ctrl. 1 14 37.71 19.26 ctrl. 1 11 19.85 8.51 ctrl. 1 13 15.24 8.33
mt 12 41.77 20.62 mt 11 50.76 25.22 mt 11 17.50 11.00 mt 10 15.38 9.41
ctrl. 2 9 28.32 15.98 ctrl. 2 14 20.00 13.00 ctrl. 2 9 24.10 21.14 ctrl. 2 13 6.03 3.86
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 12 12.08 8.56 ctrl. 1 10 9.71 7.41 ctrl. 1 11 4.55 3.91 ctrl. 1 10 1.74 2.13
mt 11 16.95 13.72 mt 12 13.76 15.10 mt 10 7.36 5.79 mt 11 2.60 3.43
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Table A24: ANOVA table of ASR and PPI testing of young and mid-aged Pink1 x Pet mice 
 




F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
NS 1.109 0.336 0.292 0.590 0.483 0.619 0.624 1.000 0.629 1.376 0.268 0.390 1.000 0.710 0.121 0.887 1.000 1.000 1.000
70 [dB] 0.548 0.581 7.893 0.006 1.481 0.235 1.000 1.000 1.000 4.760 0.016 0.017 0.118 1.000 0.290 0.750 1.000 1.000 1.000
80 [dB] 0.909 0.408 1.871 0.176 2.235 0.115 1.000 0.717 0.764 2.309 0.116 0.156 0.362 1.000 1.473 0.243 0.770 1.000 0.314
85 [dB] 0.938 0.397 1.196 0.278 1.231 0.299 1.000 0.643 0.949 1.451 0.250 0.462 0.461 1.000 0.924 0.406 1.000 1.000 0.563
90 [dB] 0.563 0.572 0.919 0.341 1.108 0.336 1.000 1.000 1.000 1.603 0.218 0.250 1.000 1.000 0.311 0.734 1.000 1.000 1.000
100 [dB] 1.389 0.256 0.358 0.552 0.701 0.500 0.396 0.533 1.000 0.717 0.496 0.826 1.000 1.000 1.322 0.279 0.772 0.358 1.000
110 [dB] 1.810 0.172 1.057 0.307 0.450 0.640 0.228 0.577 1.000 0.799 0.459 0.695 1.000 1.000 1.449 0.248 0.503 0.368 1.000
120 [dB] 0.970 0.384 1.675 0.200 0.715 0.493 0.663 0.835 1.000 0.502 0.610 1.000 1.000 1.000 1.177 0.320 1.000 0.406 1.000
67 [dB] 1.145 0.324 0.018 0.894 0.971 0.384 1.000 0.428 0.667 1.161 0.326 0.671 0.546 1.000 1.096 0.345 1.000 1.000 0.443
69 [dB] 0.200 0.819 0.162 0.689 0.768 0.468 1.000 1.000 1.000 0.421 0.660 1.000 1.000 1.000 0.636 0.536 1.000 1.000 0.805
73 [dB] 0.308 0.736 0.016 0.900 0.399 0.673 1.000 1.000 1.000 0.185 0.832 1.000 1.000 1.000 0.624 0.541 1.000 1.000 1.000
81 [dB] 0.550 0.580 0.870 0.354 0.215 0.807 1.000 0.677 1.000 0.211 0.811 1.000 1.000 1.000 0.614 0.547 1.000 1.000 1.000
global PPI 0.656 0.522 0.076 0.783 0.678 0.511 1.000 0.626 1.000 0.536 0.590 0.976 1.000 1.000 0.938 0.401 1.000 1.000 0.573
F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
NS 0.064 0.938 0.109 0.742 0.033 0.967 1.000 1.000 1.000 0.076 0.927 1.000 1.000 1.000 0.013 0.987 1.000 1.000 1.000
70 [dB] 1.071 0.349 0.666 0.418 1.170 0.317 1.000 1.000 0.443 0.191 0.827 1.000 1.000 1.000 1.441 0.252 0.676 1.000 0.347
80 [dB] 0.038 0.963 3.069 0.085 1.092 0.342 1.000 1.000 1.000 1.443 0.253 0.301 1.000 1.000 0.447 0.644 1.000 1.000 1.000
85 [dB] 0.760 0.472 1.132 0.291 0.734 0.484 1.000 1.000 0.679 1.834 0.178 0.388 1.000 0.302 0.034 0.967 1.000 1.000 1.000
90 [dB] 2.762 0.071 5.532 0.022 0.447 0.641 0.333 1.000 0.046 3.225 0.054 0.089 1.000 0.157 0.984 0.385 1.000 1.000 0.531
100 [dB] 3.903 0.025 1.778 0.187 0.876 0.421 0.062 1.000 0.030 2.734 0.082 0.082 1.000 0.646 2.382 0.109 0.844 1.000 0.110
110 [dB] 3.776 0.028 1.275 0.263 0.114 0.893 0.025 0.394 0.726 2.639 0.089 0.094 0.486 1.000 1.316 0.282 0.344 1.000 1.000
120 [dB] 4.061 0.022 0.710 0.403 3.385 0.040 0.034 0.063 1.000 9.819 0.001 0.001 0.013 1.000 0.250 0.781 1.000 1.000 1.000
67 [dB] 3.201 0.048 0.363 0.549 0.690 0.506 0.339 0.046 1.000 2.209 0.128 1.000 0.150 0.397 1.628 0.212 0.349 0.381 1.000
69 [dB] 3.078 0.053 4.511 0.038 0.610 0.547 0.116 1.000 0.144 0.829 0.447 1.000 1.000 0.663 2.459 0.102 0.165 1.000 0.234
73 [dB] 2.853 0.065 0.752 0.389 0.834 0.439 0.063 0.950 0.539 0.472 0.628 1.000 1.000 1.000 2.928 0.068 0.079 1.000 0.294
81 [dB] 2.150 0.125 0.000 0.998 0.700 0.501 0.317 1.000 0.178 0.269 0.766 1.000 1.000 1.000 2.462 0.101 0.207 1.000 0.182
global PPI 2.869 0.064 1.156 0.287 1.017 0.368 0.061 0.855 0.597 0.379 0.688 1.000 1.000 1.000 3.130 0.057 0.063 1.000 0.296
Pink1 x Pet, mid-aged, ASR/PPI males females






Pink1 x Pet, young, ASR/PPI
post-hoc Bonferoni post-hoc Bonferoni post-hoc Bonferoni
Genotype Sex Interaction p-value Genotype
ASR
PPI




Table A25: ANOVA table of ASR and PPI testing of young and mid-aged Pink1 x DAT mice 
 












stimulus [dB] mean SD n mean SD N mean SD n mean SD n mean SD n mean SD n
NS 0.91 0.25 13 1.11 0.31 12 1.08 0.35 9 1.04 0.20 14 1.07 0.30 11 1.10 0.34 14
70 1.82 0.52 13 2.52 0.70 12 1.96 0.36 9 2.97 1.42 14 2.69 1.40 11 2.63 0.68 14
80 3.50 1.63 13 4.87 2.01 12 3.68 0.78 9 5.67 3.24 14 4.47 2.56 11 4.05 1.21 14
85 5.65 2.84 13 7.76 4.66 12 5.44 2.01 9 8.47 5.05 14 7.09 3.83 11 6.34 2.85 14
90 7.37 3.14 13 10.75 5.75 12 8.91 4.30 9 10.93 5.96 14 10.25 4.52 11 9.33 4.78 14
100 12.59 4.63 13 15.79 7.94 12 15.38 7.97 9 14.90 9.52 14 19.30 10.72 11 13.19 7.16 14
110 13.78 5.80 13 18.02 9.95 12 16.92 8.89 9 16.89 8.94 14 22.22 9.38 11 16.24 8.81 14
120 13.63 4.93 13 16.66 9.81 12 16.71 9.61 9 17.95 11.48 14 21.83 8.69 11 15.77 7.65 14
stimulus [dB] mean SD n mean SD n mean SD n mean SD n mean SD n mean SD n
NS 1.33 0.39 12 1.39 0.26 11 1.38 0.47 9 1.33 0.30 12 1.35 0.34 10 1.33 0.35 13
70 1.41 0.50 12 1.49 0.27 11 1.38 0.42 9 1.93 1.42 12 1.45 0.37 10 1.34 0.38 13
80 1.78 0.73 12 2.47 1.08 11 2.08 0.93 9 3.42 3.56 12 2.44 1.10 10 2.91 1.43 13
85 2.18 0.84 12 3.57 2.57 11 3.77 2.37 9 3.82 3.36 12 3.66 1.77 10 3.95 2.20 13
90 2.44 1.00 12 3.98 1.73 11 3.88 1.85 9 4.03 3.13 12 4.49 2.05 10 5.34 1.27 13
100 3.45 1.03 12 5.81 3.39 11 4.81 1.86 9 4.34 2.69 12 5.58 2.43 10 6.64 2.42 13
110 5.23 2.22 12 8.25 4.16 11 6.19 2.30 9 6.34 3.00 12 8.61 3.72 10 7.41 2.71 13
120 7.43 2.65 12 13.86 4.73 11 8.84 2.28 9 11.30 5.22 12 11.27 4.60 10 10.15 3.33 13
Pink1 x Pet, young
males females
ctrl.1 mt ctrl.2 ctrl.1 mt ctrl.2
Pink1 x Pet, mid-aged
males females








stimulus [dB] mean SD n mean SD n mean SD n mean SD n mean SD n mean SD n
NS 0.97 0.13 12 1.24 0.39 11 1.13 0.30 12 1.25 0.50 10 1.07 0.27 12 1.25 0.32 12
70 2.20 1.12 12 2.53 0.76 11 2.67 0.69 12 2.73 1.33 10 2.78 2.10 12 3.10 0.92 12
80 4.71 3.05 12 3.99 1.44 11 5.43 2.03 12 5.05 2.80 10 4.86 2.18 12 4.66 1.69 12
85 6.74 3.48 12 7.00 3.08 11 7.94 4.00 12 7.82 3.60 10 7.31 3.46 12 6.75 2.98 12
90 9.63 4.68 12 8.33 3.26 11 10.63 6.57 12 9.83 5.11 10 10.72 5.38 12 7.59 2.87 12
100 12.67 6.41 12 12.22 3.73 11 13.21 7.39 12 10.98 4.32 10 13.17 7.24 12 10.99 6.50 12
110 13.84 8.54 12 13.75 4.53 11 15.75 9.11 12 13.50 6.23 10 15.71 7.96 12 14.44 8.30 12
120 14.77 8.84 12 15.20 5.67 11 16.36 7.61 12 15.00 9.29 10 15.54 8.77 12 13.98 8.83 12
stimulus [dB] mean SD n mean SD n mean SD n mean SD n mean SD n mean SD n
NS 0.98 0.23 11 1.08 0.39 10 0.93 0.16 10 0.94 0.20 10 1.09 0.29 11 1.17 0.30 12
70 1.22 0.41 11 1.46 0.55 10 1.13 0.31 10 1.01 0.29 10 1.74 0.72 11 1.67 0.48 12
80 2.27 1.21 11 3.71 1.48 10 2.25 1.00 10 2.09 0.57 10 3.37 1.83 11 3.24 1.72 12
85 3.18 1.60 11 5.54 2.89 10 4.24 2.19 10 3.39 1.10 10 5.78 2.49 11 4.30 1.63 12
90 4.53 1.73 11 6.75 2.77 10 5.48 2.59 10 4.84 2.71 10 7.02 2.39 11 5.62 2.21 12
100 5.58 1.31 11 8.43 2.84 10 6.71 3.16 10 5.96 3.19 10 8.11 2.96 11 6.20 3.11 12
110 8.54 2.81 11 10.01 3.05 10 9.24 5.04 10 9.41 4.56 10 10.27 4.19 11 7.12 2.73 12





ctrl.1 mt ctrl.2 ctrl.1 mt
young Pink1 x DAT















pre stimulus [dB] mean SD n mean SD n mean SD n mean SD n mean SD n mean SD n
67 46.09 14.07 13 53.09 13.48 12 44.61 12.51 9 52.67 14.36 14 48.26 14.97 11 44.25 14.16 14
69 48.60 16.05 13 54.00 13.96 12 51.96 11.32 9 53.07 18.31 14 50.40 8.91 11 46.89 12.09 14
73 56.15 14.51 13 59.37 12.74 12 58.16 9.80 9 59.81 15.99 14 60.00 8.82 11 55.06 10.79 14
81 64.69 12.04 13 67.12 7.24 12 64.70 9.75 9 64.32 13.72 14 64.66 7.88 11 60.13 10.92 14
global 53.88 12.62 13 58.40 9.86 12 54.86 8.89 9 57.47 14.05 14 55.83 8.50 11 51.58 9.85 14
pre stimulus [dB] mean SD n mean SD n mean SD n mean SD n mean SD n mean SD n
67 11.95 23.82 12 17.78 22.61 11 -4.90 24.08 9 -2.91 34.42 12 17.53 24.29 10 -1.97 24.62 13
69 26.21 22.35 12 33.51 16.23 11 37.70 20.28 9 5.09 35.68 12 28.59 19.77 10 25.17 19.83 13
73 27.42 28.14 12 38.55 21.99 11 30.00 30.76 9 7.64 40.77 12 39.50 20.47 10 29.44 25.62 13
81 35.68 21.11 12 39.83 27.17 11 43.67 22.17 9 25.54 26.07 12 47.22 21.84 10 46.48 28.10 13
global 25.32 18.53 12 32.42 20.26 11 26.62 19.78 9 8.84 30.41 12 33.21 16.74 10 24.78 16.77 13
ctrl.2 ctrl.1 mt ctrl.2
Pink1 x Pet, young
males females
ctrl.1 mt ctrl.2 ctrl.1 mt ctrl.2















pre stimulus [dB] mean SD n mean SD n mean SD n mean SD n mean SD n mean SD n
67 39.83 13.43 12 41.84 14.49 11 48.26 11.85 12 42.21 17.84 10 50.24 19.32 12 46.14 15.25 12
69 47.46 13.09 12 52.77 14.52 11 52.82 15.99 12 46.32 16.34 10 47.27 23.63 12 48.84 12.25 12
73 53.31 14.34 12 59.85 9.46 11 59.08 10.54 12 49.55 13.06 10 54.12 14.98 12 53.14 16.26 12
81 50.90 14.95 12 57.41 8.24 11 56.46 10.21 12 46.38 21.17 10 55.02 11.08 12 52.59 14.36 12
global 47.87 10.55 12 52.97 8.87 11 54.15 10.33 12 46.11 14.17 10 51.66 15.61 12 50.18 13.51 12
pre stimulus [dB] mean SD n mean SD n mean SD n mean SD n mean SD n mean SD n
67 25.67 22.66 11 18.12 28.93 10 27.17 19.24 10 33.12 13.30 10 15.27 29.68 11 21.63 24.62 12
69 32.66 25.05 11 35.22 20.05 10 31.56 19.49 10 40.84 18.16 10 37.25 21.73 11 30.60 22.45 12
73 43.02 27.45 11 43.47 21.04 10 35.77 26.32 10 52.96 14.50 10 41.69 25.42 11 39.97 19.60 12
81 49.05 22.69 11 55.91 8.36 10 57.02 21.09 10 62.34 18.60 10 50.87 21.80 11 42.66 22.13 12
global 37.60 20.58 11 38.18 16.40 10 37.88 19.03 10 47.32 13.79 10 36.27 16.89 11 33.71 13.07 12
young Pink1 x DAT
males females
ctrl.1 mt ctrl.2 ctrl.1 mt ctrl.2
mid-aged Pink1 x DAT
males females




Table A30: Description of CW parameters  
 
* Information are taken from the Reference Manual of CatWalk XT Version 10.5 
 
 
1 Cadence [steps/sec] Steps per sec
2 Stance duration [sec] Duration of contact of a paw with the glass plate during one paw placement
3 Stand [sec] Duration of contact with the glass plate
4 Stand index [cm/sec] Speed at which paw looses contact with glass plate
5 Body speed [cm/sec] Speed of the body from one initial contact of a paw to the next initial contact
6 Body speed variation [%] The absolute difference between the body speed and the average speed of a run divided by the average speed
7 Number of steps [#] Total number of selected steps
8 Swing duration [sec] Duration of no contact of a paw with the glass plate
9 Swing speed [cm/sec] Speed of paw during Swing
10 Run duration [sec] The duration of the recorded run
11 Run speed [cm/sec] The average speed of the recorded run, which is the speed of the animal´s body 
12 Run maximum variation [%] The maximum variation in walking speed in the recorded run
13 Stride length [cm] Distance between successive placements of the same paw
14 Step cycle [sec] Time between two consecutive initial contacts of the same paw
15 Duty cycle [%] Stand as percentage of step cycle
16 Base of support [cm] Average width between front paws or hind paws
17 Initial dual stance [sec] Duration of groud contact for both hind paws simultaneously
18 Terminal dual stance [sec] The second step in a step cycle of a hind paw that the contralateral hind paw also makes contact with the glass plate
19 Print position right paws [cm] Distance between the position of the hind paw and the position of the previously placed right front paw on the same side of the body
20 Print position left paws [cm] Distance between the position of the hind paw and the position of the previously placed left front paw on the same side of the body
21 Number of patterns The number of footfall patterns
22 Regularity index [%] Number of normal step sequence pattern relative to the total number of paw placements
23 Phase dispersion [%] Temporal relatioship between placement of two paws within the step cycle
24 Couplings [%] Temporal relatioship between placement of two paws within the step cycle
25  % Max contact at [%] Duration since the start of the run that a paw makes maximum contact with the glass plate in relation to stand of paw 
26 Max contact max intensity [pixel] Maximum intensity of a paw at maximum contact
27 Max contact mean intensity [pixel] Mean intensity of a paw at maximum contact
28 Maximum intensity [pixel] Maximum intensity of complete paw
29 % Maximum intensity at  [sec] Time since the start of the run that the maximum intensity is measured in relative to stand
30 Minimum intensity [pixel] Minimum intensity of complete paw
31 Mean intensity mean [pixel] Mean intensity of the mean intensity of the complete paw
32 Mean intensity of 15 most intense pixel [pixel] Mean of the 15 most intense pixel of paws with highest intensity
33 Print length [cm] The lenght of complete paw print
34 Print Width [cm] The width of complete paw print




Table A31: ANOVA table (1) of CW testing of young Pink1 x Pet mice: temporal parameters 
 
      red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP =       
      hind paws. Table XY summarises the description of the CW parameters.   
 
 
F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
1 Cadence [steps/sec] 0.332 0.719 0.011 0.917 3.321 0.043 1.000 1.000 1.000 2.313 0.118 1.000 0.154 0.321 1.268 0.294 1.000 0.894 0.396
RF 0.100 0.905 0.032 0.859 3.080 0.053 1.000 1.000 1.000 1.834 0.179 1.000 0.202 0.755 1.237 0.303 1.000 0.379 1.000
RH 0.155 0.857 0.108 0.744 2.493 0.091 1.000 1.000 1.000 1.656 0.210 1.000 0.243 0.834 0.889 0.420 1.000 0.577 1.000
LF 0.434 0.650 0.756 0.388 1.673 0.196 1.000 1.000 0.782 0.763 0.476 1.000 0.724 1.000 1.507 0.236 1.000 0.628 0.337
LH 0.289 0.750 7.777 0.007 2.116 0.129 1.000 1.000 1.000 1.508 0.239 1.000 0.602 0.324 0.752 0.479 1.000 1.000 0.708
FP 0.102 0.903 0.329 0.569 2.491 0.091 1.000 1.000 1.000 1.340 0.279 1.000 0.340 1.000 1.332 0.277 1.000 0.449 0.609
HP 0.228 0.797 3.288 0.075 2.337 0.105 1.000 1.000 1.000 1.837 0.179 1.000 0.258 0.400 0.645 0.531 1.000 1.000 1.000
RF 0.722 0.490 0.355 0.554 2.671 0.077 1.000 1.000 1.000 2.294 0.120 1.000 0.229 0.201 0.601 0.554 1.000 1.000 0.844
RH 0.264 0.769 1.220 0.274 0.993 0.376 1.000 1.000 1.000 0.955 0.398 1.000 0.593 0.909 0.159 0.854 1.000 1.000 1.000
LF 0.368 0.694 0.059 0.809 2.234 0.116 1.000 1.000 1.000 1.546 0.231 1.000 0.362 0.461 1.016 0.372 1.000 1.000 0.493
LH 0.378 0.687 7.933 0.007 1.399 0.255 1.000 1.000 1.000 1.326 0.282 1.000 0.815 0.365 0.241 0.787 1.000 1.000 1.000
FP 0.495 0.612 0.183 0.670 2.492 0.091 1.000 1.000 1.000 1.936 0.164 1.000 0.279 0.300 0.829 0.445 1.000 1.000 0.624
HP 0.369 0.693 3.915 0.052 1.167 0.318 1.000 1.000 1.000 1.229 0.308 1.000 0.593 0.501 0.134 0.875 1.000 1.000 1.000
RF 0.529 0.592 0.002 0.964 1.305 0.279 0.973 1.000 1.000 0.714 0.499 1.000 0.780 1.000 1.256 0.297 1.000 1.000 0.383
RH 0.999 0.374 0.412 0.523 1.344 0.268 0.850 0.724 1.000 1.938 0.163 0.985 0.178 0.833 0.290 0.750 1.000 1.000 1.000
LF 0.603 0.550 0.153 0.697 3.119 0.051 1.000 1.000 0.459 0.864 0.433 1.000 0.617 1.000 3.609 0.038 1.000 0.122 0.061
LH 0.682 0.509 2.189 0.144 1.935 0.153 1.000 1.000 1.000 2.704 0.085 1.000 0.198 0.125 0.220 0.804 1.000 1.000 1.000
FP 0.681 0.510 0.032 0.858 2.725 0.073 0.950 1.000 0.596 1.122 0.340 0.890 0.468 1.000 2.680 0.083 1.000 0.307 0.107
HP 0.887 0.417 1.658 0.203 2.244 0.115 1.000 0.783 1.000 2.891 0.073 1.000 0.102 0.186 0.328 0.723 1.000 1.000 1.000
RF 0.675 0.513 0.124 0.726 2.917 0.062 1.000 1.000 1.000 2.602 0.093 1.000 0.325 0.107 1.026 0.369 0.746 1.000 0.640
RH 0.879 0.420 0.134 0.716 2.547 0.087 1.000 0.865 1.000 2.417 0.108 1.000 0.251 0.156 0.991 0.381 0.715 1.000 0.711
LF 0.545 0.583 0.135 0.715 2.773 0.070 1.000 1.000 1.000 2.497 0.101 1.000 0.307 0.125 0.807 0.454 1.000 1.000 0.695
LH 0.663 0.519 0.247 0.621 2.567 0.085 1.000 1.000 1.000 2.379 0.112 1.000 0.312 0.144 0.711 0.498 1.000 1.000 0.820
FP 0.606 0.549 0.130 0.720 2.840 0.066 1.000 1.000 1.000 2.558 0.096 1.000 0.315 0.115 0.903 0.415 0.939 1.000 0.668
HP 0.765 0.470 0.190 0.664 2.578 0.084 1.000 1.000 1.000 2.417 0.108 1.000 0.276 0.147 0.852 0.435 0.895 1.000 0.756
RF 1.611 0.208 3.845 0.054 0.979 0.381 0.247 1.000 1.000 2.146 0.136 0.382 0.174 1.000 0.926 0.406 0.832 1.000 0.701
RH 1.928 0.154 1.201 0.277 0.822 0.444 0.165 1.000 0.852 1.951 0.162 0.313 0.261 1.000 1.117 0.339 0.692 1.000 0.581
LF 2.065 0.135 2.092 0.153 0.811 0.449 0.167 0.751 1.000 2.991 0.067 0.110 0.140 1.000 0.469 0.629 1.000 1.000 1.000
LH 1.080 0.346 3.720 0.058 1.941 0.152 0.560 1.000 1.000 1.804 0.184 0.974 0.205 0.940 1.008 0.375 1.000 1.000 0.519
FP 2.090 0.132 3.381 0.071 0.946 0.394 0.156 0.813 1.000 3.122 0.060 0.135 0.095 1.000 0.731 0.489 0.956 1.000 0.901
HP 1.838 0.168 2.708 0.105 1.583 0.214 0.196 0.993 1.000 2.111 0.141 0.454 0.168 1.000 1.338 0.275 0.703 1.000 0.404
7 Number of steps [#] 0.165 0.848 0.205 0.652 1.880 0.161 1.000 1.000 1.000 1.298 0.290 0.590 1.000 0.521 0.810 0.453 0.640 1.000 1.000
RF 0.493 0.613 2.459 0.122 0.935 0.398 1.000 1.000 0.710 0.586 0.564 0.999 1.000 1.000 0.962 0.392 1.000 0.923 0.612
RH 0.278 0.758 3.979 0.050 0.999 0.374 1.000 1.000 1.000 0.356 0.704 1.000 1.000 1.000 0.992 0.381 1.000 1.000 0.504
LF 0.050 0.952 0.805 0.373 2.245 0.114 1.000 1.000 1.000 1.289 0.292 1.000 0.360 1.000 1.038 0.365 0.952 0.491 1.000
LH 0.252 0.778 17.030 0.000 1.588 0.213 1.000 1.000 0.947 1.351 0.276 0.445 0.532 1.000 0.747 0.481 1.000 0.739 1.000
FP 0.072 0.930 1.691 0.198 1.613 0.208 1.000 1.000 1.000 0.907 0.416 1.000 0.600 1.000 0.883 0.423 1.000 0.635 1.000
HP 0.339 0.714 10.548 0.002 1.149 0.324 1.000 1.000 0.852 0.793 0.463 0.996 0.735 1.000 0.839 0.441 1.000 1.000 0.707
RF 0.304 0.739 2.272 0.137 1.544 0.222 1.000 1.000 1.000 1.006 0.379 1.000 0.944 0.540 0.943 0.399 0.782 1.000 0.716
RH 0.174 0.841 5.032 0.028 3.116 0.051 1.000 1.000 1.000 2.033 0.151 1.000 0.988 0.162 1.515 0.234 0.543 1.000 0.367
LF 0.422 0.658 1.210 0.276 2.031 0.140 1.000 1.000 1.000 2.265 0.123 1.000 0.529 0.134 0.316 0.731 1.000 1.000 1.000
LH 0.249 0.781 20.976 0.000 1.703 0.190 1.000 1.000 1.000 1.309 0.287 1.000 0.374 0.817 0.635 0.536 1.000 1.000 0.841
FP 0.214 0.808 1.797 0.185 1.802 0.173 1.000 1.000 1.000 1.732 0.196 1.000 0.650 0.235 0.534 0.591 1.000 1.000 0.968
HP 0.251 0.779 14.686 0.000 2.434 0.096 1.000 1.000 1.000 1.802 0.184 1.000 0.404 0.269 1.137 0.332 1.000 1.000 0.437
10 Run duration [sec] 0.386 0.682 0.019 0.890 1.790 0.176 1.000 1.000 1.000 1.976 0.158 1.000 0.765 0.172 0.339 0.715 1.000 1.000 1.000
11 Run speed [cm/sec] 0.527 0.593 0.184 0.670 2.827 0.067 1.000 1.000 1.000 2.574 0.095 1.000 0.375 0.105 0.724 0.492 1.000 1.000 0.763
12 Run maximum variation [%] 0.478 0.622 4.677 0.034 0.329 0.721 1.000 1.000 1.000 0.037 0.963 1.000 1.000 1.000 0.915 0.410 0.656 0.779 1.000
Pink1 x Pet, young, CW
Swing speed [cm/sec]9
Body speed [cm/sec]5
Body speed variation [%]6
Swing duration [sec]8
Post hoc Bonferroni, p-value
males females
Genotype Sex Interaction Post hoc Bonferroni, p-value GenotypeGenotype Post hoc Bonferroni, p-value
Stance duration [sec]2
Stand [sec]3















Table A32: ANOVA table (2) of CW testing of young Pink1 x Pet mice: comparative paws 
 
  red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP = hind     








F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
RF 0.684 0.508 0.412 0.523 1.639 0.202 1.000 1.000 0.982 1.558 0.229 0.514 1.000 0.386 0.756 0.477 0.831 0.859 1.000
RH 0.868 0.425 0.647 0.424 1.621 0.206 1.000 1.000 0.742 1.637 0.213 0.454 1.000 0.379 0.793 0.460 0.930 0.726 1.000
LF 0.552 0.579 0.373 0.544 1.481 0.235 1.000 1.000 1.000 1.326 0.282 0.653 1.000 0.459 0.613 0.548 0.911 1.000 1.000
LH 0.567 0.570 0.282 0.597 1.388 0.257 1.000 1.000 1.000 1.222 0.310 0.722 1.000 0.501 0.632 0.537 0.913 1.000 1.000
FP 0.616 0.543 0.395 0.532 1.556 0.219 1.000 1.000 1.000 1.437 0.255 0.581 1.000 0.422 0.679 0.514 0.872 0.979 1.000
HP 0.713 0.494 0.451 0.504 1.498 0.232 1.000 1.000 0.925 1.421 0.259 0.578 1.000 0.434 0.704 0.501 0.919 0.872 1.000
RF 0.357 0.701 0.079 0.779 2.287 0.110 1.000 1.000 1.000 1.596 0.221 1.000 0.303 0.539 0.936 0.402 1.000 1.000 0.545
RH 0.261 0.771 0.175 0.677 2.496 0.091 1.000 1.000 1.000 1.646 0.212 1.000 0.277 0.565 1.000 0.378 1.000 1.000 0.549
LF 0.155 0.856 0.025 0.875 2.380 0.101 1.000 1.000 1.000 1.607 0.219 1.000 0.297 0.544 0.862 0.431 1.000 0.892 0.745
LH 0.227 0.798 0.076 0.784 2.555 0.086 1.000 1.000 1.000 1.726 0.197 1.000 0.267 0.487 0.909 0.412 1.000 0.949 0.656
FP 0.242 0.786 0.047 0.830 2.333 0.105 1.000 1.000 1.000 1.608 0.219 1.000 0.298 0.539 0.875 0.426 1.000 1.000 0.634
HP 0.238 0.789 0.122 0.728 2.541 0.087 1.000 1.000 1.000 1.688 0.204 1.000 0.272 0.520 0.965 0.391 1.000 0.977 0.590
RF 1.554 0.219 4.535 0.037 1.742 0.184 1.000 0.694 0.366 3.001 0.067 1.000 0.400 0.066 0.049 0.952 1.000 1.000 1.000
RH 0.286 0.753 3.470 0.067 0.220 0.803 1.000 1.000 1.000 0.285 0.754 1.000 1.000 1.000 0.210 0.812 1.000 1.000 1.000
LF 0.390 0.679 1.409 0.240 1.577 0.215 1.000 1.000 1.000 0.694 0.508 1.000 1.000 0.759 1.254 0.298 0.475 1.000 0.668
LH 0.444 0.644 22.394 0.000 1.068 0.350 1.000 1.000 0.806 1.319 0.284 0.638 1.000 0.472 0.239 0.788 1.000 1.000 1.000
FP 0.654 0.523 3.348 0.072 1.873 0.162 1.000 0.902 1.000 2.003 0.154 1.000 0.641 0.172 0.545 0.585 0.995 1.000 1.000
HP 0.517 0.599 12.575 0.001 0.233 0.793 1.000 1.000 0.766 0.781 0.468 1.000 1.000 0.669 0.036 0.965 1.000 1.000 1.000
FP 0.556 0.577 0.098 0.755 0.909 0.408 0.825 1.000 1.000 0.069 0.933 1.000 1.000 1.000 2.046 0.144 0.152 0.695 1.000
HP 0.576 0.565 6.565 0.013 0.749 0.477 1.000 0.741 1.000 0.526 0.597 1.000 1.000 0.985 0.777 0.468 0.664 1.000 1.000
RF 0.220 0.804 0.008 0.928 0.451 0.639 1.000 1.000 1.000 0.528 0.596 1.000 1.000 1.000 0.113 0.893 1.000 1.000 1.000
RH 0.760 0.472 3.742 0.058 0.050 0.951 1.000 1.000 0.489 0.124 0.884 1.000 1.000 1.000 1.116 0.339 1.000 1.000 0.440
LF 1.151 0.323 3.479 0.067 2.878 0.064 1.000 0.530 0.808 2.516 0.100 0.784 0.956 0.102 1.175 0.321 0.403 1.000 1.000
LH 0.051 0.951 0.356 0.553 0.709 0.496 1.000 1.000 1.000 0.310 0.736 1.000 1.000 1.000 0.466 0.631 1.000 1.000 1.000
FP 0.739 0.482 1.236 0.270 1.696 0.192 1.000 0.860 1.000 1.682 0.205 1.000 0.965 0.233 0.601 0.554 0.846 1.000 1.000
HP 0.228 0.797 2.021 0.160 0.176 0.839 1.000 1.000 1.000 0.247 0.783 1.000 1.000 1.000 0.127 0.881 1.000 1.000 1.000
RF 1.117 0.334 3.840 0.055 2.966 0.059 1.000 0.438 1.000 2.182 0.132 1.000 0.790 0.139 1.645 0.207 0.238 1.000 1.000
RH 0.016 0.985 1.045 0.311 0.964 0.387 1.000 1.000 1.000 0.679 0.516 0.935 1.000 1.000 0.375 0.690 1.000 1.000 1.000
LF 0.512 0.602 0.020 0.888 0.429 0.653 1.000 1.000 1.000 0.879 0.427 1.000 0.770 0.763 0.056 0.946 1.000 1.000 1.000
LH 0.767 0.469 2.888 0.094 0.229 0.796 1.000 0.920 0.466 0.067 0.935 1.000 1.000 1.000 1.552 0.226 1.000 0.616 0.320
FP 1.040 0.359 1.210 0.276 1.743 0.183 1.000 0.553 1.000 1.902 0.169 1.000 0.570 0.199 0.734 0.487 0.704 1.000 1.000
HP 0.353 0.704 2.794 0.100 0.255 0.775 1.000 1.000 1.000 0.300 0.743 1.000 1.000 1.000 0.307 0.738 1.000 1.000 1.000
19 Print position right paws [cm] 0.597 0.553 10.049 0.002 2.991 0.058 1.000 1.000 0.575 1.728 0.197 0.228 1.000 0.994 1.818 0.177 0.473 0.217 1.000
20 Print position left paws [cm] 0.184 0.833 6.639 0.012 2.397 0.099 1.000 1.000 1.000 1.259 0.300 0.489 1.000 0.689 1.176 0.320 0.402 1.000 1.000
Pink1 x Pet, young, CW
13 Stride length [cm]
14 Step cycle [sec]
15 Duty cycle [%]
16 Base of support [cm]
17 Initial dual stance [sec]
18 Terminal dual stance [sec]














Table A33: ANOVA table (3) of CW testing of young Pink1 x Pet mice: interlimb coordination and individual paw 
 
  red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP = hind  




Genotype Sex Interaction Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-value
F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
21 Number of patterns 0.722 0.490 0.330 0.567 1.457 0.241 1.000 1.000 0.998 2.155 0.135 0.529 1.000 0.171 0.357 0.702 1.000 1.000 1.000
22 Regularity index [%] 3.544 0.035 0.026 0.872 0.757 0.473 0.153 1.000 0.027 0.402 0.673 1.000 1.000 1.000 5.366 0.009 0.120 1.000 0.009
23 Phase dispersion [%] RF-LH 0.712 0.495 3.106 0.083 0.799 0.454 1.000 0.758 0.452 0.784 0.467 0.670 1.000 1.000 1.013 0.373 1.000 0.730 0.668
LF-RH 0.416 0.661 0.533 0.468 0.149 0.862 1.000 1.000 1.000 0.417 0.663 1.000 1.000 1.000 0.355 0.704 1.000 1.000 1.000
LH-RH 0.176 0.839 8.924 0.004 2.559 0.086 1.000 1.000 1.000 0.665 0.522 0.796 1.000 1.000 2.217 0.124 0.170 1.000 0.383
LF-RF 0.252 0.778 1.348 0.250 1.757 0.181 1.000 1.000 1.000 0.436 0.651 1.000 1.000 1.000 1.507 0.236 0.281 1.000 1.000
RF-RH 1.009 0.370 0.385 0.537 1.929 0.154 0.429 1.000 1.000 0.680 0.515 1.000 1.000 0.901 2.250 0.120 0.175 1.000 0.341
LF-LH 0.918 0.405 9.601 0.003 0.108 0.898 0.571 1.000 1.000 0.419 0.662 1.000 1.000 1.000 0.621 0.543 0.874 1.000 1.000
24 Couplings [%] RF-LH 0.314 0.732 8.740 0.004 0.577 0.565 1.000 1.000 1.000 1.032 0.370 0.571 0.783 1.000 0.020 0.981 1.000 1.000 1.000
LF-RH 1.434 0.246 0.001 0.978 4.087 0.022 0.198 0.976 1.000 0.444 0.646 1.000 1.000 1.000 6.168 0.005 0.005 0.616 0.079
LH-RF 0.459 0.634 0.758 0.387 0.395 0.676 1.000 1.000 1.000 0.344 0.712 1.000 1.000 1.000 0.031 0.970 1.000 1.000 1.000
RH-LF 1.701 0.191 0.017 0.896 3.368 0.041 0.149 1.000 0.773 0.293 0.748 1.000 1.000 1.000 5.977 0.006 0.007 1.000 0.051
LH-RH 0.248 0.781 9.669 0.003 3.065 0.054 1.000 1.000 1.000 0.734 0.489 0.750 1.000 1.000 2.749 0.078 0.104 1.000 0.279
LF-RF 0.421 0.658 1.210 0.276 1.902 0.158 0.890 1.000 1.000 0.327 0.724 1.000 1.000 1.000 1.867 0.170 0.186 0.941 0.983
RH-LH 0.138 0.871 7.398 0.008 2.160 0.124 1.000 1.000 1.000 0.559 0.578 0.921 1.000 1.000 1.844 0.173 0.214 1.000 0.629
RF-LF 0.201 0.818 0.838 0.364 1.727 0.186 1.000 1.000 1.000 0.532 0.593 1.000 1.000 1.000 1.364 0.269 0.328 0.839 1.000
RF-RH 1.023 0.366 0.366 0.547 1.956 0.150 0.419 1.000 1.000 0.680 0.515 1.000 1.000 0.901 2.286 0.117 0.171 1.000 0.330
LF-LH 0.803 0.452 9.812 0.003 0.098 0.907 0.658 1.000 1.000 0.341 0.714 1.000 1.000 1.000 0.595 0.557 0.914 1.000 1.000
RH-RF 0.713 0.494 1.219 0.274 1.778 0.177 0.641 1.000 1.000 0.694 0.508 1.000 0.994 0.883 1.780 0.184 0.333 1.000 0.367
LH-LF 1.288 0.283 11.260 0.001 0.066 0.937 0.362 1.000 1.000 0.497 0.614 1.000 1.000 1.000 0.917 0.409 0.566 1.000 1.000
RF 0.523 0.596 1.221 0.273 0.246 0.783 1.000 0.969 1.000 0.508 0.608 1.000 1.000 1.000 0.094 0.911 1.000 1.000 1.000
RH 0.088 0.915 0.210 0.648 0.606 0.549 1.000 1.000 1.000 0.496 0.614 1.000 1.000 1.000 0.233 0.793 1.000 1.000 1.000
LF 0.732 0.485 0.569 0.454 3.246 0.046 0.668 0.561 1.000 0.340 0.715 1.000 1.000 1.000 4.774 0.015 0.023 0.035 1.000
LH 0.084 0.920 1.894 0.174 0.795 0.456 1.000 1.000 1.000 0.514 0.604 1.000 1.000 1.000 0.266 0.768 1.000 1.000 1.000
FP 0.876 0.421 1.441 0.235 1.272 0.288 0.886 0.436 1.000 0.202 0.818 1.000 1.000 1.000 2.214 0.124 0.191 0.230 1.000
HP 0.082 0.922 1.168 0.284 0.855 0.430 1.000 1.000 1.000 0.670 0.520 1.000 1.000 0.848 0.282 0.756 1.000 1.000 1.000
RF 0.077 0.926 31.012 0.000 1.262 0.290 1.000 1.000 1.000 0.729 0.492 1.000 0.771 1.000 0.492 0.616 1.000 0.992 1.000
RH 0.656 0.523 10.595 0.002 1.123 0.332 1.000 1.000 0.849 0.780 0.468 1.000 0.962 0.769 0.888 0.420 0.653 0.842 1.000
LF 0.457 0.636 31.774 0.000 0.254 0.776 1.000 1.000 1.000 0.504 0.610 1.000 1.000 1.000 0.226 0.799 1.000 1.000 1.000
LH 0.045 0.956 19.575 0.000 0.609 0.547 1.000 1.000 1.000 0.323 0.727 1.000 1.000 1.000 0.297 0.745 1.000 1.000 1.000
FP 0.220 0.803 34.966 0.000 0.792 0.457 1.000 1.000 1.000 0.674 0.518 0.979 0.932 1.000 0.263 0.770 1.000 1.000 1.000
HP 0.322 0.726 16.472 0.000 1.001 0.373 1.000 1.000 1.000 0.635 0.538 1.000 1.000 0.969 0.588 0.561 1.000 0.965 1.000
RF 0.074 0.929 8.376 0.005 1.524 0.226 1.000 1.000 1.000 0.798 0.461 1.000 0.698 1.000 0.718 0.495 1.000 0.721 1.000
RH 0.224 0.800 8.360 0.005 0.378 0.686 1.000 1.000 1.000 0.174 0.841 1.000 1.000 1.000 0.411 0.666 1.000 1.000 1.000
LF 0.458 0.635 6.101 0.016 0.756 0.474 1.000 1.000 1.000 0.620 0.545 1.000 0.934 1.000 0.453 0.640 1.000 1.000 1.000
LH 0.132 0.877 10.898 0.002 1.049 0.357 1.000 1.000 1.000 1.135 0.336 1.000 0.566 0.625 0.299 0.743 1.000 1.000 1.000
FP 0.240 0.788 7.692 0.007 1.167 0.318 1.000 1.000 1.000 0.732 0.490 1.000 0.787 1.000 0.534 0.591 1.000 1.000 1.000
HP 0.166 0.848 10.631 0.002 0.730 0.486 1.000 1.000 1.000 0.587 0.563 1.000 1.000 1.000 0.375 0.690 1.000 1.000 1.000
RF 0.300 0.742 2.408 0.126 0.937 0.397 1.000 1.000 1.000 0.675 0.518 1.000 0.788 1.000 0.367 0.695 1.000 1.000 1.000
RH 0.252 0.778 3.347 0.072 0.369 0.693 1.000 1.000 1.000 0.272 0.764 1.000 1.000 1.000 0.321 0.728 1.000 1.000 1.000
LF 0.300 0.742 6.032 0.017 0.633 0.535 1.000 1.000 1.000 0.495 0.615 1.000 0.994 1.000 0.202 0.818 1.000 1.000 1.000
LH 0.827 0.442 4.950 0.030 1.671 0.196 1.000 1.000 0.736 1.701 0.202 1.000 0.448 0.291 0.426 0.657 1.000 1.000 1.000
FP 0.320 0.728 4.214 0.044 0.818 0.446 1.000 1.000 1.000 0.608 0.551 1.000 0.854 1.000 0.305 0.739 1.000 1.000 1.000
HP 0.519 0.598 4.887 0.031 0.965 0.387 1.000 1.000 1.000 0.926 0.408 1.000 0.847 0.648 0.403 0.671 1.000 1.000 1.000
Pink1 x Pet, young, CW
25  % Max contact at [%]
26 Max contact max intensity [pixel ]























Table A34: ANOVA table (4) of CW testing of young Pink1 x Pet mice: individual paw 
 
  red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP = hind  
  paws. Table XY summarises the description of the CW parameters.    
 
Genotype Sex Interaction Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-value
F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
RF 0.246 0.783 6.955 0.011 1.527 0.225 1.000 1.000 1.000 1.148 0.332 0.809 0.469 1.000 0.449 0.642 1.000 1.000 1.000
RH 0.125 0.882 8.105 0.006 0.309 0.735 1.000 1.000 1.000 0.223 0.802 1.000 1.000 1.000 0.215 0.808 1.000 1.000 1.000
LF 0.486 0.617 6.319 0.015 0.859 0.428 1.000 1.000 1.000 0.654 0.528 1.000 0.949 1.000 0.638 0.534 1.000 1.000 0.842
LH 0.121 0.886 11.390 0.001 1.063 0.352 1.000 1.000 1.000 1.287 0.292 1.000 0.425 0.658 0.251 0.779 1.000 1.000 1.000
FP 0.359 0.700 7.071 0.010 1.237 0.297 1.000 1.000 1.000 0.903 0.417 0.871 0.662 1.000 0.535 0.590 1.000 1.000 1.000
HP 0.117 0.890 10.716 0.002 0.702 0.500 1.000 1.000 1.000 0.674 0.518 1.000 0.887 1.000 0.254 0.777 1.000 1.000 1.000
29 % Maximum intensity at  [sec] RF 1.457 0.241 3.999 0.050 0.708 0.496 0.299 1.000 0.619 0.447 0.644 1.000 1.000 1.000 2.020 0.148 0.456 1.000 0.200
RH 5.023 0.010 0.703 0.405 4.398 0.016 0.012 0.026 1.000 2.323 0.117 1.000 0.178 0.252 7.241 0.002 0.002 0.169 0.162
LF 2.330 0.106 6.458 0.014 2.919 0.061 0.365 1.000 0.129 0.625 0.543 1.000 0.823 1.000 5.462 0.009 0.018 1.000 0.032
LH 1.035 0.361 0.343 0.560 0.417 0.661 0.508 1.000 1.000 0.996 0.382 0.512 1.000 1.000 0.142 0.868 1.000 1.000 1.000
FP 2.938 0.060 8.910 0.004 1.913 0.156 0.104 1.000 0.105 0.043 0.958 1.000 1.000 1.000 6.208 0.005 0.019 1.000 0.011
HP 3.858 0.026 0.910 0.344 1.173 0.316 0.025 0.117 1.000 1.450 0.252 0.794 0.314 1.000 3.970 0.028 0.026 0.625 0.325
30 Minimum intensity [pixel] RF 0.027 0.973 6.093 0.016 1.528 0.225 1.000 1.000 1.000 1.042 0.366 0.541 0.833 1.000 0.582 0.564 0.886 1.000 1.000
RH 0.082 0.921 6.263 0.015 1.319 0.275 1.000 1.000 1.000 1.288 0.292 0.522 0.506 1.000 0.505 0.608 0.967 1.000 1.000
LF 1.277 0.286 0.064 0.802 3.142 0.050 0.448 1.000 1.000 4.455 0.021 0.062 0.032 1.000 0.595 0.557 1.000 1.000 1.000
LH 0.091 0.913 9.296 0.003 0.373 0.690 1.000 1.000 1.000 0.158 0.855 1.000 1.000 1.000 0.320 0.728 1.000 1.000 1.000
FP 0.452 0.639 2.130 0.150 2.572 0.085 1.000 1.000 1.000 2.774 0.080 0.139 0.155 1.000 0.465 0.632 1.000 1.000 1.000
HP 0.025 0.976 9.485 0.003 0.792 0.457 1.000 1.000 1.000 1.111 0.344 0.759 0.513 1.000 0.221 0.802 1.000 1.000 1.000
31 Mean intensity mean [pixel] RF 0.399 0.673 1.545 0.219 1.003 0.373 1.000 1.000 1.000 0.893 0.421 1.000 0.592 1.000 0.173 0.842 1.000 1.000 1.000
RH 0.175 0.840 3.015 0.087 0.405 0.669 1.000 1.000 1.000 0.252 0.779 1.000 1.000 1.000 0.299 0.743 1.000 1.000 1.000
LF 0.369 0.693 5.647 0.021 0.748 0.478 1.000 1.000 1.000 0.593 0.559 1.000 0.868 1.000 0.308 0.737 1.000 1.000 1.000
LH 0.480 0.621 4.999 0.029 1.547 0.221 1.000 1.000 1.000 1.304 0.288 1.000 0.525 0.488 0.353 0.705 1.000 1.000 1.000
FP 0.401 0.671 3.361 0.072 0.891 0.416 1.000 1.000 1.000 0.762 0.477 1.000 0.697 1.000 0.239 0.789 1.000 1.000 1.000
HP 0.316 0.730 4.502 0.038 0.921 0.403 1.000 1.000 1.000 0.762 0.477 1.000 0.852 0.883 0.308 0.737 1.000 1.000 1.000
32 Intensity of 15 most intense pixel [pixel] RF 0.295 0.745 7.395 0.008 1.196 0.309 1.000 1.000 1.000 0.849 0.439 1.000 0.625 1.000 0.302 0.741 1.000 1.000 1.000
RH 0.239 0.788 9.867 0.003 0.631 0.535 1.000 1.000 1.000 0.409 0.668 1.000 1.000 1.000 0.414 0.664 1.000 1.000 1.000
LF 0.466 0.630 10.543 0.002 0.758 0.473 1.000 1.000 1.000 0.648 0.531 1.000 0.877 1.000 0.370 0.693 1.000 1.000 1.000
LH 0.259 0.773 12.603 0.001 1.384 0.258 1.000 1.000 1.000 1.118 0.342 1.000 0.569 0.645 0.388 0.681 1.000 1.000 1.000
FP 0.374 0.689 9.118 0.004 1.005 0.372 1.000 1.000 1.000 0.770 0.473 1.000 0.716 1.000 0.317 0.730 1.000 1.000 1.000
HP 0.258 0.774 12.035 0.001 1.033 0.362 1.000 1.000 1.000 0.782 0.468 1.000 0.811 0.892 0.408 0.668 1.000 1.000 1.000
33 Print length [cm] RF 0.045 0.956 7.538 0.008 0.476 0.624 1.000 1.000 1.000 0.307 0.738 1.000 1.000 1.000 0.158 0.854 1.000 1.000 1.000
RH 0.148 0.863 12.651 0.001 0.445 0.643 1.000 1.000 1.000 0.231 0.795 1.000 1.000 1.000 0.358 0.702 1.000 1.000 1.000
LF 0.183 0.834 19.727 0.000 0.053 0.949 1.000 1.000 1.000 0.024 0.976 1.000 1.000 1.000 0.254 0.777 1.000 1.000 1.000
LH 0.259 0.773 31.789 0.000 0.287 0.751 1.000 1.000 1.000 0.518 0.601 1.000 1.000 0.959 0.040 0.961 1.000 1.000 1.000
FP 0.119 0.888 13.868 0.000 0.125 0.882 1.000 1.000 1.000 0.180 0.836 1.000 1.000 1.000 0.033 0.967 1.000 1.000 1.000
HP 0.247 0.782 22.342 0.000 0.390 0.678 1.000 1.000 1.000 0.411 0.667 1.000 1.000 1.000 0.241 0.787 1.000 1.000 1.000
34 Print Width [cm] RF 0.646 0.527 52.896 0.000 2.046 0.138 0.898 1.000 1.000 0.172 0.843 1.000 1.000 1.000 2.885 0.069 0.117 0.121 1.000
RH 0.601 0.551 8.231 0.006 0.740 0.481 1.000 1.000 0.955 1.526 0.235 1.000 0.333 0.544 0.047 0.954 1.000 1.000 1.000
LF 0.249 0.780 26.966 0.000 0.599 0.552 1.000 1.000 1.000 0.714 0.499 0.729 1.000 1.000 0.145 0.866 1.000 1.000 1.000
LH 0.085 0.918 18.969 0.000 0.423 0.657 1.000 1.000 1.000 0.526 0.597 1.000 0.945 1.000 0.064 0.938 1.000 1.000 1.000
FP 0.063 0.939 51.984 0.000 1.597 0.211 1.000 1.000 1.000 0.503 0.610 0.989 1.000 1.000 1.196 0.315 0.426 0.746 1.000
HP 0.373 0.690 14.554 0.000 0.733 0.484 1.000 1.000 1.000 1.312 0.286 1.000 0.381 0.765 0.059 0.943 1.000 1.000 1.000
35 Print area [cm] RF 0.027 0.973 23.870 0.000 1.353 0.266 1.000 1.000 1.000 0.694 0.508 1.000 0.793 1.000 0.632 0.537 1.000 0.827 1.000
RH 0.644 0.529 12.293 0.001 0.976 0.383 1.000 1.000 0.795 0.768 0.474 1.000 0.974 0.779 0.728 0.490 0.763 1.000 1.000
LF 0.608 0.548 28.096 0.000 0.692 0.504 0.815 1.000 1.000 1.074 0.356 0.556 0.734 1.000 0.214 0.809 1.000 1.000 1.000
LH 0.115 0.892 24.830 0.000 0.608 0.547 1.000 1.000 1.000 0.459 0.637 1.000 1.000 1.000 0.182 0.834 1.000 1.000 1.000
FP 0.201 0.818 28.098 0.000 1.163 0.319 1.000 1.000 1.000 0.947 0.400 0.768 0.671 1.000 0.333 0.719 1.000 1.000 1.000
HP 0.408 0.667 20.050 0.000 0.940 0.396 1.000 1.000 0.982 0.743 0.485 1.000 0.933 0.844 0.464 0.632 1.000 1.000 1.000
Pink1 x Pet, young, CW












Table A35: ANOVA table (1) of CW testing of mid-aged Pink1 x Pet mice: temporal parameters 
 
  red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP = hind  
  paws. Table XY summarises the description of the CW parameters.     
 
F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
1 Cadence [steps/sec] 0.415 0.662 4.523 0.037 2.305 0.108 1.000 1.000 1.000 2.550 0.095 0.619 0.986 0.100 0.788 0.463 1.000 0.785 0.997
RF 1.436 0.246 5.998 0.017 1.918 0.156 0.322 1.000 1.000 3.663 0.038 0.518 0.563 0.034 0.970 0.390 0.866 0.577 1.000
RH 0.996 0.375 2.993 0.089 2.306 0.108 0.697 1.000 1.000 3.635 0.039 0.654 0.452 0.035 0.582 0.564 1.000 0.866 1.000
LF 0.108 0.898 7.451 0.008 1.393 0.256 1.000 1.000 1.000 1.901 0.168 1.000 0.682 0.186 0.333 0.719 1.000 1.000 1.000
LH 0.438 0.647 5.280 0.025 2.492 0.091 1.000 0.696 1.000 2.232 0.125 0.362 1.000 0.181 1.255 0.299 1.000 0.610 0.513
FP 0.609 0.547 7.124 0.010 1.721 0.187 0.896 1.000 1.000 2.971 0.067 0.843 0.543 0.063 0.547 0.584 1.000 0.910 1.000
HP 0.666 0.518 5.087 0.028 2.887 0.063 0.740 1.000 1.000 4.129 0.026 0.269 0.792 0.025 0.951 0.397 1.000 0.624 0.928
RF 0.503 0.607 2.402 0.126 2.437 0.096 1.000 0.583 1.000 2.027 0.150 0.487 1.000 0.198 1.475 0.244 1.000 0.451 0.463
RH 0.593 0.556 0.612 0.437 1.459 0.241 1.000 0.582 1.000 0.646 0.532 1.000 1.000 0.917 1.363 0.270 1.000 0.423 0.624
LF 0.229 0.796 2.997 0.088 2.431 0.096 1.000 0.966 1.000 1.541 0.231 0.540 1.000 0.363 1.427 0.255 1.000 1.000 0.311
LH 1.398 0.255 1.190 0.280 1.768 0.179 1.000 0.165 0.627 0.754 0.479 0.716 1.000 1.000 2.230 0.124 1.000 0.235 0.250
FP 0.326 0.723 2.718 0.104 2.420 0.097 1.000 0.745 1.000 1.826 0.179 0.491 1.000 0.258 1.403 0.261 1.000 0.684 0.376
HP 0.991 0.377 0.897 0.347 1.676 0.196 1.000 0.295 0.978 0.709 0.500 0.869 1.000 1.000 1.829 0.177 1.000 0.302 0.381
RF 0.890 0.416 0.570 0.453 2.140 0.126 0.615 1.000 1.000 2.810 0.077 0.951 0.535 0.074 1.205 0.313 0.987 0.397 1.000
RH 0.571 0.568 1.283 0.262 0.268 0.766 1.000 1.000 1.000 0.868 0.431 0.629 1.000 1.000 0.150 0.861 1.000 1.000 1.000
LF 0.603 0.550 2.098 0.153 0.899 0.412 0.903 1.000 1.000 1.071 0.356 1.000 1.000 0.479 0.667 0.520 1.000 0.784 1.000
LH 0.197 0.822 2.019 0.160 0.633 0.534 1.000 1.000 1.000 0.265 0.769 1.000 1.000 1.000 0.521 0.599 1.000 1.000 1.000
FP 0.835 0.439 1.407 0.240 1.589 0.212 0.663 1.000 1.000 2.133 0.137 0.894 0.924 0.145 1.003 0.378 1.000 0.508 1.000
HP 0.020 0.980 2.112 0.151 0.510 0.603 1.000 1.000 1.000 0.285 0.754 1.000 1.000 1.000 0.269 0.766 1.000 1.000 1.000
RF 0.675 0.513 1.185 0.281 1.043 0.358 0.750 1.000 1.000 1.880 0.171 0.413 1.000 0.268 0.305 0.739 1.000 1.000 1.000
RH 0.617 0.543 0.750 0.390 1.120 0.333 0.863 1.000 1.000 2.099 0.141 0.387 1.000 0.207 0.217 0.806 1.000 1.000 1.000
LF 0.690 0.505 1.594 0.212 1.114 0.335 0.762 1.000 1.000 2.049 0.147 0.378 1.000 0.225 0.236 0.791 1.000 1.000 1.000
LH 0.725 0.488 1.203 0.277 0.969 0.385 0.725 1.000 1.000 1.846 0.176 0.445 1.000 0.267 0.261 0.772 1.000 1.000 1.000
FP 0.683 0.509 1.387 0.244 1.077 0.347 0.754 1.000 1.000 1.969 0.158 0.394 1.000 0.245 0.270 0.765 1.000 1.000 1.000
HP 0.678 0.511 0.970 0.329 1.052 0.355 0.781 1.000 1.000 2.001 0.153 0.404 1.000 0.230 0.239 0.789 1.000 1.000 1.000
RF 0.492 0.614 0.720 0.399 0.158 0.854 1.000 1.000 0.803 0.038 0.963 1.000 1.000 1.000 0.824 0.448 1.000 1.000 0.626
RH 0.223 0.801 3.335 0.073 0.098 0.907 1.000 1.000 1.000 0.227 0.798 1.000 1.000 1.000 0.027 0.974 1.000 1.000 1.000
LF 0.120 0.887 0.151 0.699 0.395 0.675 1.000 1.000 1.000 0.294 0.748 1.000 1.000 1.000 0.253 0.778 1.000 1.000 1.000
LH 0.426 0.655 2.848 0.097 0.462 0.632 1.000 1.000 0.869 0.091 0.914 1.000 1.000 1.000 0.912 0.412 1.000 1.000 0.560
FP 0.301 0.741 0.446 0.507 0.193 0.825 1.000 1.000 1.000 0.115 0.891 1.000 1.000 1.000 0.459 0.636 1.000 1.000 1.000
HP 0.201 0.819 3.497 0.066 0.035 0.965 1.000 1.000 1.000 0.027 0.973 1.000 1.000 1.000 0.262 0.771 1.000 1.000 1.000
7 Number of steps [#] 0.512 0.602 0.339 0.563 0.881 0.419 1.000 1.000 0.855 0.778 0.469 0.763 1.000 1.000 0.667 0.520 1.000 0.772 1.000
RF 0.161 0.852 10.947 0.002 1.223 0.302 1.000 1.000 1.000 1.402 0.262 1.000 0.906 0.318 0.305 0.739 1.000 1.000 1.000
RH 0.335 0.717 12.457 0.001 2.266 0.112 1.000 1.000 1.000 2.784 0.078 0.784 0.665 0.076 0.462 0.634 1.000 1.000 1.000
LF 2.008 0.143 9.358 0.003 1.665 0.198 0.179 1.000 0.884 3.085 0.061 0.498 0.850 0.060 1.146 0.331 0.579 0.569 1.000
LH 1.726 0.187 10.183 0.002 1.669 0.197 1.000 1.000 0.469 4.230 0.024 1.000 0.172 0.023 0.136 0.874 1.000 1.000 1.000
FP 0.878 0.421 10.977 0.002 1.526 0.226 0.642 1.000 1.000 2.331 0.115 0.895 0.800 0.118 0.595 0.558 1.000 0.873 1.000
HP 1.022 0.366 13.356 0.001 2.292 0.110 1.000 1.000 1.000 4.409 0.021 0.745 0.240 0.018 0.209 0.813 1.000 1.000 1.000
RF 0.753 0.475 7.245 0.009 1.005 0.372 1.000 1.000 1.000 1.950 0.160 0.686 1.000 0.188 0.014 0.987 1.000 1.000 1.000
RH 0.752 0.476 10.472 0.002 2.572 0.085 1.000 1.000 1.000 3.039 0.063 0.415 1.000 0.066 0.279 0.759 1.000 1.000 1.000
LF 1.765 0.180 7.571 0.008 1.435 0.246 0.304 1.000 0.686 3.083 0.061 0.444 0.948 0.062 0.540 0.588 1.000 1.000 1.000
LH 2.822 0.067 10.216 0.002 1.717 0.188 0.794 1.000 0.163 3.857 0.033 0.840 0.301 0.029 0.120 0.887 1.000 1.000 1.000
FP 1.209 0.305 7.740 0.007 1.199 0.309 0.628 1.000 0.871 2.582 0.093 0.540 1.000 0.100 0.171 0.844 1.000 1.000 1.000
HP 1.930 0.154 12.369 0.001 2.459 0.094 0.908 1.000 0.412 4.213 0.025 0.468 0.441 0.021 0.020 0.980 1.000 1.000 1.000
10 Run duration [sec] 0.036 0.965 1.833 0.181 1.761 0.181 1.000 1.000 1.000 1.532 0.233 0.639 1.000 0.331 0.669 0.519 1.000 1.000 0.769
11 Run speed [cm/sec] 0.389 0.680 2.336 0.132 1.191 0.311 1.000 1.000 1.000 1.352 0.275 0.797 1.000 0.379 0.438 0.649 1.000 1.000 1.000
12 Run maximum variation [%] 1.955 0.150 2.740 0.103 0.203 0.817 0.172 1.000 0.583 1.205 0.314 0.420 0.945 1.000 1.057 0.359 0.568 1.000 0.785
9 Swing speed [cm/sec]
2 Stance duration [sec]
3 Stand [sec]





6 Body speed variation [%]
8 Swing duration [sec]
Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-valueInteraction Post hoc Bonferroni, p-value Genotype















Table A36: ANOVA table (2) of CW testing of mid-aged Pink1 x Pet mice: comparative paws 
 
  red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP = hind    








F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
RF 0.253 0.777 0.000 0.986 0.851 0.432 1.000 1.000 1.000 0.876 0.427 0.621 1.000 1.000 0.209 0.813 1.000 1.000 1.000
RH 0.225 0.799 0.005 0.943 0.986 0.379 1.000 1.000 1.000 0.839 0.443 0.652 1.000 1.000 0.359 0.701 1.000 1.000 1.000
LF 0.068 0.934 0.011 0.918 0.607 0.548 1.000 1.000 1.000 0.499 0.613 1.000 1.000 1.000 0.154 0.858 1.000 1.000 1.000
LH 0.166 0.847 0.000 0.994 0.448 0.641 1.000 1.000 1.000 0.434 0.652 1.000 1.000 1.000 0.160 0.852 1.000 1.000 1.000
FP 0.146 0.865 0.002 0.964 0.721 0.491 1.000 1.000 1.000 0.675 0.517 0.813 1.000 1.000 0.165 0.849 1.000 1.000 1.000
HP 0.195 0.823 0.001 0.977 0.687 0.507 1.000 1.000 1.000 0.617 0.547 0.890 1.000 1.000 0.247 0.783 1.000 1.000 1.000
RF 0.348 0.707 5.738 0.020 2.393 0.100 1.000 0.756 1.000 2.475 0.102 0.561 1.000 0.111 1.199 0.315 1.000 0.552 0.627
RH 0.439 0.647 5.044 0.028 2.660 0.078 1.000 0.717 1.000 2.640 0.088 0.476 1.000 0.097 1.323 0.280 1.000 0.473 0.586
LF 0.350 0.706 5.954 0.018 2.167 0.123 1.000 0.997 1.000 2.899 0.071 0.330 1.000 0.084 0.835 0.443 1.000 0.837 0.833
LH 0.532 0.590 6.107 0.016 2.585 0.084 0.932 0.694 1.000 2.857 0.074 0.372 1.000 0.084 1.231 0.305 1.000 0.492 0.675
FP 0.342 0.712 5.865 0.018 2.274 0.112 1.000 0.869 1.000 2.695 0.084 0.429 1.000 0.095 1.011 0.375 1.000 0.680 0.724
HP 0.482 0.620 5.583 0.021 2.635 0.080 1.000 0.706 1.000 2.772 0.079 0.418 1.000 0.088 1.279 0.292 1.000 0.482 0.627
RF 1.051 0.356 1.022 0.316 0.790 0.459 1.000 0.432 1.000 0.451 0.642 1.000 1.000 1.000 1.396 0.262 1.000 0.394 0.644
RH 0.709 0.496 3.995 0.050 0.103 0.902 1.000 0.965 1.000 0.286 0.753 1.000 1.000 1.000 0.513 0.604 1.000 0.976 1.000
LF 1.277 0.286 0.568 0.454 1.514 0.228 0.897 1.000 0.372 0.216 0.807 1.000 1.000 1.000 2.399 0.107 0.246 1.000 0.173
LH 2.883 0.064 2.156 0.147 0.161 0.852 1.000 0.131 0.182 1.749 0.192 1.000 0.226 0.626 1.439 0.252 1.000 0.632 0.374
FP 0.804 0.452 0.938 0.337 0.990 0.377 1.000 0.869 0.718 0.327 0.724 1.000 1.000 1.000 1.472 0.245 1.000 1.000 0.290
HP 2.013 0.142 4.110 0.047 0.004 0.996 1.000 0.274 0.503 1.161 0.327 1.000 0.457 0.771 0.916 0.410 1.000 0.675 0.900
FP 2.130 0.128 0.157 0.693 0.975 0.383 0.655 0.105 1.000 0.141 0.869 1.000 1.000 1.000 3.218 0.053 0.286 0.052 1.000
HP 0.623 0.539 1.032 0.314 2.107 0.130 1.000 1.000 1.000 1.034 0.368 1.000 0.493 1.000 1.514 0.235 0.310 0.592 1.000
RF 1.337 0.270 0.231 0.633 1.237 0.298 1.000 0.247 0.475 0.120 0.888 1.000 1.000 1.000 2.801 0.076 1.000 0.158 0.153
RH 2.364 0.103 0.595 0.444 0.198 0.821 1.000 0.136 0.432 0.810 0.455 1.000 0.814 0.807 1.981 0.154 0.956 0.166 0.967
LF 0.514 0.601 0.000 0.993 3.713 0.030 1.000 1.000 0.775 0.959 0.395 0.696 1.000 0.797 3.018 0.063 0.217 1.000 0.083
LH 1.087 0.344 0.025 0.876 1.141 0.326 1.000 0.800 0.367 0.132 0.877 1.000 1.000 1.000 1.832 0.177 1.000 1.000 0.195
FP 0.780 0.463 0.081 0.777 2.426 0.097 1.000 0.740 0.506 0.493 0.616 1.000 1.000 1.000 2.689 0.083 0.932 0.769 0.081
HP 2.119 0.129 0.264 0.610 0.284 0.753 1.000 0.204 0.224 0.468 0.631 1.000 1.000 1.000 2.032 0.148 1.000 0.331 0.248
RF 0.792 0.457 0.017 0.896 3.551 0.035 1.000 1.000 0.475 0.737 0.487 0.789 1.000 1.000 3.319 0.049 0.225 1.000 0.057
RH 1.278 0.286 0.009 0.923 1.119 0.333 1.000 0.618 0.283 0.025 0.976 1.000 1.000 1.000 2.106 0.138 1.000 0.593 0.161
LF 1.218 0.303 0.146 0.704 0.864 0.426 1.000 0.277 0.722 0.234 0.793 1.000 1.000 1.000 2.264 0.120 1.000 0.227 0.246
LH 2.566 0.085 0.410 0.524 0.163 0.850 1.000 0.117 0.330 0.999 0.381 1.000 0.673 0.659 1.840 0.175 1.000 0.197 0.882
FP 0.965 0.387 0.071 0.791 2.254 0.114 1.000 0.551 0.446 0.541 0.588 0.930 1.000 1.000 2.716 0.081 0.986 0.713 0.080
HP 2.507 0.090 0.211 0.647 0.284 0.754 1.000 0.143 0.157 0.541 0.588 1.000 1.000 1.000 2.363 0.110 1.000 0.223 0.214
19 Print position right paws [cm] 0.079 0.924 6.700 0.012 5.529 0.006 1.000 1.000 1.000 2.697 0.084 0.083 0.681 1.000 2.922 0.068 0.081 0.219 1.000
20 Print position left paws [cm] 0.317 0.730 3.143 0.081 2.122 0.129 1.000 1.000 1.000 0.719 0.496 1.000 1.000 0.850 1.661 0.206 0.237 1.000 0.930
Pink1 x Pet, mid-aged, CW males females
Genotype Sex Interaction Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-value
13 Stride length [cm]
14 Step cycle [sec]
15 Duty cycle [%]
16 Base of support [cm]
17 Initial dual stance [sec]













Table A37: ANOVA table (3) of CW testing of mid-aged Pink1 x Pet mice: interlimb coordination and individual paw 
 
  red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP = hind  
  paws. Table XY summarises the description of the CW parameters.     
 
 
F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
21 Number of patterns 0.769 0.468 0.027 0.869 0.961 0.388 1.000 1.000 0.517 0.596 0.558 0.854 1.000 1.000 1.290 0.289 1.000 0.523 0.558
22 Regularity index [%] 0.735 0.484 0.253 0.617 1.241 0.296 1.000 1.000 0.977 1.366 0.271 1.000 0.770 0.344 0.526 0.596 1.000 1.000 1.000
RF-LH 1.146 0.325 0.577 0.450 0.833 0.440 0.565 1.000 0.718 0.859 0.434 1.000 1.000 0.699 1.662 0.206 0.400 0.316 1.000
LF-RH 0.729 0.487 0.730 0.396 2.221 0.117 0.764 1.000 1.000 0.694 0.508 1.000 1.000 0.804 2.233 0.124 0.210 1.000 0.262
LH-RH 0.287 0.751 0.055 0.816 0.734 0.484 1.000 1.000 1.000 0.050 0.951 1.000 1.000 1.000 1.183 0.319 0.477 1.000 0.755
LF-RF 3.277 0.044 0.309 0.580 5.500 0.006 0.097 0.077 1.000 0.215 0.808 1.000 1.000 1.000 8.358 0.001 0.002 0.005 1.000
RF-RH 0.048 0.953 1.357 0.249 2.066 0.136 1.000 1.000 1.000 0.570 0.572 1.000 1.000 1.000 1.832 0.177 1.000 0.288 0.401
LF-LH 0.049 0.952 0.143 0.707 0.378 0.687 1.000 1.000 1.000 0.110 0.896 1.000 1.000 1.000 0.437 0.650 1.000 1.000 1.000
RF-LH 1.872 0.163 3.052 0.086 2.686 0.076 0.370 1.000 0.228 2.173 0.132 0.217 1.000 0.314 1.365 0.270 0.436 0.497 1.000
LF-RH 0.801 0.454 0.661 0.419 1.177 0.315 0.986 0.726 1.000 0.699 0.505 1.000 1.000 0.789 1.082 0.351 0.941 0.473 1.000
LH-RF 1.867 0.163 1.516 0.223 1.203 0.307 1.000 0.358 0.652 1.310 0.285 1.000 0.502 0.479 1.555 0.227 0.383 0.396 1.000
RH-LF 0.901 0.411 1.371 0.246 2.540 0.087 1.000 1.000 0.328 0.603 0.554 1.000 1.000 0.960 2.264 0.120 0.934 1.000 0.123
LH-RH 0.371 0.692 0.066 0.798 0.642 0.530 1.000 1.000 1.000 0.029 0.971 1.000 1.000 1.000 1.288 0.290 0.473 1.000 0.598
LF-RF 2.621 0.081 0.395 0.532 3.813 0.028 0.101 0.288 1.000 0.099 0.906 1.000 1.000 1.000 5.818 0.007 0.008 0.035 1.000
RH-LH 0.392 0.677 0.128 0.721 0.684 0.509 1.000 1.000 1.000 0.105 0.900 1.000 1.000 1.000 1.157 0.327 0.446 1.000 0.937
RF-LF 3.059 0.054 0.502 0.481 3.356 0.041 0.122 0.085 1.000 0.169 0.846 1.000 1.000 1.000 6.074 0.006 0.008 0.023 1.000
RF-RH 0.054 0.947 1.376 0.245 2.041 0.139 1.000 1.000 1.000 0.535 0.592 1.000 1.000 1.000 1.913 0.164 1.000 0.285 0.350
LF-LH 0.024 0.976 0.085 0.772 0.398 0.673 1.000 1.000 1.000 0.110 0.896 1.000 1.000 1.000 0.433 0.652 1.000 1.000 1.000
RH-RF 0.023 0.977 1.140 0.290 1.921 0.155 1.000 1.000 1.000 0.651 0.529 1.000 1.000 0.885 1.449 0.250 1.000 0.449 0.489
LH-LF 0.018 0.982 0.089 0.767 0.249 0.780 1.000 1.000 1.000 0.087 0.917 1.000 1.000 1.000 0.230 0.796 1.000 1.000 1.000
RF 3.116 0.051 2.591 0.113 1.385 0.258 1.000 0.086 0.114 0.359 0.702 1.000 1.000 1.000 4.657 0.017 1.000 0.020 0.114
RH 1.043 0.358 2.436 0.124 0.543 0.584 1.000 0.434 0.988 1.309 0.286 1.000 0.425 0.585 0.141 0.869 1.000 1.000 1.000
LF 1.903 0.158 4.702 0.034 6.626 0.002 1.000 0.376 0.608 3.350 0.049 0.124 1.000 0.092 5.151 0.012 0.015 0.043 1.000
LH 1.057 0.354 1.777 0.188 0.362 0.698 0.425 1.000 1.000 0.776 0.469 0.809 0.958 1.000 0.693 0.507 1.000 1.000 0.871
FP 3.916 0.025 5.570 0.021 4.164 0.020 1.000 0.060 0.106 2.174 0.132 0.368 1.000 0.193 6.639 0.004 0.056 0.003 0.798
HP 0.954 0.391 3.047 0.086 0.600 0.552 0.654 0.615 1.000 1.144 0.332 1.000 0.427 1.000 0.421 0.660 1.000 1.000 1.000
RF 4.063 0.022 30.499 0.000 0.802 0.453 0.269 1.000 0.049 6.371 0.005 0.019 1.000 0.012 1.325 0.280 1.000 0.676 0.425
RH 0.552 0.579 42.400 0.000 4.602 0.014 1.000 1.000 1.000 1.383 0.267 0.592 0.414 1.000 4.040 0.027 0.836 0.026 0.267
LF 5.342 0.007 30.501 0.000 0.869 0.425 1.000 0.106 0.040 4.837 0.015 0.657 0.210 0.013 2.151 0.133 1.000 0.160 0.529
LH 1.511 0.229 29.770 0.000 1.859 0.164 1.000 0.739 0.556 0.014 0.986 1.000 1.000 1.000 4.369 0.021 1.000 0.048 0.053
FP 5.002 0.010 35.748 0.000 0.952 0.392 0.738 0.444 0.027 6.794 0.004 0.068 0.633 0.004 1.745 0.191 1.000 0.320 0.415
HP 1.201 0.308 42.581 0.000 3.255 0.045 1.000 1.000 0.740 0.406 0.670 1.000 1.000 1.000 4.664 0.017 1.000 0.023 0.086
RF 0.300 0.742 13.130 0.001 0.393 0.677 1.000 1.000 1.000 0.054 0.947 1.000 1.000 1.000 0.634 0.537 1.000 1.000 0.808
RH 3.575 0.034 25.443 0.000 2.089 0.133 1.000 0.671 0.089 3.545 0.042 0.208 1.000 0.051 1.750 0.190 1.000 0.216 0.952
LF 0.731 0.486 17.732 0.000 0.709 0.496 1.000 1.000 0.988 0.029 0.972 1.000 1.000 1.000 1.463 0.247 1.000 1.000 0.297
LH 2.450 0.095 16.389 0.000 0.081 0.922 1.000 0.735 0.184 0.766 0.474 1.000 1.000 0.677 2.180 0.130 1.000 0.363 0.188
FP 0.508 0.604 16.896 0.000 0.572 0.567 1.000 1.000 1.000 0.002 0.998 1.000 1.000 1.000 1.061 0.358 1.000 1.000 0.469
HP 3.412 0.039 23.847 0.000 0.679 0.511 1.000 0.623 0.092 2.004 0.153 0.653 1.000 0.180 2.069 0.143 1.000 0.224 0.354
RF 1.379 0.259 13.563 0.000 0.631 0.536 0.731 1.000 0.436 0.363 0.699 1.000 1.000 1.000 1.742 0.191 1.000 0.908 0.219
RH 4.357 0.017 7.339 0.009 1.651 0.200 0.327 1.000 0.033 4.737 0.017 0.201 0.726 0.016 0.461 0.635 1.000 1.000 1.000
LF 2.055 0.137 24.345 0.000 0.319 0.728 1.000 1.000 0.254 0.513 0.604 1.000 1.000 1.000 1.861 0.172 1.000 0.668 0.208
LH 1.157 0.321 9.951 0.002 0.001 0.999 1.000 1.000 0.631 0.396 0.677 1.000 1.000 1.000 0.893 0.420 1.000 1.000 0.616
FP 1.759 0.181 19.513 0.000 0.487 0.617 0.813 1.000 0.307 0.412 0.666 1.000 1.000 1.000 1.868 0.171 1.000 0.766 0.197
HP 3.012 0.057 10.319 0.002 0.484 0.619 0.706 1.000 0.104 2.357 0.113 0.698 1.000 0.119 0.761 0.475 1.000 1.000 0.718
Pink1 x Pet, mid-aged, CW
Sex Interaction Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-value
27 Max contact mean intensity [pixel ]
males females
Genotype
23 Phase dispersion [%]
24 Couplings [%]
25  % Max contact at [%]






















Table A38: ANOVA table (4) of CW testing of mid-aged Pink1 x Pet mice: individual paw 
 
  red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP = hind  
  paws. Table XY summarises the description of the CW parameters.     
 
F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
RF 0.514 0.601 13.498 0.001 0.441 0.645 1.000 1.000 1.000 0.051 0.951 1.000 1.000 1.000 0.948 0.398 1.000 1.000 0.576
RH 3.125 0.051 30.196 0.000 1.731 0.186 1.000 0.696 0.140 2.684 0.085 0.308 1.000 0.112 2.062 0.144 1.000 0.157 0.782
LF 0.866 0.426 22.415 0.000 0.734 0.484 1.000 1.000 0.918 0.032 0.969 1.000 1.000 1.000 1.547 0.228 1.000 0.830 0.284
LH 2.218 0.118 20.137 0.000 0.248 0.781 1.000 0.777 0.231 0.431 0.654 1.000 1.000 1.000 2.517 0.097 1.000 0.312 0.133
FP 0.713 0.494 18.949 0.000 0.582 0.562 1.000 1.000 1.000 0.006 0.994 1.000 1.000 1.000 1.284 0.291 1.000 0.931 0.384
HP 3.020 0.056 28.710 0.000 0.545 0.582 1.000 0.662 0.134 1.398 0.263 0.855 1.000 0.345 2.389 0.108 1.000 0.179 0.261
RF 0.690 0.506 1.665 0.202 0.036 0.965 0.745 1.000 1.000 0.179 0.837 1.000 1.000 1.000 0.602 0.554 0.881 1.000 1.000
RH 0.506 0.606 0.048 0.827 3.417 0.039 1.000 1.000 1.000 2.327 0.116 0.872 0.823 0.119 1.187 0.318 0.614 1.000 0.551
LF 0.206 0.814 6.796 0.011 3.517 0.036 1.000 1.000 1.000 3.238 0.054 0.050 0.810 0.653 0.892 0.420 0.598 1.000 1.000
LH 0.736 0.483 0.413 0.523 0.784 0.461 1.000 0.761 1.000 1.104 0.345 1.000 0.568 0.634 0.169 0.845 1.000 1.000 1.000
FP 0.086 0.918 5.285 0.025 1.187 0.312 1.000 1.000 1.000 0.323 0.727 1.000 1.000 1.000 1.009 0.376 0.533 1.000 1.000
HP 0.806 0.451 0.063 0.802 2.392 0.100 1.000 0.881 1.000 2.109 0.140 1.000 0.464 0.160 0.699 0.505 0.890 1.000 1.000
RF 0.869 0.424 4.601 0.036 0.843 0.436 1.000 0.811 0.878 0.101 0.905 1.000 1.000 1.000 1.159 0.327 1.000 0.487 0.817
RH 1.286 0.284 20.941 0.000 3.030 0.056 0.813 0.669 1.000 0.496 0.614 1.000 1.000 1.000 2.802 0.076 0.358 0.077 1.000
LF 0.056 0.945 0.369 0.546 0.294 0.746 1.000 1.000 1.000 0.137 0.872 1.000 1.000 1.000 0.223 0.802 1.000 1.000 1.000
LH 2.381 0.101 8.390 0.005 0.269 0.765 1.000 0.198 0.381 0.607 0.552 1.000 0.907 1.000 1.986 0.154 1.000 0.221 0.425
FP 0.492 0.614 2.858 0.096 0.771 0.467 1.000 1.000 1.000 0.143 0.867 1.000 1.000 1.000 0.865 0.431 1.000 0.703 0.962
HP 1.897 0.159 19.276 0.000 1.813 0.172 1.000 0.296 1.000 0.005 0.995 1.000 1.000 1.000 2.751 0.079 0.659 0.076 0.807
31 Mean intensity mean [pixel] RF 1.089 0.343 8.795 0.004 0.724 0.489 1.000 1.000 0.523 0.258 0.774 1.000 1.000 1.000 1.510 0.236 1.000 0.909 0.289
RH 4.506 0.015 8.321 0.005 0.731 0.486 0.344 0.828 0.023 3.301 0.051 0.280 1.000 0.058 1.502 0.238 1.000 0.676 0.329
LF 1.741 0.184 22.118 0.000 0.395 0.675 1.000 1.000 0.339 0.343 0.713 1.000 1.000 1.000 1.743 0.191 1.000 0.643 0.245
LH 1.346 0.268 10.738 0.002 0.457 0.635 1.000 1.000 0.433 0.147 0.864 1.000 1.000 1.000 2.151 0.133 1.000 0.387 0.188
FP 1.428 0.248 15.205 0.000 0.575 0.566 1.000 1.000 0.398 0.267 0.768 1.000 1.000 1.000 1.666 0.205 1.000 0.763 0.252
HP 3.068 0.054 10.963 0.002 0.236 0.790 0.729 0.896 0.079 1.450 0.251 0.750 1.000 0.341 2.005 0.151 1.000 0.465 0.204
32 Intensity of 15 most intense pixel [pixel] RF 1.243 0.296 15.082 0.000 0.397 0.674 0.858 1.000 0.533 0.460 0.636 1.000 1.000 1.000 1.218 0.309 1.000 1.000 0.401
RH 2.927 0.061 24.866 0.000 1.290 0.283 0.994 0.910 0.130 2.337 0.115 0.306 1.000 0.176 1.900 0.166 1.000 0.216 0.543
LF 1.450 0.243 26.360 0.000 0.401 0.671 1.000 1.000 0.501 0.192 0.826 1.000 1.000 1.000 1.574 0.223 1.000 0.790 0.279
LH 1.881 0.161 19.070 0.000 0.463 0.632 1.000 0.843 0.305 0.236 0.791 1.000 1.000 1.000 2.666 0.085 1.000 0.253 0.125
FP 1.368 0.262 21.261 0.000 0.390 0.679 1.000 1.000 0.487 0.289 0.751 1.000 1.000 1.000 1.435 0.253 1.000 0.910 0.318
HP 2.660 0.078 24.971 0.000 0.568 0.570 1.000 0.807 0.158 1.085 0.351 0.877 1.000 0.529 2.431 0.104 1.000 0.197 0.218
33 Print length [cm] RF 4.184 0.020 2.604 0.112 1.421 0.249 0.244 0.934 0.018 3.673 0.038 0.061 1.000 0.125 2.381 0.109 1.000 0.267 0.178
RH 0.831 0.440 43.287 0.000 4.426 0.016 0.895 1.000 1.000 2.106 0.140 1.000 0.262 0.222 2.985 0.065 0.463 0.061 0.971
LF 1.255 0.292 1.042 0.311 0.263 0.769 1.000 0.584 0.752 1.893 0.169 1.000 0.210 0.459 0.184 0.833 1.000 1.000 1.000
LH 0.956 0.390 24.532 0.000 3.732 0.030 0.725 1.000 1.000 1.507 0.238 0.787 1.000 0.310 3.904 0.030 1.000 0.040 0.143
FP 2.638 0.080 2.243 0.139 0.178 0.837 1.000 0.585 0.100 2.225 0.126 0.760 1.000 0.135 1.000 0.379 1.000 0.822 0.625
HP 1.118 0.334 42.151 0.000 4.672 0.013 0.652 1.000 1.000 1.909 0.166 1.000 0.754 0.182 3.919 0.030 0.720 0.028 0.339
34 Print Width [cm] RF 0.447 0.641 13.623 0.000 0.748 0.477 1.000 1.000 1.000 1.287 0.291 0.449 1.000 0.694 0.271 0.764 1.000 1.000 1.000
RH 0.030 0.970 28.304 0.000 2.774 0.070 1.000 1.000 1.000 1.558 0.228 0.751 0.287 1.000 1.348 0.274 1.000 0.339 1.000
LF 0.549 0.580 2.885 0.094 1.154 0.322 1.000 1.000 1.000 0.488 0.619 1.000 1.000 1.000 1.264 0.296 0.742 0.399 1.000
LH 0.991 0.377 35.499 0.000 1.713 0.189 1.000 1.000 0.866 0.201 0.819 1.000 1.000 1.000 2.545 0.094 1.000 0.160 0.228
FP 0.541 0.585 9.515 0.003 1.203 0.307 1.000 1.000 1.000 1.016 0.375 0.603 1.000 0.846 0.802 0.457 1.000 0.675 1.000
HP 0.397 0.674 40.232 0.000 2.596 0.083 1.000 1.000 1.000 0.893 0.420 0.985 0.650 1.000 2.131 0.135 1.000 0.181 0.430
35 Print area [cm] RF 2.499 0.091 16.071 0.000 1.137 0.327 0.475 1.000 0.147 4.062 0.028 0.038 1.000 0.126 1.208 0.312 1.000 0.601 0.565
RH 0.228 0.797 46.399 0.000 4.648 0.013 1.000 1.000 1.000 1.614 0.217 0.850 0.258 1.000 3.256 0.052 0.680 0.048 0.557
LF 2.387 0.100 12.337 0.001 0.560 0.574 1.000 0.301 0.346 1.419 0.258 1.000 0.965 0.309 1.583 0.221 1.000 0.263 0.942
LH 1.196 0.309 32.176 0.000 2.238 0.115 1.000 0.867 0.821 0.073 0.929 1.000 1.000 1.000 4.114 0.026 1.000 0.062 0.058
FP 2.439 0.096 16.658 0.000 0.972 0.384 1.000 0.775 0.174 2.738 0.081 0.223 1.000 0.130 1.449 0.250 1.000 0.359 0.660
HP 0.766 0.469 47.057 0.000 3.530 0.035 1.000 1.000 1.000 0.512 0.605 1.000 0.960 1.000 4.028 0.028 1.000 0.035 0.144
Pink1 x Pet, mid-aged, CW
Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-valueGenotype Sex Interaction Post hoc Bonferroni, p-value Genotype
males females
28 Maximum intensity [pixel]
29 % Maximum intensity at  [sec]











Table A39: ANOVA table (1) of CW testing of young Pink1 x DAT mice: temporal parameters 
 
  red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP = hind  
  paws. Table XY summarises the description of the CW parameters.     
 
F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
1 Cadence [steps/sec] 2.813 0.068 6.866 0.011 0.370 0.692 0.047 0.607 0.659 1.766 0.187 0.256 0.467 1.000 1.368 0.270 0.369 1.000 0.652
RF 2.518 0.089 10.450 0.002 0.032 0.968 0.055 0.625 0.716 2.198 0.128 0.134 0.696 1.000 0.776 0.469 0.667 1.000 1.000
RH 4.282 0.018 9.033 0.004 0.716 0.492 0.028 0.038 1.000 6.828 0.003 0.018 0.005 1.000 0.678 0.515 0.806 1.000 1.000
LF 1.913 0.156 11.678 0.001 0.014 0.986 0.109 0.708 0.995 1.470 0.245 0.291 0.966 1.000 0.643 0.533 0.806 1.000 1.000
LH 2.179 0.122 4.298 0.042 0.569 0.569 0.116 0.443 1.000 1.952 0.158 0.319 0.254 1.000 0.800 0.459 0.692 1.000 1.000
FP 2.390 0.100 11.863 0.001 0.026 0.974 0.062 0.614 0.788 1.941 0.160 0.175 0.765 1.000 0.769 0.472 0.674 1.000 1.000
HP 3.711 0.030 7.978 0.006 0.741 0.481 0.033 0.090 1.000 4.410 0.020 0.063 0.031 1.000 0.810 0.454 0.638 1.000 1.000
RF 2.741 0.072 1.941 0.168 0.213 0.809 0.065 1.000 0.331 1.317 0.282 0.344 1.000 1.000 1.622 0.214 0.336 1.000 0.413
RH 0.673 0.514 0.027 0.871 0.079 0.924 0.803 1.000 1.000 0.469 0.630 1.000 1.000 1.000 0.244 0.785 1.000 1.000 1.000
LF 2.805 0.068 2.427 0.124 0.188 0.829 0.057 1.000 0.362 1.444 0.251 0.298 1.000 1.000 1.507 0.237 0.349 1.000 0.502
LH 0.800 0.454 0.510 0.478 0.074 0.929 0.725 1.000 1.000 0.386 0.683 1.000 1.000 1.000 0.493 0.616 1.000 1.000 1.000
FP 2.835 0.066 2.240 0.139 0.200 0.819 0.057 1.000 0.335 1.396 0.262 0.315 1.000 1.000 1.612 0.216 0.325 1.000 0.441
HP 0.751 0.476 0.184 0.670 0.085 0.918 0.711 1.000 1.000 0.443 0.646 1.000 1.000 1.000 0.371 0.693 1.000 1.000 1.000
RF 2.466 0.093 6.660 0.012 0.603 0.550 0.074 0.477 1.000 1.459 0.247 0.433 0.443 1.000 1.588 0.221 0.302 1.000 0.521
RH 0.395 0.675 2.244 0.139 0.247 0.782 1.000 1.000 1.000 0.348 0.709 1.000 1.000 1.000 0.320 0.728 1.000 1.000 1.000
LF 2.453 0.094 9.548 0.003 0.971 0.384 0.064 0.607 0.811 2.634 0.087 0.117 0.244 1.000 0.639 0.534 1.000 1.000 0.933
LH 0.386 0.681 7.845 0.007 0.557 0.576 0.936 1.000 1.000 0.651 0.528 0.787 1.000 1.000 0.099 0.906 1.000 1.000 1.000
FP 2.999 0.057 9.527 0.003 0.883 0.418 0.038 0.413 0.811 2.227 0.124 0.195 0.263 1.000 1.390 0.264 0.415 1.000 0.513
HP 0.236 0.790 6.705 0.012 0.609 0.547 1.000 1.000 1.000 0.613 0.548 0.880 1.000 1.000 0.072 0.930 1.000 1.000 1.000
RF 2.989 0.058 4.003 0.050 0.538 0.586 0.113 0.092 1.000 1.455 0.248 1.000 0.295 1.000 2.138 0.135 0.156 0.560 1.000
RH 3.065 0.054 3.892 0.053 0.453 0.638 0.125 0.076 1.000 1.832 0.177 0.787 0.197 1.000 1.614 0.215 0.280 0.663 1.000
LF 3.112 0.051 3.441 0.068 0.507 0.605 0.101 0.086 1.000 1.556 0.227 0.903 0.265 1.000 2.068 0.144 0.169 0.570 1.000
LH 3.515 0.036 4.076 0.048 0.554 0.577 0.068 0.064 1.000 1.926 0.162 0.677 0.182 1.000 2.093 0.140 0.160 0.604 1.000
FP 3.059 0.054 3.724 0.058 0.524 0.595 0.106 0.088 1.000 1.505 0.237 0.953 0.280 1.000 2.113 0.138 0.160 0.563 1.000
HP 3.288 0.044 3.987 0.050 0.503 0.607 0.092 0.070 1.000 1.881 0.169 0.729 0.188 1.000 1.849 0.174 0.212 0.632 1.000
RF 2.769 0.070 0.001 0.973 0.518 0.598 0.826 0.068 0.704 2.589 0.091 1.000 0.095 0.512 0.574 0.569 1.000 0.921 1.000
RH 1.138 0.327 0.177 0.676 0.374 0.689 1.000 0.651 0.570 1.143 0.332 1.000 0.525 0.713 0.226 0.799 1.000 1.000 1.000
LF 2.737 0.072 0.224 0.638 1.247 0.294 1.000 0.094 0.257 3.507 0.042 1.000 0.059 0.140 0.170 0.844 1.000 1.000 1.000
LH 3.318 0.043 0.665 0.418 0.606 0.549 0.618 0.038 0.648 3.194 0.054 0.772 0.051 0.515 0.596 0.557 1.000 0.859 1.000
FP 2.910 0.062 0.050 0.824 0.906 0.409 1.000 0.064 0.395 3.079 0.060 1.000 0.069 0.263 0.388 0.681 1.000 1.000 1.000
HP 2.004 0.143 0.364 0.548 0.514 0.600 1.000 0.170 0.572 2.027 0.148 1.000 0.172 0.584 0.283 0.756 1.000 1.000 1.000
7 Number of steps [#] 0.396 0.675 0.793 0.377 0.297 0.744 1.000 1.000 1.000 0.145 0.865 1.000 1.000 1.000 0.539 0.589 0.937 1.000 1.000
RF 0.997 0.375 19.342 0.000 0.119 0.888 0.721 0.447 1.000 0.659 0.524 0.966 0.980 1.000 0.477 0.625 1.000 1.000 1.000
RH 1.984 0.146 28.826 0.000 0.169 0.845 0.080 0.889 0.645 1.152 0.329 0.442 0.914 1.000 0.961 0.394 0.577 1.000 0.911
LF 1.220 0.302 19.422 0.000 0.034 0.967 0.431 0.397 1.000 0.932 0.404 0.726 0.729 1.000 0.428 0.656 1.000 1.000 1.000
LH 3.303 0.043 54.423 0.000 0.927 0.401 0.022 0.111 1.000 4.415 0.020 0.048 0.038 1.000 0.504 0.609 0.971 1.000 1.000
FP 1.242 0.296 21.747 0.000 0.077 0.926 0.479 0.353 1.000 0.877 0.426 0.768 0.770 1.000 0.492 0.616 1.000 0.990 1.000
HP 2.859 0.065 48.128 0.000 0.483 0.619 0.026 0.294 0.860 2.473 0.100 0.146 0.240 1.000 0.847 0.438 0.627 1.000 1.000
RF 2.499 0.090 11.171 0.001 0.397 0.674 0.525 0.073 1.000 1.087 0.349 1.000 0.534 0.797 2.024 0.149 0.371 0.223 1.000
RH 2.557 0.086 23.462 0.000 0.526 0.593 0.080 0.169 1.000 0.981 0.386 1.000 0.526 1.000 2.362 0.111 0.115 0.682 0.993
LF 2.469 0.093 8.374 0.005 0.552 0.578 0.348 0.084 1.000 0.839 0.441 1.000 0.682 1.000 2.398 0.108 0.218 0.198 1.000
LH 6.095 0.004 35.509 0.000 0.661 0.520 0.007 0.006 1.000 3.763 0.034 0.218 0.034 1.000 2.779 0.078 0.096 0.296 1.000
FP 2.605 0.082 10.192 0.002 0.490 0.615 0.393 0.068 1.000 1.006 0.377 1.000 0.571 0.886 2.358 0.111 0.250 0.186 1.000
HP 4.541 0.014 33.011 0.000 0.571 0.568 0.017 0.024 1.000 2.262 0.121 0.499 0.133 1.000 2.905 0.070 0.076 0.363 1.000
10 Run duration [sec] 2.164 0.123 1.840 0.180 0.411 0.665 0.154 0.314 1.000 0.997 0.380 0.972 0.539 1.000 1.405 0.260 0.319 1.000 1.000
11 Run speed [cm/sec] 2.778 0.070 3.762 0.057 0.427 0.654 0.138 0.109 1.000 1.638 0.210 0.789 0.247 1.000 1.498 0.239 0.304 0.788 1.000
12 Run maximum variation [%] 1.777 0.177 1.293 0.260 0.428 0.653 1.000 0.194 0.883 3.153 0.056 1.000 0.058 0.340 0.182 0.835 1.000 1.000 1.000
9 Swing speed [cm/sec]
2 Stance duration [sec]
3 Stand [sec]





6 Body speed variation [%]
8 Swing duration [sec]
Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-valueInteraction Post hoc Bonferroni, p-value Genotype















Table A40: ANOVA table (2) of CW testing of young Pink1 x DAT mice: comparative paws 
 
  red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP = hind  








F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
RF 1.143 0.325 0.084 0.772 1.319 0.275 0.996 0.400 1.000 0.471 0.629 1.000 1.000 1.000 2.238 0.124 0.180 0.330 1.000
RH 1.255 0.292 0.059 0.809 1.372 0.261 0.820 0.369 1.000 0.467 0.631 1.000 1.000 1.000 2.369 0.110 0.149 0.338 1.000
LF 1.108 0.337 0.023 0.881 1.609 0.208 1.000 0.399 1.000 0.531 0.593 1.000 1.000 0.948 2.303 0.117 0.197 0.259 1.000
LH 1.431 0.247 0.008 0.930 1.506 0.230 0.625 0.328 1.000 0.216 0.807 1.000 1.000 1.000 2.863 0.072 0.117 0.184 1.000
FP 1.135 0.328 0.049 0.825 1.471 0.238 1.000 0.394 1.000 0.493 0.616 1.000 1.000 0.986 2.299 0.117 0.183 0.284 1.000
HP 1.353 0.266 0.005 0.943 1.420 0.249 0.709 0.343 1.000 0.331 0.720 1.000 1.000 1.000 2.618 0.089 0.131 0.248 1.000
RF 2.165 0.123 7.773 0.007 0.033 0.968 0.088 0.923 0.664 1.217 0.309 0.387 1.000 1.000 0.977 0.388 0.525 1.000 1.000
RH 2.143 0.126 7.648 0.007 0.100 0.905 0.092 0.706 0.896 1.413 0.258 0.328 0.777 1.000 0.837 0.443 0.623 1.000 1.000
LF 2.147 0.125 7.919 0.007 0.045 0.956 0.090 0.822 0.760 1.243 0.302 0.381 1.000 1.000 0.948 0.399 0.541 1.000 1.000
LH 2.289 0.110 8.961 0.004 0.293 0.747 0.078 0.633 0.890 1.811 0.180 0.243 0.462 1.000 0.828 0.446 0.664 1.000 1.000
FP 2.167 0.123 7.860 0.007 0.039 0.961 0.088 0.869 0.707 1.232 0.305 0.382 1.000 1.000 0.970 0.390 0.528 1.000 1.000
HP 2.234 0.116 8.344 0.005 0.187 0.830 0.083 0.662 0.888 1.615 0.215 0.279 0.597 1.000 0.833 0.444 0.639 1.000 1.000
RF 3.601 0.033 1.326 0.254 0.385 0.682 0.091 1.000 0.076 0.898 0.417 0.641 1.000 0.979 3.432 0.045 0.137 1.000 0.058
RH 0.090 0.914 5.669 0.020 0.027 0.974 1.000 1.000 1.000 0.076 0.927 1.000 1.000 1.000 0.034 0.966 1.000 1.000 1.000
LF 2.245 0.114 0.258 0.613 0.231 0.795 0.199 1.000 0.271 0.714 0.497 0.743 1.000 1.000 1.858 0.173 0.378 1.000 0.249
LH 0.217 0.806 17.825 0.000 0.288 0.751 1.000 1.000 1.000 0.300 0.743 1.000 1.000 1.000 0.170 0.844 1.000 1.000 1.000
FP 3.348 0.042 0.799 0.375 0.335 0.717 0.094 1.000 0.103 0.862 0.432 0.645 1.000 1.000 3.312 0.050 0.137 1.000 0.067
HP 0.007 0.993 11.850 0.001 0.088 0.916 1.000 1.000 1.000 0.021 0.980 1.000 1.000 1.000 0.088 0.916 1.000 1.000 1.000
FP 1.409 0.252 2.523 0.117 0.115 0.891 0.396 1.000 0.700 0.635 0.537 1.000 1.000 0.947 0.924 0.408 0.552 1.000 1.000
HP 1.162 0.320 5.555 0.022 4.579 0.014 0.412 0.564 1.000 4.504 0.019 0.016 0.276 0.623 1.081 0.352 0.677 1.000 0.568
RF 1.171 0.317 0.557 0.458 0.283 0.754 0.768 1.000 0.513 0.296 0.746 1.000 1.000 1.000 1.635 0.211 0.900 1.000 0.242
RH 0.903 0.411 3.660 0.060 0.391 0.678 1.000 0.695 0.813 0.717 0.496 1.000 1.000 0.793 0.423 0.659 1.000 1.000 1.000
LF 3.358 0.041 0.727 0.397 0.523 0.595 0.076 1.000 0.138 0.608 0.550 0.864 1.000 1.000 3.996 0.029 0.056 1.000 0.055
LH 0.261 0.771 2.832 0.097 0.597 0.553 1.000 1.000 1.000 0.466 0.632 1.000 1.000 1.000 0.420 0.661 1.000 1.000 1.000
FP 2.376 0.101 0.739 0.393 0.387 0.680 0.220 1.000 0.215 0.517 0.601 0.975 1.000 1.000 2.961 0.067 0.211 1.000 0.081
HP 0.199 0.820 4.032 0.049 0.099 0.906 1.000 1.000 1.000 0.177 0.838 1.000 1.000 1.000 0.026 0.975 1.000 1.000 1.000
RF 3.063 0.054 0.499 0.483 0.650 0.526 0.085 1.000 0.209 0.463 0.633 1.000 1.000 1.000 3.834 0.033 0.053 1.000 0.076
RH 0.383 0.683 3.838 0.055 0.625 0.538 1.000 1.000 0.987 0.520 0.599 1.000 1.000 1.000 0.567 0.573 1.000 0.978 1.000
LF 0.994 0.376 0.530 0.469 0.469 0.628 0.924 1.000 0.620 0.231 0.795 1.000 1.000 1.000 1.905 0.166 0.988 0.967 0.181
LH 0.717 0.492 3.488 0.066 0.165 0.848 1.000 0.844 0.996 0.400 0.673 1.000 1.000 1.000 0.767 0.473 1.000 0.674 1.000
FP 1.912 0.156 0.620 0.434 0.518 0.598 0.324 1.000 0.327 0.339 0.715 1.000 1.000 1.000 2.948 0.067 0.230 1.000 0.078
HP 0.140 0.869 4.194 0.045 0.029 0.971 1.000 1.000 1.000 0.087 0.917 1.000 1.000 1.000 0.074 0.929 1.000 1.000 1.000
19 Print position right paws [cm] 0.744 0.479 4.200 0.045 0.735 0.483 1.000 1.000 0.901 0.050 0.951 1.000 1.000 1.000 1.597 0.219 1.000 0.983 0.255
20 Print position left paws [cm] 0.370 0.692 1.706 0.196 0.878 0.421 1.000 1.000 1.000 0.560 0.576 0.917 1.000 1.000 0.733 0.489 1.000 1.000 0.710
Pink1 x DAT, young, CW
Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-valueGenotype Sex Interaction Post hoc Bonferroni, p-value Genotype
males females
13 Stride length [cm]
14 Step cycle [sec]
15 Duty cycle [%]
16 Base of support [cm]
17 Initial dual stance [sec]













Table A41: ANOVA table (3) of CW testing of young Pink1 x DAT mice: interlimb coordination and individual paw 
 
  red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP = hind    
  paws. Table XY summarises the description of the CW parameters.     
 
 
F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
21 Number of patterns 0.322 0.726 0.570 0.453 0.326 0.723 1.000 1.000 1.000 0.302 0.741 1.000 1.000 1.000 0.336 0.717 1.000 1.000 1.000
22 Regularity index [%] 0.916 0.405 0.718 0.400 0.643 0.529 0.722 1.000 0.743 1.117 0.340 1.000 1.000 0.435 0.489 0.618 1.000 1.000 1.000
RF-LH 0.988 0.378 3.674 0.060 0.985 0.379 0.932 0.517 1.000 0.972 0.389 0.869 0.591 1.000 1.734 0.193 0.681 1.000 0.225
LF-RH 0.951 0.392 0.118 0.732 0.505 0.606 1.000 0.561 1.000 0.457 0.637 1.000 1.000 1.000 1.159 0.327 1.000 0.844 0.470
LH-RH 1.935 0.153 0.331 0.567 1.467 0.238 1.000 0.477 0.163 2.670 0.085 0.712 0.899 0.083 0.454 0.639 1.000 1.000 1.000
LF-RF 0.041 0.960 0.025 0.874 0.025 0.975 1.000 1.000 1.000 0.038 0.963 1.000 1.000 1.000 0.029 0.972 1.000 1.000 1.000
RF-RH 1.819 0.171 1.293 0.260 1.079 0.346 0.459 1.000 0.236 0.119 0.888 1.000 1.000 1.000 3.245 0.053 0.109 1.000 0.087
LF-LH 6.530 0.003 2.795 0.100 0.034 0.967 0.029 1.000 0.002 2.976 0.065 0.360 1.000 0.069 3.868 0.032 0.122 1.000 0.037
RF-LH 1.358 0.265 1.836 0.180 0.658 0.522 1.000 0.404 0.675 0.908 0.413 1.000 0.562 1.000 1.955 0.159 0.891 1.000 0.171
LF-RH 1.383 0.258 1.091 0.300 0.971 0.384 0.351 1.000 0.676 0.031 0.969 1.000 1.000 1.000 2.342 0.113 0.153 1.000 0.278
LH-RF 3.157 0.049 0.831 0.366 0.107 0.899 0.462 0.790 0.037 1.621 0.214 0.792 1.000 0.257 1.787 0.184 1.000 0.800 0.213
RH-LF 1.052 0.355 0.656 0.421 0.950 0.392 0.634 1.000 0.680 0.006 0.994 1.000 1.000 1.000 1.804 0.181 0.285 1.000 0.352
LH-RH 0.857 0.430 0.017 0.898 1.049 0.356 1.000 1.000 0.507 1.517 0.235 0.553 1.000 0.348 0.312 0.734 1.000 1.000 1.000
LF-RF 0.071 0.931 0.034 0.854 0.018 0.982 1.000 1.000 1.000 0.069 0.933 1.000 1.000 1.000 0.024 0.977 1.000 1.000 1.000
RH-LH 1.180 0.314 0.049 0.826 0.664 0.518 1.000 0.976 0.356 1.501 0.238 0.739 1.000 0.306 0.423 0.659 1.000 1.000 1.000
RF-LF 0.122 0.885 0.005 0.944 0.021 0.979 1.000 1.000 1.000 0.082 0.922 1.000 1.000 1.000 0.061 0.941 1.000 1.000 1.000
RF-RH 1.725 0.187 1.209 0.276 1.076 0.347 0.541 1.000 0.250 0.107 0.899 1.000 1.000 1.000 3.170 0.056 0.130 1.000 0.084
LF-LH 6.951 0.002 1.338 0.252 0.060 0.942 0.018 1.000 0.002 3.493 0.042 0.174 1.000 0.053 3.693 0.036 0.170 1.000 0.039
RH-RF 1.469 0.238 1.115 0.295 0.838 0.437 0.644 1.000 0.326 0.051 0.950 1.000 1.000 1.000 2.592 0.091 0.252 1.000 0.116
LH-LF 5.873 0.005 1.550 0.218 0.347 0.708 0.019 1.000 0.006 2.604 0.090 0.137 1.000 0.226 4.045 0.027 0.219 0.961 0.025
RF 0.978 0.382 0.564 0.455 0.455 0.636 1.000 1.000 0.566 0.197 0.822 1.000 1.000 1.000 1.174 0.322 1.000 1.000 0.417
RH 1.453 0.242 0.541 0.465 0.097 0.908 1.000 1.000 0.298 0.455 0.639 1.000 1.000 1.000 1.257 0.299 1.000 1.000 0.382
LF 0.255 0.775 4.168 0.045 0.011 0.989 1.000 1.000 1.000 0.171 0.844 1.000 1.000 1.000 0.089 0.915 1.000 1.000 1.000
LH 2.226 0.116 0.482 0.490 2.155 0.124 1.000 0.457 0.099 2.074 0.142 0.340 1.000 0.215 2.931 0.068 0.566 0.066 1.000
FP 0.755 0.474 2.995 0.088 0.165 0.848 1.000 1.000 0.899 0.258 0.774 1.000 1.000 1.000 0.693 0.508 1.000 1.000 0.749
HP 2.428 0.096 0.000 0.990 0.913 0.407 1.000 0.572 0.085 1.448 0.250 0.584 1.000 0.372 2.550 0.094 1.000 0.120 0.328
RF 0.084 0.920 38.611 0.000 0.600 0.552 1.000 1.000 1.000 0.415 0.664 1.000 1.000 1.000 0.203 0.818 1.000 1.000 1.000
RH 0.331 0.720 18.373 0.000 1.921 0.155 1.000 1.000 1.000 1.074 0.354 0.588 0.682 1.000 1.215 0.310 1.000 0.408 0.991
LF 0.125 0.883 26.898 0.000 0.536 0.588 1.000 1.000 1.000 0.119 0.888 1.000 1.000 1.000 0.731 0.490 1.000 0.708 1.000
LH 0.809 0.450 27.938 0.000 0.343 0.711 1.000 1.000 0.838 0.482 0.622 1.000 1.000 1.000 0.833 0.444 1.000 0.839 0.817
FP 0.036 0.964 34.903 0.000 0.598 0.553 1.000 1.000 1.000 0.254 0.777 1.000 1.000 1.000 0.466 0.632 1.000 1.000 1.000
HP 0.601 0.551 25.692 0.000 1.074 0.348 1.000 1.000 1.000 0.709 0.500 0.735 1.000 1.000 1.110 0.342 1.000 0.518 0.809
RF 0.195 0.823 26.549 0.000 0.551 0.579 1.000 1.000 1.000 0.113 0.893 1.000 1.000 1.000 0.983 0.386 1.000 1.000 0.547
RH 0.352 0.704 25.652 0.000 1.136 0.328 1.000 1.000 1.000 0.838 0.442 0.635 1.000 1.000 0.656 0.526 1.000 0.799 1.000
LF 0.291 0.749 21.098 0.000 0.812 0.449 1.000 1.000 1.000 0.409 0.668 1.000 1.000 1.000 0.874 0.427 1.000 0.844 0.750
LH 0.554 0.577 33.353 0.000 0.183 0.833 1.000 0.858 1.000 0.606 0.551 1.000 1.000 0.922 0.151 0.860 1.000 1.000 1.000
FP 0.262 0.770 26.355 0.000 0.717 0.492 1.000 1.000 1.000 0.257 0.775 1.000 1.000 1.000 1.079 0.352 1.000 0.846 0.530
HP 0.410 0.666 33.148 0.000 0.413 0.663 1.000 1.000 1.000 0.406 0.670 1.000 1.000 1.000 0.455 0.638 1.000 1.000 1.000
RF 0.175 0.840 15.302 0.000 0.493 0.613 1.000 1.000 1.000 0.437 0.650 1.000 1.000 1.000 0.077 0.926 1.000 1.000 1.000
RH 0.804 0.452 14.698 0.000 0.065 0.937 1.000 1.000 0.774 0.630 0.539 1.000 1.000 0.834 0.297 0.745 1.000 1.000 1.000
LF 0.300 0.742 16.304 0.000 0.644 0.529 1.000 1.000 1.000 0.053 0.948 1.000 1.000 1.000 1.972 0.156 1.000 0.339 0.258
LH 0.622 0.540 15.407 0.000 0.236 0.791 0.789 0.888 1.000 0.565 0.574 1.000 0.887 1.000 0.295 0.747 1.000 1.000 1.000
FP 0.107 0.898 18.041 0.000 0.559 0.575 1.000 1.000 1.000 0.207 0.814 1.000 1.000 1.000 0.736 0.487 1.000 0.875 0.961
HP 0.577 0.564 18.750 0.000 0.098 0.906 1.000 0.879 1.000 0.516 0.602 1.000 1.000 1.000 0.177 0.839 1.000 1.000 1.000
Pink1 x DAT, young, CW
Genotype Post hoc Bonferroni, p-valueGenotype Sex Interaction Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-value
males females
25  % Max contact at [%]
26 Max contact max intensity [pixel ]
27 Max contact mean intensity [pixel ]























Table A42: ANOVA table (4) of CW testing of young Pink1 x DAT mice: individual paw 
 
  red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP = hind  
  paws. Table XY summarises the description of the CW parameters.     
 
F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
Maximum intensity [pixel] RF 0.219 0.804 27.636 0.000 0.509 0.604 1.000 1.000 1.000 0.103 0.903 1.000 1.000 1.000 1.070 0.355 1.000 1.000 0.462
RH 0.510 0.603 24.408 0.000 1.433 0.246 1.000 1.000 1.000 1.346 0.275 0.354 0.813 1.000 0.629 0.540 1.000 0.844 1.000
LF 0.163 0.850 25.118 0.000 0.723 0.489 1.000 1.000 1.000 0.282 0.756 1.000 1.000 1.000 0.823 0.448 1.000 1.000 0.675
LH 0.620 0.541 32.344 0.000 0.128 0.880 1.000 0.898 1.000 0.512 0.604 1.000 1.000 0.963 0.281 0.757 1.000 1.000 1.000
FP 0.206 0.814 29.014 0.000 0.662 0.519 1.000 1.000 1.000 0.199 0.821 1.000 1.000 1.000 1.091 0.349 1.000 1.000 0.454
HP 0.516 0.600 31.740 0.000 0.648 0.526 1.000 1.000 1.000 0.641 0.533 0.839 1.000 1.000 0.558 0.578 1.000 0.922 1.000
RF 0.615 0.544 25.504 0.000 0.794 0.456 1.000 1.000 0.690 0.477 0.625 1.000 1.000 1.000 1.057 0.360 1.000 0.477 1.000
RH 0.274 0.761 4.073 0.048 2.078 0.134 1.000 1.000 1.000 0.609 0.550 1.000 0.836 1.000 2.139 0.135 1.000 0.261 0.251
LF 0.132 0.877 7.390 0.008 2.412 0.098 1.000 1.000 1.000 1.875 0.170 0.186 1.000 0.919 0.716 0.497 0.739 1.000 1.000
LH 0.920 0.404 8.394 0.005 1.634 0.203 0.872 0.566 1.000 2.127 0.136 0.685 0.145 1.000 0.106 0.900 1.000 1.000 1.000
FP 0.270 0.764 18.631 0.000 1.931 0.153 1.000 1.000 0.995 1.200 0.314 0.416 1.000 0.964 1.049 0.362 0.689 0.648 1.000
HP 0.394 0.676 7.379 0.009 2.171 0.122 1.000 1.000 1.000 1.482 0.242 0.973 0.287 1.000 0.904 0.415 1.000 0.799 0.743
RF 0.669 0.516 12.638 0.001 1.507 0.229 1.000 1.000 1.000 0.121 0.887 1.000 1.000 1.000 1.607 0.217 0.270 1.000 0.631
RH 0.423 0.657 18.037 0.000 2.307 0.108 1.000 1.000 1.000 2.731 0.080 0.317 0.091 1.000 0.359 0.701 1.000 1.000 1.000
LF 1.298 0.280 2.655 0.108 0.908 0.408 0.616 0.539 1.000 2.142 0.134 0.263 0.223 1.000 0.020 0.981 1.000 1.000 1.000
LH 0.402 0.671 26.393 0.000 0.122 0.885 1.000 1.000 1.000 1.031 0.368 0.482 1.000 1.000 0.047 0.954 1.000 1.000 1.000
FP 0.995 0.375 10.331 0.002 0.413 0.663 0.722 1.000 1.000 0.389 0.681 1.000 1.000 1.000 0.858 0.434 0.618 1.000 1.000
HP 0.419 0.659 28.958 0.000 1.595 0.211 1.000 1.000 1.000 2.653 0.086 0.208 0.127 1.000 0.149 0.862 1.000 1.000 1.000
RF 0.250 0.780 11.070 0.001 0.744 0.479 1.000 1.000 1.000 0.578 0.567 0.948 1.000 1.000 0.332 0.720 1.000 1.000 1.000
RH 1.195 0.310 12.840 0.001 0.073 0.930 1.000 1.000 0.473 0.938 0.402 1.000 1.000 0.566 0.448 0.643 1.000 1.000 1.000
LF 0.279 0.757 16.780 0.000 0.616 0.543 1.000 1.000 1.000 0.169 0.845 1.000 1.000 1.000 1.187 0.319 1.000 0.888 0.441
LH 0.575 0.565 16.711 0.000 0.146 0.865 1.000 0.757 1.000 0.337 0.716 1.000 1.000 1.000 0.391 0.680 1.000 1.000 1.000
FP 0.285 0.753 15.682 0.000 0.630 0.536 1.000 1.000 1.000 0.346 0.710 1.000 1.000 1.000 0.757 0.478 1.000 0.951 0.848
HP 0.936 0.398 17.797 0.000 0.100 0.905 1.000 0.752 0.789 0.678 0.515 1.000 1.000 0.764 0.404 0.671 1.000 1.000 1.000
RF 0.246 0.783 21.132 0.000 0.659 0.521 1.000 1.000 1.000 0.299 0.744 1.000 1.000 1.000 0.774 0.470 1.000 0.941 0.827
RH 0.553 0.578 19.702 0.000 1.121 0.332 1.000 1.000 1.000 0.853 0.435 0.627 1.000 1.000 0.830 0.446 1.000 0.725 0.983
LF 0.201 0.819 19.772 0.000 1.011 0.370 1.000 1.000 1.000 0.290 0.750 1.000 1.000 1.000 1.326 0.280 1.000 0.529 0.501
LH 0.757 0.473 29.724 0.000 0.139 0.870 1.000 0.837 1.000 0.331 0.721 1.000 1.000 1.000 0.614 0.548 1.000 0.889 1.000
FP 0.234 0.792 21.942 0.000 0.865 0.426 1.000 1.000 1.000 0.299 0.744 1.000 1.000 1.000 1.135 0.334 1.000 0.653 0.581
HP 0.638 0.532 26.262 0.000 0.580 0.563 1.000 1.000 1.000 0.432 0.653 1.000 1.000 1.000 0.849 0.437 1.000 0.694 0.999
RF 0.202 0.818 9.381 0.003 0.634 0.534 1.000 1.000 1.000 0.101 0.905 1.000 1.000 1.000 0.673 0.518 1.000 0.794 1.000
RH 0.304 0.739 19.008 0.000 1.214 0.304 1.000 1.000 1.000 0.620 0.544 0.877 1.000 1.000 0.925 0.407 1.000 0.570 1.000
LF 0.983 0.380 2.950 0.091 0.345 0.709 1.000 0.464 1.000 0.089 0.915 1.000 1.000 1.000 1.531 0.232 1.000 0.270 1.000
LH 1.181 0.314 29.451 0.000 0.497 0.611 1.000 0.573 0.738 0.127 0.881 1.000 1.000 1.000 1.154 0.329 1.000 0.759 0.503
FP 0.552 0.579 6.279 0.015 0.501 0.608 1.000 0.842 1.000 0.018 0.983 1.000 1.000 1.000 1.116 0.340 1.000 0.442 1.000
HP 0.713 0.494 28.284 0.000 0.794 0.457 1.000 1.000 1.000 0.225 0.800 1.000 1.000 1.000 1.126 0.337 1.000 0.560 0.696
RF 0.389 0.679 20.112 0.000 0.125 0.882 1.000 1.000 1.000 0.072 0.930 1.000 1.000 1.000 0.447 0.644 1.000 1.000 1.000
RH 0.765 0.470 17.674 0.000 2.117 0.129 0.995 1.000 1.000 1.901 0.166 0.280 0.313 1.000 0.821 0.449 1.000 0.764 0.931
LF 0.599 0.553 8.715 0.004 1.393 0.256 1.000 1.000 0.949 1.422 0.256 0.306 1.000 1.000 0.682 0.513 1.000 0.758 1.000
LH 2.310 0.108 26.161 0.000 0.431 0.652 0.353 1.000 0.269 1.678 0.203 0.258 1.000 0.636 1.006 0.377 1.000 1.000 0.498
FP 0.414 0.663 17.127 0.000 0.481 0.620 1.000 1.000 1.000 0.262 0.771 1.000 1.000 1.000 0.631 0.539 1.000 0.837 1.000
HP 1.593 0.211 24.516 0.000 1.221 0.302 0.510 1.000 0.644 1.844 0.175 0.196 0.737 1.000 0.878 0.426 1.000 1.000 0.635
RF 0.154 0.858 23.206 0.000 0.949 0.393 1.000 1.000 1.000 0.279 0.759 1.000 1.000 1.000 0.932 0.405 1.000 0.679 0.839
RH 0.334 0.717 17.657 0.000 1.955 0.150 1.000 1.000 1.000 1.188 0.318 0.505 0.642 1.000 1.092 0.348 1.000 0.460 1.000
LF 0.325 0.724 16.016 0.000 1.252 0.293 1.000 1.000 1.000 0.249 0.781 1.000 1.000 1.000 1.656 0.207 1.000 0.255 0.732
LH 0.929 0.400 28.645 0.000 0.394 0.676 1.000 1.000 0.732 0.488 0.618 1.000 1.000 1.000 0.994 0.381 1.000 0.748 0.665
FP 0.228 0.797 21.027 0.000 1.153 0.322 1.000 1.000 1.000 0.269 0.766 1.000 1.000 1.000 1.357 0.272 1.000 0.382 0.722
HP 0.629 0.537 25.423 0.000 1.178 0.314 1.000 1.000 1.000 0.794 0.461 0.662 1.000 1.000 1.112 0.342 1.000 0.518 0.806
Pink1 x DAT, young, CW
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Table A43: ANOVA table (1) of CW testing of mid-aged Pink1 x DAT mice: temporal parameters 
 
  red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP = hind  
  paws. Table XY summarises the description of the CW parameters.     
 
F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
1 Cadence [steps/sec] 0.043 0.958 4.033 0.049 0.184 0.833 1.000 1.000 1.000 0.049 0.953 1.000 1.000 1.000 0.165 0.849 1.000 1.000 1.000
RF 0.171 0.843 10.963 0.002 2.115 0.130 1.000 1.000 1.000 0.838 0.443 0.715 1.000 0.991 1.324 0.281 0.350 1.000 0.931
RH 3.390 0.041 18.203 0.000 0.385 0.682 0.041 1.000 0.061 5.181 0.012 0.017 1.000 0.063 0.563 0.576 1.000 1.000 1.000
LF 0.101 0.904 8.566 0.005 0.538 0.587 1.000 1.000 1.000 0.153 0.859 1.000 1.000 1.000 0.533 0.592 1.000 1.000 0.982
LH 0.682 0.509 11.734 0.001 3.073 0.054 1.000 1.000 0.517 3.186 0.057 0.137 1.000 0.100 0.850 0.437 0.629 1.000 1.000
FP 0.070 0.933 10.683 0.002 1.271 0.288 1.000 1.000 1.000 0.409 0.668 1.000 1.000 1.000 0.898 0.418 0.641 1.000 0.921
HP 1.918 0.156 18.288 0.000 1.802 0.174 0.273 1.000 0.121 5.252 0.012 0.023 1.000 0.036 0.127 0.882 1.000 1.000 1.000
RF 0.181 0.835 1.855 0.178 0.061 0.941 1.000 1.000 1.000 0.095 0.910 1.000 1.000 1.000 0.140 0.870 1.000 1.000 1.000
RH 0.751 0.477 0.468 0.496 0.178 0.837 0.812 1.000 1.000 0.617 0.547 0.828 1.000 1.000 0.326 0.724 1.000 1.000 1.000
LF 0.036 0.965 1.302 0.259 0.073 0.930 1.000 1.000 1.000 0.090 0.915 1.000 1.000 1.000 0.010 0.990 1.000 1.000 1.000
LH 1.260 0.291 0.066 0.798 0.216 0.806 0.415 1.000 0.761 0.409 0.668 1.000 1.000 1.000 1.092 0.349 0.641 1.000 0.594
FP 0.096 0.909 1.600 0.211 0.051 0.951 1.000 1.000 1.000 0.096 0.908 1.000 1.000 1.000 0.046 0.955 1.000 1.000 1.000
HP 1.028 0.364 0.227 0.636 0.160 0.852 0.564 1.000 0.868 0.514 0.604 0.960 1.000 1.000 0.672 0.518 1.000 1.000 0.853
RF 0.936 0.398 0.275 0.602 0.524 0.595 1.000 0.664 0.861 1.125 0.339 1.000 1.000 0.439 0.450 0.642 1.000 1.000 1.000
RH 0.415 0.663 6.462 0.014 0.118 0.889 1.000 1.000 1.000 0.044 0.957 1.000 1.000 1.000 0.779 0.468 1.000 1.000 0.776
LF 0.104 0.901 0.036 0.850 0.413 0.664 1.000 1.000 1.000 0.461 0.635 1.000 1.000 1.000 0.129 0.879 1.000 1.000 1.000
LH 2.212 0.119 1.581 0.214 0.285 0.753 0.136 0.944 0.886 0.533 0.593 0.948 1.000 1.000 1.915 0.165 0.185 1.000 0.671
FP 0.492 0.614 0.150 0.700 0.549 0.581 1.000 1.000 1.000 0.834 0.445 1.000 1.000 0.627 0.315 0.732 1.000 1.000 1.000
HP 1.057 0.354 4.334 0.042 0.244 0.784 0.645 1.000 0.901 0.140 0.870 1.000 1.000 1.000 1.452 0.250 0.432 1.000 0.444
RF 1.326 0.273 0.953 0.333 0.519 0.598 1.000 0.881 0.438 1.607 0.218 1.000 0.428 0.359 0.225 0.800 1.000 1.000 1.000
RH 1.096 0.341 0.665 0.418 0.522 0.596 1.000 1.000 0.539 1.411 0.261 1.000 0.482 0.450 0.246 0.783 1.000 1.000 1.000
LF 1.107 0.337 0.815 0.371 0.691 0.505 1.000 1.000 0.540 1.570 0.226 1.000 0.422 0.387 0.230 0.796 1.000 1.000 1.000
LH 1.329 0.273 0.557 0.459 0.785 0.461 1.000 0.967 0.422 1.913 0.166 1.000 0.309 0.292 0.258 0.774 1.000 1.000 1.000
FP 1.206 0.307 0.887 0.350 0.607 0.548 1.000 1.000 0.491 1.587 0.222 1.000 0.426 0.373 0.218 0.805 1.000 1.000 1.000
HP 1.214 0.305 0.608 0.439 0.649 0.526 1.000 1.000 0.475 1.660 0.208 1.000 0.386 0.361 0.252 0.779 1.000 1.000 1.000
RF 0.521 0.597 0.001 0.970 0.922 0.403 1.000 1.000 1.000 0.125 0.883 1.000 1.000 1.000 1.214 0.311 0.392 1.000 1.000
RH 1.359 0.265 0.265 0.609 1.449 0.243 1.000 1.000 0.340 1.600 0.220 1.000 0.270 0.729 1.164 0.326 0.460 1.000 0.786
LF 0.221 0.803 0.003 0.956 1.551 0.221 1.000 1.000 1.000 1.049 0.364 1.000 0.497 1.000 0.802 0.458 0.868 0.824 1.000
LH 1.135 0.328 0.380 0.540 2.332 0.106 0.965 1.000 0.471 2.429 0.107 1.000 0.165 0.241 1.128 0.337 0.484 0.843 1.000
FP 0.367 0.694 0.000 0.995 1.153 0.323 1.000 1.000 1.000 0.473 0.628 1.000 1.000 1.000 0.956 0.396 0.566 1.000 1.000
HP 1.315 0.276 0.351 0.556 1.894 0.160 1.000 1.000 0.363 2.131 0.138 1.000 0.182 0.383 1.123 0.339 0.433 1.000 1.000
7 Number of steps [#] 2.959 0.060 8.137 0.006 2.892 0.064 0.224 1.000 0.053 3.110 0.060 1.000 0.230 0.072 2.259 0.122 0.140 0.482 1.000
RF 0.681 0.510 11.190 0.001 0.454 0.637 1.000 1.000 1.000 0.255 0.777 1.000 1.000 1.000 1.039 0.366 1.000 1.000 0.483
RH 1.477 0.237 16.878 0.000 2.860 0.065 0.325 1.000 0.230 3.858 0.033 0.041 1.000 0.157 0.331 0.721 1.000 1.000 1.000
LF 0.448 0.641 16.944 0.000 1.904 0.158 1.000 1.000 1.000 0.482 0.622 1.000 1.000 1.000 1.596 0.220 0.330 1.000 0.460
LH 5.050 0.010 25.847 0.000 0.778 0.464 0.005 1.000 0.045 5.455 0.010 0.008 0.444 0.262 1.133 0.336 0.623 1.000 0.564
FP 0.505 0.606 15.355 0.000 1.116 0.335 1.000 1.000 1.000 0.349 0.709 1.000 1.000 1.000 1.278 0.293 0.662 1.000 0.424
HP 3.514 0.036 25.745 0.000 2.008 0.144 0.029 1.000 0.059 5.379 0.011 0.010 0.843 0.137 0.336 0.717 1.000 1.000 1.000
RF 3.209 0.048 4.522 0.038 0.660 0.520 1.000 0.127 0.142 2.557 0.096 1.000 0.180 0.175 0.667 0.521 1.000 1.000 0.975
RH 0.928 0.401 8.391 0.005 1.082 0.346 0.518 1.000 1.000 1.503 0.240 0.324 0.636 1.000 0.006 0.994 1.000 1.000 1.000
LF 2.309 0.108 5.110 0.028 0.864 0.427 1.000 0.487 0.196 2.321 0.117 1.000 0.200 0.231 0.617 0.546 1.000 1.000 0.906
LH 3.646 0.032 13.768 0.000 0.636 0.533 0.023 0.302 0.793 3.014 0.065 0.103 0.156 1.000 1.210 0.312 0.412 1.000 0.876
FP 2.834 0.067 5.062 0.028 0.769 0.468 1.000 0.233 0.153 2.569 0.095 1.000 0.170 0.183 0.539 0.589 1.000 1.000 0.927
HP 2.309 0.108 12.607 0.001 0.881 0.420 0.096 0.514 1.000 2.501 0.100 0.140 0.264 1.000 0.314 0.733 1.000 1.000 1.000
10 Run duration [sec] 0.962 0.388 1.046 0.311 0.082 0.922 1.000 1.000 0.558 0.864 0.433 1.000 1.000 0.634 0.293 0.748 1.000 1.000 1.000
11 Run speed [cm/sec] 0.663 0.519 1.465 0.231 0.306 0.738 1.000 1.000 0.957 0.704 0.503 1.000 0.860 1.000 0.213 0.809 1.000 1.000 1.000
12 Run maximum variation [%] 0.866 0.426 1.751 0.191 0.528 0.592 1.000 0.536 1.000 0.025 0.975 1.000 1.000 1.000 1.225 0.308 0.864 0.417 1.000
9 Swing speed [cm/sec]
2 Stance duration [sec]
3 Stand [sec]





6 Body speed variation [%]
8 Swing duration [sec]
Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-valueInteraction Post hoc Bonferroni, p-value Genotype















Table A44: ANOVA table (2) of CW testing of mid-aged Pink1 x DAT mice: comparative paws 
 
  red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP = hind   








F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
RF 2.059 0.137 1.012 0.319 1.568 0.217 1.000 0.498 0.161 2.951 0.069 1.000 0.455 0.068 0.119 0.888 1.000 1.000 1.000
RH 1.711 0.190 0.747 0.391 1.456 0.242 1.000 0.454 0.284 2.480 0.102 1.000 0.508 0.108 0.258 0.774 1.000 1.000 1.000
LF 2.131 0.128 0.712 0.402 1.497 0.232 1.000 0.531 0.150 2.932 0.070 1.000 0.377 0.072 0.049 0.952 1.000 1.000 1.000
LH 1.881 0.162 0.782 0.380 1.271 0.288 1.000 0.609 0.186 2.756 0.081 1.000 0.539 0.080 0.099 0.906 1.000 1.000 1.000
FP 2.097 0.132 0.853 0.360 1.525 0.226 1.000 0.514 0.155 2.938 0.069 1.000 0.413 0.070 0.074 0.929 1.000 1.000 1.000
HP 1.804 0.174 0.767 0.385 1.379 0.260 1.000 0.516 0.226 2.634 0.090 1.000 0.515 0.092 0.161 0.852 1.000 1.000 1.000
RF 0.068 0.934 4.780 0.033 0.160 0.853 1.000 1.000 1.000 0.010 0.990 1.000 1.000 1.000 0.213 0.810 1.000 1.000 1.000
RH 0.046 0.955 5.151 0.027 0.230 0.795 1.000 1.000 1.000 0.043 0.958 1.000 1.000 1.000 0.228 0.798 1.000 1.000 1.000
LF 0.085 0.919 4.681 0.035 0.186 0.831 1.000 1.000 1.000 0.010 0.990 1.000 1.000 1.000 0.259 0.774 1.000 1.000 1.000
LH 0.037 0.964 4.158 0.046 0.189 0.828 1.000 1.000 1.000 0.030 0.971 1.000 1.000 1.000 0.193 0.825 1.000 1.000 1.000
FP 0.076 0.927 4.728 0.034 0.172 0.842 1.000 1.000 1.000 0.010 0.990 1.000 1.000 1.000 0.235 0.792 1.000 1.000 1.000
HP 0.043 0.958 4.650 0.035 0.206 0.814 1.000 1.000 1.000 0.034 0.967 1.000 1.000 1.000 0.211 0.811 1.000 1.000 1.000
RF 1.456 0.241 1.441 0.235 0.002 0.998 1.000 0.299 0.967 0.693 0.508 1.000 0.763 1.000 0.777 0.469 1.000 0.685 1.000
RH 1.627 0.205 2.754 0.102 1.022 0.366 0.293 1.000 0.320 2.711 0.084 0.103 1.000 0.325 0.140 0.870 1.000 1.000 1.000
LF 0.281 0.756 2.056 0.157 0.403 0.670 1.000 1.000 1.000 0.176 0.840 1.000 1.000 1.000 0.512 0.605 1.000 1.000 1.000
LH 4.586 0.014 6.417 0.014 0.078 0.925 0.011 1.000 0.079 2.571 0.094 0.098 1.000 0.570 2.128 0.137 0.189 1.000 0.332
FP 0.761 0.472 2.079 0.155 0.113 0.893 1.000 0.822 1.000 0.481 0.623 1.000 1.000 1.000 0.378 0.689 1.000 1.000 1.000
HP 3.430 0.039 5.164 0.027 0.386 0.681 0.039 1.000 0.108 3.157 0.058 0.062 1.000 0.337 0.861 0.433 0.832 1.000 0.732
FP 0.713 0.494 0.103 0.749 0.486 0.618 0.812 1.000 1.000 0.815 0.453 1.000 1.000 0.639 0.448 0.643 1.000 1.000 1.000
HP 3.457 0.038 8.092 0.006 6.748 0.002 0.032 0.285 1.000 8.405 0.001 0.001 0.035 0.641 0.343 0.712 1.000 1.000 1.000
RF 0.175 0.840 0.067 0.796 0.698 0.502 1.000 1.000 1.000 0.643 0.533 0.911 1.000 1.000 0.213 0.809 1.000 1.000 1.000
RH 2.827 0.067 1.047 0.310 0.309 0.735 0.088 1.000 0.157 2.020 0.151 0.190 1.000 0.511 0.922 0.409 0.837 1.000 0.653
LF 0.539 0.586 0.268 0.607 0.473 0.626 1.000 1.000 1.000 0.841 0.442 1.000 0.703 0.963 0.175 0.840 1.000 1.000 1.000
LH 2.024 0.141 1.549 0.218 0.368 0.693 0.251 1.000 0.197 1.213 0.313 0.423 1.000 0.925 1.179 0.322 1.000 1.000 0.406
FP 0.170 0.844 0.173 0.679 0.339 0.714 1.000 1.000 1.000 0.317 0.731 1.000 1.000 1.000 0.183 0.833 1.000 1.000 1.000
HP 2.790 0.070 1.425 0.237 0.377 0.688 0.106 1.000 0.126 1.850 0.176 0.222 1.000 0.584 1.153 0.329 0.906 1.000 0.441
RF 0.396 0.675 0.248 0.620 0.440 0.646 1.000 1.000 1.000 0.680 0.515 1.000 0.798 1.000 0.157 0.855 1.000 1.000 1.000
RH 2.852 0.066 1.745 0.192 0.268 0.766 0.098 1.000 0.121 1.431 0.256 0.325 1.000 0.860 1.756 0.190 0.556 1.000 0.237
LF 0.163 0.850 0.108 0.743 0.872 0.424 1.000 1.000 1.000 0.635 0.538 0.833 1.000 1.000 0.380 0.687 1.000 1.000 1.000
LH 2.320 0.107 0.885 0.351 0.460 0.634 0.145 1.000 0.223 1.945 0.162 0.202 1.000 0.556 0.601 0.555 1.000 1.000 0.892
FP 0.212 0.809 0.179 0.673 0.508 0.604 1.000 1.000 1.000 0.442 0.647 1.000 1.000 1.000 0.260 0.773 1.000 1.000 1.000
HP 2.971 0.059 1.437 0.236 0.354 0.703 0.081 1.000 0.125 1.956 0.160 0.194 1.000 0.589 1.209 0.313 0.776 1.000 0.433
19 Print position right paws [cm] 1.787 0.177 0.587 0.447 0.572 0.568 0.428 1.000 0.232 1.609 0.218 1.000 1.000 0.252 0.592 0.559 0.861 1.000 1.000
20 Print position left paws [cm] 0.921 0.404 0.777 0.382 0.522 0.596 1.000 1.000 0.529 1.333 0.280 1.000 0.880 0.358 0.053 0.949 1.000 1.000 1.000
Pink1 x DAT, mid-aged, CW males females
Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-valueGenotype Sex Interaction Post hoc Bonferroni, p-value Genotype
13 Stride length [cm]
14 Step cycle [sec]
15 Duty cycle [%]
16 Base of support [cm]
17 Initial dual stance [sec]













Table A45: ANOVA table (3) of CW testing of mid-aged Pink1 x DAT mice: interlimb coordination and individual paw 
 
  red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP = hind    
  paws. Table XY summarises the description of the CW parameters.     
 
 
F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
21 Number of patterns 4.264 0.019 7.349 0.009 3.453 0.038 0.128 1.000 0.015 4.111 0.027 1.000 0.103 0.036 3.114 0.059 0.055 0.544 0.709
22 Regularity index [%] 0.724 0.489 0.515 0.476 0.618 0.542 1.000 0.743 1.000 1.157 0.329 1.000 0.966 0.438 0.385 0.684 1.000 1.000 1.000
RF-LH 1.175 0.316 4.081 0.048 2.212 0.119 0.791 1.000 0.346 1.607 0.218 0.717 1.000 0.278 3.735 0.036 0.162 1.000 0.039
LF-RH 1.019 0.367 0.044 0.835 0.023 0.977 0.613 1.000 0.741 0.436 0.651 1.000 1.000 1.000 0.614 0.548 1.000 1.000 0.982
LH-RH 0.119 0.888 0.348 0.557 1.721 0.188 1.000 1.000 1.000 0.466 0.632 1.000 1.000 1.000 1.797 0.183 0.205 1.000 0.802
LF-RF 1.108 0.337 0.413 0.523 0.471 0.627 0.424 1.000 1.000 0.695 0.508 1.000 1.000 0.892 0.915 0.411 0.782 0.725 1.000
RF-RH 6.031 0.004 0.844 0.362 0.022 0.978 0.339 0.191 0.003 2.409 0.108 1.000 0.673 0.111 4.082 0.027 0.527 0.452 0.023
LF-LH 4.801 0.012 0.713 0.402 1.474 0.237 0.042 1.000 0.018 2.074 0.145 1.000 0.658 0.159 4.399 0.021 0.020 1.000 0.154
RF-LH 0.163 0.850 0.150 0.700 0.009 0.991 1.000 1.000 1.000 0.163 0.851 1.000 1.000 1.000 0.069 0.934 1.000 1.000 1.000
LF-RH 4.607 0.014 0.291 0.592 0.254 0.776 0.071 1.000 0.016 2.284 0.120 0.593 1.000 0.133 2.560 0.094 0.162 1.000 0.179
LH-RF 1.358 0.265 1.553 0.218 0.349 0.707 0.515 1.000 0.521 0.758 0.478 0.839 1.000 0.969 4.920 0.014 0.088 1.000 0.015
RH-LF 3.176 0.049 0.359 0.551 0.144 0.866 0.232 1.000 0.050 1.783 0.187 0.749 1.000 0.221 1.405 0.261 0.574 1.000 0.381
LH-RH 0.015 0.986 0.165 0.686 0.898 0.413 1.000 1.000 1.000 0.275 0.762 1.000 1.000 1.000 0.799 0.459 0.725 1.000 0.992
LF-RF 1.064 0.352 0.342 0.561 0.388 0.680 0.495 0.796 1.000 0.410 0.668 1.000 1.000 1.000 1.033 0.368 0.792 0.582 1.000
RH-LH 0.030 0.971 0.213 0.646 1.601 0.210 1.000 1.000 1.000 0.497 0.614 1.000 1.000 1.000 1.282 0.292 0.482 1.000 0.550
RF-LF 0.962 0.388 0.005 0.941 0.680 0.511 0.495 1.000 1.000 0.911 0.414 0.792 1.000 0.745 0.800 0.459 1.000 0.669 1.000
RF-RH 6.004 0.004 0.799 0.375 0.021 0.979 0.353 0.186 0.003 2.409 0.108 1.000 0.673 0.111 4.048 0.028 0.557 0.437 0.024
LF-LH 6.224 0.004 1.417 0.239 1.222 0.302 0.031 1.000 0.004 2.074 0.145 1.000 0.658 0.159 6.219 0.006 0.009 1.000 0.021
RH-RF 5.610 0.006 0.811 0.372 0.034 0.967 0.372 0.224 0.004 2.549 0.096 1.000 0.664 0.096 3.167 0.057 0.715 0.593 0.053
LH-LF 6.337 0.003 2.304 0.135 0.673 0.514 0.028 1.000 0.003 1.917 0.166 1.000 1.000 0.181 5.699 0.008 0.018 1.000 0.018
RF 1.746 0.183 11.343 0.001 1.895 0.159 1.000 0.662 0.416 2.675 0.086 0.912 0.086 0.597 1.088 0.350 0.552 1.000 0.708
RH 0.944 0.395 0.073 0.787 0.077 0.926 1.000 0.570 0.993 0.374 0.691 1.000 1.000 1.000 0.702 0.504 1.000 0.738 1.000
LF 1.453 0.242 3.245 0.077 0.148 0.863 1.000 0.329 0.933 0.962 0.394 1.000 0.532 1.000 0.653 0.528 1.000 0.999 1.000
LH 0.640 0.531 0.039 0.845 0.369 0.693 1.000 0.967 1.000 0.715 0.498 1.000 0.834 1.000 0.029 0.972 1.000 1.000 1.000
FP 2.629 0.081 11.276 0.001 1.320 0.275 1.000 0.194 0.286 2.679 0.086 0.780 0.085 0.699 1.186 0.319 0.986 1.000 0.412
HP 0.125 0.883 0.085 0.772 0.264 0.769 1.000 1.000 1.000 0.216 0.807 1.000 1.000 1.000 0.159 0.854 1.000 1.000 1.000
RF 1.630 0.205 20.631 0.000 0.989 0.378 0.233 0.587 1.000 2.367 0.112 0.215 0.199 1.000 0.107 0.899 1.000 1.000 1.000
RH 0.875 0.422 22.982 0.000 0.261 0.771 0.569 0.952 1.000 0.561 0.577 1.000 0.908 1.000 0.516 0.602 0.955 1.000 1.000
LF 1.569 0.217 18.431 0.000 0.712 0.495 0.404 0.418 1.000 2.125 0.138 0.596 0.154 1.000 0.225 0.800 1.000 1.000 1.000
LH 0.597 0.554 22.457 0.000 0.677 0.512 0.835 1.000 1.000 0.732 0.490 1.000 0.713 1.000 0.336 0.717 1.000 1.000 1.000
FP 1.666 0.198 20.423 0.000 0.866 0.426 0.281 0.463 1.000 2.343 0.115 0.322 0.152 1.000 0.162 0.851 1.000 1.000 1.000
HP 0.785 0.461 24.445 0.000 0.504 0.607 0.631 1.000 1.000 0.715 0.498 1.000 0.733 1.000 0.427 0.656 1.000 1.000 1.000
RF 0.432 0.651 7.729 0.007 0.564 0.572 1.000 1.000 1.000 0.641 0.534 1.000 0.879 1.000 0.151 0.861 1.000 1.000 1.000
RH 0.350 0.706 19.782 0.000 0.441 0.646 1.000 1.000 1.000 0.415 0.664 1.000 1.000 1.000 0.340 0.715 1.000 1.000 1.000
LF 0.620 0.542 12.084 0.001 0.618 0.543 1.000 1.000 1.000 0.980 0.388 1.000 0.537 1.000 0.000 1.000 1.000 1.000 1.000
LH 0.758 0.473 16.897 0.000 1.655 0.200 0.555 1.000 0.955 1.307 0.287 0.720 0.401 1.000 1.048 0.363 1.000 1.000 0.498
FP 0.538 0.587 10.360 0.002 0.595 0.555 1.000 1.000 1.000 0.823 0.449 1.000 0.670 1.000 0.040 0.961 1.000 1.000 1.000
HP 0.564 0.572 19.427 0.000 1.026 0.365 0.711 1.000 1.000 0.857 0.435 1.000 0.642 1.000 0.681 0.514 1.000 1.000 0.759
RF 0.614 0.545 7.797 0.007 0.418 0.661 1.000 0.997 1.000 0.639 0.535 1.000 0.805 1.000 0.065 0.937 1.000 1.000 1.000
RH 0.194 0.824 8.744 0.004 1.098 0.340 1.000 1.000 1.000 0.947 0.400 1.000 0.578 1.000 0.218 0.805 1.000 1.000 1.000
LF 0.700 0.501 12.101 0.001 0.796 0.456 1.000 0.914 1.000 1.056 0.361 1.000 0.473 1.000 0.003 0.997 1.000 1.000 1.000
LH 0.153 0.859 10.121 0.002 1.522 0.227 1.000 1.000 1.000 0.725 0.493 1.000 0.717 1.000 0.966 0.392 1.000 0.758 0.705
FP 0.677 0.512 10.188 0.002 0.621 0.541 1.000 0.926 1.000 0.858 0.435 1.000 0.602 1.000 0.019 0.981 1.000 1.000 1.000
HP 0.109 0.897 10.477 0.002 1.476 0.237 1.000 1.000 1.000 0.879 0.427 1.000 0.595 1.000 0.619 0.545 1.000 0.997 1.000
Pink1 x DAT, mid-aged, CW
Genotype Sex Interaction Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-value
males females
Genotype Post hoc Bonferroni, p-value
23 Phase dispersion [%]
25  % Max contact at [%]
24 Couplings [%]
26 Max contact max intensity [pixel ]






















Table A46: ANOVA table (4) of CW testing of mid-aged Pink1 x DAT mice: individual paw 
 
  red: p-value ≤ 0.05, yellow = p-value ≥ 0.05 ≤ 0.1, RF = right front paws, RH = right hind paws, LF = left front paws, LH = left hind paws, FP = front paws, HP = hind  
  paws. Table XY summarises the description of the CW parameters.     
 
F-value p-value F-value p-value F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2 F-value p-value mt vs ctrl.1 mt vs ctrl.2 ctrl.1 vs ctrl.2
RF 0.518 0.599 9.720 0.003 0.491 0.614 1.000 1.000 1.000 0.679 0.515 1.000 0.813 1.000 0.050 0.951 1.000 1.000 1.000
RH 0.272 0.763 17.955 0.000 0.339 0.714 1.000 1.000 1.000 0.300 0.743 1.000 1.000 1.000 0.293 0.748 1.000 1.000 1.000
LF 0.506 0.606 15.659 0.000 0.900 0.412 1.000 1.000 1.000 1.024 0.372 1.000 0.491 1.000 0.040 0.961 1.000 1.000 1.000
LH 0.684 0.509 15.833 0.000 1.283 0.285 0.618 1.000 1.000 1.005 0.379 0.896 0.562 1.000 0.915 0.411 1.000 1.000 0.569
FP 0.536 0.588 13.167 0.001 0.696 0.503 1.000 1.000 1.000 0.868 0.431 1.000 0.608 1.000 0.018 0.982 1.000 1.000 1.000
HP 0.493 0.613 17.851 0.000 0.808 0.451 0.799 1.000 1.000 0.652 0.529 1.000 0.855 1.000 0.617 0.547 1.000 1.000 0.829
RF 1.289 0.283 1.140 0.290 0.043 0.958 1.000 0.429 0.558 1.082 0.353 1.000 0.643 0.625 0.426 0.657 1.000 1.000 1.000
RH 0.461 0.633 10.316 0.002 0.054 0.947 1.000 1.000 1.000 0.151 0.860 1.000 1.000 1.000 0.368 0.695 1.000 1.000 1.000
LF 1.322 0.274 7.218 0.009 1.202 0.308 1.000 0.877 0.212 2.083 0.143 0.186 1.000 0.457 1.087 0.350 1.000 0.503 0.936
LH 1.089 0.343 2.087 0.154 2.051 0.138 1.000 0.585 1.000 3.129 0.059 0.676 0.056 0.592 0.087 0.917 1.000 1.000 1.000
FP 1.456 0.242 3.778 0.057 0.319 0.728 1.000 0.487 0.270 1.054 0.362 1.000 1.000 0.483 0.876 0.427 1.000 0.644 1.000
HP 1.075 0.348 8.400 0.005 0.629 0.537 1.000 0.563 1.000 1.566 0.227 1.000 0.263 1.000 0.067 0.935 1.000 1.000 1.000
RF 0.637 0.532 3.592 0.063 0.116 0.891 1.000 0.892 1.000 0.756 0.479 1.000 0.715 1.000 0.099 0.906 1.000 1.000 1.000
RH 0.686 0.508 11.093 0.002 0.611 0.546 0.629 1.000 1.000 0.012 0.988 1.000 1.000 1.000 1.068 0.356 0.503 1.000 0.881
LF 1.351 0.267 0.642 0.426 1.513 0.229 0.520 0.563 1.000 1.601 0.220 1.000 0.254 0.976 0.942 0.401 0.729 1.000 0.703
LH 0.712 0.495 10.036 0.002 1.472 0.238 0.627 1.000 1.000 0.741 0.486 1.000 0.718 1.000 1.321 0.282 0.741 1.000 0.377
FP 0.994 0.376 2.366 0.129 0.652 0.525 1.000 0.616 1.000 1.280 0.294 1.000 0.369 1.000 0.229 0.797 1.000 1.000 1.000
HP 0.850 0.433 12.672 0.001 1.009 0.371 0.503 1.000 0.887 0.254 0.777 1.000 1.000 1.000 1.373 0.269 0.480 1.000 0.462
RF 0.838 0.438 4.984 0.029 0.448 0.641 1.000 0.717 1.000 0.795 0.461 1.000 0.663 1.000 0.158 0.855 1.000 1.000 1.000
RH 0.307 0.737 8.818 0.004 0.743 0.480 1.000 1.000 1.000 0.724 0.493 1.000 0.820 1.000 0.072 0.931 1.000 1.000 1.000
LF 0.582 0.562 8.833 0.004 0.982 0.381 1.000 1.000 1.000 1.147 0.332 1.000 0.430 1.000 0.061 0.940 1.000 1.000 1.000
LH 0.136 0.873 9.109 0.004 0.921 0.404 1.000 1.000 1.000 0.587 0.563 1.000 0.898 1.000 0.374 0.691 1.000 1.000 1.000
FP 0.736 0.483 7.053 0.010 0.722 0.490 1.000 0.849 1.000 0.989 0.385 1.000 0.520 1.000 0.064 0.938 1.000 1.000 1.000
HP 0.202 0.818 9.765 0.003 0.928 0.401 1.000 1.000 1.000 0.689 0.510 1.000 0.814 1.000 0.243 0.786 1.000 1.000 1.000
RF 0.881 0.420 8.199 0.006 0.373 0.690 1.000 0.713 1.000 0.825 0.449 1.000 0.629 1.000 0.169 0.845 1.000 1.000 1.000
RH 0.378 0.687 16.551 0.000 0.504 0.606 1.000 1.000 1.000 0.542 0.588 1.000 0.926 1.000 0.250 0.781 1.000 1.000 1.000
LF 0.618 0.542 13.401 0.001 0.612 0.546 1.000 1.000 1.000 0.954 0.397 1.000 0.535 1.000 0.024 0.976 1.000 1.000 1.000
LH 0.411 0.665 15.360 0.000 1.104 0.339 0.937 1.000 1.000 0.794 0.462 1.000 0.679 1.000 0.666 0.521 1.000 1.000 0.799
FP 0.782 0.462 11.040 0.002 0.513 0.601 1.000 0.823 1.000 0.929 0.407 1.000 0.551 1.000 0.077 0.926 1.000 1.000 1.000
HP 0.408 0.667 16.850 0.000 0.848 0.434 0.951 1.000 1.000 0.710 0.500 1.000 0.746 1.000 0.467 0.632 1.000 1.000 1.000
RF 1.741 0.184 6.371 0.014 0.169 0.845 0.778 0.223 1.000 1.471 0.247 0.598 0.350 1.000 0.656 0.526 1.000 0.831 1.000
RH 0.386 0.681 10.880 0.002 0.209 0.812 1.000 1.000 1.000 0.819 0.451 0.755 0.917 1.000 0.031 0.969 1.000 1.000 1.000
LF 0.857 0.430 12.882 0.001 0.149 0.862 1.000 0.689 1.000 1.044 0.365 1.000 0.491 1.000 0.142 0.868 1.000 1.000 1.000
LH 0.794 0.457 17.025 0.000 0.525 0.595 0.506 1.000 1.000 1.128 0.338 0.604 0.609 1.000 0.317 0.731 1.000 1.000 1.000
FP 1.458 0.241 9.949 0.003 0.146 0.865 0.889 0.324 1.000 1.477 0.246 0.716 0.318 1.000 0.395 0.677 1.000 1.000 1.000
HP 0.666 0.518 16.050 0.000 0.386 0.682 0.616 1.000 1.000 1.137 0.335 0.566 0.642 1.000 0.158 0.854 1.000 1.000 1.000
RF 1.428 0.248 9.911 0.003 0.605 0.549 0.563 0.426 1.000 2.387 0.110 0.537 0.118 1.000 0.135 0.874 1.000 1.000 1.000
RH 1.882 0.161 17.206 0.000 0.693 0.504 0.141 0.754 1.000 1.748 0.193 0.438 0.284 1.000 0.863 0.432 0.700 1.000 0.881
LF 1.834 0.169 6.140 0.016 0.448 0.641 0.921 0.201 1.000 1.282 0.293 1.000 0.502 0.549 1.048 0.363 0.759 0.585 1.000
LH 0.206 0.815 25.477 0.000 0.461 0.633 1.000 1.000 1.000 0.549 0.584 1.000 0.919 1.000 0.152 0.859 1.000 1.000 1.000
FP 1.826 0.170 9.081 0.004 0.335 0.717 0.628 0.232 1.000 1.935 0.163 1.000 0.183 0.718 0.503 0.610 1.000 1.000 1.000
HP 0.844 0.435 23.193 0.000 0.635 0.533 0.499 1.000 1.000 1.124 0.339 0.969 0.458 1.000 0.429 0.655 1.000 1.000 1.000
RF 1.664 0.198 13.363 0.001 0.473 0.626 0.574 0.304 1.000 2.163 0.134 0.560 0.150 1.000 0.173 0.842 1.000 1.000 1.000
RH 0.945 0.395 20.428 0.000 0.156 0.856 0.427 1.000 1.000 0.589 0.562 1.000 1.000 1.000 0.469 0.630 1.000 1.000 1.000
LF 1.467 0.239 14.087 0.000 0.439 0.647 0.623 0.379 1.000 1.905 0.168 1.000 0.184 0.889 0.303 0.741 1.000 1.000 1.000
LH 0.556 0.576 23.046 0.000 0.657 0.522 0.776 1.000 1.000 0.732 0.490 1.000 0.732 1.000 0.338 0.716 1.000 1.000 1.000
FP 1.663 0.199 14.353 0.000 0.454 0.637 0.561 0.308 1.000 2.203 0.129 0.713 0.137 1.000 0.224 0.800 1.000 1.000 1.000
HP 0.804 0.452 23.641 0.000 0.422 0.658 0.520 1.000 1.000 0.720 0.496 1.000 0.789 1.000 0.408 0.669 1.000 1.000 1.000
Pink1 x DAT, mid-aged, CW
Genotype Post hoc Bonferroni, p-valueGenotype Sex Interaction Post hoc Bonferroni, p-value Genotype Post hoc Bonferroni, p-value
females
33 Print length [cm]
34 Print Width [cm]
males
35 Print area [cm]
28 Maximum intensity [pixel]
29 % Maximum intensity at  [sec]
30 Minimum intensity [pixel]
31 Mean intensity mean [pixel]











Table A47: Summary of results of selected CW parameters of young and mid-aged Pink1 x Pet mice 
 




age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 12 29.19 0.47 ctrl. 1 14 29.10 0.49 ctrl. 1 12 14.50 0.13 ctrl. 1 12 14.54 0.20
mt 9 28.74 0.38 mt 10 29.11 0.40 mt 11 14.47 0.18 mt 10 14.54 0.17
ctrl. 2 9 29.28 0.39 ctrl. 2 14 28.92 0.58 ctrl. 2 9 14.51 0.21 ctrl. 2 13 14.49 0.30
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 12 37.73 7.75 ctrl. 1 14 32.81 7.08 ctrl. 1 12 38.61 7.06 ctrl. 1 12 34.85 7.39
mt 9 35.00 7.91 mt 10 40.02 4.93 mt 11 32.71 6.72 mt 10 42.37 3.81
ctrl. 2 9 37.19 7.59 ctrl. 2 14 33.24 5.92 ctrl. 2 9 31.98 5.81 ctrl. 2 13 36.02 5.44
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 12 41.85 4.27 ctrl. 1 14 37.94 6.16 ctrl. 1 12 41.45 6.25 ctrl. 1 12 40.69 5.00
mt 9 40.79 6.38 mt 10 42.08 3.89 mt 11 37.81 5.58 mt 10 45.66 4.02
ctrl. 2 9 40.33 6.51 ctrl. 2 14 38.14 4.98 ctrl. 2 9 36.80 4.08 ctrl. 2 13 38.57 4.85
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 12 51.08 1.83 ctrl. 1 14 49.49 1.65 ctrl. 1 12 51.18 2.46 ctrl. 1 12 49.28 2.26
mt 9 50.39 1.66 mt 10 50.96 2.14 mt 11 50.61 1.74 mt 10 52.77 2.57






Minimum intensity [pixel] of LF paws




males females males females
 % Max contact at [%] of LF paws










Table A48: Summary (1) of results of selected CW parameters of young and mid-aged Pink1 x DAT mice 
 




age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 12 0.10 0.01 ctrl. 1 10 0.11 0.02 ctrl. 1 11 0.10 0.01 ctrl. 1 10 0.12 0.02
mt 11 0.11 0.01 mt 12 0.12 0.02 mt 10 0.11 0.01 mt 11 0.12 0.02
ctrl. 2 12 0.09 0.01 ctrl. 2 12 0.11 0.02 ctrl. 2 10 0.11 0.01 ctrl. 2 12 0.13 0.02
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 12 0.10 0.01 ctrl. 1 10 0.11 0.02 ctrl. 1 11 0.10 0.01 ctrl. 1 10 0.12 0.02
mt 11 0.11 0.01 mt 12 0.12 0.01 mt 10 0.11 0.01 mt 11 0.12 0.02
ctrl. 2 12 0.10 0.01 ctrl. 2 12 0.11 0.01 ctrl. 2 10 0.11 0.01 ctrl. 2 12 0.13 0.01
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 12 27.96 3.97 ctrl. 1 10 27.06 5.50 ctrl. 1 11 20.79 3.77 ctrl. 1 10 20.21 3.64
mt 11 25.39 4.95 mt 12 23.18 4.12 mt 10 20.78 2.91 mt 11 21.49 5.91
ctrl. 2 12 29.44 5.88 ctrl. 2 12 25.59 3.97 ctrl. 2 10 23.78 5.01 ctrl. 2 12 21.30 3.10
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 12 27.87 3.92 ctrl. 1 10 26.88 5.38 ctrl. 1 11 20.83 3.93 ctrl. 1 10 20.15 3.77
mt 11 25.38 4.91 mt 12 23.25 4.17 mt 10 20.83 2.84 mt 11 21.40 5.96
ctrl. 2 12 29.41 5.99 ctrl. 2 12 25.59 3.97 ctrl. 2 10 23.64 5.00 ctrl. 2 12 21.27 3.08
Body speed [cm/sec] of LH paws
Stance duration [sec] of RH paws
young mid-aged
males females males females
Stance duration [sec] of HP
young mid-aged
males females males females
young mid-aged
males females males females
Body speed [cm/sec] of HP
young mid-aged










Table A49: Summary (2) of results of selected CW parameters of young and mid-aged Pink1 x DAT mice 
 









age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 12 69.01 9.29 ctrl. 1 10 58.41 8.90 ctrl. 1 11 61.85 8.35 ctrl. 1 10 54.51 9.92
mt 11 61.80 9.65 mt 12 50.51 8.05 mt 10 53.95 8.49 mt 11 48.94 7.28
ctrl. 2 12 72.25 8.99 ctrl. 2 12 56.22 7.80 ctrl. 2 10 61.34 7.51 ctrl. 2 12 50.68 7.84
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 12 66.85 7.65 ctrl. 1 10 57.74 7.16 ctrl. 1 11 60.67 8.39 ctrl. 1 10 52.03 7.89
mt 11 61.47 9.63 mt 12 50.23 8.06 mt 10 52.89 7.56 mt 11 49.50 8.09
ctrl. 2 12 69.42 9.90 ctrl. 2 12 55.09 7.08 ctrl. 2 10 59.64 9.60 ctrl. 2 12 50.22 6.62
age groups n mean SD age groups n mean SD age groups n mean SD age groups n mean SD
ctrl. 1 12 2.90 0.23 ctrl. 1 10 2.61 0.20 ctrl. 1 11 3.19 0.22 ctrl. 1 10 2.85 0.23
mt 11 2.65 0.18 mt 12 2.70 0.18 mt 10 2.81 0.21 mt 11 2.91 0.16
ctrl. 2 12 2.80 0.16 ctrl. 2 12 2.71 0.17 ctrl. 2 10 3.07 0.20 ctrl. 2 12 2.88 0.15
females males females
Base of support [cm] of HP
Swing speed [cm/sec] of LH paws
young mid-aged
males female males females
Swing speed [cm/sec] of HP 
young
young mid-aged











Table A50: ANOVA table oflfac. testing of young and mid-aged males Pink1 x Pet and Pink1 x DAT mice 
 
 
F-value p-value fl,+ vs. wt,+ fl,+ vs fl,- wt,+ vs fl,- F-value p-value fl,+ vs. wt,+ fl,+ vs fl,- wt,+ vs fl,-
100 % [S+] 0.284 0.756 1.000 1.000 1.000 100 % [S+] 0.260 0.774 1.000 1.000 1.000
70 % [S+] 0.347 0.711 1.000 1.000 1.000 70 % [S+] 4.332 0.029 0.028 1.000 0.274
55 % [S+] 0.319 0.731 1.000 1.000 1.000 55 % [S+] 0.516 0.605 0.970 1.000 1.000
53 % [S+] 1.018 0.380 .580 .934 1.000 53 % [S+] 0.332 0.722 1.000 1.000 1.000










0.223 0.802 1.000 1.000 1.000
F-value p-value fl,+ vs. wt,+ fl,+ vs fl,- wt,+ vs fl,- F-value p-value fl,+ vs. wt,+ fl,+ vs fl,- wt,+ vs fl,-
100 % [S+] 0.787 0.469 0.830 0.881 1.000 100 % [S+] 0.998 0.390 1.000 1.000 0.565
70 % [S+] 2.022 0.159 0.241 1.000 0.379 70 % [S+] 1.543 0.244 0.343 1.000 0.604
55 % [S+] 0.017 0.983 1.000 1.000 1.000 55 % [S+] 0.987 0.394 1.000 0.563 1.000
53 % [S+] 0.041 0.960 1.000 1.000 1.000 53 % [S+] 1.351 0.287 0.362 1.000 1.000










0.493 0.620 1.000 1.000 1.000
post-hoc Bonferoni
Genotype p-value Genotype p-value
post-hoc Bonferoni
males Pink1 x DAT, young, Olfac. males Pink1 x DAT, mid-aged, Olfac.
post-hoc Bonferoni
Genotype p-value
























































mean SD n mean SD N mean SD n mean SD n mean SD n mean SD n
100 % of [S+] 83.76 14.09 7 87.79 9.21 8 87.64 10.98 7 100 % of [S+] 96.43 6.56 7 96.88 4.31 8 94.44 8.61 6
70 % of [S+] 86.96 12.23 7 87.46 11.41 8 82.09 16.64 7 70 % of [S+] 95.24 4.45 7 75.00 12.60 8 81.94 20.01 6
55 % of [S+] 73.81 21.21 7 72.92 19.80 8 66.67 12.73 7 55 % of [S+] 82.86 12.79 7 73.96 20.62 8 77.78 15.52 6
53 % of [S+] 66.67 15.96 7 56.25 8.63 8 64.29 19.07 7 53 % of [S+] 60.71 18.46 7 64.58 17.11 8 69.44 22.77 6








13.29 7.54 7 12.63 7.50 8 10.67 6.59 6
mean SD n mean SD n mean SD n mean SD n mean SD n mean SD n
100 % of [S+] 94.70 11.76 8 89.34 8.74 7 94.51 6.37 8 100 % of [S+] 97.22 6.80 6 93.06 6.27 6 91.67 8.33 7
70 % of [S+] 96.88 6.20 8 86.90 10.60 7 88.54 13.32 8 70 % of [S+] 69.44 31.91 6 87.50 6.97 6 83.33 6.80 7
55 % of [S+] 83.33 14.09 8 82.14 18.28 7 82.29 8.26 8 55 % of [S+] 69.44 14.59 6 73.61 13.35 6 61.90 17.25 7
53 % of [S+] 77.08 18.77 8 75.00 16.67 7 77.08 12.40 8 53 % of [S+] 61.11 16.39 6 73.61 14.35 6 66.67 8.33 7








12.83 7.11 6 11.33 5.85 6 14.86 6.28 7
males Pink1 x Pet, young males Pink1 x Pet, mid-aged
males Pink1 x DAT, mid-aged
ctrl.1 mt ctrl.2
males Pink1 x DAT, young
ctrl.1 mt ctrl.2
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